

# South Africa Country Operational Plan FY 2017



# **Budget Summary Reports**

**Summary of Planned Funding by Agency and Funding Source** 

Summary of Planned Funding by Agency and Funding Source							
	i	Funding Source				Total All	
						Funding	
				Funding	Applied	Sources and	
Agency	GAP	GHP-State	GHP-USAID	Source Total	Pipeline	Applied	
						Pipeline	
						Amount	
State		1,687,163		1,687,163	1,517,647	3,204,810	
USAID		246,932,493		246,932,493	16,820,320	263,752,813	
DOD		0		0	399,737	399,737	
PC		200,000		200,000	2,175,000	2,375,000	
HHS/CDC	3,450,000	196,818,038		200,268,038	8,828,627	209,096,665	
HHS/HRSA		2,898,910		2,898,910	0	2,898,910	
State/AF		1,595,446		1,595,446	0	1,595,446	
Total	3,450,000	450,132,050	0	453,582,050	29,741,331	483,323,381	

**Summary of Planned Funding by Budget Code and Agency** 

	Agency								
Budget Code	State	DOD	HHS/CDC	HHS/HRS A	PC	State/AF	USAID	On Hold Amount	Total
CIRC	0	0	13,715,458				12,696,967	0	26,412,425
НВНС	0		22,975,026	0	24,564	0	24,127,769	0	47,127,359
HKID	0		5,264,878		81,318	552,446	32,349,900	0	38,248,542
HLAB	0		4,817,315					0	4,817,315
HMBL	0							0	0
HMIN	0							0	0
HTXD	0	0	937,555				29,910	0	967,465
HTXS	0	0	59,347,803	0			88,249,348	0	147,597,15 1
HVAB	0	0	1,625,553		47,059	447,000	3,541,655	0	5,661,267



	1,687,163	0	8	2,898,910	200,000	1,595,446	3	0	0
			200,268,03				246,932,49		453,582,05
PDTX	0		4,112,671	0			4,455,172	0	8,567,843
PDCS	0		3,660,444	0			4,400,430	0	8,060,874
OHSS	0	0	13,922,820	2,879,685		0	8,486,439	0	25,288,944
МТСТ	0		7,100,918	0			8,789,729	0	15,890,647
IDUP	0		89,897					0	89,897
HVTB	0	0	15,953,220	0			17,900,988	0	33,854,208
HVSI	4,001		7,066,970				4,202,079	0	11,273,050
HVOP	0	0	11,628,973	19,225	47,059	298,000	16,966,183	0	28,959,440
HVMS	1,683,162	0	9,756,201		0		6,933,998	0	18,373,361
HVCT	0	0	18,292,336			298,000	13,801,926	0	32,392,262



# **Technical Areas**

### **Technical Area Summary**

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
НВНС	46,718,061	0
HKID	37,213,070	0
HVTB	33,500,152	0
PDCS	7,914,062	0
Total Technical Area Planned Funding:	125,345,345	0

**Technical Area:** Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	4,330,889	0
HVSI	8,833,076	0
OHSS	24,341,773	0
Total Technical Area Planned	27 505 720	
Funding:	37,505,738	0

**Technical Area:** Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	25,615,741	0
HVAB	4,969,970	0
HVCT	31,795,893	0
HVOP	28,039,162	0
IDUP	70,000	0
MTCT	15,651,081	0
Total Technical Area Planned	106 141 947	
Funding:	106,141,847	0



### **Technical Area:** Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	906,213	0
HTXS	146,421,984	0
PDTX	8,346,387	0
Total Technical Area Planned Funding:	155,674,584	0



## **Technical Area Summary Indicators and Targets**

Indicator Number	Label	2018
	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	582,535
	Number of new ANC and L&D clients	
	By Age (Denominator): Unknown Age	0
	By Age (Denominator): <10	862
PMTCT_STAT_DSD	By Age (Denominator): 10-14	8,749
	By Age (Denominator): <15-19	48,807
	By Age (Denominator): 20-24	144,985
	By Age (Denominator): 25-49	383,509
	By Age (Denominator): 50+	12,572
	By Number of known positives: Unknown Age	0
	By Number of known positives: <10	2
	By Number of known positives: 10-14	812
	By Number of known positives: 15-19	7,642
	By Number of known positives: 20-24	20,051
	By Number of known positives:	44,715



	25-49	
	By Number of known positives: 50+	1,224
	By Number of new positives:	
	Unknown Age	0
	By Number of new positives: <10	3
	By Number of new positives: 10-14	991
	By Number of new positives: 15-19	8,842
	By Number of new positives: 20-24	22,467
	By Number of new positives: 25-49	49,400
	By Number of new positives: 50+	1,492
	By Number of new negative: Unknown Age	0
	By Number of new negative: <10	105
	By Number of new negative: 10-14	7,049
	By Number of new negative: 15-19	
	By Number of new negative: 20-24	115,051
	By Number of new negative: 25-49	253,073
	By Number of new negative: 50+	4,719
	By Age (Numerator): Unknown Age	239
	By Age (Numerator): <10	885
	By Age (Numerator): 10-14	8,771
	By Age (Numerator): 15-19	49,111
	By Age (Numerator): 20-24	142,893
	By Age (Numerator): 25-49	368,218
	By Age (Numerator): 50+	12,145
	PMTCT_STAT_TA Number and	
PMTCT_STAT_TA	percentage of pregnant women	
	with known status (includes women	n/a
	who were tested for HIV and	
31_31/11_1/1	received their results) (TA)	
	Number of pregnant women with	
	known HIV status (includes women	132,120
	who were tested for HIV and	



received their results)	
Number of new ANC and L&D	
clients	
By Age (Denominator): Unknown	0
Age	0
By Age (Denominator): <10	49
By Age (Denominator): 10-14	2,035
By Age (Denominator): 15-19	17,697
By Age (Denominator): 20-24	33,527
By Age (Denominator): 25-49	79,002
By Age (Denominator): 50+	1,272
By known positives: <unknown< td=""><td>0</td></unknown<>	0
Age	0
By known positives: <10	0
By known positives: 10-14	134
By known positives: 15-19	2,289
By known positives: 20-24	4,192
By known positives: 25-49	9,375
By known positives: 50+	122
By new positives: Unknown Age	0
By new positives: <10	21
By new positives: 10-14	222
By new positives: 15-19	2,532
By new positives: 20-24	4,958
By new positives: 25-49	10,149
By new positives: 50+	125
By new negatives: Unknown Age	0
By new negatives: <10	208
By new negatives: 10-14	1,507
By new negatives: 15-19	12,963
By new negatives: 20-24	25,140
By new negatives: 25-49	57,081



	<u> </u>		
	By new negatives: 50+	671	
	By Age (Numerator): Unknown Age	0	
	By Age (Numerator): <10	45	
	By Age (Numerator): 10-14	2,023	
	By Age (Numerator): : 15-19	16,807	
	By Age (Numerator): 20-24	32,744	
	By Age (Numerator): 25-49	79,493	
	By Age (Numerator): 50+	1,243	
	PMTCT_ART_DSD Percentage of		
	HIV-positive pregnant women who		
	received ART to reduce risk of	25 %	
	mother-to-child-transmission		
	(MTCT) during pregnancy		
	Number of HIV-positive pregnant		
	women who received ART to		
	reduce risk of	142,730	
PMTCT_ART_DSD	mother-to-child-transmission		
	(MTCT) during pregnancy		
	Number of pregnant women with		
	known HIV status (includes women	582,535	
	who were tested for HIV and	002,000	
	received their results)		
	New on ART	82,823	
	Already on ART at beginning of	50.007	
	current pregnancy	59,907	
	PMTCT_ART_TA Percentage of		
	HIV-positive pregnant women who		
	received ART to reduce risk of	25 %	
	mother-to-child-transmission		
PMTCT_ART_TA	(MTCT) during pregnancy		
	Number of HIV-positive pregnant		
	women who received ART to	32,957	
	reduce risk of		
	mother-to-child-transmission		



	(MTCT) during pregnancy	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	132,120
	New on ART	19,158
	Already on ART at beginning of current pregnancy	13,799
	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	581,652
	By Age: 0-60 days	
	By Age: 2 months - 9 years	0
	By Age: 10-14	56,006
	By Age: 15-19	162,025
	By Age: 20-24	150,337
	By Age: 25-29	150,272
	By Age: 30-49	58,053
VMMC_CIRC_DSD	By Age: 50+	4,959
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	577,866
	By circumcision technique:	3,786



	Device-based VMMC	
	By follow-up status: Number of	
	surgically circumcised clients who	
	returned at least once for follow-up	
	care within 14 days of circumcision	
	surgery	
	By follow-up status: Number of	
	device based circumcision clients	
	who returned at least once for	
	follow-up care within 14 days of	
	device placement	
	Number of males circumcised as	
	part of the voluntary medical male	
	circumcision (VMMC) for HIV	0
	prevention program within the	
	reporting period	
	By Age: 0-60 Days	
	By Age: 2 months - 9 years	
	By Age: 10-14	0
	By Age: 15-19	0
	By Age: 20-24	0
	By Age: 25-49	0
VMMC_CIRC_TA	By Age: 25-29	
	By Age: 30-49	0
	By Age: 50+	0
	By HIV status: Number of	
	HIV-positive clients (tested HIV	
	positive at VMMC site)	
	By HIV status: Number of	
	HIV-negative clients (tested HIV	
	negative at VMMC program	
	By HIV status: Number of clients	
	with undocumented/indeterminate	
	HIV status or not tested for HIV at	



	site	
	By circumcision technique: Surgical VMMC	0
	By circumcision technique: Device-based VMMC	
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	
	By follow-up status: Number of device based circumcision clients who returned at least once for follow-up care within 14 days of device placement	
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	
	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	16,011
	Male 10-14 Male 15-19	72
	Male 20-24	360
	Male 25-49	3,190
	Male 50+	754



	Female 10-14	
	Female 15-19	1,423
	Female 20-24	5,707
	Female 25-49	4,644
	Female 50+	
	(15-19)	
	(20-24)	
	FSW	4,848
	MSM	500
	TG	
	PrEP_NEW_TA Number of	
	individuals who have received	
	antiretroviral pre-exposure	n/a
	prophylaxis (PrEP) to prevent HIV	
	infection in the reporting period.	
	Number of individuals who have	
	been newly enrolled on oral	
	antiretroviral pre-exposure	2,815
	prophylaxis (PrEP) in the reporting	
	period to prevent HIV infection	
	Male 10-14	
	Male 15-19	282
PrEP_NEW_TA	Male 20-24	422
	Male 25-49	424
	Male 50+	0
	Female 10-14	
	Female 15-19	563
	Female 20-24	600
	Female 25-49	506
	Female 50+	140
	(15-19)	
	(20-24)	
	FSW	



	MSM	
	TG	
	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	514,469
	Total number of people in the	
	target population	12.424
PP_PREV_DSD	Age/sex: 10-14 Male	13,424
	Age/sex: 15-19 Male Age/sex: 20-24 Male	70,077 64,312
	Age/sex: 25-49 Male	68,749
	Age/sex: 50+ Male	1,844
	Age/sex: 10-14 Female	42,746
	Age/sex: 15-19 Female	124,182
	Age/sex: 20-24 Female	75,536
	Age/sex: 25-49 Female	49,174
	Age/sex: 50+ Female	4,417
	Aggregated Age/sex: <15 Male	,
	Aggregated Age/sex: 15+ Male	
	Aggregated Age/sex: <15 Female	
	Aggregated Age/sex: 15+ Female	
PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention	n/a
	intervention including the minimum components during the reporting	



	period (TA-only)	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,326
	Total number of people in the	
	target population	
	Age/sex: 10-14 Male	85
	Age/sex: 15-19 Male	330
	Age/sex: 20-24 Male	501
	Age/sex: 25-49 Male	499
	Age/sex: 50+ Male	0
	Age/sex: 10-14 Female	173
	Age/sex: 15-19 Female	580
	Age/sex: 20-24 Female	664
	Age/sex: 25-49 Female	498
	Age/sex: 50+ Female	0
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	
	Aggregated Age/sex: <15 Female	
	Aggregated Age/sex: 15+ Female	
	KP_PREV_DSD Percentage of key populations reached with individual	
	and/or small group level HIV preventive interventions that are based on evidence and/or meet the	n/a
	minimum standards required (DSD)	
KP_PREV_DSD	Number of key populations reached	
	with individual and/or small group level HIV preventive interventions	
	that are based on evidence and/or	84,952
	meet the minimum standards	
	required	



Total estimated number of key	
population in the catchment area	
By key population type: Men who	
have sex with men who are sex	
workers (Numerator: Number of	
key populations reached with	0.505
individual and/or small group level	2,565
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Men who	
have sex with men who are NOT	
sex workers (Numerator: Number	
of key populations reached with	
individual and/or small group level	44,097
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	148
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	0
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Female	
sex workers (FSW) (Numerator:	38,142



Number of key populations reached	
with individual and/or small group	
evel HIV preventive interventions	
that are based on evidence and/or	
meet the minimum standards	
required)	
By key population type: Males who	
nject drugs ( Male PWID)	
Numerator: Number of key	
populations reached with individual	0
and/or small group level HIV	0
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Females	
who inject drugs (Female PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	0
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: People in	
prisons and enclosed settings	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	0
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Female	
sex workers (FSW) (Denominator:	
otal estimated number of key	
opulation in the catchment area)	
By key population type: People in	
), population type: . copie	



1	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: Men who	
have sex with men who are sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area	
By key population type: Men who	
have sex with men who are NOT	
sex workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type:	
Transgender who are sex workers	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type:	
Transgender who are NOT sex	
workers (Denominator: Total	
estimated number of key	
population in the catchment area)	
By key population type: Males who	
inject drugs ( Male PWID)	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: Females	
who inject drugs (Female PWID)	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: Men who	
have sex with men/Transgender	
(MSM/TG) (Denominator: Total	



	1	
	estimated number of key	
	population in the catchment area)	
	By key population type: MSM/TG	
	who are male sex workers (subset	
	MSM/TG) (Denominator: Total	
	estimated number of key	
	population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part	
	of the program and/or KP was	
	referred for testing as part of the	
	program	
	By New Client Status: New	
	beneficiary	
	By New Client Status: Returning	
	beneficiary within the current report	
	period	
	KP_PREV_TA Percentage of key	
	populations reached with individual	
	and/or small group level HIV	
	preventive interventions that are	n/a
	based on evidence and/or meet the	
	minimum standards required	
	(TA-only)	
	Number of key populations reached	
KP_PREV_TA	with individual and/or small group	
INF_FINEV_IM	level HIV preventive interventions	71,122
	that are based on evidence and/or	, ,,,,,,
	meet the minimum standards	
	required	
	Total estimated number of key	
	population in the catchment area	
	By key population type: Female	
	sex workers (FSW) (Numerator:	
	, , , , , , , , , , , , , , , , , , , ,	



with individual and/or small group	
level HIV preventive interventions	
that are based on evidence and/or	
meet the minimum standards	
required)	
By key population type: Males who	
inject drugs ( Male PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Females	
who inject drugs (Female PWID)	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Men who	
have sex with men and are sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: Men who	
have sex with men and are NOT	
sex workers (Numerator: Number	
of key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	



<u></u>	
the minimum standards required)	
By key population type:	
Transgender who are sex workers	
(Numerator: Number of key	
populations reached with individual	
and/or small group level HIV	
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type:	
Transgender who are NOT sex	
workers (Numerator: Number of	
key populations reached with	
individual and/or small group level	
HIV preventive interventions that	
are based on evidence and/or meet	
the minimum standards required)	
By key population type: People in	
prisons and enclosed settings	
(Numerator: Number of key	
populations reached with individual	74.400
and/or small group level HIV	71,122
preventive interventions that are	
based on evidence and/or meet the	
minimum standards required)	
By key population type: Female	
sex workers (FSW) (Denominator:	
Total estimated number of key	
population in the catchment area)	
By key population type: Males who	
inject drugs ( Male PWID)	
(Denominator: Total estimated	
number of key population in the	
catchment area)	
By key population type: Females	
who inject drugs (Female PWID)	
, , ,	



(Denominator: Total estimated number of key population in the catchment area)  By key population type: Men who have sex with men and are sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New beneficiary		
catchment area)  By key population type: Men who have sex with men and are sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	(Denominator: Total estimated	
By key population type: Men who have sex with men and are sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	number of key population in the	
have sex with men and are sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	catchment area)	
workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	By key population type: Men who	
estimated number of key population in the catchment area)  By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	have sex with men and are sex	
By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	workers (Denominator: Total	
By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By key population in the catchment of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	estimated number of key	
have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	population in the catchment area)	
sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	By key population type: Men who	
estimated number of key population in the catchment area)  By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	have sex with men and are NOT	
population in the catchment area)  By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	sex workers (Denominator: Total	
By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	estimated number of key	
Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	population in the catchment area)	
(Denominator: Total estimated number of key population in the catchment area)  By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	By key population type:	
number of key population in the catchment area)  By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	Transgender who are sex workers	
By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	(Denominator: Total estimated	
By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	number of key population in the	
Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	catchment area)	
workers (Denominator: Total estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	By key population type:	
estimated number of key population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	Transgender who are NOT sex	
population in the catchment area)  By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	workers (Denominator: Total	
By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	estimated number of key	
prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	population in the catchment area)	
(Denominator: Total estimated number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	By key population type: People in	
number of key population in the catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	prisons and enclosed settings	
catchment area)  By Service: KP known positive  By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	(Denominator: Total estimated	
By Service: KP known positive By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program By New Client Status: New	number of key population in the	
By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program  By New Client Status: New	catchment area)	
of the program and/or KP was referred for testing as part of the program  By New Client Status: New	By Service: KP known positive	
referred for testing as part of the program  By New Client Status: New	By Service: KP was tested as part	
program  By New Client Status: New	of the program and/or KP was	
By New Client Status: New	referred for testing as part of the	
	program	
beneficiary	By New Client Status: New	
	 beneficiary	



	By New Client Status: Returning	
	beneficiary within the current report	
	period	
	Number of individuals who received	
	T&C services for HIV and received	0.070.047
	their test results during the past 12	2,073,847
	months	
	By Test Result: Positive	191,014
	Service Delivery Point (Community)	
	Homebased testing: 10-14,	
	Female, Negative	
	Service Delivery Point (Community)	
	Homebased testing: 10-14,	
	Female, Positive	
	Service Delivery Point (Community)	
	Homebased testing: 10-14, Male,	
	Negative	
	Service Delivery Point (Community)	
	Homebased testing: 10-14, Male,	
HTC_TST_TA	Positive	
	Service Delivery Point (Community)	
	Homebased testing: 15-19,	
	Female, Negative	
	Service Delivery Point (Community)	
	Homebased testing: 15-19,	
	Female, Positive	
	Service Delivery Point (Community)	
	Homebased testing: 15-19, Male,	
	Negative	
	Service Delivery Point (Community)	
	Homebased testing: 15-19, Male,	
	Positive	
	Service Delivery Point (Community)	
	Homebased testing: 20-24,	
	Female, Negative	



Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	
Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	
Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	
Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative	
Service Delivery Point (Community) Homebased testing: 25-49, Female, Positive	
Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	
Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	
Service Delivery Point (Community) Homebased testing: 50+, Female, Negative	
Service Delivery Point (Community) Homebased testing: 50+, Female, Positive	
Service Delivery Point (Community) Homebased testing: 50+, Male, Negative	
Service Delivery Point (Community) Homebased testing: 50+, Male, Positive	
Service Delivery Point (Community) Homebased testing: Unknown Age,	



Female, Negative	
Service Delivery Point (Community)	
Homebased testing: Unknown Age,	
Female, Positive	
Service Delivery Point (Community)	
Homebased testing: Unknown Age,	
Male, Negative	
Service Delivery Point (Community)	
Homebased testing: Unknown Age,	
Male, Positive	
Service Delivery Point (Community)	
Homebased testing: <1, Negative	
Service Delivery Point (Community)	
Homebased testing: <1, Positive	
Service Delivery Point (Community)	
Homebased testing: 1-9, Negative	
Service Delivery Point (Community)	
Homebased testing: 1-9, Positive	
Service Delivery Point Agg Age	
(Community) Homebased testing:	
<15, Female, Negative	
Service Delivery Point Agg Age	
(Community) Homebased testing:	
<15, Female, Positive	
Service Delivery Point Agg Age	
(Community) Homebased testing:	
<15, Male, Negative	
Service Delivery Point Agg Age	
(Community) Homebased testing:	
<15, Male, Positive	
Service Delivery Point Agg Age	
(Community) Homebased testing:	
15+, Female, Negative	
Service Delivery Point Agg Age	
(Community) Homebased testing:	



15+, Female, Positive	
Service Delivery Point Agg Age	
(Community) Homebased testing:	
15+, Male, Negative	
Service Delivery Point Agg Age	
(Community) Homebased testing:	
15+, Male, Positive	
Service Delivery Point Agg Age	
(Community) Homebased testing:	
Unknown Age, Female, Negative	
Service Delivery Point Agg Age	
(Community) Homebased testing:	
Unknown Age, Female, Positive	
Service Delivery Point Agg Age	
(Community) Homebased testing:	
Unknown Age, Male, Negative	
Service Delivery Point Agg Age	
(Community) Homebased testing:	
Unknown Age, Male, Positive	
Service Delivery Point (Facility)	13
Inpatient: 10-14, Female, Negative	10
Service Delivery Point (Facility)	2
Inpatient: 10-14, Female, Positive	
Service Delivery Point (Facility)	12
Inpatient: 10-14, Male, Negative	12
Service Delivery Point (Facility)	2
Inpatient: 10-14, Male, Positive	2
Service Delivery Point (Facility)	
Inpatient: 15-19, Female, Negative	
Service Delivery Point (Facility)	
Inpatient: 15-19, Female, Positive	
Service Delivery Point (Facility)	
Inpatient: 15-19, Male, Negative	
Service Delivery Point (Facility)	



Inpatient: 15-19, Male, Positive	
Service Delivery Point (Facility)	
Inpatient: 20-24, Female, Negative	
Service Delivery Point (Facility)	
Inpatient: 20-24, Female, Positive	
Service Delivery Point (Facility)	
Inpatient: 20-24, Male, Negative	
Service Delivery Point (Facility)	
Inpatient: 20-24, Male, Positive	
Service Delivery Point (Facility)	
Inpatient: 25-49, Female, Negative	
Service Delivery Point (Facility)	
Inpatient: 25-49, Female, Positive	
Service Delivery Point (Facility)	
Inpatient: 25-49, Male, Negative	
Service Delivery Point (Facility)	
Inpatient: 25-49, Male, Positive	
Service Delivery Point (Facility)	
Inpatient: 50+, Female, Negative	
Service Delivery Point (Facility)	
Inpatient: 50+, Female, Positive	
Service Delivery Point (Facility)	
Inpatient: 50+, Male, Negative	
Service Delivery Point (Facility)	
Inpatient: 50+, Male, Positive	
Service Delivery Point (Facility)	
Inpatient: Unknown Age, Female,	
Negative	
Service Delivery Point (Facility)	
Inpatient: Unknown Age, Female,	
Positive	
Service Delivery Point (Facility)	
Inpatient: Unknown Age, Male,	
Negative	



Service Delivery Point (Facility)	
Inpatient: Unknown Age, Male, Positive	
Service Delivery Point (Facility) Inpatient: <1, Negative	100
Service Delivery Point (Facility) Inpatient: <1, Positive	10
Service Delivery Point (Facility) Inpatient: 1-9, Negative	58
Service Delivery Point (Facility) Inpatient: 1-9, Positive	6
Service Delivery Point Agg Age (Facility) Inpatient: <15, Female, Negative	2,276
Service Delivery Point Agg Age (Facility) Inpatient: <15, Female, Positive	62
Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Negative	2,276
Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Positive	61
Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Negative	26,417
Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Positive	2,136
Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Negative	17,717
Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Positive	1,452



Service Delivery Point Agg Age	
(Facility) Inpatient: Unknown Age,	
Female, Negative	
Service Delivery Point Agg Age	
(Facility) Inpatient: Unknown Age,	
Female, Positive	
Service Delivery Point Agg Age	
(Facility) Inpatient: Unknown Age,	
Male, Negative	
Service Delivery Point Agg Age	
(Facility) Inpatient: Unknown Age,	
Male, Positive	
Service Delivery Point (Facility)	
Malnutrition: Negative	3,650
Service Delivery Point (Facility)	400
Malnutrition: Positive	490
Service Delivery Point (Community)	
Mobile Testing: 10-14, Female,	
Negative	
Service Delivery Point (Community)	
Mobile Testing: 10-14, Female,	
Positive	
Service Delivery Point (Community)	
Mobile Testing: 10-14, Male,	
Negative	
Service Delivery Point (Community)	
Mobile Testing: 10-14, Male,	
Positive	
Service Delivery Point (Community)	
Mobile Testing: 15-19, Female,	
Negative	
Service Delivery Point (Community)	
Mobile Testing: 15-19, Female,	
Positive	
Service Delivery Point (Community)	
	·



Mobile Testing: 15-19, Male,
Negative
Service Delivery Point (Community)
Mobile Testing: 15-19, Male,
Positive
Service Delivery Point (Community)
Mobile Testing: 20-24, Female,
Negative
Service Delivery Point (Community)
Mobile Testing: 20-24, Female,
Positive
Service Delivery Point (Community)
Mobile Testing: 20-24, Male,
Negative
Service Delivery Point (Community)
Mobile Testing: 20-24, Male,
Positive
Service Delivery Point (Community)
Mobile Testing: 25-49, Female,
Negative
Service Delivery Point (Community)
Mobile Testing: 25-49, Female,
Positive
Service Delivery Point (Community)
Mobile Testing: 25-49, Male,
Negative
Service Delivery Point (Community)
Mobile Testing: 25-49, Male, Positive
Service Delivery Point (Community)
Mobile Testing: 50+, Female,
Negative
Service Delivery Point (Community)
Mobile Testing: 50+, Female,
Positive



Service Delivery Point (Community)	
Mobile Testing: 50+, Male,	
Negative	
Service Delivery Point (Community)	
Mobile Testing: 50+, Male, Positive	
Service Delivery Point (Community)	
Mobile Testing: Unknown Age,	
Female, Negative	
Service Delivery Point (Community)	
Mobile Testing: Unknown Age,	
Female, Positive	
Service Delivery Point (Community)	
Mobile Testing: Unknown Age,	
Male, Negative	
Service Delivery Point (Community)	
Mobile Testing: Unknown Age,	
Male, Positive	
Service Delivery Point (Community)	
Mobile Testing: <1, Negative	
Service Delivery Point (Community)	
Mobile Testing: <1, Positive	
Service Delivery Point (Community)	
Mobile Testing: 1-9, Negative	
Service Delivery Point (Community)	
Mobile Testing: 1-9, Positive	
Service Delivery Point Agg Age	
(Community) Mobile Testing: <15,	
Female, Negative	
Service Delivery Point Agg Age	
(Community) Mobile Testing: <15,	
Female, Positive	
Service Delivery Point Agg Age	
(Community) Mobile Testing: <15,	
Male, Negative	
Service Delivery Point Agg Age	



(Community) Mobile Testing: <15, Male, Positive	
Service Delivery Point Agg Age (Community) Mobile Testing: 15+, Female, Negative	
Service Delivery Point Agg Age (Community) Mobile Testing: 15+, Female, Positive	
Service Delivery Point Agg Age (Community) Mobile Testing: 15+, Male, Negative	
Service Delivery Point Agg Age (Community) Mobile Testing: 15+, Male, Positive	
Service Delivery Point Agg Age (Community) Mobile Testing: Unknown Age, Female, Negative	
Service Delivery Point Agg Age (Community) Mobile Testing: Unknown Age, Female, Positive	
Service Delivery Point Agg Age (Community) Mobile Testing: Unknown Age, Male, Negative	
Service Delivery Point Agg Age (Community) Mobile Testing: Unknown Age, Male, Positive	
Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,819
Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	284
Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	1,259
Service Delivery Point (Facility)	205



Other PITC: 10-14, Male, Positive	
Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	2,414
Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	465
Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	3,546
Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	666
Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	15,277
Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	2,345
Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	5,879
Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	954
Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	42,174
Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	7,283
Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	17,878
Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	3,195
Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	5,163
Service Delivery Point (Facility)	916



Other PITC: 50+, Female, Positive	
Service Delivery Point (Facility)	2,811
Other PITC: 50+, Male, Negative Service Delivery Point (Facility)	
Other PITC: 50+, Male, Positive	471
Service Delivery Point (Facility)	
Other PITC: Unknown Age,	0
Female, Negative	
Service Delivery Point (Facility)	_
Other PITC: Unknown Age,	0
Female, Positive	
Service Delivery Point (Facility)	
Other PITC: Unknown Age, Male,	0
Negative	
Service Delivery Point (Facility)	
Other PITC: Unknown Age, Male,	0
Positive	
Service Delivery Point (Facility)	1,730
Other PITC: <1, Negative	
Service Delivery Point (Facility)	251
Other PITC: <1, Positive	
Service Delivery Point (Facility)	5,263
Other PITC: 1-9, Negative	5,205
Service Delivery Point (Facility) Other PITC: 1-9, Positive	913
Service Delivery Point Agg Age	65 457
(Facility) Other PITC: <15, Female, Negative	65,457
Service Delivery Point Agg Age (Facility) Other PITC: <15, Female,	2 254
Positive	3,251
Service Delivery Point Agg Age	150 456
(Facility) Other PITC: <15, Male,	150,456
Negative	



Service Delivery Point Agg Age	
(Facility) Other PITC: <15, Male,	7,698
Positive	
Service Delivery Point Agg Age	
(Facility) Other PITC: 15+, Female,	789,339
Negative	
Service Delivery Point Agg Age	
(Facility) Other PITC: 15+, Female,	83,249
Positive	
Service Delivery Point Agg Age	
(Facility) Other PITC: 15+, Male,	632,428
Negative	
Service Delivery Point Agg Age	
(Facility) Other PITC: 15+, Male,	63,994
Positive	
Service Delivery Point Agg Age	
(Facility) Other PITC: Unknown	
Age, Female, Negative	
Service Delivery Point Agg Age	
(Facility) Other PITC: Unknown	
Age, Female, Positive	
Service Delivery Point Agg Age	
(Facility) Other PITC: Unknown	
Age, Male, Negative	
Service Delivery Point Agg Age	
(Facility) Other PITC: Unknown	
Age, Male, Positive	
Service Delivery Point (Community)	
Other: 10-14, Female, Negative	
Service Delivery Point (Community)	
Other: 10-14, Female, Positive	
Service Delivery Point (Community)	
Other: 10-14, Male, Negative	
Service Delivery Point (Community)	
Other: 10-14, Male, Positive	
Other. 10-14, Maie, Fusitive	



Service Delivery Point (Community)	
Other: 15-19, Female, Negative	
Service Delivery Point (Community)	
Other: 15-19, Female, Positive	
Service Delivery Point (Community)	
Other: 15-19, Male, Negative	
Service Delivery Point (Community)	
Other: 15-19, Male, Positive	
Service Delivery Point (Community)	
Other: 20-24, Female, Negative	
Service Delivery Point (Community)	
Other: 20-24, Female, Positive	
Service Delivery Point (Community)	
Other: 20-24, Male, Negative	
Service Delivery Point (Community)	
Other: 20-24, Male, Positive	
Service Delivery Point (Community)	
Other: 25-49, Female, Negative	
Service Delivery Point (Community)	
Other: 25-49, Female, Positive	
Service Delivery Point (Community)	
Other: 25-49, Male, Negative	
Service Delivery Point (Community)	
Other: 25-49, Male, Positive	
Service Delivery Point (Community)	
Other: 50+, Female, Negative	
Service Delivery Point (Community)	
Other: 50+, Female, Positive	
Service Delivery Point (Community)	
Other: 50+, Male, Negative	
Service Delivery Point (Community)	
Other: 50+, Male, Positive	
Service Delivery Point (Community)	
Other: Unknown Age, Female,	



Negative	
Service Delivery Point (Community) Other: Unknown Age, Female, Positive	
Service Delivery Point (Community) Other: Unknown Age, Male, Negative	
Service Delivery Point (Community) Other: Unknown Age, Male, Positive	
Service Delivery Point (Community) Other: <1, Negative	
Service Delivery Point (Community) Other: <1, Positive Service Delivery Point (Community)	
Other: 1-9, Negative	
Service Delivery Point (Community) Other: 1-9, Positive	
Service Delivery Point Agg Age (Community) Other: <15, Female, Negative	
Service Delivery Point Agg Age (Community) Other: <15, Female, Positive	
Service Delivery Point Agg Age (Community) Other: <15, Male, Negative	
Service Delivery Point Agg Age (Community) Other: <15, Male, Positive	
Service Delivery Point Agg Age (Community) Other: 15+, Female, Negative	
Service Delivery Point Agg Age (Community) Other: 15+, Female,	



Positive	
Service Delivery Point Agg Age (Community) Other: 15+, Male, Negative	
Service Delivery Point Agg Age (Community) Other: 15+, Male, Positive	
Service Delivery Point Agg Age (Community) Other: Unknown Age, Female, Negative	
Service Delivery Point Agg Age (Community) Other: Unknown Age, Female, Positive	
Service Delivery Point Agg Age (Community) Other: Unknown Age, Male, Negative	
Service Delivery Point Agg Age (Community) Other: Unknown Age, Male, Positive	
Service Delivery Point (Facility) Pediatric : <5 Negative	41,553
Service Delivery Point (Facility) Pediatric : <5 Positive	2,479
Service Delivery Point (Facility) TB: 10-14, Female, Negative	14
Service Delivery Point (Facility) TB: 10-14, Female, Positive	4
Service Delivery Point (Facility) TB: 10-14, Male, Negative	10
Service Delivery Point (Facility) TB: 10-14, Male, Positive	1
Service Delivery Point (Facility) TB: 15-19, Female, Negative	78
Service Delivery Point (Facility) TB:	45



Service Delivery Point (Facility) TB: 15-19, Male, Negative  Service Delivery Point (Facility) TB: 15-19, Male, Positive  Service Delivery Point (Facility) TB: 15-19, Male, Positive  Service Delivery Point (Facility) TB: 20-24, Female, Negative  Service Delivery Point (Facility) TB: 20-24, Female, Positive  Service Delivery Point (Facility) TB: 20-24, Male, Negative  Service Delivery Point (Facility) TB: 20-24, Male, Positive  Service Delivery Point (Facility) TB: 20-24, Male, Positive  Service Delivery Point (Facility) TB: 25-49, Female, Negative  Service Delivery Point (Facility) TB: 25-49, Female, Positive  Service Delivery Point (Facility) TB: 25-49, Male, Negative  Service Delivery Point (Facility) TB: 25-49, Male, Positive  Service Delivery Point (Facility) TB: 50+, Female, Negative  Service Delivery Point (Facility) TB: 50+, Female, Positive  Service Delivery Point (Facility) TB: 50+, Female, Positive  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: 50+, Male, Positive			
Service Delivery Point (Facility) TB: 15-19, Male, Positive  Service Delivery Point (Facility) TB: 20-24, Female, Negative  Service Delivery Point (Facility) TB: 20-24, Female, Positive  Service Delivery Point (Facility) TB: 20-24, Female, Positive  Service Delivery Point (Facility) TB: 20-24, Male, Negative  Service Delivery Point (Facility) TB: 20-24, Male, Positive  Service Delivery Point (Facility) TB: 20-24, Male, Positive  Service Delivery Point (Facility) TB: 25-49, Female, Negative  Service Delivery Point (Facility) TB: 25-49, Male, Negative  Service Delivery Point (Facility) TB: 25-49, Male, Negative  Service Delivery Point (Facility) TB: 25-49, Male, Positive  Service Delivery Point (Facility) TB: 50+, Female, Negative  Service Delivery Point (Facility) TB: 50+, Female, Positive  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: Unknown Age, Female, Negative  Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	1:	5-19, Female, Positive	
15-19, Male, Positive  Service Delivery Point (Facility) TB: 20-24, Female, Negative  Service Delivery Point (Facility) TB: 20-24, Female, Positive  Service Delivery Point (Facility) TB: 20-24, Male, Negative  Service Delivery Point (Facility) TB: 20-24, Male, Positive  Service Delivery Point (Facility) TB: 20-24, Male, Positive  Service Delivery Point (Facility) TB: 25-49, Female, Negative  Service Delivery Point (Facility) TB: 25-49, Female, Positive  Service Delivery Point (Facility) TB: 25-49, Male, Negative  Service Delivery Point (Facility) TB: 25-49, Male, Positive  Service Delivery Point (Facility) TB: 50+, Female, Negative  Service Delivery Point (Facility) TB: 50+, Female, Positive  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: Unknown Age, Female, Negative  Service Delivery Point (Facility) TB: Unknown Age, Female, Positive  Service Delivery Point (Facility) TB: Unknown Age, Female, Positive		• ` •	39
20-24, Female, Negative  Service Delivery Point (Facility) TB: 20-24, Female, Positive  Service Delivery Point (Facility) TB: 20-24, Male, Negative  Service Delivery Point (Facility) TB: 20-24, Male, Positive  Service Delivery Point (Facility) TB: 20-24, Male, Positive  Service Delivery Point (Facility) TB: 25-49, Female, Negative  Service Delivery Point (Facility) TB: 25-49, Male, Positive  Service Delivery Point (Facility) TB: 25-49, Male, Negative  Service Delivery Point (Facility) TB: 25-49, Male, Positive  Service Delivery Point (Facility) TB: 50+, Female, Negative  Service Delivery Point (Facility) TB: 50+, Female, Positive  Service Delivery Point (Facility) TB: 50+, Female, Positive  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: Unknown Age, Female, Negative  Service Delivery Point (Facility) TB: Unknown Age, Female, Positive		, , ,	38
20-24, Female, Positive  Service Delivery Point (Facility) TB: 20-24, Male, Negative  Service Delivery Point (Facility) TB: 20-24, Male, Positive  Service Delivery Point (Facility) TB: 25-49, Female, Negative  Service Delivery Point (Facility) TB: 25-49, Female, Positive  Service Delivery Point (Facility) TB: 25-49, Male, Negative  Service Delivery Point (Facility) TB: 25-49, Male, Negative  Service Delivery Point (Facility) TB: 25-49, Male, Positive  Service Delivery Point (Facility) TB: 50+, Female, Negative  Service Delivery Point (Facility) TB: 50+, Female, Positive  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: Unknown Age, Female, Negative  Service Delivery Point (Facility) TB: Unknown Age, Female, Positive		, , , , , , , , , , , , , , , , , , , ,	224
20-24, Male, Negative  Service Delivery Point (Facility) TB: 20-24, Male, Positive  Service Delivery Point (Facility) TB: 25-49, Female, Negative  Service Delivery Point (Facility) TB: 25-49, Female, Positive  Service Delivery Point (Facility) TB: 25-49, Male, Negative  Service Delivery Point (Facility) TB: 25-49, Male, Negative  Service Delivery Point (Facility) TB: 25-49, Male, Positive  Service Delivery Point (Facility) TB: 50+, Female, Negative  Service Delivery Point (Facility) TB: 50+, Female, Positive  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: Unknown Age, Female, Negative  Service Delivery Point (Facility) TB: Unknown Age, Female, Positive			136
20-24, Male, Positive  Service Delivery Point (Facility) TB: 25-49, Female, Negative  Service Delivery Point (Facility) TB: 25-49, Female, Positive  Service Delivery Point (Facility) TB: 25-49, Male, Negative  Service Delivery Point (Facility) TB: 25-49, Male, Negative  Service Delivery Point (Facility) TB: 25-49, Male, Positive  Service Delivery Point (Facility) TB: 50+, Female, Negative  Service Delivery Point (Facility) TB: 50+, Female, Positive  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: Unknown Age, Female, Negative  Service Delivery Point (Facility) TB: Unknown Age, Female, Positive		• • • • • • • • • • • • • • • • • • • •	107
25-49, Female, Negative  Service Delivery Point (Facility) TB: 25-49, Female, Positive  Service Delivery Point (Facility) TB: 25-49, Male, Negative  Service Delivery Point (Facility) TB: 25-49, Male, Positive  Service Delivery Point (Facility) TB: 50+, Female, Negative  Service Delivery Point (Facility) TB: 50+, Female, Positive  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: Unknown Age, Female, Negative  Service Delivery Point (Facility) TB: Unknown Age, Female, Positive		• • • • • • • • • • • • • • • • • • • •	98
25-49, Female, Positive  Service Delivery Point (Facility) TB: 25-49, Male, Negative  Service Delivery Point (Facility) TB: 25-49, Male, Positive  Service Delivery Point (Facility) TB: 50+, Female, Negative  Service Delivery Point (Facility) TB: 50+, Female, Positive  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: Unknown Age, Female, Negative  Service Delivery Point (Facility) TB: Unknown Age, Female, Positive  0		• • • • • • • • • • • • • • • • • • • •	667
25-49, Male, Negative  Service Delivery Point (Facility) TB: 25-49, Male, Positive  Service Delivery Point (Facility) TB: 50+, Female, Negative  Service Delivery Point (Facility) TB: 50+, Female, Positive  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: Unknown Age, Female, Negative  Service Delivery Point (Facility) TB: Unknown Age, Female, Negative  Service Delivery Point (Facility) TB: Unknown Age, Female, Positive		` ` ` ,	301
25-49, Male, Positive  Service Delivery Point (Facility) TB: 50+, Female, Negative  Service Delivery Point (Facility) TB: 50+, Female, Positive  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: Unknown Age, Female, Negative  Service Delivery Point (Facility) TB: Unknown Age, Female, Positive  0		• • • • • • • • • • • • • • • • • • • •	383
58 50+, Female, Negative  Service Delivery Point (Facility) TB: 50+, Female, Positive  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: Unknown Age, Female, Negative  Service Delivery Point (Facility) TB: Unknown Age, Female, Negative  O Unknown Age, Female, Positive		• • • • • • • • • • • • • • • • • • • •	244
50+, Female, Positive  Service Delivery Point (Facility) TB: 50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: Unknown Age, Female, Negative  Service Delivery Point (Facility) TB: Unknown Age, Female, Positive  0		• • • • • • • • • • • • • • • • • • • •	58
50+, Male, Negative  Service Delivery Point (Facility) TB: 50+, Male, Positive  Service Delivery Point (Facility) TB: Unknown Age, Female, Negative  Service Delivery Point (Facility) TB: Unknown Age, Female, Positive  0			53
50+, Male, Positive  Service Delivery Point (Facility) TB: Unknown Age, Female, Negative  Service Delivery Point (Facility) TB: Unknown Age, Female, Positive		, , , , , , , , , , , , , , , , , , , ,	41
Unknown Age, Female, Negative  Service Delivery Point (Facility) TB: Unknown Age, Female, Positive		, , , , , , , , , , , , , , , , , , , ,	24
Unknown Age, Female, Positive		, , , , , , , , , , , , , , , , , , , ,	0
	S	ervice Delivery Point (Facility) TB:	0
	S	ervice Delivery Point (Facility) TB:	0



1	
Unknown Age, Male, Negative	
Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
Service Delivery Point (Facility) TB: <1, Negative	2
Service Delivery Point (Facility) TB: <1, Positive	0
Service Delivery Point (Facility) TB: 1-9, Negative	3
Service Delivery Point (Facility) TB: 1-9, Positive	3
Service Delivery Point Agg Age (Facility) TB: <15, Female, Negative	949
Service Delivery Point Agg Age (Facility) TB: <15, Female, Positive	301
Service Delivery Point Agg Age (Facility) TB: <15, Male, Negative	1,434
Service Delivery Point Agg Age (Facility) TB: <15, Male, Positive	768
Service Delivery Point Agg Age (Facility) TB: 15+, Female, Negative	19,693
Service Delivery Point Agg Age (Facility) TB: 15+, Female, Positive	4,974
Service Delivery Point Agg Age (Facility) TB: 15+, Male, Negative	15,958
Service Delivery Point Agg Age (Facility) TB: 15+, Male, Positive	5,071
Service Delivery Point Agg Age (Facility) TB: Unknown Age, Female, Negative	
Service Delivery Point Agg Age (Facility) TB: Unknown Age,	



Female, Positive	
Service Delivery Point Agg Age (Facility) TB: Unknown Age, Male, Negative	
Service Delivery Point Agg Age (Facility) TB: Unknown Age, Male, Positive	
Service Delivery Point (Facility) VMMC: <1, Negative	0
Service Delivery Point (Facility) VMMC: <1, Positive	0
Service Delivery Point (Facility) VMMC: 10-14, Negative	133
Service Delivery Point (Facility) VMMC: 10-14, Positive	0
Service Delivery Point (Facility) VMMC: 15-19, Negative	297
Service Delivery Point (Facility) VMMC: 15-19, Positive	15
Service Delivery Point (Facility) VMMC: 1-9, Negative	153
Service Delivery Point (Facility) VMMC:	3
Service Delivery Point (Facility) VMMC: 20-24, Negative	766
Service Delivery Point (Facility) VMMC: 20-24, Positive	1,006
Service Delivery Point (Facility) VMMC: 25-49, Negative	2,254
Service Delivery Point (Facility) VMMC: 25-49, Positive	549
Service Delivery Point (Facility) VMMC: 50+, Negative	1,344
Service Delivery Point (Facility)	4



VMMC: 50+, Positive	
Service Delivery Point (Facility)	
VMMC: Unknown Age, Negative	
Service Delivery Point (Facility)	
VMMC: Unknown Age, Positive	
Service Delivery Point Agg Age	
(Facility) VMMC: <15, Negative	39
Service Delivery Point Agg Age	
(Facility) VMMC: <15, Positive	0
Service Delivery Point Agg Age	
(Facility) VMMC: 15+, Negative	554
Service Delivery Point Agg Age	00
(Facility) VMMC: 15+, Positive	62
Service Delivery Point Agg Age	
(Facility) VMMC: Unknown Age,	
Negative	
Service Delivery Point Agg Age	
(Facility) VMMC: Unknown Age,	
Positive	
Service Delivery Point (Facility)	
Index: 10-14, Female, Negative	
Service Delivery Point (Facility)	
Index: 10-14, Female, Positive	
Service Delivery Point (Facility)	
Index: 10-14, Male, Negative	
Service Delivery Point (Facility)	
Index: 10-14, Male, Positive	
Service Delivery Point (Facility)	
Index: 15-19, Female, Negative	
Service Delivery Point (Facility)	
Index: 15-19, Female, Positive	
Service Delivery Point (Facility)	
Index: 15-19, Male, Negative	
Service Delivery Point (Facility)	



Index: 15-19, Male, Positive	
Service Delivery Point (Facility)	
Index: 20-24, Female, Negative	
Service Delivery Point (Facility)	
Index: 20-24, Female, Positive	
Service Delivery Point (Facility)	
Index: 20-24, Male, Negative	
Service Delivery Point (Facility)	
Index: 20-24, Male, Positive	
Service Delivery Point (Facility)	
Index: 25-49, Female, Negative	
Service Delivery Point (Facility)	
Index: 25-49, Female, Positive	
Service Delivery Point (Facility)	
Index: 25-49, Male, Negative	
Service Delivery Point (Facility)	
Index: 25-49, Male, Positive	
Service Delivery Point (Facility)	
Index: 50+, Female, Negative	
Service Delivery Point (Facility)	
Index: 50+, Female, Positive	
Service Delivery Point (Facility)	
Index: 50+, Male, Negative	
Service Delivery Point (Facility)	
Index: 50+, Male, Positive	
Service Delivery Point (Facility)	
Index: Unknown Age, Female,	
Negative	
Service Delivery Point (Facility)	
Index: Unknown Age, Female,	
Positive	
Service Delivery Point (Facility)	
Index: Unknown Age, Male,	
Negative	



Service Delivery Point (Facility)	
Index: Unknown Age, Male,	
Positive	
Service Delivery Point (Facility)	
Index: <1, Negative	
Service Delivery Point (Facility)	0
Index: <1, Positive	Ů,
Service Delivery Point (Facility)	
Index: 1-9, Negative	
Service Delivery Point (Facility)	
Index: 1-9, Positive	
Service Delivery Point Agg Age	
(Facility) Index: <15, Female,	
Negative	
Service Delivery Point Agg Age	
(Facility) Index: <15, Female,	
Positive	
Service Delivery Point Agg Age	
(Facility) Index: <15, Male,	
Negative	
Service Delivery Point Agg Age	
(Facility) Index: <15, Male, Positive	
Service Delivery Point Agg Age	
(Facility) Index: 15+, Female,	
Negative	
Service Delivery Point Agg Age	
(Facility) Index: 15+, Female,	
Positive	
Service Delivery Point Agg Age	
(Facility) Index: 15+, Male,	
Negative	
Service Delivery Point Agg Age	
(Facility) Index: 15+, Male, Positive	
Service Delivery Point Agg Age	
(Facility) Index: Unknown Age,	



Female, Negative	
Service Delivery Point Agg Age	
(Facility) Index: Unknown Age,	
Female, Positive	
Service Delivery Point Agg Age	
(Facility) Index: Unknown Age,	
Male, Negative	
Service Delivery Point Agg Age	
(Facility) Index: Unknown Age,	
Male, Positive	
By Key Population: FSW, Negative	
By Key Population: FSW, Positive	
By Key Population: MSM, Negative	
By Key Population: MSM, Positive	
By Key Population: People in	
prisons and other enclosed	26,144
settings, Negative	
By Key Population: People in	
prisons and other enclosed	3,488
settings, Positive	
By Key Population: PWID,	
Negative	
By Key Population: PWID, Positive	
By Key Population: TG, Negative	
By Key Population: TG, Positive	
Service Delivery Point (Community)	
Index Mod: 10-14, Female,	
Negative	
Service Delivery Point (Community)	
Index Mod: 10-14, Female, Positive	
Service Delivery Point (Community)	
Index Mod: 10-14, Male, Negative	
Service Delivery Point (Community)	
Index Mod: 10-14, Male, Positive	



Service Delivery Point (Community)	
Index Mod: 15-19, Female,	
Negative	
Service Delivery Point (Community)	
Index Mod: 15-19, Female, Positive	
Service Delivery Point (Community)	
Index Mod: 15-19, Male, Negative	
Service Delivery Point (Community)	
Index Mod: 15-19, Male, Positive	
Service Delivery Point (Community)	
Index Mod: 20-24, Female,	
Negative	
Service Delivery Point (Community)	
Index Mod: 20-24, Female, Positive	
Service Delivery Point (Community)	
Index Mod: 20-24, Male, Negative	
Service Delivery Point (Community)	
Index Mod: 20-24, Male, Positive	
Service Delivery Point (Community)	
Index Mod: 25-49, Female,	
Negative	
Service Delivery Point (Community)	
Index Mod: 25-49, Female, Positive	
Service Delivery Point (Community)	
Index Mod: 25-49, Male, Negative	
Service Delivery Point (Community)	
Index Mod: 25-49, Male, Positive	
Service Delivery Point (Community)	
Index Mod: 50+, Female, Negative	
Service Delivery Point (Community)	
Index Mod: 50+, Female, Positive	
Service Delivery Point (Community)	
Index Mod: 50+, Male, Negative	
Service Delivery Point (Community)	



Index Mod: 50+, Male, Positive	
Service Delivery Point (Community)	
Index Mod: Unknown Age, Female,	
Negative	
Service Delivery Point (Community)	
Index Mod: Unknown Age, Female, Positive	
Service Delivery Point (Community)	
Index Mod: Unknown Age, Male,	
Negative	
Service Delivery Point (Community)	
Index Mod: Unknown Age, Male,	
Positive	
Service Delivery Point (Community)	
Index Mod: <1, Negative	
Service Delivery Point (Community)	
Index Mod: <1, Positive	
Service Delivery Point (Community) Index Mod: 1-9, Negative	
Service Delivery Point (Community)	
Index Mod: 1-9, Positive	
Service Delivery Point Agg Age	
(Community) Index Mod: <15,	
Female, Negative	
Service Delivery Point Agg Age	
(Community) Index Mod: <15,	
Female, Positive	
Service Delivery Point Agg Age	
(Community) Index Mod: <15, Male, Negative	
Service Delivery Point Agg Age	
(Community) Index Mod: <15,	
Male, Positive	 
Service Delivery Point Agg Age	
(Community) Index Mod: 15+,	



T	
Female, Negative	
Service Delivery Point Agg Age	
(Community) Index Mod: 15+,	
Female, Positive	
Service Delivery Point Agg Age	
(Community) Index Mod: 15+,	
Male, Negative	
Service Delivery Point Agg Age	
(Community) Index Mod: 15+,	
Male, Positive	
Service Delivery Point Agg Age	
(Community) Index Mod: Unknown	
Age, Female, Negative	
Service Delivery Point Agg Age	
(Community) Index Mod: Unknown	
Age, Female, Positive	
Service Delivery Point Agg Age	
(Community) Index Mod: Unknown	
Age, Male, Negative	
Service Delivery Point Agg Age	
(Community) Index Mod: Unknown	
Age, Male, Positive	
Service Delivery Point (Facility)	
ANC: <1, Negative	0
Service Delivery Point (Facility)	
ANC: <1, Positive	0
Service Delivery Point (Facility)	_
ANC: 10-14, Negative	0
Service Delivery Point (Facility)	
ANC: 10-14, Positive	0
Service Delivery Point (Facility)	
ANC: 15-19, Negative	0
Service Delivery Point (Facility)	
ANC: 15-19, Positive	0



	Service Delivery Point (Facility)  NC: 1-9, Negative	0
S	Service Delivery Point (Facility) NC: 1-9, Positive	0
	Service Delivery Point (Facility)  NC: 20-24, Negative	0
	Service Delivery Point (Facility) NC: 20-24, Positive	0
	Service Delivery Point (Facility) NC: 25-49, Negative	0
	Service Delivery Point (Facility) NC: 25-49, Positive	0
	Service Delivery Point (Facility) NC: 50+, Negative	0
	Service Delivery Point (Facility) NC: 50+, Positive	0
	Service Delivery Point (Facility)  NC: Unknown Age, Negative	
	Service Delivery Point (Facility)  NC: Unknown Age, Positive	
	Service Delivery Point Agg Age Facility) ANC: <15, Negative	
	Service Delivery Point Agg Age Facility) ANC: <15, Positive	
	Service Delivery Point Agg Age Facility) ANC: 15+, Negative	
	Service Delivery Point Agg Age Facility) ANC: 15+, Positive	
(I	Service Delivery Point Agg Age Facility) ANC: Unknown Age, legative	
(I	Service Delivery Point Agg Age Facility) ANC: Unknown Age, Positive	



Service Delivery Point (Facility) VCT: 10-14, Female, Negative	12
Service Delivery Point (Facility) VCT: 10-14, Female, Positive	0
Service Delivery Point (Facility) VCT: 10-14, Male, Negative	6
Service Delivery Point (Facility) VCT: 10-14, Male, Positive	0
Service Delivery Point (Facility) VCT: 15-19, Female, Negative	57
Service Delivery Point (Facility) VCT: 15-19, Female, Positive	8
Service Delivery Point (Facility) VCT: 15-19, Male, Negative	27
Service Delivery Point (Facility) VCT: 15-19, Male, Positive	2
Service Delivery Point (Facility) VCT: 20-24, Female, Negative	399
Service Delivery Point (Facility) VCT: 20-24, Female, Positive	71
Service Delivery Point (Facility) VCT: 20-24, Male, Negative	262
Service Delivery Point (Facility) VCT: 20-24, Male, Positive	39
Service Delivery Point (Facility) VCT: 25-49, Female, Negative	1,151
Service Delivery Point (Facility) VCT: 25-49, Female, Positive	156
Service Delivery Point (Facility) VCT: 25-49, Male, Negative	742
Service Delivery Point (Facility) VCT: 25-49, Male, Positive	95
 Service Delivery Point (Facility) VCT: 50+, Female, Negative	143



Service Delivery Point (Facility) VCT: 50+, Female, Positive	11
Service Delivery Point (Facility) VCT: 50+, Male, Negative	93
Service Delivery Point (Facility) VCT: 50+, Male, Positive	5
Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
Service Delivery Point (Facility) VCT: Unknown Age, Male, Negative	0
Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
Service Delivery Point (Facility) VCT: <1, Negative	2
Service Delivery Point (Facility) VCT: <1, Positive	1
Service Delivery Point (Facility) VCT: 1-9, Negative	22
Service Delivery Point (Facility) VCT: 1-9, Positive	0
Service Delivery Point Agg Age (Facility) VCT: <15, Female, Negative	1,511
Service Delivery Point Agg Age (Facility) VCT: <15, Female, Positive	75
Service Delivery Point Agg Age (Facility) VCT: <15, Male, Negative	3,729
Service Delivery Point Agg Age	204



(Facility) VCT: <15, Male, Positive	
Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative	20,524
Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive	2,170
Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative	19,596
Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive	2,138
Service Delivery Point Agg Age (Facility) VCT: Unknown Age, Female, Negative	
Service Delivery Point Agg Age (Facility) VCT: Unknown Age, Female, Positive	
Service Delivery Point Agg Age (Facility) VCT: Unknown Age, Male, Negative	
Service Delivery Point Agg Age (Facility) VCT: Unknown Age, Male, Positive	
Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	
Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	
Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	
Service Delivery Point (Community) VCT Mod: 10-14, Male, Positive	
Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	_
Service Delivery Point (Community)	



VCT Mod: 15-19, Female, Positive	
Service Delivery Point (Community)	
VCT Mod: 15-19, Male, Negative	
Service Delivery Point (Community)	
VCT Mod: 15-19, Male, Positive	
Service Delivery Point (Community)	
VCT Mod: 20-24, Female, Negative	
Service Delivery Point (Community)	
VCT Mod: 20-24, Female, Positive	
Service Delivery Point (Community)	
VCT Mod: 20-24, Male, Negative	
Service Delivery Point (Community)	
VCT Mod: 20-24, Male, Positive	
Service Delivery Point (Community)	
VCT Mod: 25-49, Female, Negative	
Service Delivery Point (Community)	
VCT Mod: 25-49, Female, Positive	
Service Delivery Point (Community)	
VCT Mod: 25-49, Male, Negative	
Service Delivery Point (Community)	
VCT Mod: 25-49, Male, Positive	
Service Delivery Point (Community)	
VCT Mod: 50+, Female, Negative	
Service Delivery Point (Community)	
VCT Mod: 50+, Female, Positive	
Service Delivery Point (Community)	
VCT Mod: 50+, Male, Negative	
Service Delivery Point (Community)	
VCT Mod: 50+, Male, Positive	
Service Delivery Point (Community)	
VCT Mod: Unknown Age, Female,	
Negative	
Service Delivery Point (Community)	
VCT Mod: Unknown Age, Female,	



Positive	
Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Negative	
Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Positive	
Service Delivery Point (Community) VCT Mod: <1, Negative	
Service Delivery Point (Community) VCT Mod: <1, Positive	
Service Delivery Point (Community) VCT Mod: 1-9, Negative	
Service Delivery Point (Community) VCT Mod: 1-9, Positive	
Service Delivery Point Agg Age (Community) VCT Mod: <15, Female, Negative	
Service Delivery Point Agg Age (Community) VCT Mod: <15, Female, Positive	
Service Delivery Point Agg Age (Community) VCT Mod: <15, Male, Negative	
Service Delivery Point Agg Age (Community) VCT Mod: <15, Male, Positive	
Service Delivery Point Agg Age (Community) VCT Mod: 15+, Female, Negative	
Service Delivery Point Agg Age (Community) VCT Mod: 15+, Female, Positive	
Service Delivery Point Agg Age (Community) VCT Mod: 15+, Male,	



	Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: 15+, Male, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: Unknown Age, Male, Positive	
	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	99 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	152,037
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	154,059
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status,	



	I
during the reporting period)	
Age/Sex: Male 10-14 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 15-19 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 20-24 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 25-49 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 50+ (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 10-14	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 15-19	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	



Age/Sex: Female 20-24 (Numerator: Number of registered	
new and relapsed TB cases with documented HIV status, during the	
reporting period)	
Age/Sex: Female 25-49	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 50+ (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Male <15	
(Numerator: Number of registered	
new and relapsed TB cases with	5,220
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Male 15+	
(Numerator: Number of registered	
new and relapsed TB cases with	60,747
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Female <15	
(Numerator: Number of registered	
new and relapsed TB cases with	6,056
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Female 15+	
(Numerator: Number of registered	
new and relapsed TB cases with	79,931
documented HIV status, during the	
reporting period)	
 Result: Known HIV positive at	
·	<del></del>



parties entry	
service entry	
Result: New HIV positive	
Result: HIV Negative	
Age/Sex: <1 (Denominator: Total	
number of registered new and	
relapsed TB cases, during the	
reporting period.)	
Age/Sex: 1-9 (Denominator: Total	
number of registered new and	
relapsed TB cases, during the	
reporting period.)	
Age/Sex: Male 10-14	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period.)	
Age/Sex: Male 15-19	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period.)	
Age/Sex: Male 20-24	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period.)	
Age/Sex: Male 25-49	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period.)	
Age/Sex: Male 50+ (Denominator:	
Total number of registered new and	
relapsed TB cases, during the	
reporting period.)	
Age/Sex: Female 10-14	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period.)	



	Age/Sex: Female 15-19	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period.)	
	Age/Sex: Female 20-24	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period.)	
	Age/Sex: Female 25-49	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period.)	
	Age/Sex: Female 50+	
	(Denominator: Total number of	
	registered new and relapsed TB	
	cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15	
	(Denominator: Total number of	
	registered new and relapsed TB	5,318
	cases, during the reporting period)	
	Aggregated Age/Sex: Male 15+	
	(Denominator: Total number of	
	registered new and relapsed TB	61,609
	cases, during the reporting period)	
	Aggregated Age/Sex: Female <15	
	(Denominator: Total number of	
	registered new and relapsed TB	6,213
	cases, during the reporting period)	
	Aggregated Age/Sex: Female 15+	
	(Denominator: Total number of	
	registered new and relapsed TB	80,687
	cases, during the reporting period)	
	TB_STAT_TA Percentage of	
TB_STAT_TA	registered new and relapsed TB	97 %
		J. /U



Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	40,020
Total number of registered new and relapsed TB cases, during the reporting period.	41,306
Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,352
Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,230
Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	20,514
Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	18,618
Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
Age/Sex: Male 10-14 (Numerator: Number of registered new and	



relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 15-19 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 20-24 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 25-49 (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Male 50+ (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 10-14	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 15-19	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 20-24	
(Numerator: Number of registered	
new and relapsed TB cases with	



documented HIV status, during the	
reporting period)	
Age/Sex: Female 25-49	
(Numerator: Number of registered	
new and relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Age/Sex: Female 50+ (Numerator:	
Number of registered new and	
relapsed TB cases with	
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Male <15	
(Numerator: Number of registered	
new and relapsed TB cases with	1,175
documented HIV status, during the	, -
reporting period)	
Aggregated Age/Sex: Male 15+	
(Numerator: Number of registered	
new and relapsed TB cases with	17,852
documented HIV status, during the	17,032
reporting period)	
Aggregated Age/Sex: Female <15	
(Numerator: Number of registered	4.004
new and relapsed TB cases with	1,301
documented HIV status, during the	
reporting period)	
Aggregated Age/Sex: Female 15+	
(Numerator: Number of registered	
new and relapsed TB cases with	19,894
documented HIV status, during the	
reporting period)	
Result: Known HIV positive at	
service entry	
Result: New HIV positive	
Total Title Poolato	



	1
Result: HIV negative	
Age/Sex: <1 (Denominator: Total	
number of registered new and	
relapsed TB cases, during the	
reporting period)	
Age/Sex: 1-9 (Denominator: Total	
number of registered new and	
relapsed TB cases, during the	
reporting period)	
Age/Sex: Male 10-14	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period)	
Age/Sex: Male 15-19	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period)	
Age/Sex: Male 20-24	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period)	
Age/Sex: Male 25-49	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period)	
Age/Sex: Male 50+ (Denominator:	
Total number of registered new and	
relapsed TB cases, during the	
reporting period)	
Age/Sex: Female 10-14	
(Denominator: Total number of	
registered new and relapsed TB	
cases, during the reporting period)	
Age/Sex: Female 15-19	
(Denominator: Total number of	



registered new and relapsed TB cases, during the reporting period)  Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Number of individuals who received T&C services for HIV and received their test results during the past 12 months  By Test Result: Positive  Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative  Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive  Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	cases, during the reporting period)  Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Number of individuals who received T&C services for HIV and received
Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Number of individuals who received T&C services for HIV and received their test results during the past 12 months  By Test Result: Positive 787,902  Service Delivery Point (Community) Homebased testing: 10-14, 5,011 Female, Negative  Service Delivery Point (Community) Homebased testing: 10-14, 410 Female, Positive	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Number of individuals who received T&C services for HIV and received
(Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Number of individuals who received T&C services for HIV and received their test results during the past 12 months  By Test Result: Positive 787,902  Service Delivery Point (Community) Homebased testing: 10-14, 5,011 Female, Negative  Service Delivery Point (Community) Homebased testing: 10-14, 410 Female, Positive	(Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Number of individuals who received T&C services for HIV and received
registered new and relapsed TB cases, during the reporting period)  Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Number of individuals who received T&C services for HIV and received their test results during the past 12 months  By Test Result: Positive 787,902  Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative  Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	registered new and relapsed TB cases, during the reporting period)  Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Number of individuals who received T&C services for HIV and received
cases, during the reporting period)  Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Number of individuals who received T&C services for HIV and received their test results during the past 12 months  By Test Result: Positive 787,902  Service Delivery Point (Community) Homebased testing: 10-14, 5,011 Female, Negative  Service Delivery Point (Community) Homebased testing: 10-14, 410 Female, Positive	cases, during the reporting period)  Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Number of individuals who received T&C services for HIV and received
Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Number of individuals who received T&C services for HIV and received their test results during the past 12 months  By Test Result: Positive 787,902  Service Delivery Point (Community) Homebased testing: 10-14, 5,011 Female, Negative  Service Delivery Point (Community) Homebased testing: 10-14, 410 Female, Positive	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Number of individuals who received T&C services for HIV and received
(Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Number of individuals who received T&C services for HIV and received their test results during the past 12 months  By Test Result: Positive 787,902  Service Delivery Point (Community) Homebased testing: 10-14, 5,011  Female, Negative  Service Delivery Point (Community) Homebased testing: 10-14, 410  Female, Positive	(Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Number of individuals who received T&C services for HIV and received
registered new and relapsed TB cases, during the reporting period)  Number of individuals who received T&C services for HIV and received their test results during the past 12 months  By Test Result: Positive  Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative  Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative  Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	registered new and relapsed TB cases, during the reporting period)  Number of individuals who received T&C services for HIV and received
cases, during the reporting period)  Number of individuals who received T&C services for HIV and received their test results during the past 12 months  By Test Result: Positive  Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative  Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative  Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	cases, during the reporting period)  Number of individuals who received  T&C services for HIV and received
Number of individuals who received T&C services for HIV and received their test results during the past 12 months  By Test Result: Positive  Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative  Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive  17,968,212  7,968,212	Number of individuals who received  T&C services for HIV and received
T&C services for HIV and received their test results during the past 12 months  By Test Result: Positive 787,902  Service Delivery Point (Community) Homebased testing: 10-14, 5,011 Female, Negative  Service Delivery Point (Community) Homebased testing: 10-14, 410 Female, Positive	T&C services for HIV and received
their test results during the past 12 months  By Test Result: Positive 787,902  Service Delivery Point (Community) Homebased testing: 10-14, 5,011  Female, Negative  Service Delivery Point (Community) Homebased testing: 10-14, 410 Female, Positive	T&C services for HIV and received
their test results during the past 12 months  By Test Result: Positive 787,902  Service Delivery Point (Community) Homebased testing: 10-14, 5,011 Female, Negative  Service Delivery Point (Community) Homebased testing: 10-14, 410 Female, Positive	7 000 040
By Test Result: Positive 787,902  Service Delivery Point (Community) Homebased testing: 10-14, 5,011 Female, Negative  Service Delivery Point (Community) Homebased testing: 10-14, 410 Female, Positive	their test results during the past 12
Service Delivery Point (Community) Homebased testing: 10-14, 5,011 Female, Negative Service Delivery Point (Community) Homebased testing: 10-14, 410 Female, Positive	months
Homebased testing: 10-14, 5,011  Female, Negative  Service Delivery Point (Community)  Homebased testing: 10-14, 410  Female, Positive	By Test Result: Positive 787,902
Female, Negative  Service Delivery Point (Community)  Homebased testing: 10-14, 410  Female, Positive	Service Delivery Point (Community)
Service Delivery Point (Community) Homebased testing: 10-14, 410 Female, Positive	Homebased testing: 10-14, 5,011
Homebased testing: 10-14, 410 Female, Positive	Female, Negative
Female, Positive	Service Delivery Point (Community)
	Homebased testing: 10-14, 410
Comition Delivery Delivery (Commercial)	Female, Positive
Service Delivery Point (Community)	Service Delivery Point (Community)
HTC_TST_DSD Homebased testing: 10-14, Male, 181	D Homebased testing: 10-14, Male, 181
Negative	Negative
Service Delivery Point (Community)	Service Delivery Point (Community)
Homebased testing: 10-14, Male, 6	Homebased testing: 10-14, Male, 6
Positive	Positive
Service Delivery Point (Community)	
Homebased testing: 15-19, 25,003	Service Delivery Point (Community)
Female, Negative	· · · · · · · · · · · · · · · · · · ·
Service Delivery Point (Community)	Homebased testing: 15-19, 25,003
Homebased testing: 15-19, 2,161	Homebased testing: 15-19, 25,003 Female, Negative
Female, Positive	Homebased testing: 15-19, 25,003  Female, Negative  Service Delivery Point (Community)
Service Delivery Point (Community)	Homebased testing: 15-19, 25,003  Female, Negative  Service Delivery Point (Community)  Homebased testing: 15-19, 2,161
Homebased testing: 15-19, Male,	Homebased testing: 15-19, 25,003  Female, Negative  Service Delivery Point (Community)  Homebased testing: 15-19, 2,161  Female, Positive  Service Delivery Point (Community)



Negative	
Service Delivery Point (Community) Homebased testing: 15-19, Male, Positive	38
Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	18,612
Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	1,585
Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	7,896
Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	684
Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative	1,289
Service Delivery Point (Community) Homebased testing: 25-49, Female, Positive	109
Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	12,052
Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	1,026
Service Delivery Point (Community) Homebased testing: 50+, Female, Negative	396
Service Delivery Point (Community) Homebased testing: 50+, Female, Positive	35
Service Delivery Point (Community)	225



	_
Homebased testing: 50+, Male, Negative	
Service Delivery Point (Community Homebased testing: 50+, Male, Positive	20
Service Delivery Point (Community Homebased testing: Unknown Age Female, Negative	· ·
Service Delivery Point (Community Homebased testing: Unknown Age Female, Positive	
Service Delivery Point (Community Homebased testing: Unknown Age Male, Negative	
Service Delivery Point (Community Homebased testing: Unknown Age Male, Positive	
Service Delivery Point (Community Homebased testing: <1, Negative	1,886
Service Delivery Point (Community Homebased testing: <1, Positive	y) 21
Service Delivery Point (Community Homebased testing: 1-9, Negative	´`l 13.213
Service Delivery Point (Community Homebased testing: 1-9, Positive	129
Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative	32,271
Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive	402
Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative	20,577
Service Delivery Point by Agg Age	214



(Community) Homebased testing: <15, Male, Positive	
Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative	163,455
Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive	14,351
Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Negative	107,371
Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Positive	9,479
Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Female, Negative	
Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Female, Positive	
Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Male, Negative	
Service Delivery Point by Agg Age (Community) by Aggregated Age: Homebased testing: Unknown Age, Male, Positive	
Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,685
Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	75
Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	1,521
Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	57



Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	2,262
Service Delivery Point (Facility)	308
Inpatient: 15-19, Female, Positive	
Service Delivery Point (Facility)	1 500
Inpatient: 15-19, Male, Negative	1,509
Service Delivery Point (Facility)	207
Inpatient: 15-19, Male, Positive	207
Service Delivery Point (Facility)	0.740
Inpatient: 20-24, Female, Negative	2,716
Service Delivery Point (Facility)	070
Inpatient: 20-24, Female, Positive	370
Service Delivery Point (Facility)	4.000
Inpatient: 20-24, Male, Negative	1,809
Service Delivery Point (Facility)	0.40
Inpatient: 20-24, Male, Positive	246
Service Delivery Point (Facility)	0.007
Inpatient: 25-49, Female, Negative	3,897
Service Delivery Point (Facility)	500
Inpatient: 25-49, Female, Positive	530
Service Delivery Point (Facility)	0.504
Inpatient: 25-49, Male, Negative	2,594
Service Delivery Point (Facility)	055
Inpatient: 25-49, Male, Positive	355
Service Delivery Point (Facility)	477
Inpatient: 50+, Female, Negative	177
Service Delivery Point (Facility)	00
Inpatient: 50+, Female, Positive	23
Service Delivery Point (Facility)	400
Inpatient: 50+, Male, Negative	120
Service Delivery Point (Facility)	40
Inpatient: 50+, Male, Positive	18
Service Delivery Point (Facility)	
Inpatient: Unknown Age, Female,	



Negative	
Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	
Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	
Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	
Service Delivery Point (Facility) Inpatient: <1, Negative	1,183
Service Delivery Point (Facility) Inpatient: <1, Positive	105
Service Delivery Point (Facility) Inpatient: 1-9, Negative	3,828
Service Delivery Point (Facility) Inpatient: 1-9, Positive	225
Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	10,240
Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	442
Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	9,906
Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	431
Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	92,353
Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female,	9,109



Positive	
Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	62,616
Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	6,356
Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	
Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	
Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	
Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	
Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	17,123
Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	1,525
Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	79
Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	6
Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	92,553
Service Delivery Point (Community)	8,248



Mobile Testing: 15-19, Female, Positive	
Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	664
Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	72
Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	61,429
Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	5,525
Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	25,467
Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	2,303
Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	3,280
Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	338
Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	38,666
Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	3,509
Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	718



Service Delivery Point (Community) Mobile Testing: 50+, Female,	80
Positive	
Service Delivery Point (Community)	
Mobile Testing: 50+, Male,	406
Negative	
Service Delivery Point (Community)	
Mobile Testing: 50+, Male, Positive	44
Service Delivery Point (Community)	
Mobile Testing: Unknown Age,	0
Female, Negative	
Service Delivery Point (Community)	
Mobile Testing: Unknown Age,	0
Female, Positive	
Service Delivery Point (Community)	
Mobile Testing: Unknown Age,	0
Male, Negative	
Service Delivery Point (Community)	
Mobile Testing: Unknown Age,	0
Male, Positive	
Service Delivery Point (Community)	0
Mobile Testing: <1, Negative	
Service Delivery Point (Community)	0
Mobile Testing: <1, Positive	•
Service Delivery Point (Community)	0
Mobile Testing: 1-9, Negative	0
Service Delivery Point (Community)	0
Mobile Testing: 1-9, Positive	J
Service Delivery Point by Agg	
Age(Community) Mobile Testing:	3,495
<15, Female, Negative	
Service Delivery Point by Agg	
Age(Community) Mobile Testing:	389
<15, Female, Positive	
Service Delivery Point by Agg	0



Age(Community) Mobile Testing:	
<15, Male, Negative	
Service Delivery Point by Agg	
Age(Community) Mobile Testing:	0
<15, Male, Positive	
Service Delivery Point by Agg	
Age(Community) Mobile Testing:	278,005
15+, Female, Negative	
Service Delivery Point by Agg	
Age(Community) Mobile Testing:	31,171
15+, Female, Positive	
Service Delivery Point by Agg	
Age(Community) Mobile Testing:	201,891
15+, Male, Negative	
Service Delivery Point by Agg	
Age(Community) Mobile Testing:	22,786
15+, Male, Positive	
Service Delivery Point by Agg	
Age(Community) Mobile Testing:	0
Unknown Age, Female, Negative	
Service Delivery Point by Agg	
Age(Community) Mobile Testing:	0
Unknown Age, Female, Positive	
Service Delivery Point by Agg	
Age(Community) Mobile Testing:	0
Unknown Age, Male, Negative	
Service Delivery Point by Agg	
Age(Community) Mobile Testing:	0
Unknown Age, Male, Positive	
Service Delivery Point (Facility)	
Other PITC: 10-14, Female,	12,620
Negative	
Service Delivery Point (Facility)	
Other PITC: 10-14, Female,	1,427
Positive	



	ery Point (Facility) 0-14, Male, Negative	10,203
	ery Point (Facility) 0-14, Male, Positive	1,136
Service Delive Other PITC: 19 Negative	ery Point (Facility) 5-19, Female,	82,639
	ery Point (Facility) 5-19, Female,	11,553
	ery Point (Facility) 5-19, Male, Negative	59,345
	ery Point (Facility) 5-19, Male, Positive	7,800
Service Delive Other PITC: 20 Negative	ery Point (Facility) 0-24, Female,	136,227
Service Delive Other PITC: 20 Positive	ery Point (Facility) 0-24, Female,	18,672
	ery Point (Facility) 0-24, Male, Negative	79,173
	ery Point (Facility) 0-24, Male, Positive	11,011
Service Delive Other PITC: 29 Negative	ery Point (Facility) 5-49, Female,	281,837
Service Delive Other PITC: 29 Positive	ery Point (Facility) 5-49, Female,	41,906
	ery Point (Facility) 5-49, Male, Negative	188,392
	ery Point (Facility) 5-49, Male, Positive	28,468



Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	41,428
Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	5,779
Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	25,488
Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	3,748
Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
Service Delivery Point (Facility)Other PITC: <1, Negative	7,096
Service Delivery Point (Facility) Other PITC: <1, Positive	833
Service Delivery Point (Facility) Other PITC: 1-9, Negative	26,529
Service Delivery Point (Facility) Other PITC: 1-9, Positive	3,195
Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	118,560
Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	10,421



(	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	148,249
; (	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male,	11,402
(	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	2,121,744
(	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	226,056
(	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	1,435,136
(	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	158,105
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	
(	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	
(	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	
(	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	
	Service Delivery Point (Community) Other: 10-14, Female, Positive	



Service Delivery Point (Community)	
Other: 10-14, Male, Negative	
Service Delivery Point (Community)	
Other: 10-14, Male, Positive	
Service Delivery Point (Community)	
Other: 15-19, Female, Negative	
Service Delivery Point (Community)	
Other: 15-19, Female, Positive	
Service Delivery Point (Community)	
Other: 15-19, Male, Negative	
Service Delivery Point (Community)	
Other: 15-19, Male, Positive	
Service Delivery Point (Community)	
Other: 20-24, Female, Negative	
Service Delivery Point (Community)	
Other: 20-24, Female, Positive	
Service Delivery Point (Community)	
Other: 20-24, Male, Negative	
Service Delivery Point (Community)	
Other: 20-24, Male, Positive	
Service Delivery Point (Community)	
Other: 25-49, Female, Negative	
Service Delivery Point (Community)	
Other: 25-49, Female, Positive	
Service Delivery Point (Community)	
Other: 25-49, Male, Negative	
Service Delivery Point (Community)	
Other: 25-49, Male, Positive	
Service Delivery Point (Community)	
Other: 50+, Female, Negative	
Service Delivery Point (Community)	
Other: 50+, Female, Positive	
Service Delivery Point (Community)	
Other: 50+, Male, Negative	



Service Delivery Point (Community)	
Other: 50+, Male, Positive	
Service Delivery Point (Community)	
Other: Unknown Age, Female,	
Negative	
Service Delivery Point (Community)	
Other: Unknown Age, Female,	
Positive	
Service Delivery Point (Community)	
Other: Unknown Age, Male,	
Negative	
Service Delivery Point (Community)	
Other: Unknown Age, Male,	
Positive	
Service Delivery Point (Community)	
Other: <1, Negative	
Service Delivery Point (Community)	
Other: <1, Positive	
Service Delivery Point (Community)	
Other: 1-9, Negative	
Service Delivery Point (Community)	
Other: 1-9, Positive	
Service Delivery Point by Agg Age	
(Community) Other: <15, Female,	179
Negative	
Service Delivery Point by Agg Age	
(Community) Other: <15, Female,	4
Positive	
Service Delivery Point by Agg Age	
(Community) Other: <15, Male,	119
Negative	
Service Delivery Point by Agg Age	
(Community) Other: <15, Male,	4
Positive	
Service Delivery Point by Agg Age	43,829



(Community) Other: 15+, Female, Negative	
Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	4,834
Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	65,172
Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	8,709
Service Delivery Point by Agg Age (Community) Other: Unknown Age, Female, Negative	
Service Delivery Point by Agg Age (Community) Other: Unknown Age, Female, Positive	
Service Delivery Point by Agg Age (Community) Other: Unknown Age, Male, Negative	
Service Delivery Point by Agg Age (Community) Other: Unknown Age, Male, Positive	
Service Delivery Point (Facility) Pediatric : <5 Negative	176,896
Service Delivery Point (Facility) Pediatric : <5 Positive	6,996
Service Delivery Point (Facility) TB: 10-14, Female, Negative	69
Service Delivery Point (Facility) TB: 10-14, Female, Positive	72
Service Delivery Point (Facility) TB: 10-14, Male, Negative	62
Service Delivery Point (Facility) TB: 10-14, Male, Positive	63



Service Delivery Point (Facility) TB: 15-19, Female, Negative	1,401
Service Delivery Point (Facility) TB: 15-19, Female, Positive	317
Service Delivery Point (Facility) TB: 15-19, Male, Negative	962
Service Delivery Point (Facility) TB: 15-19, Male, Positive	267
Service Delivery Point (Facility) TB: 20-24, Female, Negative	1,908
Service Delivery Point (Facility) TB: 20-24, Female, Positive	602
Service Delivery Point (Facility) TB: 20-24, Male, Negative	1,266
Service Delivery Point (Facility) TB: 20-24, Male, Positive	374
Service Delivery Point (Facility) TB: 25-49, Female, Negative	4,389
Service Delivery Point (Facility) TB: 25-49, Female, Positive	1,783
Service Delivery Point (Facility) TB: 25-49, Male, Negative	3,386
Service Delivery Point (Facility) TB: 25-49, Male, Positive	1,346
Service Delivery Point (Facility) TB: 50+, Female, Negative	397
Service Delivery Point (Facility) TB: 50+, Female, Positive	400
Service Delivery Point (Facility) TB: 50+, Male, Negative	274
Service Delivery Point (Facility) TB: 50+, Male, Positive	218
Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0



Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
Service Delivery Point (Facility) TB: <1, Negative	4
Service Delivery Point (Facility) TB: <1, Positive	4
Service Delivery Point (Facility) TB: 1-9, Negative	72
Service Delivery Point (Facility) TB: 1-9, Positive	161
Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	2,434
Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	682
Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	2,666
Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	868
Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	60,063
Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	14,136
Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	45,385
Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	13,715
Service Delivery Point by Agg Age (Facility) TB: Unknown Age,	29



Female, Negative	
Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Positive	
Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Negative	450
Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Positive	
Service Delivery Point (Facility) VMMC: <1, Negative	0
Service Delivery Point (Facility)  VMMC: <1, Positive	0
Service Delivery Point (Facility) VMMC: 10-14, Negative	30
Service Delivery Point (Facility) VMMC: 10-14, Positive	0
Service Delivery Point (Facility) VMMC: 15-19, Negative	385
Service Delivery Point (Facility) VMMC: 15-19, Positive	12
Service Delivery Point (Facility) VMMC: 1-9, Negative	3
Service Delivery Point (Facility) VMMC: 1-9, Positive	0
Service Delivery Point (Facility) VMMC: 20-24, Negative	965
Service Delivery Point (Facility) VMMC: 20-24, Positive	38
Service Delivery Point (Facility) VMMC: 25-49, Negative	6,219
Service Delivery Point (Facility) VMMC: 25-49, Positive	828



Service Delivery Point (Facility) VMMC: 50+, Negative	1,588
Service Delivery Point (Facility) VMMC: 50+, Positive	196
Service Delivery Point (Facility) VMMC: Unknown Age, Negative	0
Service Delivery Point (Facility) VMMC: Unknown Age, Positive	0
Service Delivery Point (Facility) VMMC: <15, Negative	2,026
Service Delivery Point by Agg Age (Facility) VMMC: <15, Positive	35
Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative	7,420
Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive	193
Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Negative	
Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Positive	
Service Delivery Point (Facility) Index: 10-14, Female, Negative	
Service Delivery Point (Facility) Index: 10-14, Female, Positive	
Service Delivery Point (Facility) Index: 10-14, Male, Negative	
Service Delivery Point (Facility) Index: 10-14, Male, Positive	
Service Delivery Point (Facility) Index: 15-19, Female, Negative	
Service Delivery Point (Facility) Index: 15-19, Female, Positive	



Service Delivery Point (Facility)	
Index: 15-19, Male, Negative	
Service Delivery Point (Facility)	
Index: 15-19, Male, Positive	
Service Delivery Point (Facility)	
Index: 20-24, Female, Negative	
Service Delivery Point (Facility)	
Index: 20-24, Female, Positive	
Service Delivery Point (Facility)	
Index: 20-24, Male, Negative	
Service Delivery Point (Facility)	
Index: 20-24, Male, Positive	
Service Delivery Point (Facility)	
Index: 25-49, Female, Negative	
Service Delivery Point (Facility)	
Index: 25-49, Female, Positive	
Service Delivery Point (Facility)	
Index: 25-49, Male, Negative	
Service Delivery Point (Facility)	
Index: 25-49, Male, Positive	
Service Delivery Point (Facility)	
Index: 50+, Female, Negative	
Service Delivery Point (Facility)	
Index: 50+, Female, Positive	
Service Delivery Point (Facility)	
Index: 50+, Male, Negative	
Service Delivery Point (Facility)	
Index: 50+, Male, Positive	
Service Delivery Point (Facility)	
Index: Unknown Age, Female,	
Negative	
Service Delivery Point (Facility)	
Index: Unknown Age, Female,	
Positive	



Service Delivery Point (Facility)	
Index: Unknown Age, Male,	
Negative	
Service Delivery Point (Facility)	
Index: Unknown Age, Male,	
Positive	
Service Delivery Point (Facility)	
Index: <1, Negative	
Service Delivery Point (Facility)	
Index: <1, Positive	
Service Delivery Point (Facility)	
Index: 1-9, Negative	
Service Delivery Point (Facility)	
Index: 1-9, Positive	
Service Delivery Point Agg Age	
(Facility) Index: <15, Female,	
Negative	
Service Delivery Point Agg Age	
(Facility) Index: <15, Female,	
Positive	
Service Delivery Point Agg Age	
(Facility) Index: <15, Male,	
Negative	
Service Delivery Point Agg Age	
(Facility) Index: <15, Male, Positive	
Service Delivery Point Agg Age	
(Facility) Index: 15+, Female,	
Negative	
Service Delivery Point Agg Age	
(Facility) Index: 15+, Female,	
Positive	
Service Delivery Point Agg Age	
(Facility) Index: 15+, Male,	
Negative	
Service Delivery Point Agg Age	



18,657
3,064
48,796
6,819
8,138
1,112
24
0
9,390



Negative	
Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	741
Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	70
Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	1
Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	46,051
Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	3,626
Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	217
Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	18
Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	37,589
Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	3,002
Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	16,162
Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	1,290
Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	765
Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	66
Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	23,459
Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	1,953



Service Delivery Point (Community) Index Mod: 50+, Female, Negative	264
Service Delivery Point (Community) Index Mod: 50+, Female, Positive	22
Service Delivery Point (Community) Index Mod: 50+, Male, Negative	150
Service Delivery Point (Community) Index Mod: 50+, Male, Positive	12
Service Delivery Point (Community) Index Mod: Unknown Age, Female, Negative	51
Service Delivery Point (Community) Index Mod: Unknown Age, Female, Positive	1
Service Delivery Point (Community) Index Mod: Unknown Age, Male, Negative	0
Service Delivery Point (Community) Index Mod: Unknown Age, Male, Positive	0
Service Delivery Point (Community) Index Mod: <1, Negative	444
Service Delivery Point (Community) Index Mod: <1, Positive	11
Service Delivery Point (Community) Index Mod: 1-9, Negative	2,556
Service Delivery Point (Community) Index Mod: 1-9, Positive	46
Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Negative	7,920
Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Positive	163



Service Delivery Point by Agg Age (Community) Index Mod: <15, 5,550  Male, Negative  Service Delivery Point by Agg Age (Community) Index Mod: <15, 102  Male, Positive  Service Delivery Point by Agg Age (Community) Index Mod: 15+, 173,722  Female, Negative  Service Delivery Point by Agg Age (Community) Index Mod: 15+, 15,115  Female, Positive  Service Delivery Point by Agg Age (Community) Index Mod: 15+, 120,963  Male, Negative  Service Delivery Point by Agg Age (Community) Index Mod: 15+, 120,963  Male, Negative  Service Delivery Point by Agg Age (Community) Index Mod: 15+, 10,601
Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Positive  Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative  Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive  Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive  Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative  Service Delivery Point by Agg Age (Community) Index Mod: 15+,  Male, Negative  Service Delivery Point by Agg Age (Community) Index Mod: 15+,  10,601
Service Delivery Point by Agg Age (Community) Index Mod: 15+, 173,722  Female, Negative  Service Delivery Point by Agg Age (Community) Index Mod: 15+, 15,115  Female, Positive  Service Delivery Point by Agg Age (Community) Index Mod: 15+, 120,963  Male, Negative  Service Delivery Point by Agg Age (Community) Index Mod: 15+, 10,601
(Community) Index Mod: 15+, 15,115  Female, Positive  Service Delivery Point by Agg Age (Community) Index Mod: 15+, 120,963  Male, Negative  Service Delivery Point by Agg Age (Community) Index Mod: 15+, 10,601
(Community) Index Mod: 15+, 120,963  Male, Negative  Service Delivery Point by Agg Age (Community) Index Mod: 15+, 10,601
(Community) Index Mod: 15+, 10,601
Male, Positive
Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Negative
Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Positive
Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Negative
Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Positive
Service Delivery Point (Facility)  ANC: <1, Negative
Service Delivery Point (Facility)  ANC: <1, Positive
Service Delivery Point (Facility) 0



ANC: 10-14, Negative	
Service Delivery Point (Facility) ANC: 10-14, Positive	0
Service Delivery Point (Facility) ANC: 15-19, Negative	0
Service Delivery Point (Facility) ANC: 15-19, Positive	0
Service Delivery Point (Facility) ANC: 1-9, Negative	0
Service Delivery Point (Facility) ANC: 1-9, Positive	0
Service Delivery Point (Facility) ANC: 20-24, Negative	0
Service Delivery Point (Facility) ANC: 20-24, Positive	0
Service Delivery Point (Facility) ANC: 25-49, Negative	0
Service Delivery Point (Facility) ANC: 25-49, Positive	0
Service Delivery Point (Facility) ANC: 50+, Negative	0
Service Delivery Point (Facility) ANC: 50+, Positive	0
Service Delivery Point (Facility) ANC: Unknown Age, Negative	
Service Delivery Point (Facility) ANC: Unknown Age, Positive	
Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	
Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	
Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	
Service Delivery Point by Agg Age	



(Facility) ANC: 15+, Positive	
Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	
Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	
Service Delivery Point (Facility) VCT: 10-14, Female, Negative	852
Service Delivery Point (Facility) VCT: 10-14, Female, Positive	100
Service Delivery Point (Facility) VCT: 10-14, Male, Negative	837
Service Delivery Point (Facility) VCT: 10-14, Male, Positive	96
Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1,126
Service Delivery Point (Facility) VCT: 15-19, Female, Positive	154
Service Delivery Point (Facility) VCT: 15-19, Male, Negative	817
Service Delivery Point (Facility) VCT: 15-19, Male, Positive	96
Service Delivery Point (Facility) VCT: 20-24, Female, Negative	3,287
Service Delivery Point (Facility) VCT: 20-24, Female, Positive	375
Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,128
Service Delivery Point (Facility) VCT: 20-24, Male, Positive	120
Service Delivery Point (Facility) VCT: 25-49, Female, Negative	4,474
Service Delivery Point (Facility)	506



VCT: 25-49, Female, Positive	
Service Delivery Point (Facility) VCT: 25-49, Male, Negative	3,890
Service Delivery Point (Facility) VCT: 25-49, Male, Positive	476
Service Delivery Point (Facility) VCT: 50+, Female, Negative	783
Service Delivery Point (Facility) VCT: 50+, Female, Positive	164
Service Delivery Point (Facility) VCT: 50+, Male, Negative	453
Service Delivery Point (Facility) VCT: 50+, Male, Positive	49
Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
Service Delivery Point (Facility) VCT:	0
Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
Service Delivery Point (Facility) VCT: <1, Negative	48
Service Delivery Point (Facility) VCT: <1, Positive	5
Service Delivery Point (Facility) VCT: 1-9, Negative	395
Service Delivery Point (Facility) VCT: 1-9, Positive	54
Service Delivery Point by Agg Age (Facility) VCT: <15, Female,	3,936
Negative	



Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	665
Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	5,038
Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	744
Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	55,767
Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	5,311
Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	47,128
Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	4,552
Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Negative	0
Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Positive	
Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Negative	
Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Positive	
Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	
Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	
Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	



Service Delivery Point (Community)	
VCT Mod: 10-14, Male, Positive	
Service Delivery Point (Community)	
VCT Mod: 15-19, Female, Negative	
Service Delivery Point (Community)	
VCT Mod: 15-19, Female, Positive	
Service Delivery Point (Community)	
VCT Mod: 15-19, Male, Negative	
Service Delivery Point (Community)	
VCT Mod: 15-19, Male, Positive	
Service Delivery Point (Community)	
VCT Mod: 20-24, Female, Negative	
Service Delivery Point (Community)	
VCT Mod: 20-24, Female, Positive	
Service Delivery Point (Community)	
VCT Mod: 20-24, Male, Negative	
Service Delivery Point (Community)	
VCT Mod: 20-24, Male, Positive	
Service Delivery Point (Community)	
VCT Mod: 25-49, Female, Negative	
Service Delivery Point (Community)	
VCT Mod: 25-49, Female, Positive	
Service Delivery Point (Community)	
VCT Mod: 25-49, Male, Negative	
Service Delivery Point (Community)	
VCT Mod: 25-49, Male, Positive	
Service Delivery Point (Community)	
VCT Mod: 50+, Female, Negative	
Service Delivery Point (Community)	
VCT Mod: 50+, Female, Positive	
Service Delivery Point (Community)	
VCT Mod: 50+, Male, Negative	
Service Delivery Point (Community)	
VCT Mod: 50+, Male, Positive	



1	
Service Delivery Point (Community)	
VCT Mod: Unknown Age, Female,	
Negative	
Service Delivery Point (Community)	
VCT Mod: Unknown Age, Female,	
Positive	
Service Delivery Point (Community)	
VCT Mod: Unknown Age, Male,	
Negative	
Service Delivery Point (Community)	
VCT Mod: Unknown Age, Male,	
Positive	
Service Delivery Point (Community)	
VCT Mod: <1, Negative	
Service Delivery Point (Community)	
VCT Mod: <1, Positive	
Service Delivery Point (Community)	
VCT Mod: 1-9, Negative	
Service Delivery Point (Community)	
VCT Mod: 1-9, Positive	
Service Delivery Point by Agg Age	
(Community) VCT Mod: <15,	
Female, Negative	
Service Delivery Point by Agg Age	
(Community) VCT Mod: <15,	
Female, Positive	
Service Delivery Point by Agg Age	
(Community) VCT Mod: <15, Male,	
Negative	
Service Delivery Point by Agg Age	
(Community) VCT Mod: <15, Male, Positive	
Service Delivery Point by Agg Age	•
(Community) VCT Mod: 15+,	0
Female, Negative	



	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Positive	0
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male, Negative	1,122
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male, Positive	198
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Male, Positive	
	Number of people receiving post-GBV care	9,359
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,275
	By type of service: Sexual Violence (Post-Rape Care)	8,084
	By PEP service provision (related to sexual violence services provided)	7,456
	<10, Female, Physical and/or Emotional Violence	1
	<10, Female, Sexual Violence (Post-Rape Care)	8



<10, Male, Physical and/or	0
Emotional Violence <10, Male, Sexual Violence	2
(Post-Rape Care)  10-14, Female, Physical and/or	84
Emotional Violence  10-14, Female, Sexual Violence (Post-Rape Care)	1,552
10-14, Male, Physical and/or Emotional Violence	0
10-14, Male, Sexual Violence (Post-Rape Care)	0
15-19, Female, Physical and/or Emotional Violence	357
15-19, Female, Sexual Violence (Post-Rape Care)	2,686
15-19, Male, Physical and/or Emotional Violence	55
15-19, Male, Sexual Violence (Post-Rape Care)	97
20-24, Female, Physical and/or Emotional Violence	471
20-24, Female, Sexual Violence (Post-Rape Care)	2,206
20-24, Male, Physical and/or Emotional Violence	59
20-24, Male, Sexual Violence (Post-Rape Care)	108
25-49, Female, Physical and/or Emotional Violence	172
25-49, Female, Sexual Violence (Post-Rape Care)	1,063
25-49, Male, Physical and/or Emotional Violence	68



	25-49, Male, Sexual Violence	118
	(Post-Rape Care) 50+, Female, Physical and/or Emotional Violence	8
	50+, Female, Sexual Violence (Post-Rape Care)	231
	50+, Male, Physical and/or Emotional Violence	4
	50+, Male, Sexual Violence (Post-Rape Care)	14
	Unknown Age, Female, Physical and/or Emotional Violence	0
	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
	Unknown Age, Male, Physical and/or Emotional Violence	0
	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
	Number of people receiving post-GBV care	51
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	17
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	34
	By PEP service provision (related to sexual violence services provided)	51
	<10, Female, Physical and/or Emotional Violence	0
	<10, Female, Sexual Violence (Post-Rape Care)	0
	<10, Male, Physical and/or Emotional Violence	0



<10, Male, Sexual Violence (Post-Rape Care)	0
10-14, Female, Physical and/or Emotional Violence	0
10-14, Female, Sexual Violence (Post-Rape Care)	0
10-14, Male, Physical and/or Emotional Violence	0
10-14, Male, Sexual Violence (Post-Rape Care)	0
15-19, Female, Physical and/or Emotional Violence	0
15-19, Female, Sexual Violence (Post-Rape Care)	0
15-19, Male, Physical and/or Emotional Violence	0
15-19, Male, Sexual Violence (Post-Rape Care)	0
20-24, Female, Physical and/or Emotional Violence	3
20-24, Female, Sexual Violence (Post-Rape Care)	11
20-24, Male, Physical and/or Emotional Violence	0
20-24, Male, Sexual Violence (Post-Rape Care)	4
25-49, Female, Physical and/or Emotional Violence	9
25-49, Female, Sexual Violence (Post-Rape Care)	11
25-49, Male, Physical and/or Emotional Violence	5
25-49, Male, Sexual Violence (Post-Rape Care)	8



	50+, Female, Physical and/or Emotional Violence	0
	50+, Female, Sexual Violence (Post-Rape Care)	0
	50+, Male, Physical and/or Emotional Violence	0
	50+, Male, Sexual Violence (Post-Rape Care)	0
	Unknown Age, Female, Physical and/or Emotional Violence	
	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
	Unknown Age, Male, Physical and/or Emotional Violence	
	Unknown Age, Male, Sexual Violence (Post-Rape Care)	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	524,308
	Age/Sex: 10-14 Male	47,039
	Age/Sex: 15-17 Male	48,041
	By: Age/sex: Male 18-24	21,300
	By: Age/sex: Male 25+	4,577
	Age/Sex: 18+ Male	
	Age/Sex: 10-14 Female	71,834
	Age/Sex: 15-17 Female	169,950
	By: Age/sex: 18-24 Female	43,931
	By: Age/sex: 25+ Female	29,534
	Age/Sex: 18+ Female	
	Sum of Age/Sex disaggregates	336,864
	Required only for DREAMS	
	countries - By service, age and sex: Education Support Female <1	



countries - B	y for DREAMS y service, age and on Support Female 8,686	
countries - B	y for DREAMS y service, age and on Support Female	3
countries - B	y for DREAMS y service, age and on Support Female	
countries - B	y for DREAMS y service, age and on Support Female	
countries - B	y for DREAMS y service, age and on Support Male <1	
countries - B	y for DREAMS y service, age and on Support Male 10-14	
countries - B	y for DREAMS y service, age and on Support Male 15-17	
countries - B	y for DREAMS y service, age and on Support Male 18-24	
countries - B	y for DREAMS y service, age and on Support Male 25+	
countries - B	y for DREAMS y service, age and g/Caregiver Programs	



Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	5,585
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	6,315
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	2,624
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	1,744
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	165
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	128
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	0
Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs	0



Male 25+	
Required only for DREAMS	
countries - By service, age and	
sex: Social Protection Female <1	
Required only for DREAMS	
countries - By service, age and	0.606
sex: Social Protection Female	9,696
10-14	
Required only for DREAMS	
countries - By service, age and	40.404
sex: Social Protection Female	12,181
15-17	
Required only for DREAMS	
countries - By service, age and	5,410
sex: Social Protection Female	5,410
18-24	
Required only for DREAMS	
countries - By service, age and	9
sex: Social Protection Female 25+	
Required only for DREAMS	
countries - By service, age and	
sex: Social Protection Male <1	
Required only for DREAMS	
countries - By service, age and	161
sex: Social Protection Male 10-14	
Required only for DREAMS	
countries - By service, age and	76
sex: Social Protection Male 15-17	
Required only for DREAMS	
countries - By service, age and	9
sex: Social Protection Male 18-24	
Required only for DREAMS	
countries - By service, age and	9
sex: Social Protection Male 25+	
Required only for DREAMS	



<u> </u>	
countries - By service, age and	
sex: Economic Strengthening	
Female <1	
Required only for DREAMS	
countries - By service, age and	2,374
sex: Economic Strengthening	2,374
Female 10-14	
Required only for DREAMS	
countries - By service, age and	4.4.470
sex: Economic Strengthening	14,172
Female 15-17	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening	8,708
Female 18-24	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening	3,783
Female 25+	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening Male	
<1	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening Male	1,744
10-14	
Required only for DREAMS	
countries - By service, age and	4,410
sex: Economic Strengthening Male 15-17	
Required only for DREAMS	
countries - By service, age and	5,316
sex: Economic Strengthening Male	
18-24	



Required only for DREAMS	
countries - By service, age and	863
sex: Economic Strengthening Male	003
25+	
Required only for DREAMS	
countries - By service, age and	
sex: Other Services Female <1	
Required only for DREAMS	
countries - By service, age and	21,736
sex: Other Services Female 10-14	
Required only for DREAMS	
countries - By service, age and	57,365
sex: Other Services Female 15-17	
Required only for DREAMS	
countries - By service, age and	13,772
sex: Other Services Female 18-24	
Required only for DREAMS	
countries - By service, age and	7,340
sex: Other Services Female 25+	
Required only for DREAMS	
countries - By service, age and	
sex: Other Services Male <1	
Required only for DREAMS	
countries - By service, age and	9,044
sex: Other Services Male 10-14	
Required only for DREAMS	
countries - By service, age and	11,810
sex: Other Services Male 15-17	
Required only for DREAMS	
countries - By service, age and	8,873
sex: Other Services Male 18-24	
Required only for DREAMS	
countries - By service, age and	1,590
sex: Other Services Male 25+	
Age/Sex: <1	4,571



Age/Sex: 1-9	83,531
Required only for DREAMS	
countries - By service, age and	
sex: Education Support 1-9 Male	
Required only for DREAMS	
countries - By service, age and	
sex: Parenting/Caregiver Programs	
Male 1-9	
Required only for DREAMS	
countries - By service, age and	
sex: Social Protection Programs	
Male 1-9	
Required only for DREAMS	
countries - By service, age and	
sex: Economic Strengthening Male	
1-9	
Required only for DREAMS	
countries - By service, age and	
sex: Other Services Male 1-9	
Program Completion: Active	514,182
Program Completion: Graduation	6,836
Program Completion: Transferred	246
Program Completion: Exited	3,044
without graduation	
By Aggregated Age/Sex: <18 Male	
By Aggregated Age/Sex: 18+ Male	
By Aggregated Age/Sex: <18	
Female	
By Aggregated Age/Sex: 18+	
Female	
Required only for DREAMS	
countries - By service, age and	
sex: Education Support Female 1-9	
Required only for DREAMS	



Γ	i T	
	countries - By service, age and	
	sex: Parenting/Caregiver Programs	
	Female 1-9	
	Required only for DREAMS	
	countries - By service, age and	
	sex: Social Protection Programs	
	Female 1-9	
	Required only for DREAMS	
	countries - By service, age and	
	sex: Economic Strengthening	
	Female 1-9	
	Required only for DREAMS	
	countries - By service, age and	
	sex: Other Services Female 1-9	
	Number of active beneficiaries	
	served by PEPFAR OVC programs for children and families affected by	110,326
	HIV/AIDS	
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-9 Male	
	Age/Sex: 10-14 Male	12,491
	Age/Sex: 15-17 Male	11,548
OVC_SERV_TA	By age/sex: 18-24 Male	5,397
	By age/sex: 25+ Male	772
	Age/Sex: 18+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-9 Female	
	Age/Sex: 10-14 Female	13,204
	Age/Sex: 15-17 Female	32,330
	By age/sex: 18-24 Female	8,808
	By age/sex: 25+ Female	4,542
	Age/Sex: 18+ Female	
Custom	Dogg 107 of 709	ACTS Info v2 9 21 10



Sum of Age/Sex disaggregates  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female <1  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24  Required only for DREAMS		
countries: By Service Area, age and sex: Education Support Female <1  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24  Required only for DREAMS	Sum of Age/Sex disaggregates	69,573
and sex: Education Support Female <1 Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4 Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9 Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14 Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17 Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17 Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24 Required only for DREAMS	Required only for DREAMS	
Female <1 Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4 Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9 Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14 Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17 Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17 Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24 Required only for DREAMS	countries: By Service Area, age	
Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24  Required only for DREAMS	and sex: Education Support	
countries: By Service Area, age and sex: Education Support Female 1-4  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24  Required only for DREAMS	Female <1	
and sex: Education Support Female 1-4  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24  Required only for DREAMS	Required only for DREAMS	
Female 1-4  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24  Required only for DREAMS	countries: By Service Area, age	
Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24  Required only for DREAMS	and sex: Education Support	
countries: By Service Area, age and sex: Education Support Female 5-9 Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14 Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17 Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17 Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24 Required only for DREAMS	Female 1-4	
and sex: Education Support Female 5-9  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24  Required only for DREAMS	Required only for DREAMS	
Female 5-9  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24  Required only for DREAMS	countries: By Service Area, age	
Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24  Required only for DREAMS	and sex: Education Support	
countries: By Service Area, age and sex: Education Support Female 10-14  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24  Required only for DREAMS	Female 5-9	
and sex: Education Support  Female 10-14  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24  Required only for DREAMS	Required only for DREAMS	
and sex: Education Support Female 10-14  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24  Required only for DREAMS	countries: By Service Area, age	470
Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17 Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24 Required only for DREAMS	and sex: Education Support	1/2
countries: By Service Area, age and sex: Education Support Female 15-17 Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24 Required only for DREAMS	Female 10-14	
and sex: Education Support  Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support  Female 18-24  Required only for DREAMS	Required only for DREAMS	
and sex: Education Support Female 15-17  Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24  Required only for DREAMS	countries: By Service Area, age	004
Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24 Required only for DREAMS	and sex: Education Support	321
countries: By Service Area, age and sex: Education Support Female 18-24 Required only for DREAMS	Female 15-17	
and sex: Education Support  Female 18-24  Required only for DREAMS	Required only for DREAMS	
and sex: Education Support  Female 18-24  Required only for DREAMS	countries: By Service Area, age	0.7
Required only for DREAMS	and sex: Education Support	87
	Female 18-24	
countries: By Service Area, age	Required only for DREAMS	
countries. By Service Area, age	countries: By Service Area, age	
and sex: Education Support	and sex: Education Support	
Female 25+	Female 25+	
Required only for DREAMS	Required only for DREAMS	
countries: By Service Area, age	countries: By Service Area, age	
and sex: Education Support Male	and sex: Education Support Male	
<1	<1	
Required only for DREAMS	Required only for DREAMS	
countries: By Service Area, age	countries: By Service Area, age	



and sex: Education Suppor	t Male
Required only for DREAMS	<u> </u>
countries: By Service Area,	
and sex: Education Suppor	· ·
5-9	
Required only for DREAMS	3
countries: By Service Area,	age
and sex: Education Suppor	t Male
10-14	
Required only for DREAMS	3
countries: By Service Area,	age 126
and sex: Education Suppor	
15-17	
Required only for DREAMS	
countries: By Service Area,	<sup>-</sup> 1 76
and sex: Education Suppor	t Male
18-24	
Required only for DREAMS	
countries: By Service Area,	=
and sex: Education Suppor 25+	t Male
Required only for DREAMS	
countries: By Service Area,	
and sex: Parenting/Caregiv	
Program Female <1	
Required only for DREAMS	3
countries: By Service Area,	age
and sex: Parenting/Caregiv	rer
Program Female 1-4	
Required only for DREAMS	3
countries: By Service Area,	age
and sex: Parenting/Caregiv	rer
Program Female 5-9	
Required only for DREAMS	0



countries: By Service Area, age	
and sex: Parenting/Caregiver	
Program Female 10-14	
Required only for DREAMS	
countries: By Service Area, age	0
and sex: Parenting/Caregiver	0
Program Female 15-17	
Required only for DREAMS	
countries: By Service Area, age	0
and sex: Parenting/Caregiver	0
Program Female 18-24	
Required only for DREAMS	
countries: By Service Area, age	
and sex: Parenting/Caregiver	
Program Female 25+	
Required only for DREAMS	
countries: By Service Area, age	
and sex: Parenting/Caregiver	
Program Male <1	
Required only for DREAMS	
countries: By Service Area, age	
and sex: Parenting/Caregiver	
Program Male 1-4	
Required only for DREAMS	
countries: By Service Area, age	
and sex: Parenting/Caregiver	
Program Male 5-9	
Required only for DREAMS	
countries: By Service Area, age	
and sex: Parenting/Caregiver	0
Program Male 10-14	
Required only for DREAMS	
countries: By Service Area, age	
and sex: Parenting/Caregiver	0
Program Male 15-17	
1 - 3	



Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24	0
Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+	
Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female <1	
Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 1-4	
Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 5-9	
Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14	201
Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17	376
Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24	101
Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female	



25+	
Required only for DREAMS	
countries: By Service Area, age and sex: Social Protection Male <1	
Required only for DREAMS	
countries: By Service Area, age and sex: Social Protection Male 1-4	
Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 5-9	
Required only for DREAMS	
countries: By Service Area, age and sex: Social Protection Male 10-14	189
Required only for DREAMS	
countries: By Service Area, age	148
and sex: Social Protection Male 15-17	110
Required only for DREAMS	
countries: By Service Area, age	87
and sex: Social Protection Male 18-24	Ç.
Required only for DREAMS	
countries: By Service Area, age	
and sex: Social Protection Male 25+	
Required only for DREAMS	
countries: By Service Area, age	
and sex: Economic Strengthening	
Female <1	
Required only for DREAMS countries: By Service Area, age	
and sex: Economic Strengthening	
Female 1-4	
Required only for DREAMS	



countries: By Service Area, age and sex: Economic Strengthening Female 5-9	
Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 10-14	0
Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 15-17	0
Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 18-24	0
Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 25+	
Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male <1	
Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 1-4	
Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 5-9	
Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14	0



	T
Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 15-17	0
Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24	0
Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 25+	
Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female <1	
Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 1-4	
Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 5-9	
Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14	2,054
Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17	5,896
Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas	1,483



Female 18-24	
Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 25+	1,182
Age/Sex: <1	553
Age/Sex: 1-9	20,677
Required only for DREAMS countries: By Service Area, age and sex: Education Support 1-9	·
Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program 1-9	
Required only for DREAMS countries: By Service Area, age and sex: Social Protection 1-9	
Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening 1-9	
Program Completion: Active	101,057
Program Completion: Graduated	5,700
Program Completion: Transferred	10
Program Completion: Exited without graduation	3,559
Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas <1	
Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 10-14	2,039
Required only for DREAMS	1,990



count	tries: By Service Area, age	
and s	ex: Other Service Areas Male	
15-17	7	
Requ	ired only for DREAMS	
count	tries: By Service Area, age	1 012
and s	ex: Other Service Areas Male	1,012
18-24	1	
Requ	ired only for DREAMS	
count	tries: By Service Area, age	183
and s	ex: Other Service Areas Male	103
25+		
Ву А	ggregated Age/Sex: <18 Male	
Ву А	ggregated Age/Sex: 18+ Male	
Ву А	ggregated Age/Sex: <18	
Fema	ale	
Ву А	ggregated Age/Sex: 18+	
Fema		
Requ	ired only for DREAMS	
-	tries - By service, age and	
	Education Support 1-9 Female	
Requ	ired only for DREAMS	
-	tries - By service, age and	
	Parenting/Caregiver Program	
	emale	
Requ	ired only for DREAMS	
	tries - By service, age and	
	Economic Strengthening 1-9	
Fema		
Requ	ired only for DREAMS	
	tries - By service, age and	
sex: (	Other Service Areas 1-9	
ema	ale	
₹equ	ired only for DREAMS	
-	tries - By service, age and	
	Social Protection 1-9 Female	



		1
	Required only for DREAMS	
	countries: By Service Area, age	
	and sex: Other Service Areas 1-9	
	TB_ART_DSD Percentage of	
	HIV-positive new and relapsed	108 %
	registered TB cases on ART during	106 %
	TB treatment	
	The number of registered new and	
	relapse TB cases with documented	
	HIV-positive status who are on	99,099
	ART during TB treatment during	
	the reporting period	
	The number of registered new and	
	relapse TB cases with documented	
	HIV-positive status during TB	91,411
	treatment during the reporting	
	period	
	Age/Sex: <1 (Numerator: The	
	number of registered new and	
TB_ART_DSD	relapse TB cases with documented	
	HIV-positive status who are on	
	ART during TB treatment during	
	the reporting period)	
	Age/Sex: 1-9 (Numerator: The	
	number of registered new and	
	relapse TB cases with documented	
	HIV-positive status who are on	
	ART during TB treatment during	
	the reporting period)	
	Age/Sex: Male 10-14 (Numerator:	
	The number of registered new and	
	relapse TB cases with documented	
	HIV-positive status who are on	
	ART during TB treatment during	
	the reporting period)	
	Age/Sex: Male 15-19 (Numerator:	
	, -	



The number of registered new and
relapse TB cases with documented
HIV-positive status who are on
ART during TB treatment during
the reporting period)
Age/Sex: Male 20-24 (Numerator:
The number of registered new and
relapse TB cases with documented
HIV-positive status who are on
ART during TB treatment during
the reporting period)
Age/Sex: Male 25-49 (Numerator:
The number of registered new and
relapse TB cases with documented
HIV-positive status who are on
ART during TB treatment during
the reporting period)
Age/Sex: Male 50+ (Numerator:
The number of registered new and
relapse TB cases with documented
HIV-positive status who are on
ART during TB treatment during
the reporting period)
Age/Sex: Female 10-14
(Numerator: The number of
registered new and relapse TB
cases with documented
HIV-positive status who are on
ART during TB treatment during
the reporting period)
Age/Sex: Female 15-19
(Numerator: The number of
registered new and relapse TB
cases with documented
HIV-positive status who are on
ART during TB treatment during
<u>-</u>



the reporting period)	
Age/Sex: Female 20-24	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 25-49	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 50+ (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Male <15	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	3,562
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Male 15+	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	39,435
HIV-positive status who are on	,,,,,,
ART during TB treatment during	
the reporting period)	
	4.076
Aggregated Age/Sex: Female <15	4,076



(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Female 15+	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	51,766
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
On ART: Already on ART	
On ART: New on ART	
Age/Sex: >1 (Denominator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: 1-9 (Denominator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 10-14	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 15-19	
(Denominator: The number of	
 NECTON MICHOLICA THE HUMBER OF	



registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 20-24	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 25-49	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Male 50+ (Denominator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 10-14	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 15-19	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	



HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 20-24	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 25-49	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: Female 50+	
(Denominator: The number of	
·	
registered new and relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Aggregated Age/Sex: Male <15	
(Denominator: The number of	
registered new and relapse TB	
cases with documented	3,597
HIV-positive status during TB	
treatment during the reporting	
period)	
Aggregated Age/Sex: Male 15+	
(Denominator: The number of	
registered new and relapse TB	37,036
cases with documented	
HIV-positive status during TB	



	treatment during the reporting	
	period)	
	Aggregated Age/Sex: Female <15	
	(Denominator: The number of	
	registered new and relapse TB	
	cases with documented	4,111
	HIV-positive status during TB	
	treatment during the reporting	
	period)	
	Aggregated Age/Sex: Female 15+	
	(Denominator: The number of	
	registered new and relapse TB	
	cases with documented	46,809
	HIV-positive status during TB	
	treatment during the reporting	
	period)	
	TB_ART_TA Percentage of	
	HIV-positive new and relapsed	
	registered TB cases on ART during	98 %
	TB treatment	
	The number of registered new and	
	relapse TB cases with documented	
	HIV-positive status who are on	24,099
	ART during TB treatment during	·
	the reporting period	
	The number of registered new and	
TB_ART_TA	relapse TB cases with documented	
	HIV-positive status during TB	24,639
	treatment during the reporting	,
	period	
	Age/Sex: <1 (Numerator: The	
	number of registered new and	
	relapse TB cases with documented	
	HIV-positive status who are on	
	ART during TB treatment during	
	the reporting period)	
	the reporting period)	



Age/Sex: 1-9 (Numerator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 10-14 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 15-19 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 20-24 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 25-49 (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Male 50+ (Numerator:	
The number of registered new and	
relapse TB cases with documented	
LIDV 20 (- (   L	
HIV-positive status who are on	
ART during TB treatment during	



Age/Sex: Female 10-14	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 15-19	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 20-24	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 25-49	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Age/Sex: Female 50+ (Numerator:	
The number of registered new and	
relapse TB cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Male <15	789
(Numerator: The number of	. 30



1	1
registered new and relapse TB	
cases with documented	
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Male 15+	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	10,737
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Female <15	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	845
HIV-positive status who are on	
ART during TB treatment during	
the reporting period)	
Aggregated Age/Sex: Female 15+	
(Numerator: The number of	
registered new and relapse TB	
cases with documented	11,725
HIV-positive status who are on	,
ART during TB treatment during	
the reporting period)	
On ART: Already on ART	
On ART: New on ART	
Age/Sex: <1 (Denominator: The	
number of registered new and	
relapse TB cases with documented	
HIV-positive status during TB	
treatment during the reporting	
period)	
Age/Sex: 1-9 (Denominator: The	
number of registered new and	



relapse TB cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Male 10-14
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Male 15-19
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Male 20-24
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Male 25-49
(Denominator: The number of
registered new and relapse TB cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Male 50+ (Denominator:
The number of registered new and
relapse TB cases with documented
HIV-positive status during TB



treatment during the reporting
period)
Age/Sex: Female 10-14
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Female 15-19
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Female 20-24
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Female 25-49
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting
period)
Age/Sex: Female 50+
(Denominator: The number of
registered new and relapse TB
cases with documented
HIV-positive status during TB
treatment during the reporting



	period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	824
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	10,902
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	867
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	12,037
	TB_PREV_DSD TB_PREV_DSD	50 %
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	86,439



,	
The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	171,826
By Age/Sex (Denominator): <15, Female	8,442
By Age/Sex (Denominator): <15, Male	7,183
By Age/Sex (Denominator): 15+, Female	90,430
By Age/Sex (Denominator): 15+, Male	64,425
By Therapy type (Denominator): 6-12 Month IPT	109,482
By Therapy type (Denominator): Alternative Regimen	0
By Therapy type (Denominator): Continuous IPT	3,489
By Age/Sex (Numerator): <15, Female	4,269
By Age/Sex (Numerator): <15, Male	3,647
By Age/Sex (Numerator): 15+, Female	45,776
By Age/Sex (Numerator): 15+, Male	32,703
By Therapy type (Numerator): 6-12 Month IPT	55,595
By Therapy type (Numerator):	0



	Alternative Regimen	
	By Therapy type (Numerator): Continuous IPT	1,755
	TB_PREV_TA TB_PREV_TA	51 %
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	26,121
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	50,971
	By Age/Sex (Denominator): <15, Female	1,795
	By Age/Sex (Denominator): <15, Male	1,928
	By Age/Sex (Denominator): 15+, Female	23,528
	By Age/Sex (Denominator): 15+, Male	24,458
	By Therapy type (Denominator): 6-12 Month IPT	15,150
	By Therapy type (Denominator):Alternative Regimen	0
	By Therapy type (Denominator):Continuous IPT	932
	By Age/Sex (Numerator): <15,	901



	Female	
	By Age/Sex (Numerator): <15, Male	883
	By Age/Sex (Numerator): 15+, Female	11,902
	By Age/Sex (Numerator): 15+, Male	12,394
	By Therapy type (Numerator): 6-12 Month IPT	7,845
	By Therapy type (Numerator): Alternative Regimen	14
	By Therapy type (Numerator): Continuous IPT	477
	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	n/a
	Number of ART patients who were started on TB treatment during the reporting period.	0
	Number of ART patients who were screened for TB at least once during the reporting period	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	0
	Numerator: By Aggregated Age/Sex: <15, Male	0
	Numerator: By Aggregated Age/Sex: 15+, Female	0
	Numerator: By Aggregated Age/Sex: 15+, Male	0
	Denominator: By Aggregated Age/Sex: <15, Female	0
	Denominator: By Aggregated Age/Sex: <15, Male	0



	Denominator: By Aggregated	
	Age/Sex:15+, Female	0
	Denominator: By Aggregated	
	Age/Sex:15+, Male	0
	Denominator: By Screen Result:	_
	Negative	0
	Denominator: By Screen Result:	0
	Positive	0
	Denominator: Number of ART	
	patients who had a specimen sent	0
	for bacteriologic diagnosis of active	O
	TB disease	
	Denominator: By Diagnostic Test	
	[Subdisagg of Specimen Sent]:	0
	Other (No Xpert)	
	Denominator: By Diagnostic Test	
	[Subdisagg of Specimen Sent]:	0
	Smear Only	
	Denominator: By Diagnostic Test	
	[Subdisagg of Specimen Sent]:	0
	Gene Xpert MTB / R if Assay	
	TX_TB_TA The proportion of ART	
	patients who were screened who	n/a
	are receiving TB treatment	
	Number of ART patients who were	
	started on TB treatment during the	0
	reporting period.	
	Number of ART patients who were	
TX_TB_TA	screened for TB at least once	0
	during the reporting period	
	Numerator: By Aggregated	
	Age/Sex: <15, Female	0
	Numerator: By Aggregated	
	Age/Sex: <15, Male	0
	Numerator: By Aggregated	0
	, , , , , , , , , , , , , , , , , , , ,	



	Age/Sex: 15+, Female	
	Numerator: By Aggregated Age/Sex: 15+, Male	0
	Denominator: By Aggregated Age/Sex: <15, Female	0
	Denominator: By Aggregated Age/Sex: <15, Male	0
	Denominator: By Aggregated Age/Sex: 15+, Female	0
	Denominator: By Aggregated Age/Sex: 15+, Male	0
	Denominator: By Screen Result: Negative	0
	Denominator: By Screen Result: Positive	0
	Denominator: By Specimen Sent:  Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	0
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	0
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	0
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	0
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	133,961



	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	
	By infants who received their first virologic HIV test between 2 and 12 months of age	
	Sum of Infant Age disaggregates  By infants with a positive virologic	
	test result within 12 months of birth  Number of infants with a positive virological test result within 2	1,417
	months of birth  Number of infants with a positive	
	virological test result within 12 months of birth Unknown, <= 2 months	36
	Unknown, 2 - 12 months	111
	Number of infants with a negative virological test result within 2 months of birth	83,606
	Number of infants with a positive virological test result between 2 and 12 months of birth	781
	Number of infants with a negative virological test result between 2 and 12 months of birth	48,010
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a	39,176



	virologic HIV test within 12 months	
	of birth during the reporting period	
	Number of HIV- positive pregnant	
	women identified during the	
	reporting period (include known	
	HIV-positive women at entry into	
	PMTCT)	
	By infants who received a virologic	
	test within 2 months of birth	
	By infants who received their first	
	virologic HIV test between 2 and 12	
	months of age	
	Sum of Infant Age disaggregates	
	By infants with a positive virologic	
	test result within 12 months of birth	
	Unknown, <= 2 months	
	Unknown, 2 - 12 months	
	Number of infants with a positive	
	virological test result within 2	655
	months of birth	
	Number of infants with a negative	
	virological test result within 2	19,777
	months of birth	
	Number of infants with a positive	
	virological test result between 2	156
	and 12 months of birth	
	Number of infants with a negative	
	virological test result between 2	18,588
	and 12 months of birth	
	Number of infants with a positive	
	virological test result within 12	
	months of birth	
	Number of adults and children	
TX_CURR_DSD	receiving antiretroviral therapy	3,683,337



	Age/Sex: 15-19 Male	24,518
	Age/Sex: 15-19 Female	39,075
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	81,554
	Aggregated Age/Sex: 15+ Male	750,464
	Aggregated Age/Sex: <15 Female	87,396
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	1,340,703
	Sum of Aggregated Age/Sex <15	168,950
	Sum of Aggregated Age/Sex 15+	2,091,167
	Sum of Aggregated Age/Sex disaggregates	2,260,117
	Age/Sex: <1	3,596
	Age/Sex: <1-9	41,367
	Age/Sex: 10-14 Male	11,958
	Age/Sex: 10-14 Female	12,785
	Aggregated Age/Sex: 1-14 Male	
	Age/Sex: 20-24 Male	84,599
	Age/Sex: 25-49 Male	319,488
	Age/Sex: 50+ Male	68,563
	Age/Sex: 20-24 Female	145,457
	Age/Sex: 25-49 Female	574,744
	Age/Sex: 50+ Female	95,945
	Number of adults and children receiving antiretroviral therapy (ART)	687,682
TX_CURR_TA	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	2,699



	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	6,765
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	9,464
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	11,814
	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	181,232
	Aggregated Age/Sex: <15 Female	12,463
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	349,115
	Sum of Aggregated Age/Sex <15	24,277
	Sum of Aggregated Age/Sex 15+	530,347
	Sum of Aggregated Age/Sex	554.004
	disaggregates	554,624
	Age/Sex: <1	280
	Age/Sex: 1-9	1,883
	Age/Sex: 10-14 Male	401
	Age/Sex: 10-14 Female	461
	Sum of Aggregated Age/Sex (<1	
	and 1-14) <15	
	Age/Sex: 20-24 Male	9,176
	Age/Sex: 25-49 Male	25,712
	Age/Sex: 50+ Male	5,078
	Age/Sex: 20-24 Female	22,445
	Age/Sex: 25-49 Female	58,460
	Age/Sex: 50+ Female	10,461
TX_NEW_DSD	Number of adults and children	860,049



newly enrolled on antiretroviral	
therapy (ART)	
By Age/Sex: <1	750
By Age/Sex: 1-9	7,328
By Age/Sex: 10-14 Male	2,280
By Age/Sex: 15-19 Male	4,438
By Age/Sex: 20-24 Male	14,992
By Age/Sex: 25-49 Male	52,426
By Age/Sex: 50+ Male	10,915
By Age/Sex: 10-14 Female	2,457
By Age/Sex: 15-19 Female	7,061
By Age/Sex: 20-24 Female	25,859
By Age/Sex: 25-49 Female	91,859
By Age/Sex: 50+ Female	15,707
Aggregated Grouping by Age: <1	
Aggregated Grouping by Age: <1	
Male	
Aggregated Grouping by Age/Sex: <15 Male	22,277
Aggregated Grouping by Age/Sex: 1-14 Male	
Aggregated Grouping by Age/Sex: 15+ Male	211,610
Aggregated Grouping by Age/Sex: <1 Female	
Aggregated Grouping by Age/Sex: <15 Female	24,151
Aggregated Grouping by Age/Sex: 15+ Female	368,037
Pregnancy status	96,759
Breastfeeding status	3,144
FSW	163
MSM	892
•	



	People in prisons and other enclosed settings	9
	TG	2
	Aggregated Grouping by Age/Sex: 1-14 Female	
	By Key populations: People who inject drugs (PWID)	0
	Number of adults and children newly enrolled on antiretroviral therapy (ART)	173,362
	By Age/Sex: <1	100
	By Age/Sex: 1-9	605
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	181
	By Age/Sex: 15-19 Male	367
TV NIEW TA	By Age/Sex: 20-24 Male	1,199
	By Age/Sex: 25-49 Male	3,176
	By Age/Sex: 50+ Male	887
TX_NEW_TA	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	189
	By Age/Sex: 15-19 Female	824
	By Age/Sex: 20-24 Female	2,685
	By Age/Sex: 25-49 Female	6,899
	By Age/Sex: 50+ Female	1,454
	Sum of Age/Sex disaggregates	17,861
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex:	3,079



	<15 Male	
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	49,916
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	3,249
	Aggregated Grouping by Age/Sex: 1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	98,750
	Sum of Aggregated Age/Sex disaggregates	154,994
	Pregnancy status	26,122
	Breastfeeding status	0
	FSW	
	MSM	
	People in prisons and other enclosed settings	4,758
	TG	
	By Key populations: People who inject drugs (PWID)	
	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record	
TX_PVLS_DSD	and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral	90 %
	load (<1000 copies/ml)	
	Number of adults and pediatric	
	patients on ART with suppressed viral load results (<1,000 copies/ml)	2,923,487



documented in the medical records	
and /or supporting laboratory	
results within the past 12 months.	
Number of adult and pediatric ART	
patients with a viral load result	
documented in the patient medical	3,259,074
record and /or laboratory records	
in the past 12 months.	
Numerator: Indication: Routine	2,794,519
Numerator: Indication: Targeted	1,194
Numerator: Preg/BF by Indication:	220.204
Pregnant Routine	228,394
Numerator: Preg/BF by Indication:	040
Breastfeeding Routine	213
Numerator: Preg/BF by Indication:	0.4
Pregnant Targeted	61
Numerator: Preg/BF by Indication:	0.5
Breastfeeding Targeted	35
Numerator: Age/Sex by Indication:	
<1 Routine	
Numerator: Age/Sex by Indication:	
1-9 Routine	
Numerator: Age/Sex by Indication:	
10-14 Male Routine	
Numerator: Age/Sex by Indication:	
15-19 Male Routine	
Numerator: Age/Sex by Indication:	
20-24 Male Routine	
Numerator: Age/Sex by Indication:	
25-49 Male Routine	
Numerator: Age/Sex by Indication:	
50+ Male Routine	
Numerator: Age/Sex by Indication:	
10-14 Female Routine	



Numerator: Age/Sex by Indication:	
15-19 Female Routine  Numerator: Age/Sex by Indication:  20-24 Female Routine	
Numerator: Age/Sex by Indication: 25-49 Female Routine	
Numerator: Age/Sex by Indication: 50+ Female Routine	
Numerator: Age/Sex by Indication: <1 Targeted	
Numerator: Age/Sex by Indication: 1-9 Targeted	
Numerator: Age/Sex by Indication: 10-14 Male Targeted	
Numerator: Age/Sex by Indication: 15-19 Male Targeted	
Numerator: Age/Sex by Indication: 20-24 Male Targeted	
Numerator: Age/Sex by Indication: 25-49 Male Targeted	
Numerator: Age/Sex by Indication: 50+ Male Targeted	
Numerator: Age/Sex by Indication: 10-14 Female Targeted	
Numerator: Age/Sex by Indication: 15-19 Female Targeted	
Numerator: Age/Sex by Indication: 20-24 Female Targeted	
Numerator: Age/Sex by Indication: 25-49 Female Targeted	
Numerator: Age/Sex by Indication: 50+ Female Targeted	
Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	46



Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	484
Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	46
Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	606
Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	126,532
Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	961,585
Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	128,917
Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,575,128
Denominator: Indication: Routine	2,866,406
Denominator: Indication: Targeted	3,412
Denominator: Preg/BF by Indication: Pregnant Routine	231,438
Denominator: Preg/BF by Indication: Breastfeeding Routine	24,647
Denominator: Preg/BF by Indication: Pregnant Targeted	130
Denominator: Preg/BF by Indication: Breastfeeding Targeted	82
Denominator: Age/Sex by Indication: <1 Routine	
Denominator: Age/Sex by Indication: 1-9 Routine	
Denominator: Age/Sex by Indication: 10-14 Male Routine	
Denominator: Age/Sex by Indication: 15-19 Male Routine	
Denominator: Age/Sex by Indication: 20-24 Male Routine	



Denominator: Age/Sex by
Indication: 25-49 Male Routine
Denominator: Age/Sex by
Indication: 50+ Male Routine
Denominator: Age/Sex by
Indication: 10-14 Female Routine
Denominator: Age/Sex by
Indication: 15-19 Female Routine
Denominator: Age/Sex by
Indication: 20-24 Female Routine
Denominator: Age/Sex by
Indication: 25-49 Female Routine
Denominator: Age/Sex by
Indication: 50+ Female Routine
Denominator: Age/Sex by
Indication: <1 Targeted
Denominator: Age/Sex by
Indication: 1-9 Targeted
Denominator: Age/Sex by
Indication: 10-14 Male Targeted
Denominator: Age/Sex by
Indication: 15-19 Male Targeted
Denominator: Age/Sex by
Indication: 20-24 Male Targeted
Denominator: Age/Sex by
Indication: 25-49 Male Targeted
Denominator: Age/Sex by
Indication: 50+ Male Targeted
Denominator: Age/Sex by
Indication: 10-14 Female Targeted
Denominator: Age/Sex by
Indication: 15-19 Female Targeted
Denominator: Age/Sex by
Indication: 20-24 Female Targeted



Denominator: Age/Sex by	
Indication: 25-49 Female Targeted	
Denominator: Age/Sex by	
Indication: 50+ Female Targeted	
Denominator: Aggregate Age/Sex	
by Indication: <15 Male Targeted	59
Denominator: Aggregate Age/Sex	
by Indication: 15+ Male Targeted	536
Denominator: Aggregate Age/Sex	
by Indication: <15 Female Targeted	59
Denominator: Aggregate Age/Sex	
by Indication: 15+ Female Targeted	671
Denominator: Aggregate Age/Sex	
by Indication: <15 Male Routine	105,637
Denominator: Aggregate Age/Sex	
by Indication: 15+ Male Routine	1,070,812
Denominator: Aggregate Age/Sex	119,411
by Indication: <15 Female Routine	
Denominator: Aggregate Age/Sex	1,821,892
by Indication: 15+ Female Routine	
Numerator Aggregated Age/Sex:	
<15 Male	
Numerator Aggregated Age/Sex:	
15+ Male	
Numerator Aggregated Age/Sex:	
<15 Female	
Numerator Aggregated Age/Sex:	
15+ Female	
Denominator Aggregated Age/Sex:	
<15 Male	
Denominator Aggregated Age/Sex:	
15+ Male	
Denominator Aggregated Age/Sex:	
<15 Female	



Denominator Aggregated Age/Sex:	
15+ Female	
<15, Routine, Unknown Sex	283
<15, Targeted, Unknown Sex	
<15, Undocumented Test	2.040
Indication, Female	2,818
<15, Undocumented Test	2 724
Indication, Male	2,721
<15, Undocumented Test	
Indication, Unknown Sex	
15+, Routine, Unknown Sex	3,761
15+, Targeted, Unknown Sex	
15+, Undocumented Test	00.075
Indication, Female	92,675
15+, Undocumented Test	44.540
Indication, Male	44,512
15+, Undocumented Test	
Indication, Unknown Sex	
Unknown Age, Routine, Female	
Unknown Age, Routine, Male	2,192
Unknown Age, Routine, Unknown	
Sex	
Unknown Age, Targeted, Female	
Unknown Age, Targeted, Male	
Unknown Age, Targeted, Unknown	
Sex	
Unknown Age, Undocumented Test	
Indication, Female	
Unknown Age, Undocumented Test	
Indication, Male	
Unknown Age, Undocumented Test	
Indication, Unknown Sex	
Breastfeeding, Undocumented Test	
Indication	



Pregnant, Undocumented Test Indication	14
Undocumented Test Indication	142,060
<15, Routine, Unknown Sex	80
<15, Targeted, Unknown Sex	
<15, Undocumented Test Indication, Female	2,341
<15, Undocumented Test Indication, Male	2,244
<15, Undocumented Test Indication, Unknown Sex	
15+, Routine, Unknown Sex	569
15+, Targeted, Unknown Sex	
15+, Undocumented Test Indication, Female	84,413
15+, Undocumented Test Indication, Male	39,455
15+, Undocumented Test Indication, Unknown Sex	
Unknown Age, Routine, Female	97
Unknown Age, Routine, Male	94
Unknown Age, Routine, Unknown Sex	
Unknown Age, Targeted, Female	
Unknown Age, Targeted, Male	
Unknown Age, Targeted, Unknown Sex	
Unknown Age, Undocumented Test Indication, Female	0
Unknown Age, Undocumented Test Indication, Male	0
Unknown Age, Undocumented Test Indication, Unknown Sex	



	Breastfeeding, Undocumented Test Indication	
	Pregnant, Undocumented Test Indication	
	Undocumented Test Indication	127,774
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	89 %
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	547,929
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	615,820
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	



Numerator: Age/Sex by Indication:	
10-14 Male Routine	
Numerator: Age/Sex by Indication: 10-14 Male Targeted	
Numerator: Age/Sex by Indication: 15-19 Female Routine	
Numerator: Age/Sex by Indication: 15-19 Female Targeted	
Numerator: Age/Sex by Indication: 15-19 Male Routine	
Numerator: Age/Sex by Indication: 15-19 Male Targeted	
Numerator: Age/Sex by Indication: 20-24 Female Routine	
Numerator: Age/Sex by Indication: 20-24 Female Targeted	
Numerator: Age/Sex by Indication: 20-24 Male Routine	
Numerator: Age/Sex by Indication: 20-24 Male Targeted	
Numerator: Age/Sex by Indication: 25-49 Female Routine	
Numerator: Age/Sex by Indication: 25-49 Female Targeted	
Numerator: Age/Sex by Indication: 25-49 Male Routine	
Numerator: Age/Sex by Indication: 25-49 Male Targeted	
Numerator: Age/Sex by Indication: 50+ Female Routine	
Numerator: Age/Sex by Indication: 50+ Female Targeted	
Numerator: Age/Sex by Indication: 50+ Male Routine	



Numerator: Age/Sex by Indication: 50+ Male Targeted	
30+ Male Targeted	
Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	19,130
Numerator: Aggregate Age/Sex by	
Indication: <15 Female Targeted	
Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	14,731
Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	
Numerator: Aggregate Age/Sex by	
Indication: 15+ Female Routine	331,808
Numerator: Aggregate Age/Sex by	
Indication: 15+ Female Targeted	
Numerator: Aggregate Age/Sex by	400 = 40
Indication: 15+ Male Routine	169,718
Numerator: Aggregate Age/Sex by	
Indication: 15+ Male Targeted	
Numerator: Indication: Routine	534,911
Numerator: Indication: Targeted	
Numerator: Preg/BF by Indication:	
Breastfeeding Routine	
Numerator: Preg/BF by Indication:	
Breastfeeding Targeted	
Numerator: Preg/BF by Indication:	00 =04
Pregnant Routine	69,501
Numerator: Preg/BF by Indication:	
Pregnant Targeted	
Denominator: Indication: Routine	556,758
Denominator: Indication: Targeted	
Denominator: Age/Sex by	
Indication: <1 Routine	
Denominator: Age/Sex by	
Indication: <1 Targeted	



Denominator: Age/Sex by
Indication: 1-9 Routine
Denominator: Age/Sex by
Indication: 1-9 Targeted
Denominator: Age/Sex by
Indication: 10-14 Female Routine
Denominator: Age/Sex by
Indication: 10-14 Female Targeted
Denominator: Age/Sex by
Indication: 10-14 Male Routine
Denominator: Age/Sex by
Indication: 10-14 Male Targeted
Denominator: Age/Sex by
Indication: 15-19 Female Routine
Denominator: Age/Sex by
Indication: 15-19 Female Targeted
Denominator: Age/Sex by
Indication: 15-19 Male Routine
Denominator: Age/Sex by
Indication: 15-19 Male Targeted
Denominator: Age/Sex by
Indication: 20-24 Female Routine
Denominator: Age/Sex by
Indication: 20-24 Female Targeted
Denominator: Age/Sex by
Indication: 20-24 Male Routine
Denominator: Age/Sex by
Indication: 20-24 Male Targeted
Denominator: Age/Sex by
Indication: 25-49 Female Routine
Denominator: Age/Sex by
Indication: 25-49 Female Targeted
Denominator: Age/Sex by
Indication: 25-49 Male Routine



Denominator: Age/Sex by		
Indication: 25-49 Male Targeted		
Denominator: Age/Sex by		
Indication: 50+ Female Routine		
Denominator: Age/Sex by		
Indication: 50+ Female Targeted		
Denominator: Age/Sex by		
Indication: 50+ Male Routine		
Denominator: Age/Sex by		
Indication: 50+ Male Targeted		
Denominator: Aggregate Age/Sex	44.054	
by Indication: <15 Female Routine	14,351	
Denominator: Aggregate Age/Sex		
by Indication: <15 Female Targeted		
Denominator: Aggregate Age/Sex	40.500	
by Indication: <15 Male Routine	12,523	
Denominator: Aggregate Age/Sex		
by Indication: <15 Male Targeted		
Denominator: Aggregate Age/Sex	000 700	
by Indication: 15+ Female Routine	382,703	
Denominator: Aggregate Age/Sex		
by Indication: 15+ Female Targeted		
Denominator: Aggregate Age/Sex	400.000	
by Indication: 15+ Male Routine	192,369	
Denominator: Aggregate Age/Sex		
by Indication: 15+ Male Targeted		
Denominator: Preg/BF by		
Indication: Breastfeeding Routine		
Denominator: Preg/BF by	0	
Indication: Breastfeeding Targeted	0	
Denominator: Preg/BF by	75 004	
Indication: Pregnant Routine	75,231	
Denominator: Preg/BF by		
Indication: Pregnant Targeted		



Numerator Aggregated Age/Sex:	
<15 Male  Numerator Aggregated Age/Sex:	
15+ Male	
Numerator Aggregated Age/Sex: <15 Female	
Numerator Aggregated Age/Sex: 15+ Female	
Denominator Aggregated Age/Sex: <15 Male	
Denominator Aggregated Age/Sex: 15+ Male	
Denominator Aggregated Age/Sex: <15 Female	
Denominator Aggregated Age/Sex: 15+ Female	
<15, Routine, Unknown Sex	
<15, Targeted, Unknown Sex	
<15, Undocumented Test Indication, Female	162
<15, Undocumented Test Indication, Male	150
<15, Undocumented Test Indication, Unknown Sex	
15+, Routine, Unknown Sex	
15+, Targeted, Unknown Sex	
15+, Undocumented Test Indication, Female	10,373
15+, Undocumented Test Indication, Male	3,910
15+, Undocumented Test Indication, Unknown Sex	
Unknown Age, Routine, Female	22
Unknown Age, Routine, Male	22
<u> </u>	



Unknown Age, Routine, Unknown Sex	
Unknown Age, Targeted, Female	
Unknown Age, Targeted, Male	
Unknown Age, Targeted, Unknown Sex	
Unknown Age, Undocumented Test Indication, Female	
Unknown Age, Undocumented Test Indication, Male	
Unknown Age, Undocumented Test Indication, Unknown Sex	
Breastfeeding, Undocumented Test Indication	
Pregnant, Undocumented Test Indication	
Undocumented Test Indication	14,515
<15, Routine, Unknown Sex	
<15, Targeted, Unknown Sex	
<15, Undocumented Test Indication, Female	135
<15, Undocumented Test Indication, Male	105
<15, Undocumented Test Indication, Unknown Sex	
15+, Routine, Unknown Sex	
15+, Targeted, Unknown Sex	
15+, Undocumented Test Indication, Female	9,427
15+, Undocumented Test Indication, Male	3,440
15+, Undocumented Test Indication, Unknown Sex	
Unknown Age, Routine, Female	200



	Unknown Age, Routine, Male	204
	Unknown Age, Routine, Unknown Sex	
	Unknown Age, Targeted, Female	
	Unknown Age, Targeted, Male	
	Unknown Age, Targeted, Unknown Sex	
	Unknown Age, Undocumented Test Indication, Female	
	Unknown Age, Undocumented Test Indication, Male	
	Unknown Age, Undocumented Test Indication, Unknown Sex	
	Breastfeeding, Undocumented Test Indication	
	Pregnant, Undocumented Test Indication	
	Undocumented Test Indication	13,018
	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	77 %
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	927,699
	Total number of adults and children who initiated ART in the 12 months	
	prior to the beginning of the reporting period, including those	1,202,354
	who have died, those who have stopped ART, and those lost to follow-up	
	Age/Sex: <1 (Numerator: Number of adults and children who are still	



	,	
alive and on treatment	at 12	
months after initiating	ART	
Age/Sex: 1-9 (Numera	tor: Number	
of adults and children	who are still	
alive and on treatment	at 12	
months after initiating	ART	
Age/Sex: 10-14 Male (	Numerator:	
Number of adults and	children who	
are still alive and on tre	eatment at	
12 months after initiation	ng ART	
Age/Sex: 15-19 Male (	Numerator:	
Number of adults and	children who	
are still alive and on tre	eatment at	
12 months after initiation	ng ART	
Age/Sed: 20-24 Male (	Numerator:	
Number of adults and	children who	
are still alive and on tre	eatment at	
12 months after initiation	ng ART	
Age/Sex: 25-49 Male (	Numerator:	
Number of adults and	children who	
are still alive and on tre	eatment at	
12 months after initiation	ng ART	
Age/Sex: 50+ Male (N	umerator:	
Number of adults and	children who	
are still alive and on tre	eatment at	
12 months after initiation	ng ART	
Age/Sex: 10-14 Femal	e	
(Numerator: Number o	f adults and	
children who are still a	live and on	
treatment at 12 months	s after	
initiating ART		
Age/Sex: 15-19 Femal	e	
(Numerator: Number o	f adults and	
children who are still a	live and on	
treatment at 12 months	safter	



¥	
initiating ART	
Age/Sex: 20-24 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART	
Age/Sex: 25-49 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART	
Age/Sex: 50+ Female (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART	
Age/Sex: >1 (Denominator: Total	
number of adults and children who	
initiated ART in the 12 months prior	
to the beginning of the reporting	
period, including those who have	
died, those who have stopped	
ART, and those lost to follow-up)	
Age/Sex: 1-9 (Denominator: Total	
number of adults and children who	
initiated ART in the 12 months prior	
to the beginning of the reporting	
period, including those who have	
died, those who have stopped	
ART, and those lost to follow-up)	
Age/Sex: 10-14 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	



1	
those lost to follow-up)	
Age/Sex: 15-19 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 20-24 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 25-49 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 50+ Male (Denominator:	
Total number of adults and children	
who initiated ART in the 12 months	
prior to the beginning of the	
reporting period, including those	
who have died, those who have	
stopped ART, and those lost to	
follow-up)	
Age/Sex: 10-14 Female	
(Denominator: Total number of	
adults and children who initiated	



ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 15-19 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 20-24 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 25-49 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 50+ Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	



1	
those lost to follow-up)	
Aggregated Age: <15 (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Aggregated Age: 15+ (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Aggregated Age: <15	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age: 15+	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Numerator by Status: Pregnant	83,781
Numerator by Status:	
Breastfeeding	6,955
Denominator by Status: Pregnant	114,083
Denominator by Status:	
Breastfeeding	7,643
Aggregated Age/Sex: <15 Male	
(Numerator: Number of adults and	
children who are still alive and on	27,207
treatment at 12 months after	
1	



initiating ART)	
Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	311,948
Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	28,908
Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	559,198
Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	31,650
Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	395,690
Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the	33,347



beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)  Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)  TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy  Number of adults and children who are still alive and on treatment at 12 months after initiating ART  Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those 234,517
those who have stopped ART, and those lost to follow-up)  Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)  TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy  Number of adults and children who are still alive and on treatment at 12 months after initiating ART  Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those 234,517
those lost to follow-up)  Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)  TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy  Number of adults and children who are still alive and on treatment at 12 months after initiating ART  Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those  234,517
Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)  TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy  Number of adults and children who are still alive and on treatment at 12 months after initiating ART  Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those  234,517
(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)  TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy  Number of adults and children who are still alive and on treatment at 12 months after initiating ART  Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those 234,517
adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)  TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy  Number of adults and children who are still alive and on treatment at 12 months after initiating ART  Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those  741,662  741,662
ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)  TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy  Number of adults and children who are still alive and on treatment at 12 months after initiating ART  Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those
beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)  TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy  Number of adults and children who are still alive and on treatment at 12 months after initiating ART  Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those 234,517
beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)  TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy  Number of adults and children who are still alive and on treatment at 151,604  12 months after initiating ART  Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those 234,517
those who have stopped ART, and those lost to follow-up)  TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy  Number of adults and children who are still alive and on treatment at 12 months after initiating ART  Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those 234,517
those lost to follow-up)  TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy  Number of adults and children who are still alive and on treatment at 151,604  12 months after initiating ART  Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those 234,517
TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy  Number of adults and children who are still alive and on treatment at 151,604  12 months after initiating ART  Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those 234,517
children known to be alive and on treatment 12 months after initiation of antiretroviral therapy  Number of adults and children who are still alive and on treatment at 12 months after initiating ART  Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those 234,517
treatment 12 months after initiation of antiretroviral therapy  Number of adults and children who are still alive and on treatment at 12 months after initiating ART  Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those 234,517
treatment 12 months after initiation of antiretroviral therapy  Number of adults and children who are still alive and on treatment at 12 months after initiating ART  Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those 234,517
Number of adults and children who are still alive and on treatment at 151,604 12 months after initiating ART  Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those 234,517
are still alive and on treatment at 12 months after initiating ART  Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those 234,517
12 months after initiating ART  Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those  234,517
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those 234,517
who initiated ART in the 12 months prior to the beginning of the reporting period, including those 234,517
prior to the beginning of the reporting period, including those 234,517
reporting period, including those 234,517
who have died, those who have
TX_RET_TA stopped ART, and those lost to
follow-up
Age/Sex: <1 (Numerator: Number
of adults and children who are still
alive and on treatment at 12
months after initiating ART)
Age/Sex: 1-9 (Numerator: Number
of adults and children who are still
alive and on treatment at 12
months after initiating ART)
Age/Sex: 10-14 Male (Numerator:
rigoreon to trivialo (transolator



are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 15-19 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 20-24 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 25-49 Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 50+ Male (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Age/Sex: 10-14 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART)	
Age/Sex: 15-19 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART)	
Age/Sex: 20-24 Female	
(Numerator: Number of adults and	
children who are still alive and on	
treatment at 12 months after	
initiating ART)	
Age/Sex: 25-49 Female	
(Numerator: Number of adults and	



children who are still alive and on
treatment at 12 months after
initiating ART)
Age/Sex: 50+ Female (Numerator:
Number of adults and children who
are still alive and on treatment at
12 months after initiating ART)
Age/Sex: <1 (Denominator: Total
number of adults and children who
initiated ART in the 12 months prior
to the beginning of the reporting
period, including those who have
died, those who have stopped
ART, and those lost to follow-up)
Age/Sex: 1-9 (Denominator: Total
number of adults and children who
initiated ART in the 12 months prior
to the beginning of the reporting
period, including those who have
died, those who have stopped
ART, and those lost to follow-up)
Age/Sex: 10-14 Male
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)
Age/Sex: 15-19 Male
(Denominator: Total number of
adults and children who initiated
ART in the 12 months prior to the
beginning of the reporting period,
including those who have died,
those who have stopped ART, and



The state of the s	
those lost to follow-up)	
Age/Sex: 20-24 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 25-49 Male	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 50+ Male (Denominator:	
Total number of adults and children	
who initiated ART in the 12 months	
prior to the beginning of the	
reporting period, including those	
who have died, those who have	
stopped ART, and those lost to	
· ·	
follow-up)	
Age/Sex: 10-14 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 15-19 Female	
(Denominator: Total number of	
adults and children who initiated	



ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 20-24 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 25-49 Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Age/Sex: 50+ Female	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age: <15 (Numerator:	
Number of adults and children who	
are still alive and on treatment at	
12 months after initiating ART)	
Aggregated Age: 15+ (Numerator:	
Number of adults and children who	
are still alive and on treatment at	



¥	
12 months after initiating ART)	
Aggregated Age: <15	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Aggregated Age: 15+	
(Denominator: Total number of	
adults and children who initiated	
ART in the 12 months prior to the	
beginning of the reporting period,	
including those who have died,	
those who have stopped ART, and	
those lost to follow-up)	
Numerator by Status: Pregnant	23,374
Numerator by Status:	0
Breastfeeding	0
Denominator by Status: Pregnant	33,790
Denominator by Status:	0
Breastfeeding	0
Aggregated Age/Sex: <15 Male	
(Numerator: Number of adults and	
children who are still alive and on	2,996
treatment at 12 months after	
initiating ART)	
Aggregated Age/Sex: 15+ Male	
(Numerator: Number of adults and	
children who are still alive and on	46,552
treatment at 12 months after	
initiating ART)	
Aggregated Age/Sex: <15 Female	
(Numerator: Number of adults and	3,013
1.	



c	children who are still alive and on	
t	reatment at 12 months after	9 dd 100,148 3,969 dd 71,323 dd 9 3,971 dd
ir	nitiating ART)	
A	Aggregated Age/Sex: 15+ Female	
(	(Numerator: Number of adults and	
2	children who are still alive and on	100,148
I	reatment at 12 months after	
	nitiating ART)	
	Aggregated Age/Sex: <15 Male	
	Denominator: Total number of	
`	adults and children who initiated	
	ART in the 12 months prior to the	
	peginning of the reporting period,	3,969
	ncluding those who have died,	
t	those who have stopped ART, and	
	those lost to follow-up)	
A	Aggregated Age/Sex: 15+ Male	
	(Denominator: Total number of	
`	adults and children who initiated	
	ART in the 12 months prior to the	
	beginning of the reporting period,	71,323
	ncluding those who have died,	
tl	those who have stopped ART, and	
	those lost to follow-up)	
A	Aggregated Age/Sex: <15 Female	
	(Denominator: Total number of	
•	adults and children who initiated	
	ART in the 12 months prior to the	
	peginning of the reporting period,	3,971
	ncluding those who have died,	
	those who have stopped ART, and	
	hose lost to follow-up)	
	Aggregated Age/Sex: 15+ Female	
	Denominator: Total number of	
	dults and children who initiated	155,263
	RT in the 12 months prior to the	
-	TITLE IZ IIIOIIIIIS PIIOI IO IIIE	



beginning of the reporting period,
including those who have died,
those who have stopped ART, and
those lost to follow-up)



## **Partners and Implementing Mechanisms**

## **Partner List**

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
9464	Africare	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
9526	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development	GHP-State	0
9562	National Alliance of State and Territorial AIDS Directors	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
9569	Edication Development Center	NGO	U.S. Agency for International Development	GHP-State	3,424,291
9610	International Organization for Migration	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	0
9816	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-State	0
11498	U.S. Peace Corps	Other USG	U.S. Peace Corps	GHP-State	200,000



		Agency			
11500	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	1,595,446
12510	South Africa Partners	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12887	AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13000	COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13558	Human Science Research Council of South Africa	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13567	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers	GHP-State	0



			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	Population		Human		
13570	Services	NGO	Services/Centers	GHP-State	0
	International		for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
			Human		
13577	HIV Managed	NGO	Services/Centers	GHP-State	0
	Care Solutions		for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	Shout It Now	NGO	Human		
13585			Services/Centers	GHP-State	0
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
			Human		
13608	University of	University		GHP-State	0
	Washington		for Disease		
			Control and		
			Prevention		
			U.S. Department		
	Columbia		of Health and		
13618	University	University	Human	GHP-State	0
	Mailman School		Services/Centers		
	of Public Health		for Disease		



			Control and		
			Prevention		
			U.S. Department of Health and		
			Human		
13619	JHPIEGO	University		GHP-State	0
10010	0	-	for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
			Human		
13644	University of Cape	University	Services/Centers	GHP-State	0
	Town		for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	Hoolth Information		Human		
13682	Health Information Systems Program	Private Contractor	Services/Centers	GHP-State	0
	Systems Frogram		for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	Health and		Human		
13688	Development	NGO	Services/Centers	GHP-State	0
	Africa		for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
13695	Epicentre AIDS	NGO	Human	GHP-State	0
	Risk Management		Services/Centers		
			for Disease		
			Control and		



			Prevention		
13709	University of	University	U.S. Department of Health and Human Services/Health	GHP-State	2,694,225
	Washington	· · · · · · · · · · · · · · · · · · ·	Resources and Services Administration		-,55 ,_55
42750	University of		U.S. Department of Health and Human	CUD Ctate	
13750	Stellenbosch, South Africa	University	Services/Centers for Disease Control and Prevention	GHP-State	0
13761	Aurum Health Research	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	0
			Prevention U.S. Department		
13767	Re-Action!	NGO	of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13771	Howard University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0



	1	1			
13789	South African Clothing & Textile Workers' Union	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13793	TB/HIV Care	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13797	Health Systems Trust	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13798	Soul City	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13800	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13888	Population	NGO	U.S. Department	GHP-State	0



	Services		of Health and		
	International		Human		
			Services/Centers		
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
			Human		
13903	Community Media	NGO	Services/Centers	GHP-State	0
	Trust		for Disease		
			Control and		
			Prevention		
			U.S. Department		
		Implementing Agency	of Health and		
			Human		
13904	TB/HIV Care		Services/Centers	GHP-State	0
			for Disease		
			Control and		
			Prevention		
	International		U.S. Department		
	Center for AIDS		of Health and		
	Care and		Human		
13923	Treatment	University	Services/Health	GHP-State	0
	Programs,		Resources and		
	Columbia		Services		
	University		Administration		
			U.S. Department		
			of Health and		
			Human		
13938	Catholic Medical	FBO	Services/Centers	GHP-State	0
	Mission Board		for Disease		
			Control and		
			Prevention		
	South Africa		U.S. Department		
14126	Partners	NGO	of Health and	GHP-State	0



			<u> </u>		
			Human		
			Services/Centers		
			for Disease		
			Control and		
			Prevention		
14291	Hospice and Palliative Care Assn. Of South Africa	NGO	U.S. Agency for International Development	GHP-State	8,405,979
			U.S. Agency for		
14295	FHI 360	NGO	International	GHP-State	16,424,193
			Development		
	Management		U.S. Agency for		
14617	Sciences for	NGO	International	GHP-State	0
	Health		Development		
	Foundation for		U.S. Agency for		
14623	Professional	NGO	International	GHP-State	0
	Development		Development		
			U.S. Agency for		
14631	Pact, Inc.	Private Contractor	International	GHP-State	13,950,208
			Development		
			U.S. Agency for		
14667	Tulane University	University	International	GHP-State	0
			Development		
	University of North		•		
	Carolina at		U.S. Agency for		
14846	Chapel Hill,	University	International	GHP-State	3,654,520
	Carolina	,	Development		, , .
	Population Center				
			U.S. Agency for		
16372	Right To Care,	NGO	International	GHP-State	0
.00,2	South Africa		Development		
			U.S. Department		
16583	Aurum Health	NGO	of Health and	GHP-State	0
10000	Research			Or II -Olale	
			Human		



			<u> </u>	1	
			Services/Centers for Disease Control and Prevention		
			U.S. Department of Health and Human		
16584	Beyond Zero	NGO	Services/Centers for Disease Control and Prevention	GHP-State	0
16772	National Department of Health	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	22,242,958
16773	South African National AIDS Council	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	387,331
16775	Aurum Health Research	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,214,975
16807	University of Stellenbosch, South Africa	University	U.S. Department of Health and Human Services/Centers	GHP-State	1,500,000



			for Disease		
			Control and		
			Prevention		
16808	University of Kwazulu-Natal, Nelson Mandela School of Medicine, Comprehensive International Program for Research on AIDS	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,000,000
16929	TBD	TBD	Redacted	Redacted	Redacted
16979	Regional Psychosocial Support Initiative, South Africa	NGO	U.S. Agency for International Development	GHP-State	0
16980	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	0
16981	Africa Health Placements	NGO	U.S. Agency for International Development	GHP-State	0
16982	Foundation for Professional Development	NGO	U.S. Agency for International Development	GHP-State	8,464,652
16984	South Africa Partners	NGO	U.S. Agency for International Development	GHP-State	707,872
16987	Childline Mpumalanga	NGO	U.S. Agency for International Development	GHP-State	750,000
16988	Kheth'Impilo	NGO	U.S. Agency for International	GHP-State	0



			Development		
16989	Childwelfare Bloemfontein & Childline Free State	NGO	U.S. Agency for International Development	GHP-State	397,634
16990	Children in Distress	NGO	U.S. Agency for International Development	GHP-State	1,702,727
16991	Future Families	Implementing Agency	U.S. Agency for International Development	GHP-State	0
16992	HIVSA	Implementing Agency	U.S. Agency for International Development	GHP-State	953,076
16993	NACOSA (Networking AIDS Community of South Africa)	Implementing Agency	U.S. Agency for International Development	GHP-State	1,611,864
17017	National Association of Childcare Workers	NGO	U.S. Agency for International Development	GHP-State	4,553,580
17018	AgriAIDS	NGO	U.S. Agency for International Development	GHP-State	2,199,767
17019	Anova Health Institute	NGO	U.S. Agency for International Development	GHP-State	2,909,005
17020	Anova Health Institute	NGO	U.S. Agency for International Development	GHP-State	12,572,403
17021	Right To Care, South Africa	NGO	U.S. Agency for International Development	GHP-State	19,350,805
17022	The South-to-South	Private Contractor	U.S. Agency for International	GHP-State	0



	Partnership for		Development		
	Comprehensive		Bevelopment		
	Family HIV Care				
	and Treatment				
	Program (S2S)				
	i rogram (626)		II.C. Aganay for		
17023	Broadreach	NGO	U.S. Agency for International	GHP-State	20 209 547
17023	Broadreach	INGO	Development	GHF-State	30,208,547
	E. J. C. J. C.		·		
17004	Foundation for	NOO	U.S. Agency for		
17024	Professional	NGO	International	GHP-State	0
	Development		Development		
	Wits Health				
	Consortium,	Implementing	U.S. Agency for		
17025	Health Economics	Agency	International	GHP-State	3,800,000
	and Epidemiology		Development		
	Research Office				
	Mothers to	Implementing	U.S. Agency for		
17026	Mothers (M2M)	Agency	International	GHP-State	0
	Woulder (WZW)	rigorioy	Development		
	Wits Reproductive		U.S. Agency for		
17027	Health& HIV	NGO	International	GHP-State	3,300,000
	Institute		Development		
	Wits Reproductive		U.S. Agency for		
17028	Health& HIV	NGO	International	GHP-State	3,720,044
	Institute		Development		
	Witkoppen Health		U.S. Agency for		
17029	& Welfare Centre	NGO	International	GHP-State	2,233,441
	(WHWC)		Development		
			U.S. Department		
			of Health and		
			Human		
17033	Medical Research		Services/Centers	GHP-State	130,056
	Council	Agency	for Disease		
			Control and		
			Prevention		



Equadation for		II S. Agonov for		
	NCO		CHD State	27 927 492
	NGO		GnP-State	27,837,483
		-		
·				
	NGO		GHP-State	7,401,625
Institute		Development		
Maternal,		U.S. Agency for		
	Implementing		GHP-State	13,469,013
Child Health	Agency			, , , , , , , , , , , , , , , , , , , ,
(MatCH)				
		U.S. Agency for		
Broadreach	NGO	International	GHP-State	0
		Development		
Wits Reproductive		U.S. Agency for		
Health& HIV	NGO	International	GHP-State	0
Institute		Development		
		U.S. Agency for		
Kheth'Impilo	NGO	International	GHP-State	9,449,379
		Development		
		U.S. Department		
		of Health and		
American		Human		
International	NGO	Services/Health	GHP-State	204,685
Health Alliance		Resources and		
		Services		
		Administration		
		U.S. Department		
		of Health and		
		Human		
	Private Contractor	Services/Centers	GHP-State	410,000
Research Council		for Disease		
		Control and		
		Prevention		
National Health		U.S. Department		
Laboratory	Parastatal	of Health and	GHP-State	4,930,269
	Health& HIV Institute  Maternal, Adolscent and Child Health (MatCH)  Broadreach  Wits Reproductive Health& HIV Institute  Kheth'Impilo  American International Health Alliance  Human Sciences Research Council	Professional Development  Wits Reproductive Health& HIV Institute  Maternal, Adolscent and Child Health (MatCH)  Broadreach  Wits Reproductive Health& HIV Institute  Kheth'Impilo  American International International Health Alliance  Human Sciences Research Council  National Health  Parastatal	Professional Development  Wits Reproductive Health& HIV Institute  Maternal, Adolscent and Child Health (MatCH)  Broadreach  Wits Reproductive Health& HIV Institute  Modernal, Adolscent and Child Health (MatCH)  Broadreach  Wits Reproductive Health& HIV Institute  Wits Reproductive Health& HIV Institute  NGO  International Development  U.S. Agency for International Development  U.S. Department of Health and Human Services Administration  U.S. Department of Health and Human Services Administration  U.S. Department of Health and Human Services Control and Prevention  National Health  Parastatal	Professional Development  Wits Reproductive Health& HIV Institute  Maternal, Adolscent and Child Health (MatCH)  Broadreach  Wits Reproductive Health& HIV Institute  Maternal, Adolscent and Child Health (MatCH)  Broadreach  Wits Reproductive Health& HIV Institute  Moo  Broadreach  Wits Reproductive Health& HIV Institute  Wits Reproductive Health& HIV Institute  Wits Reproductive Health& HIV Institute  Moo  Moo  Moo  Moo  Moo  Moo  Moo  M



	Services		Human		
			Services/Centers		
			for Disease		
			Control and		
			Prevention		
			U.S. Department of Health and		
			Human		
17505	United Nations	Multi-lateral		GHP-State	500,000
	Children's Fund	Agency	for Disease		,
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
			Human		
17506	Beyond Zero	NGO	Services/Centers	GHP-State	1,800,000
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
			Human		
17507	Kheth'Impilo	NGO	Services/Centers	GHP-State	2,325,000
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
			Human		
17510	Macro Atlanta	Private Contractor	Services/Centers	GHP-State	0
			for Disease		
			Control and		
			Prevention		
	\\/ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\	Multi lote :-!	U.S. Department		
17512	World Health	Multi-lateral	of Health and	GHP-State	256,177
	Organization	Agency	Human		



				1	
			Services/Centers		
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	Cauth Africa		Human		
17533	South Africa	NGO	Services/Centers	GHP-State	4,258,017
	Partners		for Disease		
			Control and		
			Prevention		
			U.S. Agency for		
17536	FHI 360	NGO	International	GHP-State	0
			Development		
	Johns Hopkins				
	Health and		U.S. Agency for		
17537	Education in	NGO	International	GHP-State	4,966,195
	South Africa		Development		
	Johns Hopkins				
	Health and		U.S. Agency for		
17538	Education in	NGO	International	GHP-State	6,342,102
	South Africa		Development		
			U.S. Department		
			of Health and		
			Human		
17767	Broadreach	NGO	Services/Centers	GHP-State	300,000
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	Columbia		Human		
17768	University	University	Services/Centers	GHP-State	450,000
	Mailman School		for Disease		
	of Public Health		Control and		
			Prevention		



		1	<u> </u>	1	1
17769	University of Washington	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,175,000
17790	The Centre for HIV and AIDS Prevention Studies	NGO	U.S. Agency for International Development	GHP-State	0
17791	Grassroots Soccer	NGO	U.S. Agency for International Development	GHP-State	0
17792	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-State	0
17801	University of North Carolina at Chapel Hill, Carolina Population Center	University	U.S. Agency for International Development	GHP-State	600,000
17968	Wits Health Consortium, Reproductive Health Research Unit	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	818,550
17969	University of Stellenbosch, South Africa	University	U.S. Department of Health and Human Services/Health Resources and Services	GHP-State	0



			Administration		
17980	South African Military Health Service	Host Country Government Agency	U.S. Department of Defense	GHP-State	0
17981	Society for Family Health - South Africa	NGO	U.S. Department of Defense	GHP-State	0
18021	Health Information Systems Program	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,350,000
18022	TBD	TBD	Redacted	Redacted	Redacted
18023	TBD	TBD	Redacted	Redacted	Redacted
18083	COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	650,000
18231	Population Services International/Soci ety for Family Health	NGO	U.S. Department of Defense	GHP-State	0
18254	TBD	TBD	Redacted	Redacted	Redacted
18298	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	1,000,000
18299	TBD	TBD	Redacted	Redacted	Redacted
18300	Chemonics International	Private Contractor	U.S. Agency for International	GHP-State	0



			Development		
18307	UCSF CDC HQ	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	200,000
18313	UNAIDS - Joint United Nations Programme on HIV/AIDS	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	350,000
18314	National Alliance of State and Territorial AIDS Directors	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
18321	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	8,076,885
18480	Foundation for Professional Development	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,943,068
18481	Health Systems Trust	NGO	U.S. Department of Health and Human Services/Centers	GHP-State	46,958,429



				1	
			for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
		Landa a de Car	Human		
18482	TB/HIV Care	Implementing	Services/Centers	GHP-State	35,640,460
		Agency	for Disease		
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
	Wits Health		Human		
18483	Consortium (Pty)	Private Contractor		GHP-State	2,157,296
	Limited		for Disease		,
			Control and		
			Prevention		
			U.S. Department		
			of Health and		
			Human		
18484	Aurum Health	NGO		GHP-State	36,024,762
	Research		for Disease		, -
			Control and		
			Prevention		
18547	TBD	TBD	Redacted	Redacted	Redacted
			U.S. Department		
			of Health and		
			Human		
18576	Cardno Emerging	NGO	Services/Centers	GHP-State	300,000
<del>-</del>	Markets		for Disease	2 13.22	-,
			Control and		
			Prevention		
			U.S. Agency for		
18594	Population	NGO	International	GHP-State	400,000
	Council		Development		,
18650	TBD	TBD	Redacted	Redacted	Redacted
	I .	1	1		





# Implementing Mechanism(s)

**Implementing Mechanism Details** 

mipromoting moontained potante				
Mechanism ID: 9464	Mechanism Name: Africare			
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement			
Prime Partner Name: Africare				
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: No			
Global Fund / Multilateral Engagement: N/A				
G2G: No	Managing Agency:			

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A				
Applied Pipeline Amount: 0					
Total All Funding Sources and Applied Pipeline A	Amount: 0				
Funding Source Funding Amount					
GHP-State	0				

### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information** 

Budget Code Information						
Mechanism ID:	9464					
Mechanism Name:	Africare					
Prime Partner Name:	Africare					
Strategic Area	Budget Code	Planned Amount	On Hold Amount			
Care	НВНС	0	0			
Strategic Area	Budget Code	Planned Amount	On Hold Amount			



Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

### **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 9526	Mechanism Name: Supply Chain Management System (SCMS)	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: Partnership for Supply Chain Management		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 0			
Funding Source Funding Amount			
GHP-State	0		

(No data provided.)

Budget Code Information				
Mechanism ID: 9526				
Mechanism Name:	Supply Chain Management System (SCMS)			
Prime Partner Name:	Partnership for Supply	Partnership for Supply Chain Management		
Strategic Area	Budget Code Planned Amount On Hold Amount			
Governance and Systems	OHSS	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	CIRC	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	HTXD	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	HTXS	0	0	

# **Implementing Mechanism Indicator Information**



**Implementing Mechanism Details** 

Mechanism ID: 9562	Mechanism Name: National Alliance of State and Territorial AIDS Directors	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: National Alliance of State and Territorial AIDS Directors		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 0			
Funding Source Funding Amount			
GHP-State	0		

# **Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information** 

Budget Code information				
Mechanism ID:	9562			
Mechanism Name:	National Alliance of State and Territorial AIDS Directors			
Prime Partner Name:	National Alliance of State and Territorial AIDS Directors			
Strategic Area	ea Budget Code Planned Amount On Hold Amount			
Care	НВНС	0	0	

#### **Implementing Mechanism Indicator Information**



(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 9569	Mechanism Name: South Africa School-Based Sexuality and HIV Prevention Education Activity	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: Edication Development Center		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 3,424,291	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 392,003			
Total All Funding Sources and Applied Pipeline Amount: 3,816,294			
Funding Source Funding Amount			
GHP-State	3,424,291		

**Cross-Cutting Budget Attribution(s)** 

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	150,000
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Water	100,000
Motor Vehicles: Purchased	37,963
Education	100,000
Condom programming	100,000

**Budget Code Information** 

Budget Code information			
Mechanism ID: Mechanism Name:	South Africa School-Based Sexuality and HIV Prevention Education Activity		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	1,548,651	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,875,640	0

### **Implementing Mechanism Indicator Information**



Indicator Number	Label	2018
	Number of the target population who completed a	
PP_PREV_DSD	standardized HIV prevention intervention including the minimum components during the reporting period.	88,074
PP_PREV_DSD	Age/sex: 10-14 Male	8,806
PP_PREV_DSD	Age/sex: 15-19 Male	21,129
PP_PREV_DSD	Age/sex: 20-24 Male	4,407
PP_PREV_DSD	Age/sex: 25-49 Male	1,763
PP_PREV_DSD	Age/sex: 50+ Male	883
PP_PREV_DSD	Age/sex: 10-14 Female	13,214
PP_PREV_DSD	Age/sex: 15-19 Female	30,819
PP_PREV_DSD	Age/sex: 20-24 Female	4,407
PP_PREV_DSD	Age/sex: 25-49 Female	1,763
PP_PREV_DSD	Age/sex: 50+ Female	883
PP_PREV_DSD	Sum of Age/Sex disaggregates	88,074

Mechanism ID: 9610	Mechanism Name: Migrants and Mobile Populations HIV Prevention Program	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: International Organization for Migration		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source Funding Amount		
GHP-State	0	



(No data provided.)

**Budget Code Information** 

Budget Code Information			
Mechanism ID:	9610		
Mechanism Name:	Migrants and Mobile Populations HIV Prevention Program		
Prime Partner Name:	International Organizati	on for Migration	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

# **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 9816	Mechanism Name: The Thogomleo Project (AIDSTAR)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Program for Appropriate Technology in Health		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipe	eline Amount: 0	
Funding Source	Funding Amount	
GHP-State	0	

(No data provided.)

**Budget Code Information** 

Budgot Godo information			
Mechanism ID:	9816		
Mechanism Name:	The Thogomleo Project (AIDSTAR)		
Prime Partner Name:	Program for Appropriate Technology in Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

#### **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 11498	Mechanism Name: U.S. Peace Corps	
Funding Agency: PC	Procurement Type: USG Core	
Prime Partner Name: U.S. Peace Corps		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 200,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 225,000		
Total All Funding Sources and Applied Pip	eline Amount: 425,000	
Funding Source	Funding Amount	
GHP-State	200,000	

Gender: Gender Equality	5,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Gender: GBV	5,000
Focus Area:	GBV Prevention

**Budget Code Information** 

Mechanism ID: Mechanism Name: Prime Partner Name:	U.S. Peace Corps		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	24,564	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	81,318	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	47,059	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	47,059	0

# **Implementing Mechanism Indicator Information**

Indicator Number	Label	2018
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	2,540
PP_PREV_TA	Age/sex: 10-14 Male	66
PP_PREV_TA	Age/sex: 15-19 Male	251
PP_PREV_TA	Age/sex: 20-24 Male	382
PP_PREV_TA	Age/sex: 25-49 Male	380
PP_PREV_TA	Age/sex: 50+ Male	0
PP_PREV_TA	Age/sex: 10-14 Female	133
PP_PREV_TA	Age/sex: 15-19 Female	442
PP_PREV_TA	Age/sex: 20-24 Female	507
PP_PREV_TA	Age/sex: 25-49 Female	379
PP_PREV_TA	Age/sex: 50+ Female	0
PP_PREV_TA	Sum of Age/Sex disaggregates	2,540
GEND_GBV_TA	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	2,000
OVC_SERV_TA	Age/Sex: 10-14 Male	200
OVC_SERV_TA	Age/Sex: 15-17 Male	204
OVC_SERV_TA	By age/sex: 18-24 Male	104
OVC_SERV_TA	By age/sex: 25+ Male	19
OVC_SERV_TA	Age/Sex: 10-14 Female	209
OVC_SERV_TA	Age/Sex: 15-17 Female	602



OVC_SERV_TA	By age/sex: 18-24 Female	153
OVC_SERV_TA	By age/sex: 25+ Female	119
OVC_SERV_TA	Sum of Age/Sex disaggregates	1,215
OVC_SERV_TA	Age/Sex: <1	35
OVC_SERV_TA	Age/Sex: 1-9	354
OVC_SERV_TA	Program Completion: Active	2,000

**Implementing Mechanism Details** 

g g g g			
Mechanism ID: 11500	Mechanism Name: Community Grants		
Funding Agency: State/AF	Procurement Type: Cooperative Agreement		
Prime Partner Name: U.S. Department of State			
greement Start Date: Redacted Agreement End Date: Redacted			
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: No	Managing Agency:		

Total All Funding Sources: 1,595,446	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 1,595,446			
Funding Source Funding Amount			
GHP-State	1,595,446		

## **Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information** 

Mechanism ID:	11500		
Mechanism Name:	Community Grants		
Prime Partner Name:	U.S. Department of Stat	е	
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	552,446	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	447,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	298,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	298,000	0

# **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 12510 Mechanism Name: South Africa Part		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: South Africa Partners		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		



Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source Funding Amount		
GHP-State	0	

(No data provided.)

**Budget Code Information** 

Budget Code Informa	alion		
Mechanism ID:	12510		
Mechanism Name:	South Africa Partners		
Prime Partner Name:	South Africa Partners		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0

# **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 12887	Mechanism Name: Comp Prev GH000233
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

(No data provided.)

**Budget Code Information** 

Budget Code Information			
Mechanism ID:	12887		
Mechanism Name:	Comp Prev GH000233		
Prime Partner Name:	AIDS Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

### **Implementing Mechanism Indicator Information**

(No data provided.)

Machaniam ID: 12000	Mechanism Name: Council of Scientific and	
Mechanism ID: 13000	Industrial Research	



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH	
Agreement Start Date: Redacted Agreement End Date: Redacted	
TBD: No New Mechanism: No	
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	
GHP-State	0	

(No data provided.)

**Budget Code Information** 

- 3	zaagot oodo iiio:madon			
	Mechanism ID:	13000		
	Mechanism Name:	Council of Scientific and	d Industrial Research	
	Prime Partner Name:	COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH		
	Strategic Area	Budget Code	Planned Amount	On Hold Amount
	Care	HVTB	0	0

# **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 13558	Mechanism Name: GH000258
INICCHAINSIN ID. 13330	Wiechanisin Name. Gridduzso



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Human Science Research Council of South Africa		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	
GHP-State	0	

(No data provided.)

**Budget Code Information** 

Budget Code Information			
Mechanism ID:	13558		
Mechanism Name:	GH000258		
Prime Partner Name:	Human Science Research Council of South Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

### **Implementing Mechanism Indicator Information**



(No data provided.)

**Implementing Mechanism Details** 

mprementing meentament pertane		
Mechanism ID: 13567	Mechanism Name: GH000251	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of California at San Francisco		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 0			
Funding Source	Funding Amount		
GHP-State	0		

# **Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information** 

Mechanism ID: Mechanism Name: Prime Partner Name:			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

### **Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 13570	Mechanism Name: MMC GH000248		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Population Services International			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: No	Managing Agency:		

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied	Pipeline Amount: 0
Funding Source	Funding Amount
GHP-State	0

#### **Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information** 

	•		
Mechanism ID:	13570		
Mechanism Name:	MMC GH000248		
Prime Partner Name:	Population Services Inte	ernational	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

# **Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 13577	Mechanism Name: GH000291	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: HIV Managed Care S	olutions	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	
GHP-State	0	

### **Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information** 

Budget Code information			
Mechanism ID:	13577		
Mechanism Name:	GH000291		
Prime Partner Name:	HIV Managed Care Solu	tions	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

### **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 13585	Mechanism Name: GH000285
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Shout It Now	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No New Mechanism: No	
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 0			
Funding Source	Funding Amount		
GHP-State	0		



(No data provided.)

**Budget Code Information** 

Budget Code Informa	ation		
Mechanism ID:	13585		
Mechanism Name:	GH000285		
Prime Partner Name:	Shout It Now		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0

#### **Implementing Mechanism Indicator Information**

(No data provided.)

mipromorning moontainem 2 ctaine		
Mechanism ID: 13608	Mechanism Name: GH000324	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of Washington		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source Funding Amount		
GHP-State	0	



(No data provided.)

**Budget Code Information** 

Budget Code Informa	ation		
Mechanism ID:	13608		
Mechanism Name:	GH000324		
Prime Partner Name:	University of Washingto	on	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

### **Implementing Mechanism Indicator Information**

(No data provided.)

<u> </u>		
Mechanism ID: 13618	Mechanism Name: GH000249	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Columbia University Mailman School of Public Health		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		



Funding Source	Funding Amount
GHP-State	0

(No data provided.)

**Budget Code Information** 

Budget Code Illionia	ation		
Mechanism ID:	13618		
Mechanism Name:	GH000249		
Prime Partner Name:	Columbia University Mailman School of Public Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

#### **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 13619	Mechanism Name: GH000237	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: JHPIEGO		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	
GHP-State	0	

(No data provided.)

**Budget Code Information** 

Budget Code Illionia	ation		
Mechanism ID:	13619		
Mechanism Name:	GH000237		
Prime Partner Name:	JHPIEGO		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

### **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 13644	Mechanism Name: GH000371	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of Cape Town		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	
GHP-State	0	

(No data provided.)

**Budget Code Information** 

Baaget Gode Information			
Mechanism ID:	13644		
Mechanism Name:	GH000371		
Prime Partner Name:	University of Cape Town		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

#### **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 13682	Mechanism Name: GH00460		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement		
Prime Partner Name: Health Information Systems Program			
Agreement Start Date: Redacted	Agreement End Date: Redacted		



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipelin	e Amount: 0
Funding Source	Funding Amount
GHP-State	0

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	GH00460		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

(No data provided.)

**Implementing Mechanism Details** 

implementing incontained betaile		
Mechanism ID: 13688	Mechanism Name: GH000252	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Health and Development Africa		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline	Amount: 0
Funding Source	Funding Amount
GHP-State	0

### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

|--|



Mechanism Name:	GH000252		
Prime Partner Name:	Health and Developmen	nt Africa	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 13695	Mechanism Name: GH00372	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Epicentre AIDS Risk Management		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 0
Funding Source	Funding Amount
GHP-State	0

#### **Cross-Cutting Budget Attribution(s)**



Budget Code Information			
Mechanism ID: 13695			
Mechanism Name:	GH00372		
Prime Partner Name:	Epicentre AIDS Risk Ma	nagement	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

### **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 13709	Mechanism Name: University of Washington - ITECH	
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of Washington		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	



Total All Funding Sources: 2,694,225	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 2,694,225		
Funding Source Funding Amount		
GHP-State	2,694,225	

Human Resources for Health	2,675,000

**Budget Code Information** 

Budget Code illionia	20011		
Mechanism ID:	3709		
Mechanism Name:	University of Washington - ITECH		
Prime Partner Name:	University of Washington		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	2,675,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	19,225	0

#### **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 13750	Mechanism Name: GH000320	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of Stellenbosch, South Africa		



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	
GHP-State	0	

(No data provided.)

**Budget Code Information** 

Mechanism ID:	3750		
Mechanism Name:	GH000320		
Prime Partner Name:	University of Stellenbos	sch, South Africa	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

#### **Implementing Mechanism Indicator Information**



(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 13761	Mechanism Name: District HRH GH000162	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Aurum Health Research		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source Funding Amount		
GHP-State	0	

## **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Mechanism ID:	13761		
Mechanism Name:	District HRH GH000162		
Prime Partner Name:	Aurum Health Research		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Indicator Number	Label	2018
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Negative	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Negative	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VMMC: 15+, Negative	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative	0
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of	0



	Isoniazid Preventive Therapy (IPT) during the reporting period	
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	0
TB_PREV_TA	By Therapy type (Numerator): Continuous IPT	0

**Implementing Mechanism Details** 

Mechanism ID: 13767 Mechanism Name: GH000255	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Re-Action!	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	
GHP-State	0	

### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Baagot Goao iiii oi iiii			
Mechanism ID:	13767		
Mechanism Name:	GH000255		
Prime Partner Name:	Re-Action!		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

(No data provided.)

**Implementing Mechanism Details** 

implementing meenanism betans		
Mechanism ID: 13771	Mechanism Name: GH000391	
Funding Agency: HHS/CDC Procurement Type: Cooperative Agreement		
Prime Partner Name: Howard University		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 0
Funding Source	Funding Amount
GHP-State	0

### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Mechanism ID:	13771
Mechanism Name:	GH000391
Prime Partner Name:	Howard University



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0

(No data provided.)

**Implementing Mechanism Details** 

implementing incondition betains		
Mechanism ID: 13789	Mechanism Name: GH000265	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: South African Clothing & Textile Workers' Union		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 0
Funding Source	Funding Amount
GHP-State	0

### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Mechanism ID:	13789
Mechanism Name:	GH000265
Prime Partner Name:	South African Clothing & Textile Workers' Union



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 13793	Mechanism Name: Comprehensive HIV prevention GH000306
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: TB/HIV Care	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline	Amount: 0
Funding Source	Funding Amount
GHP-State	0

### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Mechanism ID:	13793



Mechanism Name: Prime Partner Name:	Comprehensive HIV prevention GH000306 TB/HIV Care		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 13797	Mechanism Name: District Support GH000175
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Systems Trust	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 0
Funding Source	Funding Amount
GHP-State	0

### **Cross-Cutting Budget Attribution(s)**



Budget Code Information			
Mechanism ID: 13797			
Mechanism Name:	District Support GH000175		
Prime Partner Name:	Health Systems Trust		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	0	0

Indicator Number	Label	2018
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	848
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,697
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	70
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	48
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	947
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	632
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	1,697
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	35
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	64
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	475
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	288
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	848

Mechanism ID: 13798	Mechanism Name: GH000294
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Soul City	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline	Amount: 0
Funding Source	Funding Amount
GHP-State	0

(No data provided.)

**Budget Code Information** 

Budget Code Illionia	ation		
Mechanism ID:	13798		
Mechanism Name:	GH000294		
Prime Partner Name:	Soul City		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

### **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 13800	Mechanism Name: TB Capacity Building



	GH000388	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Columbia University Mailman School of Public Health		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	
GHP-State	0	

(No data provided.)

**Budget Code Information** 

- 3				
	Mechanism ID:	13800		
ı	Mechanism Name:	TB Capacity Building GH000388		
	Prime Partner Name:	Columbia University Mailman School of Public Health		
	Strategic Area	Budget Code	Planned Amount	On Hold Amount
	Care	HVTB	0	0

## **Implementing Mechanism Indicator Information**

(No data provided.)



Mechanism ID: 13888	Mechanism Name: Combination Prevention GH000243	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Population Services International		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source Funding Amount		
GHP-State	0	

(No data provided.)

Mechanism ID:	13888		
Mechanism Name:	Combination Prevention GH000243		
Prime Partner Name:	Population Services Int	ernational	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
ŭ	3		

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 13903	Mechanism Name: GH000293	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Community Media Trust		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	
GHP-State	0	

### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Baagot Goao IIII of Illic	
Mechanism ID:	13903



Mechanism Name:	GH000293		
Prime Partner Name:	Community Media Trus	t	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 13904	Mechanism Name: Key Pops GH000257
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: TB/HIV Care	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline A	Amount: 0	
Funding Source	Funding Amount	
GHP-State	0	

#### **Cross-Cutting Budget Attribution(s)**



Mechanism ID:	13904		
Mechanism Name:	Key Pops GH000257		
Prime Partner Name:	TB/HIV Care		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

## **Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 13923	Mechanism Name: NEPI
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center fo	r AIDS Care and Treatment Programs, Columbia University
Agreement Start Date: Redacted Agreement End Date: Redacted	
TBD: No New Mechanism: No	
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline A	Amount: 0	
Funding Source	Funding Amount	
GHP-State	0	

### **Cross-Cutting Budget Attribution(s)**



Daaget Gode Inform	411011		
Mechanism ID:  Mechanism Name:  Prime Partner Name:	NEPI   International Center for	AIDS Care and Treatmen	nt Programs, Columbia
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

## **Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details** 

implementing Mechanism Details	
Mechanism ID: 13938	Mechanism Name: Catholic Medical Mission Board
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Medical Missi	on Board
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied	Pipeline Amount: 0
Funding Source	Funding Amount
GHP-State	o

#### **Cross-Cutting Budget Attribution(s)**



Baagot Goad Inform	uu. u		
Mechanism ID:	13938		
Mechanism Name:	Catholic Medical Mission	n Board	
Prime Partner Name:	Catholic Medical Mission	n Board	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

### **Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 14126	Mechanism Name: MARPs GH000250
Funding Agency: HHS/CDC Procurement Type: Cooperative Agreeme	
Prime Partner Name: South Africa Partners	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied	Pipeline Amount: 0
Funding Source	Funding Amount
GHP-State	o

#### **Cross-Cutting Budget Attribution(s)**



Buaget Gode Inform	411011		
Mechanism ID:	14126		
Mechanism Name:	MARPs GH000250		
Prime Partner Name:	South Africa Partners		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

## **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 14291	Mechanism Name: Care and Support to Improve Patient Outcomes	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Hospice and Palliative Care A	ssn. Of South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 8,405,979	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 1,094,021		
Total All Funding Sources and Applied Pipeline Amount: 9,500,000		
Funding Source Funding Amount		
GHP-State	8,405,979	



Food and Nutrition: Policy, Tools, and Service Delivery	99,520
Condom programming	59,550
Motor Vehicles: Leased	17,350
Human Resources for Health	691,002

Budget Code Information			
Mechanism ID: 14291			
Mechanism Name: Care and Support to Improve Patient Outcomes			
Prime Partner Name:	Hospice and Palliative Care Assn. Of South Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	1,681,196	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	840,598	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	5,884,185	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0



(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 14295	Mechanism Name: Capacity Development and Support Program	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: FHI 360		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 16,424,193	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 1,820,586			
Total All Funding Sources and Applied Pipeline Amount: 18,244,779			
Funding Source Funding Amount			
GHP-State	16,424,193		

**Cross-Cutting Budget Attribution(s)** 

Gender: GBV	308,186
Focus Area:	GBV Prevention
Sub Area:	Implementation
Gender: Gender Equality	308,186
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Focus Area:	Equity in HIV prevention, care, treatment and support
Water	525,000
Motor Vehicles: Purchased	120,000



<b>Budget Code Informa</b>	ation		
Mechanism ID:	14295		
Mechanism Name:	Capacity Development and Support Program		
Prime Partner Name:	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	10,029,558	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	515,553	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	3,979,082	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Indicator Number	Label	2018
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	63,352
PP_PREV_DSD	Age/sex: 10-14 Male	1,581
PP_PREV_DSD	Age/sex: 15-19 Male	6,335
PP_PREV_DSD	Age/sex: 20-24 Male	9,504
PP_PREV_DSD	Age/sex: 25-49 Male	9,504
PP_PREV_DSD	Age/sex: 50+ Male	0
PP_PREV_DSD	Age/sex: 10-14 Female	3,169
PP_PREV_DSD	Age/sex: 15-19 Female	11,085
PP_PREV_DSD	Age/sex: 20-24 Female	12,670
PP_PREV_DSD	Age/sex: 25-49 Female	9,504
PP_PREV_DSD	Age/sex: 50+ Female	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	63,352
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	127,245
HTC_TST_DSD	By Test Result: Positive	10,058
HTC_TST_DSD	Sum of Test Result disaggregates	10,058
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	309



HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	1,548
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	127
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	1,234
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	110
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	530
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	47
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	793
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	64
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: <1, Negative	313
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 1-9, Negative	997
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 1-9, Positive	12
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative	1,449
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: <15, Female, Positive	16
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: <15, Male, Negative	968
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: <15, Male, Positive	9



HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative	8,433
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive	729
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: 15+, Male, Negative	5,617
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Positive	488
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	1,608
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	136
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	8,034
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	675
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	6,431
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	541
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	2,756
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	232
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	4,136
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	350
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Negative	3,495
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Positive	389
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	9,195



HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	1,023
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	8,460
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	940
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: <15, Female, Negative	179
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: <15, Female, Positive	4
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: <15, Male, Negative	119
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: <15, Male, Positive	4
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	16,714
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	1,452
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	11,142
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	969
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	1,578
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	117
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	7,898
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	601



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	6,321
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	483
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	2,710
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	205
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	4,062
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	308
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Negative	0



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	39
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9,  Negative	119
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male, Positive	0
GEND_GBV_DSD	Number of people receiving post-GBV care	922
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	320
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	602
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	602
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	6
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	12
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	80



GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	153
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	49
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	90
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	80
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	152
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	33
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	58
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	64
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	120
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	6
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	12
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	6
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	166,399
OVC_SERV_DSD	Age/Sex: 10-14 Male	16,501
OVC_SERV_DSD	Age/Sex: 15-17 Male	16,513
OVC_SERV_DSD	By: Age/sex: Male 18-24	8,287
OVC_SERV_DSD	By: Age/sex: Male 25+	1,653
OVC_SERV_DSD	Age/Sex: 10-14 Female	16,513
OVC_SERV_DSD	Age/Sex: 15-17 Female	49,536
OVC_SERV_DSD	By: Age/sex: 18-24 Female	12,624



OVC_SERV_DSD	By: Age/sex: 25+ Female	10,833
OVC_SERV_DSD	Sum of Age/Sex disaggregates	99,063
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,031
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	1,576
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	863
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	863
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	863
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	863
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	863
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	863
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	863
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	4,351
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	2,607
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	1,744
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	0



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	11
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	36
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	9
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	9
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	11
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	36
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	9
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	9
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	1,744
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	12,866
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	5,233
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	2,607
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	1,744
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	4,351
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	5,233
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	863
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	1,744



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	12,866
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	5,233
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	1,744
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	4,351
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	5,233
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	863
OVC_SERV_DSD	Age/Sex: <1	1,672
OVC_SERV_DSD	Age/Sex: 1-9	32,267
OVC_SERV_DSD	Program Completion: Active	166,399
OVC_SERV_DSD	Program Completion: Graduation	0
OVC_SERV_DSD	Program Completion: Transferred	0
OVC_SERV_DSD	Program Completion: Exited without graduation	0

9	
Mechanism ID: 14617	Mechanism Name: Systems for Improved Access to Pharmaceuticals and Services Program (SIAPS)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Management Sciences for H	lealth
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source Funding Amount	
GHP-State	0

(No data provided.)

**Budget Code Information** 

Budget Code Information			
Mechanism ID: Mechanism Name: Prime Partner Name:  Mechanism Name: Program (SIAPS)  Management Sciences for Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

### **Implementing Mechanism Indicator Information**

(No data provided.)



Mechanism ID: 14623	Mechanism Name: Increasing Services to Survivors of Sexual Assault	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Foundation for Professional Development		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied	Pipeline Amount: 0
Funding Source	Funding Amount
GHP-State	0

# **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Mechanism ID:	14623		
Mechanism Name:	Increasing Services to Survivors of Sexual Assault		
Prime Partner Name:	Foundation for Professi	Foundation for Professional Development	
Strategic Area	Budget Code Planned Amount On Hold Amount		On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
ŭ	3		

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 14631	Mechanism Name: Government Capacity Building and Support Mechanism	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: Pact, Inc.		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A	4	
G2G: No	Managing Agency:	

Total All Funding Sources: 13,950,208	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipe	eline Amount: 13,950,208	
Funding Source Funding Amount		
GHP-State	13,950,208	

**Cross-Cutting Budget Attribution(s)** 

Gender: GBV	861,006
Focus Area:	GBV Prevention
Sub Area:	Implementation
Gender: Gender Equality	861,006
Focus Area:	Changing harmful gender norms and promoting



	positive gender norms
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Focus Area:	Equity in HIV prevention, care, treatment and support
Human Resources for Health	1,000,000
Water	525,000

**Budget Code Information** 

Budget Code Informa	ation	tion	
Mechanism ID:	4631		
Mechanism Name:	Government Capacity B	Government Capacity Building and Support Mechanism	
Prime Partner Name:	Pact, Inc.		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Care	HKID	13,450,208	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	500,000	0

## **Implementing Mechanism Indicator Information**

Indicator Number	Label	2018
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	207,646
OVC_SERV_DSD	Age/Sex: 10-14 Male	20,764
OVC_SERV_DSD	Age/Sex: 15-17 Male	20,764
OVC_SERV_DSD	By: Age/sex: Male 18-24	10,383
OVC_SERV_DSD	By: Age/sex: Male 25+ 2,0	



OVC_SERV_DSD	Age/Sex: 10-14 Female	20,764
OVC_SERV_DSD	Age/Sex: 15-17 Female	62,303
OVC_SERV_DSD	By: Age/sex: 18-24 Female	15,574
OVC_SERV_DSD	By: Age/sex: 25+ Female	13,500
OVC_SERV_DSD	Sum of Age/Sex disaggregates	124,595
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	7,280
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	21,840
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	5,460
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	4,733
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	7,280
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	7,280
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	3,640
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	727
OVC_SERV_DSD	Age/Sex: <1	2,074
OVC_SERV_DSD	Age/Sex: 1-9	39,446
OVC_SERV_DSD	Program Completion: Active	207,646
OVC_SERV_DSD	Program Completion: Graduation	0
OVC_SERV_DSD	Program Completion: Transferred	0
OVC_SERV_DSD	Program Completion: Exited without graduation	0
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	52,162
OVC_SERV_TA	SERV_TA Age/Sex: 10-14 Male	
OVC_SERV_TA	Age/Sex: 15-17 Male	5,213
OVC_SERV_TA	By age/sex: 18-24 Male	2,611



	<u> </u>	
OVC_SERV_TA	By age/sex: 25+ Male	518
OVC_SERV_TA	Age/Sex: 10-14 Female	5,213
OVC_SERV_TA	Age/Sex: 15-17 Female	15,685
OVC_SERV_TA	By age/sex: 18-24 Female	3,911
OVC_SERV_TA	By age/sex: 25+ Female	3,386
OVC_SERV_TA	Sum of Age/Sex disaggregates	31,324
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14	1,820
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17	5,461
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24	1,365
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 25+	1,182
OVC_SERV_TA	Age/Sex: <1	518
OVC_SERV_TA	Age/Sex: 1-9	9,891
OVC_SERV_TA	Program Completion: Active	52,162
OVC_SERV_TA	Program Completion: Graduated	0
OVC_SERV_TA	Program Completion: Transferred	0
OVC_SERV_TA	Program Completion: Exited without graduation	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 10-14	1,820
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 15-17	1,820
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 18-24	911
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 25+	183

1	
	Mechanism Name: Tulane University - Compiling
Mechanism ID: 14667	Evidence Base for Orphans and Vulnerable
	Children
Funding Agency: USAID	Procurement Type: Cooperative Agreement



Prime Partner Name: Tulane University	
Agreement Start Date: Redacted Agreement End Date: Redacted	
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 0
Funding Source	Funding Amount
GHP-State	0

(No data provided.)

**Budget Code Information** 

Budget Code inform	alion		
Mechanism ID: Mechanism Name: Prime Partner Name:	Tulane University - Compiling Evidence Base for Orphans and Vulnerable Children		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Care	HKID 0 0		

## **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 14846	Mechanism Name: Strategic Information for
---------------------	---



	Evidence-Based Management of HIV and Related Health Program in South Africa
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina at	Chapel Hill, Carolina Population Center
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,654,520	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 345,480	
Total All Funding Sources and Applied Pipe	eline Amount: 4,000,000
Funding Source	Funding Amount
GHP-State	3,654,520

(No data provided.)

Mechanism ID: Mechanism Name: Prime Partner Name:	14846 Strategic Information for Evidence-Based Management of HIV and Related Health Program in South Africa University of North Carolina at Chapel Hill, Carolina Population Center		
Strategic Area	Budget Code Planned Amount On Hold Amount		On Hold Amount
Governance and Systems	HVSI	2,154,520	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	OHSS	1,500,000	0



Systems		

(No data provided.)

Implementing Mechanism Details

implementing wechanism Details	1
Mechanism ID: 16372	Mechanism Name: Voluntary Medical Male Circumcision Service Delivery II Project (VMMC II)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Right To Care, South Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

## **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Mechanism ID:	16372
Mechanism Name:	Voluntary Medical Male Circumcision Service Delivery II Project (VMMC
Prime Partner Name:	II)



	Right To Care, South Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

(No data provided.)

**Implementing Mechanism Details** 

implementing modification because		
Mechanism ID: 16583	Mechanism Name: District Support GH000887	
Funding Agency: HHS/CDC Procurement Type: Cooperative Agreeme		
Prime Partner Name: Aurum Health Research		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Mechanism ID: 16583	
---------------------	--



Mechanism Name: Prime Partner Name:	District Support GH0008  Aurum Health Research		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

(No data provided.)



Mechanism ID: 16584	Mechanism Name: District Support GH000889
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Beyond Zero	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied	Pipeline Amount: 0
Funding Source	Funding Amount
GHP-State	0

# **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Budget Code information				
Mechanism ID:	16584			
Mechanism Name:	District Support GH000889			
Prime Partner Name:	Beyond Zero	Beyond Zero		
Strategic Area	Budget Code Planned Amount On Hold Amount			
Care	НВНС	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HKID	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	



Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

(No data provided.)

Mechanism ID: 16772	Mechanism Name: NDOH (CDC GH001172)	
Funding Agency: HHS/CDC Procurement Type: Cooperative Agreement		
Prime Partner Name: National Department of Health		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
ΓΒD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		



G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 22,242,958	Total Mechanism Pipeline: N/A			
Applied Pipeline Amount: 0				
Total All Funding Sources and Applied Pipeline Amount: 22,242,958				
Funding Source Funding Amount				
GHP-State	22,242,958			

Human Resources for Health	650,000
i idilian resources for ricalin	030,000

Mechanism ID:			
Mechanism Name:	NDOH (CDC GH001172)		
Prime Partner Name:	National Department of	Health	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	6,600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	125,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	450,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	5,650,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	202,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	184,745	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	906,213	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	6,100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	125,000	0

(No data provided.)



Mechanism ID: 16773	Mechanism Name: South African National AIDS Council (CDC GH001173)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: South African National AIDS Council		
Agreement Start Date: Redacted	ent Start Date: Redacted Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 387,331	Total Mechanism Pipeline: N/A			
Applied Pipeline Amount: 0				
Total All Funding Sources and Applied Pipeline Amount: 387,331				
Funding Source Funding Amount				
GHP-State	387,331			

**Cross-Cutting Budget Attribution(s)** 

Key Populations: FSW	50,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Collection and use of strategic information on SWs and clients
Key Populations: MSM and TG	50,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information



**Budget Code Information** 

Budget Code Information				
Mechanism ID:	16773			
Mechanism Name:	Mechanism Name: South African National AIDS Council (CDC GH001173)			
Prime Partner Name:	·			
	Couli Airican National Airic Council			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HLAB	100,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HVSI	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	OHSS	187,331	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVAB	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVCT	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVOP	100,000	0	

## **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 16775	Mechanism Name: AURUM Correctional Services (CDC GH001175)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Aurum Health Research	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,214,975	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipe	eline Amount: 5,214,975	
Funding Source Funding Amount		
GHP-State	5,214,975	

Key Populations: MSM and TG	500,000
Focus Area:	Training of health workers and community outreach
	workers
Focus Area:	Implementation of core HIV prevention interventions
	for MSM/TG that are consistent with the current
	PEPFAR technical guidance
Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Gender: Gender Equality	50,000
Focus Area:	Equity in HIV prevention, care, treatment and
	support
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	700,000
Condom programming	50,000



Budget Code Informa	Budget Code Information		
Mechanism ID:	16775		
Mechanism Name:	AURUM Correctional Services (CDC GH001175)		
Prime Partner Name:	Aurum Health Research		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	1,120,070	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	635,557	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	10,620	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	82,799	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,047,408	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prev	ention	MTCT	0	0
Strate	gic Area	Budget Code	Planned Amount	On Hold Amount
Trea	atment	HTXS	2,118,521	0

Indicator Number	Label	2018
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	650
VMMC_CIRC_DSD	By Age: 15-19	107
VMMC_CIRC_DSD	By Age: 20-24	265
VMMC_CIRC_DSD	By Age: 25-29	198
VMMC_CIRC_DSD	By Age: 30-49	59
VMMC_CIRC_DSD	By Age: 50+	21
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	393
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	650
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	642
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	8
KP_PREV_TA	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	71,122
KP_PREV_TA	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	71,122
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	0



	· · · · · · · · · · · · · · · · · · ·	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	29,453
HTC_TST_TA	By Test Result: Positive	3,504
HTC_TST_TA	Sum of Test Result disaggregates	3,504
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Negative	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Negative	16
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Positive	6
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative	707
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive	231
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative	21,663
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Positive	2,912
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Male, Negative	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Negative	11
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Positive	3
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Negative	573
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Positive	76
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VMMC: 15+, Negative	450
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VMMC: 15+, Positive	61
HTC_TST_TA	By Key Population: People in prisons and other	26,144



	enclosed settings, Negative	
HTC_TST_TA	By Key Population: People in prisons and other enclosed settings, Positive	3,488
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative	105
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive	16
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative	2,350
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive	376
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	0
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	0
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,722
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	2,838
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	31
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,807
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,691
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	31
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0



TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,345
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,346
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,298
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	47
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with	1,293



	documented HIV-positive status during TB treatment	
	during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	47
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	25,666
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	25,025
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	641
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	25,666
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	25,666
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	0
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,754
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	4,601
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	157
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	4,758
TX_NEW_TA	Pregnancy status	0
TX_NEW_TA	People in prisons and other enclosed settings	4,758
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	20,974
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	23,306
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	374



TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male	20,596
	Routine	
TX_PVLS_TA	Numerator: Indication: Routine	20,974
TX_PVLS_TA	Denominator: Indication: Routine	23,265
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15  Male Routine	42
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	663
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+  Male Routine	22,588
TX_PVLS_TA	Denominator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_TA	Unknown Age, Routine, Male	4
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,908
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,343
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,784
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	124
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,084
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	134



	· · · · · · · · · · · · · · · · · · ·	
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	0
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	0
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	473
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	947
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	33
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	903
TB_PREV_TA	By Therapy type (Denominator):Continuous IPT	932
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	14
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	459
TB_PREV_TA	By Therapy type (Numerator): Continuous IPT	471
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	0
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	0

Mechanism ID: 16807	Mechanism Name: University of Stellenbosch
INIACHANISM III: 16XII/	INIACHANISM NAMA: LINIVARSITY OF STAILANNOSCH



	Capacity Building (CDC GH001536)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of Stellenbosch, South Africa		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 1,500,000	Total Mechanism Pipeline: N/A			
Applied Pipeline Amount: 0				
Total All Funding Sources and Applied Pipeline Amount: 1,500,000				
Funding Source Funding Amount				
GHP-State	1,500,000			

Human Resources for Health	1.500.000
Haman Researces for Health	1,000,000

Mechanism ID:	16807			
Mechanism Name:	University of Stellenbosch Capacity Building (CDC GH001536)			
Prime Partner Name:	University of Stellenbos	University of Stellenbosch, South Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	НВНС	70,132	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HVTB	56,433	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	



Care	PDCS	15,028	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	20,113	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	215,580	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	22,714	0

(No data provided.)

Mechanism ID: 16808	Mechanism Name: UKZA CAPRISA Advanced Clinical Care Centres (CDC GH001142)	
Funding Agency: HHS/CDC Procurement Type: Cooperative Agreement		
Prime Partner Name: University of Kwazulu-Natal, Nelson Mandela School of Medicine, Comprehensive		
International Program for Research on AIDS		



Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 3,000,000	Total Mechanism Pipeline: N/A			
Applied Pipeline Amount: 0				
Total All Funding Sources and Applied Pipeline Amount: 3,000,000				
Funding Source Funding Amount				
GHP-State	3,000,000			

Human Resources for Health	1,021,499
	1,521,100

Mechanism ID:  Mechanism Name:  Prime Partner Name:	16808  UKZA CAPRISA Advanced Clinical Care Centres (CDC GH001142)  University of Kwazulu-Natal, Nelson Mandela School of Medicine,  Comprehensive International Program for Research on AIDS		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	525,988	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	423,253	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	112,713	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	MTCT	150,845	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,616,847	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	170,354	0

(No data provided.)

#### **Implementing Mechanism Details**

Mechanism ID: 16929	TBD: Yes	
REDACTED		

Mechanism ID: 16979	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - Regional Psychosocial Support Initiative (REPSSI)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Regional Psychosocial Support Initiative, South Africa		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	



|--|

(No data provided.)

**Budget Code Information** 

Budget Code information			
	16979		
Mechanism ID:	Service Delivery and Support for Families Caring for Orphans and		
Mechanism Name:	Vulnerable Children (OVC) - Regional Psychosocial Support Initiative		
Prime Partner Name:	(REPSSI)		
	Regional Psychosocial Support Initiative, South Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

### **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 16980	Mechanism Name: Applying Science to Strengthen and Improve Systems (ASSIST)	
Funding Agency: USAID Procurement Type: Cooperative Agreement		
Prime Partner Name: University Research Corporation, LLC		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
------------------------------	-------------------------------



Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	
GHP-State	0	

(No data provided.)

**Budget Code Information** 

Dadget Gode Information			
Mechanism ID:	16980		
Mechanism Name:	Applying Science to Strengthen and Improve Systems (ASSIST)		
Prime Partner Name:	University Research Co	rporation, LLC	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

## **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 16981	Mechanism Name: Africa Health Placements NPC
Funding Agency: USAID	Procurement Type: Cooperative Agreement



Prime Partner Name: Africa Health Placements		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied	Pipeline Amount: 0
Funding Source	Funding Amount
GHP-State	0

(No data provided.)

**Budget Code Information** 

Budget Code Illioi Illation			
Mechanism ID:	16981		
Mechanism Name:	Africa Health Placements NPC		
Prime Partner Name:	e: Africa Health Placements		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

## **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 16982	Mechanism Name: A Comprehensive
---------------------	---------------------------------



	Community-Based HIV Prevention, Counselling and Testing Programme for Reduced HIV Incidence		
Funding Agency: USAID	Procurement Type: Cooperative Agreement		
Prime Partner Name: Foundation for Professional Development			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: No	Managing Agency:		

Total All Funding Sources: 8,464,652	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 1,036,441		
Total All Funding Sources and Applied Pipeline Amount: 9,501,093		
Funding Source	Funding Amount	
GHP-State	8,464,652	

Gender: GBV	90,000	
Focus Area:	GBV Prevention	
Sub Area:	Collection and Use of Gender-related Strategic	
	Information	
Sub Area:	Capacity building	
Sub Area:	Monitoring and Evaluation	

	16982
Mechanism ID:	A Comprehensive Community-Based HIV Prevention, Counselling and
Prime Partner Name:	Tasting Programme for Reduced HIV Incidence
Prime Partner Name:	Foundation for Professional Development



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	8,464,652	0

Indicator Number	Label	2018
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	517,456
HTC_TST_DSD	By Test Result: Positive	44,620
HTC_TST_DSD	Sum of Test Result disaggregates	44,620
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	1,286
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	100
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Male, Negative	104
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	6,156
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	539
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Male, Negative	324
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	5,112
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	445
HTC_TST_DSD	Service Delivery Point (Community) Homebased	2,289



	testing: 20-24, Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	200
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative	1,146
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Female, Positive	100
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	3,761
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	325
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Female, Negative	396
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Male, Negative	225
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 1-9, Negative	2,194
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 1-9, Positive	21
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative	7,744
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive	80
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: <15, Male, Negative	5,166
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: <15, Male, Positive	53
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative	64,718
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)	5,707



	Handra Harris AF. Fanda Barris	
	Homebased testing: 15+, Female, Positive	
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: 15+, Male, Negative	43,150
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: 15+, Male, Positive	3,810
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	2,112
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	167
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	11,464
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	924
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	587
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	66
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	9,509
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	779
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	4,258
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	353
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	2,076
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	230
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	6,975
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	600
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	718



	50+, Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	80
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	406
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	44
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	117,049
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	13,388
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	78,030
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	8,917
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14,	865



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	62
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	70
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	4,147
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	313
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	217
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	3,443
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	262
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	1,541
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	117
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	765
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	66
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	2,532
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	196
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	264
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+,	22



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	150
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1,  Negative	219
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9,  Negative	1,229
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	23
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Negative	5,014
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Positive	105
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Negative	3,508
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Positive	66
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative	43,151
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive	3,806
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	28,766
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	2,535

Mechanism ID: 16984	Mechanism Name: South Africa Executive Leadership Program for Health
Funding Agency: USAID	Procurement Type: Cooperative Agreement



Prime Partner Name: South Africa Partners		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 707,872	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 92,128	
Total All Funding Sources and Applied Pipel	ine Amount: 800,000
Funding Source	Funding Amount
GHP-State	707,872

Human Resources for Health	707,872
Education	707,872

**Budget Code Information** 

-uugut oous misim			
Mechanism ID:	16984		
Mechanism Name:	South Africa Executive Leadership Program for Health		
Prime Partner Name:	me Partner Name: South Africa Partners		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	707,872	0

#### **Implementing Mechanism Indicator Information**

(No data provided.)



implementing meenamen betane	
Mechanism ID: 16987	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - Childline Mpumalanga & Limpopo
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Childline Mpumalanga	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 750,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pip	peline Amount: 750,000	
Funding Source	Funding Amount	
GHP-State	750,000	

**Cross-Cutting Budget Attribution(s)** 

Gender: GBV	60,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Gender: Gender Equality	40,000
	Changing harmful gender norms and promoting positive gender norms
	Equity in HIV prevention, care, treatment and support
Water	50,000



**Budget Code Information** 

Mechanism ID:  Mechanism Name:  Prime Partner Name:	Service Delivery and Support for Families Caring for Orphans and  Vulnerable Children (OVC) - Childline Moumalanga & Limpono		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	750,000	C

# **Implementing Mechanism Indicator Information**

Indicator Number	Label	2018
	Number of active beneficiaries served by PEPFAR	
OVC_SERV_DSD	OVC programs for children and families affected by HIV/AIDS	16,500
OVC_SERV_DSD	Age/Sex: 10-14 Male	2,950
OVC_SERV_DSD	Age/Sex: 15-17 Male	2,950
OVC_SERV_DSD	By: Age/sex: Male 18-24	195
OVC_SERV_DSD	By: Age/sex: Male 25+	100
OVC_SERV_DSD	Age/Sex: 10-14 Female	4,415
OVC_SERV_DSD	Age/Sex: 15-17 Female	4,415
OVC_SERV_DSD	By: Age/sex: 18-24 Female	265
OVC_SERV_DSD	By: Age/sex: 25+ Female	165
OVC_SERV_DSD	Sum of Age/Sex disaggregates	14,730
OVC_SERV_DSD	Age/Sex: <1	225
OVC_SERV_DSD	Age/Sex: 1-9	820
OVC_SERV_DSD	Program Completion: Active	16,500
OVC_SERV_DSD	Program Completion: Graduation	0
OVC_SERV_DSD	Program Completion: Transferred	0
OVC_SERV_DSD	Program Completion: Exited without graduation	0



Mechanism ID: 16988	Mechanism Name: Kheth''Impilo Pharmacist Assistant PPP
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Kheth'Impilo	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source Funding Amount		
GHP-State	0	

(No data provided.)

**Budget Code Information** 

Daugot Couc information			
Mechanism ID:	16988		
Mechanism Name:	Kheth"Impilo Pharmacist Assistant PPP		
Prime Partner Name:	Kheth'Impilo		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

#### **Implementing Mechanism Indicator Information**

(No data provided.)



implementing meenamem betane		
Mechanism ID: 16989	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - Childwelfare/Childline Bloemfontein	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Childwelfare Bloemfontein & C	hildline Free State	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 397,634	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 397,634		
Funding Source Funding Amount		
GHP-State	397,634	

**Cross-Cutting Budget Attribution(s)** 

Gender: GBV	30,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Gender: Gender Equality	30,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Focus Area:	Equity in HIV prevention, care, treatment and support
Water	50,000



**Budget Code Information** 

Baagot Goas Illionin			
Mechanism ID:	Service Delivery and Support for Families Caring for Orphans and		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	397,634	0

# **Implementing Mechanism Indicator Information**

Indicator Number	Label	2018
	Number of active beneficiaries served by PEPFAR	
OVC_SERV_DSD	OVC programs for children and families affected by	6,500
	HIV/AIDS	
OVC_SERV_DSD	Age/Sex: 10-14 Male	650
OVC_SERV_DSD	Age/Sex: 15-17 Male	649
OVC_SERV_DSD	By: Age/sex: Male 18-24	325
OVC_SERV_DSD	By: Age/sex: Male 25+	65
OVC_SERV_DSD	Age/Sex: 10-14 Female	651
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,949
OVC_SERV_DSD	By: Age/sex: 18-24 Female	488
OVC_SERV_DSD	By: Age/sex: 25+ Female	423
OVC_SERV_DSD	Sum of Age/Sex disaggregates	3,899
OVC_SERV_DSD	Age/Sex: <1	0
OVC_SERV_DSD	Age/Sex: 1-9	1,300
OVC_SERV_DSD	Program Completion: Active	6,500
OVC_SERV_DSD	Program Completion: Graduation	0
OVC_SERV_DSD	Program Completion: Transferred	0
OVC_SERV_DSD	Program Completion: Exited without graduation	0



Mechanism ID: 16990	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - Children in Distress (CINDI)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Children in Distress	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,702,727	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 1,702,727		
Funding Source	Funding Amount	
GHP-State	1,702,727	

Gender: GBV	60,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Gender: Gender Equality	60,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Focus Area:	Equity in HIV prevention, care, treatment and support



**Budget Code Information** 

Budget Code information			
Mechanism ID:	Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - Children in Distress (CINDI)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	766,556	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	623,120	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	313,051	0

Indicator Number	Label	2018
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	7,162
PP_PREV_DSD	Age/sex: 10-14 Male	0
PP_PREV_DSD	Age/sex: 15-19 Male	0
PP_PREV_DSD	Age/sex: 20-24 Male	0
PP_PREV_DSD	Age/sex: 25-49 Male	0
PP_PREV_DSD	Age/sex: 50+ Male	0
PP_PREV_DSD	Age/sex: 10-14 Female	716
PP_PREV_DSD	Age/sex: 15-19 Female	6,446
PP_PREV_DSD	Age/sex: 20-24 Female	0
PP_PREV_DSD	Age/sex: 25-49 Female	0
PP_PREV_DSD	Age/sex: 50+ Female	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	7,162



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	33,450
HTC_TST_DSD	By Test Result: Positive	2,676
HTC_TST_DSD	Sum of Test Result disaggregates	2,676
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	391
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Male, Negative	77
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	2,825
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	246
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Male, Negative	77
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	390
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	76
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative	143
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Homebased	0



	testing: 25-49, Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	2,686
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	233
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	79
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	20,033
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	1,743
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	77
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	2,688
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	234
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	78
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	5



	20-24, Male, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	1,154
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	103
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	9,459
OVC_SERV_DSD	Age/Sex: 10-14 Male	188
OVC_SERV_DSD	Age/Sex: 15-17 Male	188
OVC_SERV_DSD	By: Age/sex: Male 18-24	188
OVC_SERV_DSD	By: Age/sex: Male 25+	0
OVC_SERV_DSD	Age/Sex: 10-14 Female	946
OVC_SERV_DSD	Age/Sex: 15-17 Female	6,815
OVC_SERV_DSD	By: Age/sex: 18-24 Female	946
OVC_SERV_DSD	By: Age/sex: 25+ Female	188
OVC_SERV_DSD	Sum of Age/Sex disaggregates	8,137
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	192
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	281



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	10
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	71
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	152
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	685
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	0
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14		15
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	128
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	0
OVC_SERV_DSD	OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	0
OVC_SERV_DSD	C_SERV_DSD Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	0



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	155
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	28
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	9
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	23
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	0
OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14		174
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	7,337
OVC_SERV_DSD	OVC_SERV_DSD Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	0



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	179
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
OVC_SERV_DSD	Age/Sex: <1	0
OVC_SERV_DSD	Age/Sex: 1-9	0
OVC_SERV_DSD	Program Completion: Active	8,986
OVC_SERV_DSD	Program Completion: Graduation	188
OVC_SERV_DSD	Program Completion: Transferred	188
OVC_SERV_DSD	Program Completion: Exited without graduation	97

Mechanism ID: 16991	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - Future Families	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Future Families		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	
GHP-State	0	



(No data provided.)

**Budget Code Information** 

Budget Code Illionia	ation		
Mechanism ID:	Service Delivery and Su Vulnerable Children (OV	rpport for Families Carinດ C) - Future Families	g for Orphans and
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

#### **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 16992	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - HIV SA	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: HIVSA		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 953,076	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 953,076		
Funding Source	Funding Amount	



GHP-State	953,076
S. ii State	000,010

Cross-Cutting Budget Attribution(s)		
Gender: GBV	30,776	
Focus Area:	GBV Prevention	
Sub Area:	Implementation	
Gender: Gender Equality	30,776	
Focus Area:	Changing harmful gender norms and promoting positive gender norms	
Focus Area:	Increase gender-equitable access to income and productive resources, including education	
Focus Area:	Equity in HIV prevention, care, treatment and support	

**Budget Code Information** 

budget code information			
Mechanism ID:  Mechanism Name:	Service Delivery and Su Vulnerable Children (OV)	pport for Families Caring	ງ for Orphans and
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	953,076	C

Indicator Number	Label	2018
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by	11,279
	HIV/AIDS	



OVC_SERV_DSD	Age/Sex: 10-14 Female	5,586
OVC_SERV_DSD	Age/Sex: 15-17 Female	5,129
OVC_SERV_DSD	By: Age/sex: 18-24 Female	564
OVC_SERV_DSD	Sum of Age/Sex disaggregates	10,715
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	1,650
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	569
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	457
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	454
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	564
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	3,479
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	4,106
OVC_SERV_DSD	Program Completion: Active	11,279

p.oon g moonamen zotane		
	Mechanism Name: Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - The Networking HIV/AIDS Community of South Africa (NACOSA)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: NACOSA (Networking AIDS Community of South Africa)		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 1,611,864	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 1,611,864	
Funding Source Funding Amount	
GHP-State	1,611,864

Dross Cutting Budget Attributio	(5)
Gender: GBV	122,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Gender: Gender Equality	122,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Focus Area:	Equity in HIV prevention, care, treatment and support
Water	150,000
Human Resources for Health	60,000

**Budget Code Information** 

	16993		
Mechanism ID:	Service Delivery and Support for Families Caring for Orphans and		
Mechanism Name:	Vulnerable Children (OVC) - The Networking HIV/AIDS Community of		
Prime Partner Name:	ame: South Africa (NACOSA)		
	NACOSA (Networking AIDS Community of South Africa)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,294,216	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	50,493	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	267,155	0

Indicator Number	Label	2018
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,112
PP_PREV_DSD	Age/sex: 10-14 Female	2,934
PP_PREV_DSD	Age/sex: 15-19 Female	3,178
PP_PREV_DSD	Sum of Age/Sex disaggregates	6,112
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,750
HTC_TST_DSD	By Test Result: Positive	172
HTC_TST_DSD	Sum of Test Result disaggregates	172
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	38
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	190
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	152
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	64



HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	98
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 1-9, Negative	268
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	124
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	620
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	54
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	496
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	42
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	212
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	318
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	28
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	16,750
OVC_SERV_DSD	Age/Sex: 10-14 Male	570



OVC_SERV_DSD	Age/Sex: 15-17 Male	653
OVC_SERV_DSD	By: Age/sex: Male 18-24	285
OVC_SERV_DSD	By: Age/sex: Male 25+	57
OVC_SERV_DSD	Age/Sex: 10-14 Female	3,497
OVC_SERV_DSD	Age/Sex: 15-17 Female	9,067
OVC_SERV_DSD	By: Age/sex: 18-24 Female	1,111
OVC_SERV_DSD	By: Age/sex: 25+ Female	370
OVC_SERV_DSD	Sum of Age/Sex disaggregates	13,787
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	1,411
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	3,289
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	282
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	659
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	140
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	610
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	188
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	846
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	1,974
OVC_SERV_DSD	Age/Sex: <1	0
OVC_SERV_DSD	Age/Sex: 1-9	1,140
OVC_SERV_DSD	Program Completion: Active	16,750

	Mechanism Name: Service Delivery and Support	ı
Mechanism ID: 17017	for Families Caring for Orphans and Vulnerable	ı
	Children (OVC) - National Association of	ì



	Childcare Workers (Roll-out of ISIBINDI model)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: National Association of Childcare Workers		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 4,553,580 Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 4,553,580		
Funding Source Funding Amount		
GHP-State	4,553,580	

Gender: GBV	250,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Gender: Gender Equality	240,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Focus Area:	Equity in HIV prevention, care, treatment and support
Human Resources for Health	500,000

**Budget Code Information** 

saaget oode iinoinii	
Mechanism ID:	17017



Prime Partner Name:	Service Delivery and Support for Families Caring for Orphans and Vulnerable Children (OVC) - National Association of Childcare Workers (Roll-out of ISIBINDI model)  National Association of Childcare Workers		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	3,849,062	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	704,518	0

Indicator Number	Label	2018
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	16,118
PP_PREV_DSD	Age/sex: 10-14 Female	7,736
PP_PREV_DSD	Age/sex: 15-19 Female	8,382
PP_PREV_DSD	Sum of Age/Sex disaggregates	16,118
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	27,018
OVC_SERV_DSD	Age/Sex: 10-14 Male	754
OVC_SERV_DSD	Age/Sex: 15-17 Male	596
OVC_SERV_DSD	By: Age/sex: Male 18-24	350
OVC_SERV_DSD	Age/Sex: 10-14 Female	9,458
OVC_SERV_DSD	Age/Sex: 15-17 Female	11,236
OVC_SERV_DSD	By: Age/sex: 18-24 Female	3,652
OVC_SERV_DSD	Sum of Age/Sex disaggregates	22,044
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	6,052



OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	6,810
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	2,269
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	45
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	51
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	17
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	7,092
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	7,976
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	2,658
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	33
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	37
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	12
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	8,213
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	9,242
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	3,079
OVC_SERV_DSD	Age/Sex: 1-9	972
OVC_SERV_DSD	Program Completion: Active	21,614
OVC_SERV_DSD	Program Completion: Graduation	2,702
OVC_SERV_DSD	Program Completion: Exited without graduation	2,702
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR  OVC programs for children and families affected by	35,140



	HIV/AIDS	
OVC_SERV_TA	Age/Sex: 10-14 Male	4,921
OVC_SERV_TA	Age/Sex: 15-17 Male	3,871
OVC_SERV_TA	By age/sex: 18-24 Male	2,216
OVC_SERV_TA	Age/Sex: 10-14 Female	5,281
OVC_SERV_TA	Age/Sex: 15-17 Female	9,840
OVC_SERV_TA	By age/sex: 18-24 Female	2,680
OVC_SERV_TA	Sum of Age/Sex disaggregates	23,913
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14	172
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 15-17	321
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24	87
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14	161
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17	126
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 18-24	76
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area,	0



	age and sex: Parenting/Caregiver Program Male 18-24	
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14	201
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17	376
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 18-24	101
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 10-14	189
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 15-17	148
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 18-24	87
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 10-14	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 15-17	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 18-24	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 10-14	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 15-17	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24	0
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14	234
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17	435
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24	118
OVC_SERV_TA	Age/Sex: 1-9	6,331
OVC_SERV_TA	Program Completion: Active	28,110
OVC_SERV_TA	Program Completion: Graduated	3,515



OVC_SERV_TA	Program Completion: Exited without graduation	3,515
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 10-14	219
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 15-17	170
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 18-24	101

Mechanism ID: 17018	Mechanism Name: HIV Innovations for Improved Patient Outcomes in South Africa (Innovation for HCTC)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: AgriAIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	A
G2G: No	Managing Agency:

Total All Funding Sources: 2,199,767	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 286,295			
Total All Funding Sources and Applied Pipeline Amount: 2,486,062			
Funding Source Funding Amount			
GHP-State	2,199,767		

**Cross-Cutting Budget Attribution(s)** 

Gender: GBV	8,900
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic
	Information
Sub Area:	Implementation
Gender: Gender Equality	8,900



Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation

**Budget Code Information** 

Mechanism ID: Mechanism Name:	HIV Innovations for Imp (Innovation for HCTC)	roved Patient Outcomes	in South Africa
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	199,247	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	132,831	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	1,535,611	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	332,078	0

Indicator Number	Label	2018
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	99,235
HTC_TST_DSD	By Test Result: Positive	8,277
HTC_TST_DSD	Sum of Test Result disaggregates	8,277
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative	3,965
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: <15, Female, Positive	111
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: <15, Male, Negative	2,228
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: <15, Male, Positive	23
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: 15+, Female, Negative	13,898
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: 15+, Female, Positive	1,207
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: 15+, Male, Negative	8,646
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: 15+, Male, Positive	733



HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	20,010
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	2,287
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	13,936
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	1,552
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	1,072
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	56
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	119
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	7
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Negative	415
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Positive	7
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Negative	274
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Positive	3
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative	15,832
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive	1,376
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	10,557
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	918
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	286



TB_STAT_DSD	Total number of registered new and relapsed TB cases,	295
	during the reporting period.	
	Aggregated Age/Sex: Male <15 (Numerator: Number of	
TB_STAT_DSD	registered new and relapsed TB cases with	16
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: Number of	
TB_STAT_DSD	registered new and relapsed TB cases with	111
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: Number	
TB_STAT_DSD	of registered new and relapsed TB cases with	16
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number	
TB_STAT_DSD	of registered new and relapsed TB cases with	143
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	16
	during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	117
	during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	16
	during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	146
	during the reporting period)	
	The number of registered new and relapse TB cases	
TB_ART_DSD	with documented HIV-positive status who are on ART	164
	during TB treatment during the reporting period	
	The number of registered new and relapse TB cases	
TB_ART_DSD	with documented HIV-positive status during TB	190
	treatment during the reporting period	
	Aggregated Age/Sex: Male <15 (Numerator: The	
TB_ART_DSD	number of registered new and relapse TB cases with	6
	documented HIV-positive status who are on ART during	
	, ,	



	1	
	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	64
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	88
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	8
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	76
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	8
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	98
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	9,972
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	495
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	3,989
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	495
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	4,991



TX_CURR_DSD	Sum of Aggregated Age/Sex <15	990
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	8,980
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	9,970
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,164
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	311
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,460
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	311
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	3,082
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,164
TX_NEW_DSD	Pregnancy status	297
TX_NEW_DSD	Breastfeeding status	145
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	5,960
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	6,620
TX_PVLS_DSD	Numerator: Indication: Routine	4,766
TX_PVLS_DSD	Numerator: Indication: Targeted	1,194
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	245
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	135
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	61
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	35
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	46
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	484
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	46



TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	606
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	209
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,935
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	207
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,413
TX_PVLS_DSD	Denominator: Indication: Routine	5,295
TX_PVLS_DSD	Denominator: Indication: Targeted	1,324
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	287
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	133
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	72
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding  Targeted	82
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15  Male Targeted	59
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+  Male Targeted	536
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	59
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	671
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15  Male Routine	229
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+  Male Routine	2,154
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	229
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,682



	Number of adults and abilities of beauty (0.10)	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,077
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,571
TX_RET_DSD	Numerator by Status: Pregnant	106
TX_RET_DSD	Numerator by Status: Breastfeeding	50
TX_RET_DSD	Denominator by Status: Pregnant	280
TX_RET_DSD	Denominator by Status: Breastfeeding	63
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	106
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	823
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	106
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,042
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	131
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,024
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	131



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,285
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	419
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	835
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	40
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	41
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	417
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	337
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	557
TB_PREV_DSD	By Therapy type (Denominator): Continuous IPT	278
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	20
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	20
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	210
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	163
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	280
TB_PREV_DSD	By Therapy type (Numerator): Continuous IPT	138

## **Implementing Mechanism Details**

Mechanism ID: 17019	Mechanism Name: HIV Innovations for Improved
incondition is: 17015	Patient Outcomes for Priority Populations



	(Innovative Models for Capacity Building & Support of Scale Up of Effective HIV-related Services for MSM) - Health4Men Program
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Anova Health Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,909,005	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 313,527		
Total All Funding Sources and Applied Pip	eline Amount: 3,222,532	
Funding Source	Funding Amount	
	2,909,005	

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	2,909,005
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Motor Vehicles: Leased	91,385



Condom procurement	57,500

<b>Budget Code Inform</b>	ation		
	17019		
Mechanism ID:	D: HIV Innovations for Improved Patient Outcomes for Priority Populations		
Mechanism Name:	Mechanism Name: (Innovative Models for Capacity Building & Support of Scale Up of		
Prime Partner Name:	Prime Partner Name: Effective HIV-related Services for MSM) - Health4Men Program		
	Anova Health Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	937,867	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	69,417	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	105,136	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,796,585	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

## **Implementing Mechanism Indicator Information**



Indicator Number	Label	2018
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	3,876
PrEP_NEW_DSD	Male 15-19	72
PrEP_NEW_DSD	Male 20-24	110
PrEP_NEW_DSD	Male 25-49	2,940
PrEP_NEW_DSD	Male 50+	754
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	26,827
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	805
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	26,022
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	30,506
HTC_TST_DSD	By Test Result: Positive	4,031
HTC_TST_DSD	Sum of Test Result disaggregates	4,031
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	6,884
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	565
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other:	19,382



	15+, Male, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	3,423
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	56
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	93
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	7
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative	47
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive	6
HTC_TST_DSD	By Key Population: MSM, Negative	26,475
HTC_TST_DSD	By Key Population: MSM, Positive	4,031
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	264
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	267
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	264
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	267
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	155



TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	163
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	155
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	163
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	4,019
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	0
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	4,019
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	0
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	4,019
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	4,019
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	892
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	892
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	892
TX_NEW_DSD	MSM	892
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting	3,617



	laboratory results within the past 12 months.	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	4,823
TX_PVLS_DSD	Numerator: Indication: Routine	3,617
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,617
TX_PVLS_DSD	Denominator: Indication: Routine	3,839
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+  Male Routine	2,631
TX_PVLS_DSD	Unknown Age, Routine, Male	2,192
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,265
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,020
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,265
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,020
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	32
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting	65



	period).	
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	65
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	39
TB_PREV_DSD	By Therapy type (Denominator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Denominator): Continuous IPT	26
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	32
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	19
TB_PREV_DSD	By Therapy type (Numerator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Numerator): Continuous IPT	4

**Implementing Mechanism Details** 

Mechanism ID: 17020	Mechanism Name: Systems Strengthening for Better HIV/TB Patient Outcomes	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Anova Health Institute		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 12,572,403	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 1,383,357		
Total All Funding Sources and Applied Pipe	line Amount: 13,955,760	
Funding Source	Funding Amount	
GHP-State	12,572,403	

**Cross-Cutting Budget Attribution(s)** 

Motor Vehicles: Leased	131,885



**Budget Code Information** 

Baaget Gode Informs	udget Code Information		
Mechanism ID:	Mechanism ID: 17020		
Mechanism Name:	Systems Strengthening for Better HIV/TB Patient Outcomes		
Prime Partner Name:	Anova Health Institute		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	1,967,691	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,601,522	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	417,235	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	424,891	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	288,290	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	834,468	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	6,621,071	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	417,235	0

## **Implementing Mechanism Indicator Information**



Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	9,568
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	63,461
PMTCT_ART_DSD	New on ART	6,477
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,091
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	63,461
PMTCT_STAT_DSD	By Age (Denominator): <10	2
PMTCT_STAT_DSD	By Age (Denominator): 10-14	31
PMTCT_STAT_DSD	By Age (Denominator): <15-19	2,856
PMTCT_STAT_DSD	By Age (Denominator): 20-24	12,689
PMTCT_STAT_DSD	By Age (Denominator): 25-49	48,016
PMTCT_STAT_DSD	By Age (Denominator): 50+	436
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	5
PMTCT_STAT_DSD	By Number of known positives: 15-19	316
PMTCT_STAT_DSD	By Number of known positives: 20-24	1,402
PMTCT_STAT_DSD	By Number of known positives: 25-49	5,328
PMTCT_STAT_DSD	By Number of known positives: 50+	46
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	5
PMTCT_STAT_DSD	By Number of new positives: 15-19	377
PMTCT_STAT_DSD	By Number of new positives: 20-24	1,711
PMTCT_STAT_DSD	By Number of new positives: 25-49	6,378
PMTCT_STAT_DSD	By Number of new positives: 50+	54
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	39



PMTCT_STAT_DSD	By Number of new negative: 15-19	2,136
PMTCT_STAT_DSD	By Number of new negative: 20-24	9,428
PMTCT_STAT_DSD	By Number of new negative: 25-49	35,871
PMTCT_STAT_DSD	By Number of new negative: 50+	326
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	45
PMTCT_STAT_DSD	By Age (Numerator): 15-19	2,830
PMTCT_STAT_DSD	By Age (Numerator): 20-24	12,541
PMTCT_STAT_DSD	By Age (Numerator): 25-49	47,584
PMTCT_STAT_DSD	By Age (Numerator): 50+	438
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	260,904
HTC_TST_DSD	By Test Result: Positive	19,065
HTC_TST_DSD	Sum of Test Result disaggregates	19,065
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	102
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	504
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	45
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	405
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	36
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	174
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Community) Homebased	261



	tootings OF 40 Mala Nagative	
	testing: 25-49, Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,200
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	1,159
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male,	0



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	234
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	2,389
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	41
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	1,332
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	9
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	1,153
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	6
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	20
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	17
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	735
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	48
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	3,672
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	173
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	2,937
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	186
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	1,260



	20-24, Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	81
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	1,887
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	120
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	2,261
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	2,194
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	568
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	116
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	308
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,965
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	317
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	291
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	78
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	30,270
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49,	4,830



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	14,414
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	2,364
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	5,881
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1,015
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	4,437
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	833
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1,  Negative	454
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9,  Negative	4,517
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	38
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	2,523
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	8
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	2,173
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	6
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	81,275
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	3,575
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other	40,867



	PITC: 15+, Male, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	1,804
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	6,474
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	1,143
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	6,168
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female,  Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female,  Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female,  Negative	178
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	413
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	87
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	195
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female,	24



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	82
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	55
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	1
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	12
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15,  Male, Positive	8
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	239
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	417
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	121
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	213
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19,  Negative	76
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24,  Negative	67
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49,  Negative	3,645
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	543
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	1,120
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	172
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC:	329



	15+, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	624
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	3,117
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	188
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	2,493
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	159
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	1,068
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	69
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	1,602
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	102
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female,	32



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female,  Negative	640
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	96
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	297
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	125
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	6
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	3,710
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	197
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	1,865
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	94
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	13,534
TB_STAT_DSD	Total number of registered new and relapsed TB cases,	13,669



1	
during the reporting period.	
Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	254
Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,256
Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	254
Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7,727
Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	256
Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	5,335
Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	263
Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	7,803
Number of people receiving post-GBV care	795
By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	238
By type of service: Sexual Violence (Post-Rape Care)	557
By PEP service provision (related to sexual violence services provided)	557
10-14, Female, Physical and/or Emotional Violence	48
10-14, Female, Sexual Violence (Post-Rape Care)	111
15-19, Female, Physical and/or Emotional Violence	96
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)  Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)  Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)  Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)  Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Naggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)  Number of people receiving post-GBV care  By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)  By type of service: Sexual Violence (Post-Rape Care)  By PEP service provision (related to sexual violence services provided)  10-14, Female, Physical and/or Emotional Violence



GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	223
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	94
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	223
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	9,152
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	9,629
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	157
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,570
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	157
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5,259
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	161
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	3,759
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with	265



<u></u>	1	
	documented HIV-positive status during TB treatment	
	during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	5,435
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment	0



	<u> </u>	
	during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	11,890
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	163
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	5,803
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	466
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	5,458
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	327,046
TX_CURR_DSD	Age/Sex: 15-19 Male	1,201
TX_CURR_DSD	Age/Sex: 15-19 Female	2,199
TX_CURR_DSD	Sum of age/sex disaggregates	3,400
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,659
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	30,035
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	3,081
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	59,718
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	5,740
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	89,753
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	95,493
TX_CURR_DSD	Age/Sex: <1	291
TX_CURR_DSD	Age/Sex: <1-9	2,915



TX_CURR_DSD	Age/Sex: 10-14 Male	1,418
TX_CURR_DSD	Age/Sex: 10-14 Female	1,462
TX_CURR_DSD	Age/Sex: 20-24 Male	1,125
TX_CURR_DSD	Age/Sex: 25-49 Male	55,904
TX_CURR_DSD	Age/Sex: 50+ Male	17,212
TX_CURR_DSD	Age/Sex: 20-24 Female	7,620
TX_CURR_DSD	Age/Sex: 25-49 Female	117,396
TX_CURR_DSD	Age/Sex: 50+ Female	22,793
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	35,549
TX_NEW_DSD	By Age/Sex: <1	19
TX_NEW_DSD	By Age/Sex: 1-9	308
TX_NEW_DSD	By Age/Sex: 10-14 Male	151
TX_NEW_DSD	By Age/Sex: 15-19 Male	133
TX_NEW_DSD	By Age/Sex: 20-24 Male	119
TX_NEW_DSD	By Age/Sex: 25-49 Male	6,006
TX_NEW_DSD	By Age/Sex: 50+ Male	1,847
TX_NEW_DSD	By Age/Sex: 10-14 Female	162
TX_NEW_DSD	By Age/Sex: 15-19 Female	239
TX_NEW_DSD	By Age/Sex: 20-24 Female	817
TX_NEW_DSD	By Age/Sex: 25-49 Female	12,608
TX_NEW_DSD	By Age/Sex: 50+ Female	2,449
TX_NEW_DSD	Sum of Age/Sex disaggregates	24,531
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	298
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,357
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	345
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	6,676
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	10,676
TX_NEW_DSD	Pregnancy status	3,781
TX_NEW_DSD	Breastfeeding status	2,978
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml)	277,336



	documented in the medical records and /or supporting laboratory results within the past 12 months.	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	307,615
TX_PVLS_DSD	Numerator: Indication: Routine	277,336
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	29,595
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	78
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	5,093
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	99,201
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	8,140
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	163,736
TX_PVLS_DSD	Denominator: Indication: Routine	307,613
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	32,846
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	24,514
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	58
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15  Male Routine	5,513
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+  Male Routine	111,049
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	5,922
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	185,031
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	14
TX_PVLS_DSD	Unknown Age, Routine, Female	10
TX_PVLS_DSD	Unknown Age, Routine, Male	9
TX_RET_DSD	Number of adults and children who are still alive and on	86,122
TX_PVLS_DSD  TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine  Pregnant, Undocumented Test Indication  Unknown Age, Routine, Female	14 10



	treatment at 12 months after initiating ART	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	95,845
TX_RET_DSD	Numerator by Status: Pregnant	9,212
TX_RET_DSD	Numerator by Status: Breastfeeding	6,905
TX_RET_DSD	Denominator by Status: Pregnant	10,123
TX_RET_DSD	Denominator by Status: Breastfeeding	7,580
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,462
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	31,514
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,550
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	51,240
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,621
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	35,027
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	1,716



	The state of the s	
	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	57,318
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	4,051
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	8,069
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	416
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	396
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	3,612
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	3,581
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	4,803
TB_PREV_DSD	By Therapy type (Denominator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Denominator): Continuous IPT	3,185
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	200
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	193
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,816
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,802
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	2,400
TB_PREV_DSD	By Therapy type (Numerator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Numerator): Continuous IPT	1,613
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting	412



	period	
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	788
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	47
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	45
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	349
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	344
TB_PREV_TA	By Therapy type (Denominator): 6-12 Month IPT	474
TB_PREV_TA	By Therapy type (Denominator):Alternative Regimen	0
TB_PREV_TA	By Therapy type (Denominator):Continuous IPT	313
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	19
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	18
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	175
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	174
TB_PREV_TA	By Therapy type (Numerator): 6-12 Month IPT	233
TB_PREV_TA	By Therapy type (Numerator): Alternative Regimen	14
TB_PREV_TA	By Therapy type (Numerator): Continuous IPT	165
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	0
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	0
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	0
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	0
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	0



TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	0
TX_TB_DSD	Denominator: By Screen Result: Negative	0
TX_TB_DSD	Denominator: By Screen Result: Positive	0
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of	

**Implementing Mechanism Details** 

implementing meenanism betans		
Mechanism ID: 17021	Mechanism Name: Performance for Health through Focused Outputs, Results and Management	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Right To Care, South Africa		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 19,350,805	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 280,520		
Total All Funding Sources and Applied Pipeline Amount: 19,631,325		
Funding Source Funding Amount		
GHP-State	19,350,805	

**Cross-Cutting Budget Attribution(s)** 

Motor Vehicles: Leased	87,000
Human Resources for Health	1,070,421



Budget Code Information			
Mechanism ID:  Mechanism Name:  Mechanism Name:  Prime Partner Name:  Right To Care, South Africa			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	3,158,244	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	2,575,766	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	669,880	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	212,449	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	63,142	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,339,760	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	10,661,684	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	669,880	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	7,399
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	23,552
PMTCT_ART_DSD	New on ART	4,223
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,176
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	14,821
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	49,596
PMTCT_ART_TA	New on ART	8,758
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	6,063
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	23,552
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	73
PMTCT_STAT_DSD	By Age (Denominator): <15-19	4,084
PMTCT_STAT_DSD	By Age (Denominator): 20-24	7,210
PMTCT_STAT_DSD	By Age (Denominator): 25-49	12,658
PMTCT_STAT_DSD	By Age (Denominator): 50+	1
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	3



	1	
PMTCT_STAT_DSD	By Number of known positives: 15-19	579
PMTCT_STAT_DSD	By Number of known positives: 20-24	1,023
PMTCT_STAT_DSD	By Number of known positives: 25-49	1,796
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	4
PMTCT_STAT_DSD	By Number of new positives: 15-19	693
PMTCT_STAT_DSD	By Number of new positives: 20-24	1,227
PMTCT_STAT_DSD	By Number of new positives: 25-49	2,151
PMTCT_STAT_DSD	By Number of new positives: 50+	6
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	53
PMTCT_STAT_DSD	By Number of new negative: 15-19	2,731
PMTCT_STAT_DSD	By Number of new negative: 20-24	4,823
PMTCT_STAT_DSD	By Number of new negative: 25-49	8,463
PMTCT_STAT_DSD	By Number of new negative: 50+	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	73
PMTCT_STAT_DSD	By Age (Numerator): 15-19	4,003
PMTCT_STAT_DSD	By Age (Numerator): 20-24	7,059
PMTCT_STAT_DSD	By Age (Numerator): 25-49	12,415
PMTCT_STAT_DSD	By Age (Numerator): 50+	1
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	49,596
PMTCT_STAT_TA	By Age (Denominator): <10	0
PMTCT_STAT_TA	By Age (Denominator): 10-14	145
PMTCT_STAT_TA	By Age (Denominator): 15-19	8,595
PMTCT_STAT_TA	By Age (Denominator): 20-24	15,189
PMTCT_STAT_TA	By Age (Denominator): 25-49	26,684
PMTCT_STAT_TA	By Age (Denominator): 50+	2



PMTCT_STAT_TA	By known positives: <10	0
PMTCT_STAT_TA	By known positives: 10-14	4
PMTCT_STAT_TA	By known positives: 15-19	1,170
PMTCT_STAT_TA	By known positives: 20-24	2,080
PMTCT_STAT_TA	By known positives: 25-49	3,643
PMTCT_STAT_TA	By known positives: 50+	0
PMTCT_STAT_TA	By new positives: <10	0
PMTCT_STAT_TA	By new positives: 10-14	8
PMTCT_STAT_TA	By new positives: 15-19	1,484
PMTCT_STAT_TA	By new positives: 20-24	2,606
PMTCT_STAT_TA	By new positives: 25-49	4,585
PMTCT_STAT_TA	By new positives: 50+	0
PMTCT_STAT_TA	By new negatives: <10	0
PMTCT_STAT_TA	By new negatives: 10-14	103
PMTCT_STAT_TA	By new negatives: 15-19	5,786
PMTCT_STAT_TA	By new negatives: 20-24	10,207
PMTCT_STAT_TA	By new negatives: 25-49	17,914
PMTCT_STAT_TA	By new negatives: 50+	1
PMTCT_STAT_TA	By Age (Numerator): <10	0
PMTCT_STAT_TA	By Age (Numerator): 10-14	149
PMTCT_STAT_TA	By Age (Numerator): : 15-19	8,428
PMTCT_STAT_TA	By Age (Numerator): 20-24	14,875
PMTCT_STAT_TA	By Age (Numerator): 25-49	26,142
PMTCT_STAT_TA	By Age (Numerator): 50+	3
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	252,011
HTC_TST_DSD	By Test Result: Positive	30,466
HTC_TST_DSD	Sum of Test Result disaggregates	30,466



HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	51
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	253
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	202
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	87
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	130
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Negative	414
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	367
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	1,835
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	117
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	1,468



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	94
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	629
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	944
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	60
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	306
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	63
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	306
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	63
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	567
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	116
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	377
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	78
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,699
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	349
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,132
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	233



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	2,832
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	580
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	1,887
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	387
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	567
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	116
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	377
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	78
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1,  Negative	204
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9,  Negative	1,222
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	252
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	2,751
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	378
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	2,751
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	378
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	109,379



HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	14,232
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	72,938
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	9,525
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	2,126
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	341
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female,  Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female,  Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	1



HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	7
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	268
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	655
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	327
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	807
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19,  Negative	264
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	791
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	1,319
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	264
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	312



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	1,558
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	99
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	1,247
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	80
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	534
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	801
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	51
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Negative	51
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female,  Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	7



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	60
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	39
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female,  Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	3,415
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	469
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	2,325
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	314
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	565,605
HTC_TST_TA	By Test Result: Positive	73,022
HTC_TST_TA	Sum of Test Result disaggregates	73,022
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14,	784



	Female, Negative	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	160
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	784
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	160
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,448
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	299
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	968
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	199
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	4,350
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	873
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,896
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	596
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	7,255
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	1,488
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	4,838
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	992
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,448
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+,	299



	Female, Positive	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	968
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	199
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1,  Negative	520
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Positive	104
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9,  Negative	3,139
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	646
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Negative	6,919
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Positive	975
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Negative	7,035
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Positive	1,323
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative	256,048
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive	34,246
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative	170,745
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Positive	23,159
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	5,527
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	906
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female,	14



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	18
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female,  Negative	15
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	47
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	21
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	58
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Negative	30
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Positive	81
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Negative	37
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Positive	98
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	18
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Female, Negative	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Female, Positive	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Male, Negative	0



HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Male, Positive	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Negative	599
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Positive	1,399
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Negative	737
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Positive	1,723
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19,  Negative	80
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24,  Negative	239
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49,  Negative	397
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	80
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	29
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	19
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	87
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	18
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male,	58



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	147
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	29
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	97
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	19
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female,  Negative	29
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	19
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Positive	2
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative	8,574
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive	1,207
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative	5,705
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive	792
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	4,402
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	4,453
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	145



TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with	2,397
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: Number	
TB_STAT_DSD	of registered new and relapsed TB cases with	109
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number	
TB_STAT_DSD	of registered new and relapsed TB cases with	1,735
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	149
	during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	2,435
	during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	111
	during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	1,757
	during the reporting period)	
TD CTAT TA	Number of registered new and relapsed TB cases with	40.740
TB_STAT_TA	documented HIV status, during the reporting period.	12,749
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	12,853
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases,	323
IB_STAT_TA	during the reporting period)	323
	Aggregated Age/Sex: Male <15 (Denominator: Total	
TB_STAT_TA	number of registered new and relapsed TB cases,	453
ID_OIAI_IA	during the reporting period)	700
	Aggregated Age/Sex: Female 15+ (Denominator: Total	
TB_STAT_TA	number of registered new and relapsed TB cases,	5,057
ום_סותו_ות	during the reporting period)	5,057
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total	7,030
ID_GIAI_IA	riggrogated rigorock. Male for (Denominator, Total	7,000



	number of registered new and relapsed TB cases,	
	during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of	
TB_STAT_TA	registered new and relapsed TB cases with	449
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: Number of	
TB_STAT_TA	registered new and relapsed TB cases with	6,914
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: Number	
TB_STAT_TA	of registered new and relapsed TB cases with	323
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number	
TB_STAT_TA	of registered new and relapsed TB cases with	4,992
	documented HIV status, during the reporting period)	
GEND_GBV_DSD	Number of people receiving post-GBV care	241
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence	120
02115_051_505	(Other Post-GBV Care)	.20
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	121
GEND_GBV_DSD	By PEP service provision (related to sexual violence	60
OLIND_ODV_DOD	services provided)	
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	30
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	20
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	45
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	60
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	45
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	41
	The number of registered new and relapse TB cases	
TB_ART_DSD	with documented HIV-positive status who are on ART	3,011
	during TB treatment during the reporting period	
	The number of registered new and relapse TB cases	
TB_ART_DSD	with documented HIV-positive status during TB	2,357
	treatment during the reporting period	
TR ART DOD	Aggregated Age/Sex: Male <15 (Numerator: The	102
TB_ART_DSD	number of registered new and relapse TB cases with	102



	T Company of the Comp	
	documented HIV-positive status who are on ART during	
	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,634
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	74
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,191
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	75
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1,292
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	54
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	938
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	8,641
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB	8,806



	treatment during the reporting period	
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	304
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4,700
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	216
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,419
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	327
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	4,783
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	219
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	3,472
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	7,360



PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	227
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	4,405
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	39
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	2,689
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	14,530
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	542
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	8,224
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	92
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	5,672
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	148,611
TX_CURR_DSD	Age/Sex: 15-19 Male	590
TX_CURR_DSD	Age/Sex: 15-19 Female	1,540
TX_CURR_DSD	Sum of age/sex disaggregates	2,130
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,555
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	34,838
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,555
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	85,388
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	5,110
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	120,226
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	125,336
TX_CURR_DSD	Age/Sex: <1	20



TX_CURR_DSD	Age/Sex: <1-9	114
TX_CURR_DSD	Age/Sex: 10-14 Male	29
TX_CURR_DSD	Age/Sex: 10-14 Female	29
TX_CURR_DSD	Age/Sex: 20-24 Male	1,766
TX_CURR_DSD	Age/Sex: 25-49 Male	2,950
TX_CURR_DSD	Age/Sex: 50+ Male	590
TX_CURR_DSD	Age/Sex: 20-24 Female	4,622
TX_CURR_DSD	Age/Sex: 25-49 Female	7,701
TX_CURR_DSD	Age/Sex: 50+ Female	1,540
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	320,497
TX_CURR_TA	Age/Sex: 15-19 Male	2,389
TX_CURR_TA	Age/Sex: 15-19 Female	6,235
TX_CURR_TA	Sum of Age/Sex disaggregations	8,624
TX_CURR_TA	Aggregated Age/Sex: <15 Male	5,113
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	63,656
TX_CURR_TA	Aggregated Age/Sex: <15 Female	5,114
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	159,077
TX_CURR_TA	Sum of Aggregated Age/Sex <15	10,227
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	222,733
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	232,960
TX_CURR_TA	Age/Sex: <1	80
TX_CURR_TA	Age/Sex: 1-9	460
TX_CURR_TA	Age/Sex: 10-14 Male	117
TX_CURR_TA	Age/Sex: 10-14 Female	117
TX_CURR_TA	Age/Sex: 20-24 Male	7,167
TX_CURR_TA	Age/Sex: 25-49 Male	11,938
TX_CURR_TA	Age/Sex: 50+ Male	2,387
TX_CURR_TA	Age/Sex: 20-24 Female	18,705
TX_CURR_TA	Age/Sex: 25-49 Female	31,178
TX_CURR_TA	Age/Sex: 50+ Female	6,235
TX_NEW_DSD	Number of adults and children newly enrolled on	27,855



	antiretroviral therapy (ART)	
TX_NEW_DSD	By Age/Sex: <1	10
TX_NEW_DSD	By Age/Sex: 1-9	66
TX_NEW_DSD	By Age/Sex: 10-14 Male	16
TX_NEW_DSD	By Age/Sex: 15-19 Male	61
TX_NEW_DSD	By Age/Sex: 20-24 Male	184
TX_NEW_DSD	By Age/Sex: 25-49 Male	306
TX_NEW_DSD	By Age/Sex: 50+ Male	60
TX_NEW_DSD	By Age/Sex: 10-14 Female	16
TX_NEW_DSD	By Age/Sex: 15-19 Female	159
TX_NEW_DSD	By Age/Sex: 20-24 Female	476
TX_NEW_DSD	By Age/Sex: 25-49 Female	795
TX_NEW_DSD	By Age/Sex: 50+ Female	159
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,232
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	585
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	7,116
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	585
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	17,264
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	25,550
TX_NEW_DSD	Pregnancy status	6,073
TX_NEW_DSD	Breastfeeding status	0
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	57,393
TX_NEW_TA	By Age/Sex: <1	44
TX_NEW_TA	By Age/Sex: 1-9	266
TX_NEW_TA	By Age/Sex: 10-14 Male	66
TX_NEW_TA	By Age/Sex: 15-19 Male	250
TX_NEW_TA	By Age/Sex: 20-24 Male	745
TX_NEW_TA	By Age/Sex: 25-49 Male	1,238
TX_NEW_TA	By Age/Sex: 50+ Male	249
TX_NEW_TA	By Age/Sex: 10-14 Female	66
TX_NEW_TA	By Age/Sex: 15-19 Female	643



TX_NEW_TA	By Age/Sex: 20-24 Female	1,927
TX_NEW_TA	By Age/Sex: 25-49 Female	3,210
TX_NEW_TA	By Age/Sex: 50+ Female	643
TX_NEW_TA	Sum of Age/Sex disaggregates	9,037
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	1,104
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	13,120
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	1,107
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	32,712
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	48,043
TX_NEW_TA	Pregnancy status	12,859
TX_NEW_TA	Breastfeeding status	0
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	121,534
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	135,039
TX_PVLS_DSD	Numerator: Indication: Routine	121,534
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	26,473
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	2,176
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	33,689
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	2,166
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	83,503
TX_PVLS_DSD	Denominator: Indication: Routine	135,039
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	28,152
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15  Male Routine	2,418
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+	37,432



	Male Routine	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,418
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	92,770
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	260,947
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	289,941
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	10,034
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	6,485
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	175,058
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	68,969
TX_PVLS_TA	Numerator: Indication: Routine	260,947
TX_PVLS_TA	Numerator: Preg/BF by Indication: Pregnant Routine	59,769
TX_PVLS_TA	Denominator: Indication: Routine	289,940
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	5,539
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15  Male Routine	5,146
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	200,303
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+  Male Routine	78,908
TX_PVLS_TA	Denominator: Preg/BF by Indication: Pregnant Routine	63,099
TX_PVLS_TA	Unknown Age, Routine, Female	22
TX_PVLS_TA	Unknown Age, Routine, Male	22



TX_PVLS_TA	Unknown Age, Routine, Female	200
TX_PVLS_TA	Unknown Age, Routine, Male	200
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	27,674
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	31,409
TX_RET_DSD	Numerator by Status: Pregnant	6,244
TX_RET_DSD	Numerator by Status: Breastfeeding	0
TX_RET_DSD	Denominator by Status: Pregnant	7,093
TX_RET_DSD	Denominator by Status: Breastfeeding	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	427
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,627
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	427
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19,189
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	495
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,650



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	495
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	21,772
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	65,018
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	72,041
TX_RET_TA	Numerator by Status: Pregnant	15,187
TX_RET_TA	Numerator by Status: Breastfeeding	0
TX_RET_TA	Denominator by Status: Pregnant	16,828
TX_RET_TA	Denominator by Status: Breastfeeding	0
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	952
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17,739
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	951
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	46,076
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	1,052



	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19,639
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,055
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	50,283
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	4,256
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	8,517
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	202
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	276
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	3,384
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	4,655
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	99
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	137
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,688



TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	2,333
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	15,622
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	31,040
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	715
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	1,171
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	12,359
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	16,851
TB_PREV_TA	By Therapy type (Denominator): 6-12 Month IPT	0
TB_PREV_TA	By Therapy type (Denominator):Continuous IPT	0
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	353
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	511
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	6,200
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	8,542
TB_PREV_TA	By Therapy type (Numerator): 6-12 Month IPT	0
TB_PREV_TA	By Therapy type (Numerator): Continuous IPT	0
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	0
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	0
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	0
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	0
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Female	0
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Male	0



TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	0
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	0
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	0
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	0
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	0
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	0
TX_TB_TA	Denominator: By Screen Result: Negative	0
TX_TB_TA	Denominator: By Screen Result: Positive	0
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	0
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	0
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	0
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	0

**Implementing Mechanism Details** 

Mechanism ID: 17022	Mechanism Name: HIV Innovations for Improved Patient Outcomes in South Africa (Developing & Institutionalizing an Innovative Capacity Building Model to Support SA Government Priorities & to Improve HIV/TB Health Outcomes for Priority Populations - "South to South Stellenbosch")	
Funding Agency: USAID Procurement Type: Cooperative Agreement		
Prime Partner Name: The South-to-South Partnership for Comprehensive Family HIV Care and Treatment Program (S2S)		
greement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No Managing Agency:		



Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	
GHP-State	0	

## **Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information** 

Budget Code Information			
17022			
HIV Innovations for Improved Patient Outcomes in South Africa			
Mechanism ID:	(Developing & Institution	nalizing an Innovative Ca	pacity Building Model to
Mechanism Name:	Support SA Government	Priorities & to Improve H	HIV/TB Health Outcomes
Prime Partner Name:	for Priority Populations	- "South to South Stelle	nbosch")
	The South-to-South Par	tnership for Comprehens	sive Family HIV Care
	and Treatment Program	(S2S)	
Ctuatania Auga	Dudget Cada	Diament Amount	On Hald Amazont
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

## **Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 17023	Mechanism Name: Systems Strengthening for Better HIV/TB Patient Outcomes	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Broadreach		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 30,208,547 Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 327,451		
Total All Funding Sources and Applied Pipeline Amount: 30,535,998		
Funding Source Funding Amount		
GHP-State	30,208,547	

**Cross-Cutting Budget Attribution(s)** 

Human Resources for Health	2,345,003
Food and Nutrition: Policy, Tools, and Service	20,000
Delivery	



**Budget Code Information** 

Budget Code Information			
Mechanism ID:	17023		
Mechanism Name:	Systems Strengthening for Better HIV/TB Patient Outcomes		
Prime Partner Name:			
T Timo T di tiloi Ttamo.	Di oddi odoli		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	4,935,840	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	4,138,171	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	1,118,950	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	2,237,901	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	16,658,735	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,118,950	0

## **Implementing Mechanism Indicator Information**

Indicator Number	Label	2018
	Number of HIV-positive pregnant women who received	
PMTCT_ART_DSD	ART to reduce risk of mother-to-child-transmission	22,184
	(MTCT) during pregnancy	



DMTOT ART DOR	Number of pregnant women with known HIV status	04.005
PMTCT_ART_DSD	(includes women who were tested for HIV and received their results)	91,235
PMTCT_ART_DSD	New on ART	12,197
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	9,987
FWITCT_ART_D3D		9,907
PMTCT_ART_TA	Number of HIV-positive pregnant women who received  ART to reduce risk of mother-to-child-transmission	881
FWITCI_ARTI_TA	(MTCT) during pregnancy	001
	Number of pregnant women with known HIV status	
PMTCT_ART_TA	(includes women who were tested for HIV and received	4,336
	their results)	,
PMTCT_ART_TA	New on ART	484
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	397
	Number of pregnant women with known HIV status	
PMTCT_STAT_DSD	(includes women who were tested for HIV and received	91,235
	their results)	
PMTCT_STAT_DSD	By Age (Denominator): <15-19	9,254
PMTCT_STAT_DSD	By Age (Denominator): 20-24	27,764
PMTCT_STAT_DSD	By Age (Denominator): 25-49	55,419
PMTCT_STAT_DSD	By Age (Denominator): 50+	285
PMTCT_STAT_DSD	By Number of known positives: 15-19	1,218
PMTCT_STAT_DSD	By Number of known positives: 20-24	3,638
PMTCT_STAT_DSD	By Number of known positives: 25-49	7,287
PMTCT_STAT_DSD	By Number of new positives: 15-19	1,637
PMTCT_STAT_DSD	By Number of new positives: 20-24	4,898
PMTCT_STAT_DSD	By Number of new positives: 25-49	9,803
PMTCT_STAT_DSD	By Number of new negative: 15-19	6,269
PMTCT_STAT_DSD	By Number of new negative: 20-24	18,821
PMTCT_STAT_DSD	By Number of new negative: 25-49	37,665
PMTCT_STAT_DSD	By Age (Numerator): 10-14	150
PMTCT_STAT_DSD	By Age (Numerator): 15-19	9,423
PMTCT_STAT_DSD	By Age (Numerator): 20-24	27,911
PMTCT_STAT_DSD	By Age (Numerator): 25-49	53,751



	Number of pregnant women with known HIV status	
PMTCT_STAT_TA	(includes women who were tested for HIV and received	4,336
	their results)	
PMTCT_STAT_TA	By Age (Denominator): 10-14	53
PMTCT_STAT_TA	By Age (Denominator): 15-19	551
PMTCT_STAT_TA	By Age (Denominator): 20-24	1,486
PMTCT_STAT_TA	By Age (Denominator): 25-49	2,332
PMTCT_STAT_TA	By known positives: 10-14	8
PMTCT_STAT_TA	By known positives: 15-19	77
PMTCT_STAT_TA	By known positives: 20-24	211
PMTCT_STAT_TA	By known positives: 25-49	330
PMTCT_STAT_TA	By new positives: 10-14	7
PMTCT_STAT_TA	By new positives: 15-19	86
PMTCT_STAT_TA	By new positives: 20-24	238
PMTCT_STAT_TA	By new positives: 25-49	407
PMTCT_STAT_TA	By new negatives: 10-14	23
PMTCT_STAT_TA	By new negatives: 15-19	343
PMTCT_STAT_TA	By new negatives: 20-24	964
PMTCT_STAT_TA	By new negatives: 25-49	1,642
PMTCT_STAT_TA	By Age (Numerator): 10-14	47
PMTCT_STAT_TA	By Age (Numerator): : 15-19	526
PMTCT_STAT_TA	By Age (Numerator): 20-24	1,441
PMTCT_STAT_TA	By Age (Numerator): 25-49	2,322
	Number of individuals who received T&C services for	
HTC_TST_DSD	HIV and received their test results during the past 12	1,068,918
	months	
HTC_TST_DSD	By Test Result: Positive	109,660
HTC_TST_DSD	Sum of Test Result disaggregates	109,660
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	891
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	159
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient:	891
1110_101_000	Convide Delivery Fount by Agg Age (Facility) inpatient.	031



	<15, Male, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	161
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	16,054
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	2,836
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	11,896
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	2,097
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	24,621
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	2,736
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	24,626
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	2,736
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	443,576
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	49,261
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	328,459
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	36,499
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	75,001
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	1,145
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	175
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	283
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15,	174



	Male, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15,  Male, Positive	286
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	2,594
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	3,874
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	3,486
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	5,245
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <15, Negative	1,964
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: <15, Positive	34
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative	5,872
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive	163
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	566
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	30
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	566
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	32
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	10,350
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	1,158
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	7,702
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	867



HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12	28,122
	months	
HTC_TST_TA	By Test Result: Positive	2,800
HTC_TST_TA	Sum of Test Result disaggregates	2,800
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Negative	661
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Positive	73
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Negative	661
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Positive	73
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative	11,918
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive	1,325
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative	8,829
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Positive	981
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	2,309
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	36
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Female, Negative	1
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Female, Positive	3
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Male, Negative	1
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Male, Positive	3
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Negative	69
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+,	96



	Female, Positive	
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Negative	89
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Positive	133
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VMMC: <15,  Negative	39
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VMMC: <15, Positive	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VMMC: 15+, Negative	104
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VMMC: 15+, Positive	1
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Female, Negative	15
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Female, Positive	1
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15,  Male, Negative	15
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15,  Male, Positive	1
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative	350
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive	37
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative	269
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive	25
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	24,307
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	24,557
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of	844



	registered new and relapsed TB cases with	
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: Number of	
TB_STAT_DSD	registered new and relapsed TB cases with	13,124
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: Number	
TB_STAT_DSD	of registered new and relapsed TB cases with	843
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number	
TB_STAT_DSD	of registered new and relapsed TB cases with	9,496
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	854
	during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	13,266
15_01/(1_505	during the reporting period)	. 0,200
	Aggregated Age/Sex: Female <15 (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	853
10_01/(1_000	during the reporting period)	000
	Aggregated Age/Sex: Female 15+ (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	9,584
	during the reporting period)	0,004
	Number of registered new and relapsed TB cases with	
TB_STAT_TA	documented HIV status, during the reporting period.	1,354
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	1,367
	Aggregated Age/Sex: Female <15 (Denominator: Total	40
TB_STAT_TA	number of registered new and relapsed TB cases,	49
	during the reporting period)	
TD 0T:	Aggregated Age/Sex: Male <15 (Denominator: Total	
TB_STAT_TA	number of registered new and relapsed TB cases,	49
	during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total	533
	number of registered new and relapsed TB cases,	



	during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	736
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	48
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	729
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	47
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	529
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	15,356
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	16,134
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	546
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8,270
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	546
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The	5,994



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	572
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	8,690
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	574
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	6,298
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	628
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	659
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	20
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	341
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with	20



	documented HIV-positive status who are on ART during	
	TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	247
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	20
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	358
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	20
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	261
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	21,571
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	92
PMTCT_EID_DSD	Unknown, <= 2 months	36
PMTCT_EID_DSD	Unknown, 2 - 12 months	25
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	12,793
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	42
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	8,583
PMTCT_EID_TA	Number of infants who had a virologic HIV test within	1,120
•		



	40 months of high during the governing region	
	12 months of birth during the reporting period	
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	4
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	669
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	1
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	446
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	606,200
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	42,441
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	218,230
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	42,438
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	303,091
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	84,879
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	521,321
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	606,200
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	21,140
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,479
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	7,614
TX_CURR_TA	Aggregated Age/Sex: <15 Female	1,479
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	10,568
TX_CURR_TA	Sum of Aggregated Age/Sex <15	2,958
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	18,182
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	21,140
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	151,426
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	10,605
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	54,515
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	10,603
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	75,703



TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	151,426	
TX_NEW_DSD	Pregnancy status	18,175	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,957	
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	276	
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	1,426	
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	273	
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	1,982	
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	3,957	
TX_NEW_TA	Pregnancy status	475	
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	481,854	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	532,329	
TX_PVLS_DSD	Numerator: Indication: Routine	481,854	
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	75,125	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	33,646	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	173,056	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	33,726	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	240,777	
TX_PVLS_DSD	Denominator: Indication: Routine	532,329	
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	79,319	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15  Male Routine		
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+  Male Routine	191,640	



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	37,263
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	
TX_PVLS_DSD	<15, Routine, Unknown Sex	80
TX_PVLS_DSD	15+, Routine, Unknown Sex	569
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	15,020
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	16,690
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	1,053
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	1,049
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	7,512
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	5,406
TX_PVLS_TA	Numerator: Indication: Routine	15,020
TX_PVLS_TA	Numerator: Preg/BF by Indication: Pregnant Routine	2,254
TX_PVLS_TA	Denominator: Indication: Routine	16,690
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,166
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15  Male Routine	1,166
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	8,346
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	6,012
TX_PVLS_TA	Denominator: Preg/BF by Indication: Pregnant Routine	2,492
TX_RET_DSD	Number of adults and children who are still alive and on	105,563



	treatment at 12 months after initiating ART	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	117,299
TX_RET_DSD	Numerator by Status: Pregnant	15,824
TX_RET_DSD	Denominator by Status: Pregnant	17,598
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,400
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	37,994
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,398
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	52,771
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,212
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	42,222
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,211
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total	58,654



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)  Number of adults and children who are still alive and on	
TX_RET_TA	treatment at 12 months after initiating ART	3,676
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,083
TX_RET_TA	Numerator by Status: Pregnant	550
TX_RET_TA	Denominator by Status: Pregnant	617
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	256
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,326
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	256
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,838
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	286
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,471
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total	286



	number of adults and children who initiated ART in the	
	12 months prior to the beginning of the reporting period, including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	2,040
	stopped ART, and those lost to follow-up)  The number of ART patients who completed a course	
TB_PREV_DSD	of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	18,035
	The number of ART patients who were newly started on	
	TB preventive therapy (including those who newly	
TD DDEV DOD	started on TB preventive therapy in this reporting period	00.044
TB_PREV_DSD	and those who started in the previous reporting period but had not been reported as they did not fulfill the	36,041
	minimum requirements for the previous reporting	
	period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	2,523
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	2,526
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	18,015
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	12,977
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	36,041
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	1,259
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	1,257
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	9,017
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	6,502
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	18,035
	The number of ART patients who completed a course	
TB_PREV_TA	of TB preventive therapy or at least 6 months of	644
ID_INEV_IA	Isoniazid Preventive Therapy (IPT) during the reporting	
	period	



TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	87
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	86
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	643
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	468
TB_PREV_TA	By Therapy type (Denominator): 6-12 Month IPT	1,284
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	45
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	45
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	321
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	233
TB_PREV_TA	By Therapy type (Numerator): 6-12 Month IPT	644

**Implementing Mechanism Details** 

mpromorming moontainem zottane		
	Mechanism Name: Comprehensive	
Mechanism ID: 17024	District-Based Support for Better HIV/TB Patient	
	Outcomes (Hybrid)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Foundation for Professional Development		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source	Funding Amount	
GHP-State	0	



## **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Budget Code Information			
Mechanism ID: Mechanism Name: Prime Partner Name:	Comprehensive District-Based Support for Better HIV/TB Patient Outcomes (Hybrid)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0



Indicator Number	Label	2018
PMTCT_STAT_TA	By Age (Denominator): 50+	0

**Implementing Mechanism Details** 

Mechanism ID: 17025	Mechanism Name: HIV Innovations for Improved Patient Outcomes for Priority Populations (INROADS: Innovations Research on HIV/AIDS)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Wits Health Consortium, Health Economics and Epidemiology Research Office		
Agreement Start Date: Redacted Agreement End Date: Redacted		
BD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 3,800,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 3,800,000		
Funding Source Funding Amount		
GHP-State	3,800,000	

**Cross-Cutting Budget Attribution(s)** 

Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research



Budget Code Information				
	17025			
Mechanism ID:	Mechanism ID: HIV Innovations for Improved Patient Outcomes for Priority Populations			
Mechanism Name:	Mechanism Name: (INROADS: Innovations Research on HIV/AIDS)			
Prime Partner Name:	Wits Health Consortium	, Health Economics and I	Epidemiology Research	
	Office			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	НВНС	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HVTB	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	PDCS	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HVSI	500,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	OHSS	1,800,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	MTCT	0	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	HTXS	1,500,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	PDTX	0	0	



(No data provided.)

Implementing Mechanism Details

implementing mechanism betans		
Mechanism ID: 17026	Mechanism Name: HIV Innovations for Improved Patient Outcomes in South Africa (Developing the Capacity of the South African Government to Achieve the eMTCT Action Framework Goals)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Mothers to Mothers (M2M)	-	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source Funding Amount		
GHP-State	О	

### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information** 

Mechanism ID:	17026
Mechanism Name:	HIV Innovations for Improved Patient Outcomes in South Africa
Prime Partner Name:	(Developing the Capacity of the South African Government to Achieve



	the eMTCT Action Framework Goals)  Mothers to Mothers (M2M)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 17027	Mechanism Name: HIV Innovations for Improved Patient Outcomes for Priority Populations (Supporting the SA Government to Develop, Implement and Evaluate a National Sex Worker and Male Client Plan)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Wits Reproductive Health& HIV Institute		
Agreement Start Date: Redacted	Agreement End Date: Redacted	



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,300,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipe	eline Amount: 3,300,000
Funding Source Funding Amount	
GHP-State	3,300,000

## **Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information** 

Mechanism ID: HIV Innovations for Improved Patient Outcomes for Priority Populations Mechanism Name: (Supporting the SA Government to Develop, Implement and Evaluate a Prime Partner Name: National Sex Worker and Male Client Plan) Wits Reproductive Health& HIV Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	845,284	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	177,745	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	230,253	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,046,718	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Indicator Number	Label	2018
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	2,369
PrEP_NEW_DSD	Female 25-49	2,369
PrEP_NEW_DSD	FSW	2,369
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	16,452
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,760
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	148



KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	14,544
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	12,839
HTC_TST_DSD	By Test Result: Positive	1,772
HTC_TST_DSD	Sum of Test Result disaggregates	1,772
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	9,137
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	1,516
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	1,146
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	171
HTC_TST_DSD	By Key Population: FSW, Negative	770
HTC_TST_DSD	By Key Population: FSW, Positive	85
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	59
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	59
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	59
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	59
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,026
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	0
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	224



TX_CURR_DSD	Aggregated Age/Sex: <15 Female	0
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	802
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	0
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,026
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,026
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	186
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	21
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	84
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	105
TX_NEW_DSD	FSW	163
TX_NEW_DSD	MSM	0
TX_NEW_DSD	People in prisons and other enclosed settings	9
TX_NEW_DSD	TG	2
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	0
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,011
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,111
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	907
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	204
TX_PVLS_DSD	Undocumented Test Indication	1,111
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	825
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	186
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0



TX_PVLS_DSD	Undocumented Test Indication	1,011
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	602
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	661
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	93
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	509
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	99
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	562

**Implementing Mechanism Details** 

Mechanism ID: 17028	Mechanism Name: HIV Innovations for Improved
	Patient Outcomes for Priority Populations
	(Adolescent Friendly Services for Prenatally &
	Behaviorally HIV Infected Adolescents)



Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Wits Reproductive Health& HI\	/ Institute	
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 3,720,044	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pip	eline Amount: 3,720,044	
Funding Source Funding Amount		
GHP-State	3,720,044	

**Cross-Cutting Budget Attribution(s)** 

Gender: Gender Equality	121,302
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: GBV	181,953
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	89,795
Condom programming	274,644
Education	9,893



Budget Code Information			
	17028		
Mechanism ID:	HIV Innovations for Improved Patient Outcomes for Priority Populations		
Mechanism Name:	(Adolescent Friendly Services for Prenatally & Behaviorally HIV Infected		
Prime Partner Name:	Adolescents)		
	Wits Reproductive Heal	th& HIV Institute	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	450,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	450,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,720,044	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	150,000	0



Indicator Number	Label	2018
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,668
PrEP_NEW_DSD	Female 15-19	325
PrEP_NEW_DSD	Female 20-24	1,343
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	27,225
HTC_TST_DSD	By Test Result: Positive	2,723
HTC_TST_DSD	Sum of Test Result disaggregates	2,723
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	533
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	59
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	531
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	730
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	79
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	487
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,996
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	226
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	503



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	772
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	85
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	772
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	85



HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	3,764
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	420
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	942
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	104
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	653
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	70
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	652
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	69
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	879
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	108
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	594
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	2,451
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	270
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	612
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	66
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	0



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	943
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	104
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	943
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	104
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	4,602
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	512
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	1,151
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	128



	<u> </u>	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	3,358
HTC_TST_TA	By Test Result: Positive	329
HTC_TST_TA	Sum of Test Result disaggregates	329
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	86
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	86
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	97
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	63
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	261
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	30
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	63
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	8
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Negative	86
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Positive	10
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC:	78



	45 Mala Nagativa	
LITO TOT TA	<15, Male, Negative Service Delivery Point Agg Age (Facility) Other PITC:	40
HTC_TST_TA	<15, Male, Positive	10
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative	369
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive	40
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative	91
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male,	0



	Positive	
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Female, Negative	106
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Female, Positive	10
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15,  Male, Negative	101
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Male, Positive	10
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative	448
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive	50
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative	113
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive	11
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	429
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	434
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	48
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	64
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	53
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	264
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total	49



	i I	
	number of registered new and relapsed TB cases,	
	during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	66
	during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	54
	during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	265
	during the reporting period)	
	Number of registered new and relapsed TB cases with	
TB_STAT_TA	documented HIV status, during the reporting period.	159
	Total number of registered new and relapsed TB cases,	
TB_STAT_TA	during the reporting period.	159
	Aggregated Age/Sex: Female <15 (Denominator: Total	
TB_STAT_TA	number of registered new and relapsed TB cases,	27
ID_STAT_TA	during the reporting period)	21
TD CTAT TA	Aggregated Age/Sex: Male <15 (Denominator: Total	17
TB_STAT_TA	number of registered new and relapsed TB cases, during the reporting period)	17
TD OTAT TA	Aggregated Age/Sex: Female 15+ (Denominator: Total	00
TB_STAT_TA	number of registered new and relapsed TB cases,	90
	during the reporting period)	
TD 0747 T4	Aggregated Age/Sex: Male 15+ (Denominator: Total	0.5
TB_STAT_TA	number of registered new and relapsed TB cases,	25
	during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of	
TB_STAT_TA	registered new and relapsed TB cases with	17
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: Number of	
TB_STAT_TA	registered new and relapsed TB cases with	25
	documented HIV status, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number	27
10_01/(11/1/	of registered new and relapsed TB cases with	<u>~1</u>



	documented HIV status, during the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	90
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	298
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	32
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	45
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	39
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	182
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	105
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	17
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The	18



	number of registered new and relapse TB cases with	
	documented HIV-positive status who are on ART during	
	TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The	
TB_ART_TA	number of registered new and relapse TB cases with	60
	documented HIV-positive status who are on ART during	
	TB treatment during the reporting period)	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	10,368
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,228
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,595
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,232
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	6,313
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,460
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	7,908
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	10,368
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,359
TX_CURR_TA	Aggregated Age/Sex: <15 Male	102
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	280
TX_CURR_TA	Aggregated Age/Sex: <15 Female	112
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	865
TX_CURR_TA	Sum of Aggregated Age/Sex <15	214
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	1,145
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	1,359
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,099
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	365
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	465
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	370
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,886
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,086
TX_NEW_DSD	FSW	13



	\	
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	386
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	45
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	85
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	63
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	193
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	386
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	7,981
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	8,975
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	1,100
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	1,095
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	5,424
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	1,356
TX_PVLS_DSD	Undocumented Test Indication	8,975
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	946
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	941
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	4,874
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	1,220
TX_PVLS_DSD	Undocumented Test Indication	7,981
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,052
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,161
TX_PVLS_TA	<15, Undocumented Test Indication, Female	102
TX_PVLS_TA	<15, Undocumented Test Indication, Male	83



	,	
TX_PVLS_TA	15+, Undocumented Test Indication, Female	747
TX_PVLS_TA	15+, Undocumented Test Indication, Male	229
TX_PVLS_TA	Undocumented Test Indication	1,161
TX_PVLS_TA	<15, Undocumented Test Indication, Female	96
TX_PVLS_TA	<15, Undocumented Test Indication, Male	75
TX_PVLS_TA	15+, Undocumented Test Indication, Female	675
TX_PVLS_TA	15+, Undocumented Test Indication, Male	206
TX_PVLS_TA	Undocumented Test Indication	1,052
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	11,050
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	12,273
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,295
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,688
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,309
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,758
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,448
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	1,860



	<u> </u>	
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,454
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,511
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,429
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,582
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	93
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	327
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	113
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	896
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	102



TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	366
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	123
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	991
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	117
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	232
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	31
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	22
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	141
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	38
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	232
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	18
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	8
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	71
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	20



TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	117
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	37
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	81
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	18
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	7
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	41
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	15
TB_PREV_TA	By Therapy type (Denominator): 6-12 Month IPT	81
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	8
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	0
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	26
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	3
TB_PREV_TA	By Therapy type (Numerator): 6-12 Month IPT	37

**Implementing Mechanism Details** 

Mechanism ID: 17029	Mechanism Name: HIV Innovations for Improved Patient Outcomes in South Africa (Innovation Clinic)		
Funding Agency: USAID	Procurement Type: Cooperative Agreement		
Prime Partner Name: Witkoppen Health & Welfare Centre (WHWC)			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: No	Managing Agency:		



Total All Funding Sources: 2,233,441	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipe	line Amount: 2,233,441	
Funding Source	Funding Amount	
GHP-State	2,233,441	

## **Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information** 

Budget Code Illionnation			
Mechanism ID: Mechanism Name: Prime Partner Name:	HIV Innovations for Improved Patient Outcomes in South Africa (Innovation Clinic)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	271,280	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	271,280	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	90,427	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	424,905	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	180,854	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	904,268	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	90,427	0

# **Implementing Mechanism Indicator Information**

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	479
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,857
PMTCT_ART_DSD	New on ART	307
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	172
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,857
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	0
PMTCT_STAT_DSD	By Age (Denominator): <15-19	142
PMTCT_STAT_DSD	By Age (Denominator): 20-24	535
PMTCT_STAT_DSD	By Age (Denominator): 25-49	1,218
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0



PMTCT_STAT_DSD	By Number of known positives: 15-19	29
PMTCT_STAT_DSD	By Number of known positives: 20-24	108
PMTCT_STAT_DSD	By Number of known positives: 25-49	246
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	13
PMTCT_STAT_DSD	By Number of new positives: 20-24	48
PMTCT_STAT_DSD	By Number of new positives: 25-49	109
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	0
PMTCT_STAT_DSD	By Age (Numerator): 15-19	139
PMTCT_STAT_DSD	By Age (Numerator): 20-24	524
PMTCT_STAT_DSD	By Age (Numerator): 25-49	1,194
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	26,359
HTC_TST_DSD	By Test Result: Positive	1,690
HTC_TST_DSD	Sum of Test Result disaggregates	1,690
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	101
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	506



HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	44
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	404
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	173
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	260
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: <1, Positive	0



HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 1-9, Negative	828
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 1-9, Positive	8
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	346
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	4
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	221
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	2
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	1,733
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	193
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	600
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	117
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	734
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	47
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	3,671
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	234
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	0



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	2,937
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	187
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	1,259
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	80
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	1,888
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	121
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Positive	0



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	794
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	623
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	40
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	3,117
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	199
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	2,494
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	159
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	1,069



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	68
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	1,603
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	102
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1,  Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9,  Negative	103
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	2



TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	561
Total number of registered new and relapsed T		
TB_STAT_DSD	Total number of registered new and relapsed TB cases,	567
during the reporting period.		
	Aggregated Age/Sex: Male <15 (Numerator: Number of	
TB_STAT_DSD	registered new and relapsed TB cases with	20
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: Number of	
TB_STAT_DSD	registered new and relapsed TB cases with	290
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: Number	
TB_STAT_DSD	of registered new and relapsed TB cases with	13
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number	
TB_STAT_DSD	of registered new and relapsed TB cases with	238
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	20
	during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	294
	during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	13
	during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: Total	
TB_STAT_DSD	number of registered new and relapsed TB cases,	240
	during the reporting period)	
	The number of registered new and relapse TB cases	
TB_ART_DSD	with documented HIV-positive status who are on ART	322
	during TB treatment during the reporting period	<b></b>
	The number of registered new and relapse TB cases	
TB_ART_DSD	with documented HIV-positive status during TB	387
ID_ART_DOD	treatment during the reporting period	507
TB_ART_DSD		7
I D_AK I _DOD	Aggregated Age/Sex: Male <15 (Numerator: The	1



	<u>,                                      </u>	
	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	158
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	12
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	145
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	9
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	174
Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)		13
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	191
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	464
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	3



PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	99
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	0
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	362
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	9,834
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	61
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	3,715
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	244
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	5,814
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	305
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	9,529
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	9,834
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	8,376
TX_PVLS_DSD	_DSD Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	
TX_PVLS_DSD	Numerator: Indication: Routine	8,376
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	52
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,164
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	208
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	4,952
TX_PVLS_DSD	Denominator: Indication: Routine	9,306
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15  Male Routine	58



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+  Male Routine	3,515
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	231
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	5,502
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,884
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,205
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,088
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	74
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,703
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	21
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,209
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total	82



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,893
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	

**Implementing Mechanism Details** 

Mechanism ID: 17033	Mechanism Name: Medical Research Council (CDC GH1150)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Medical Research Counc	cil
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 130,056	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 3,000,000		
Total All Funding Sources and Applied Pipeline Amount: 3,130,056		
Funding Source	Funding Amount	
GHP-State	130,056	

### **Cross-Cutting Budget Attribution(s)**



(No data provided.)

Budget Code Inform	ation		
Mechanism ID: 17033  Mechanism Name: Medical Research Council (CDC GH1150)  Prime Partner Name: Medical Research Council			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	30,056	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	100,000	0

### **Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 17036	Mechanism Name: Systems Strengthening for Better HIV/TB Patient Outcomes
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Foundation for Professional Development	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 27,837,483	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 1,252,537		
Total All Funding Sources and Applied Pipeline Amount: 29,090,020		
Funding Source	Funding Amount	
GHP-State	27,837,483	

Cross-Cutting Budget Attribution(s)

Gender: GBV	80,000
Focus Area:	GBV Prevention
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	80,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: GBV	80,000
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Human Resources for Health	120,000



Budget Code Inform	ation		
Mechanism ID:	17036		
Mechanism Name:	Systems Strengthening	for Better HIV/TB Patient	Outcomes
Prime Partner Name:	Prime Partner Name: Foundation for Professional Development		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	4,584,687	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	3,778,004	(
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	995,891	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	(
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,991,780	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	15,491,230	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	995,891	

### **Implementing Mechanism Indicator Information**



Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	16,441
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	87,640
PMTCT_ART_DSD	New on ART	12,749
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,692
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	5,280
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	27,483
PMTCT_ART_TA	New on ART	4,131
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,149
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	87,640
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	5,283
PMTCT_STAT_DSD	By Age (Denominator): <15-19	10,550
PMTCT_STAT_DSD	By Age (Denominator): 20-24	26,151
PMTCT_STAT_DSD	By Age (Denominator): 25-49	47,441
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	416
PMTCT_STAT_DSD	By Number of known positives: 15-19	834
PMTCT_STAT_DSD	By Number of known positives: 20-24	1,867
PMTCT_STAT_DSD	By Number of known positives: 25-49	3,265
PMTCT_STAT_DSD	By Number of known positives: 50+	0



	,	
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	607
PMTCT_STAT_DSD	By Number of new positives: 15-19	1,225
PMTCT_STAT_DSD	By Number of new positives: 20-24	3,075
PMTCT_STAT_DSD	By Number of new positives: 25-49	5,633
PMTCT_STAT_DSD	By Number of new positives: 50+	12
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	4,121
PMTCT_STAT_DSD	By Number of new negative: 15-19	8,281
PMTCT_STAT_DSD	By Number of new negative: 20-24	20,679
PMTCT_STAT_DSD	By Number of new negative: 25-49	37,596
PMTCT_STAT_DSD	By Number of new negative: 50+	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	5,169
PMTCT_STAT_DSD	By Age (Numerator): 15-19	10,349
PMTCT_STAT_DSD	By Age (Numerator): 20-24	25,636
PMTCT_STAT_DSD	By Age (Numerator): 25-49	46,486
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	27,483
PMTCT_STAT_TA	By Age (Denominator): <10	1
PMTCT_STAT_TA	By Age (Denominator): 10-14	1,575
PMTCT_STAT_TA	By Age (Denominator): 15-19	3,158
PMTCT_STAT_TA	By Age (Denominator): 20-24	8,263
PMTCT_STAT_TA	By Age (Denominator): 25-49	15,093
PMTCT_STAT_TA	By Age (Denominator): 50+	0
PMTCT_STAT_TA	By known positives: <10	0
PMTCT_STAT_TA	By known positives: 10-14	107
PMTCT_STAT_TA	By known positives: 15-19	227
PMTCT_STAT_TA	By known positives: 20-24	528
PMTCT_STAT_TA	By known positives: 25-49	934



PMTCT_STAT_TA	By known positives: 50+	0
PMTCT_STAT_TA	By new positives: <10	21
PMTCT_STAT_TA	By new positives: 10-14	194
PMTCT_STAT_TA	By new positives: 15-19	378
PMTCT_STAT_TA	By new positives: 20-24	982
PMTCT_STAT_TA	By new positives: 25-49	1,797
PMTCT_STAT_TA	By new positives: 50+	10
PMTCT_STAT_TA	By new negatives: <10	208
PMTCT_STAT_TA	By new negatives: 10-14	1,231
PMTCT_STAT_TA	By new negatives: 15-19	2,483
PMTCT_STAT_TA	By new negatives: 20-24	6,514
PMTCT_STAT_TA	By new negatives: 25-49	11,993
PMTCT_STAT_TA	By new negatives: 50+	97
PMTCT_STAT_TA	By Age (Numerator): <10	0
PMTCT_STAT_TA	By Age (Numerator): 10-14	1,575
PMTCT_STAT_TA	By Age (Numerator): : 15-19	3,099
PMTCT_STAT_TA	By Age (Numerator): 20-24	8,030
PMTCT_STAT_TA	By Age (Numerator): 25-49	14,779
PMTCT_STAT_TA	By Age (Numerator): 50+	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,025,739
HTC_TST_DSD	By Test Result: Positive	78,699
HTC_TST_DSD	Sum of Test Result disaggregates	78,699
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	5,396
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	107
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	5,381
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	106
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient:	73,882



	15+ Female Magative	
	15+, Female, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient:  15+, Female, Positive	5,993
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	49,154
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	4,035
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	5,409
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	640
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	1,816
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	34
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	413,483
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	39,061
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	238,590
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	19,552
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	49,895
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	1,046
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	1,808
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	37
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	1,807
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15,  Male, Positive	28
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+,	46,932



	Female, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	4,015
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	34,731
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	2,674
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	9,782
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	854
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	6,457
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	530
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	365,447
HTC_TST_TA	By Test Result: Positive	27,621
HTC_TST_TA	Sum of Test Result disaggregates	27,621
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: <15, Female, Negative	2,036
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: <15, Female, Positive	42



	•	
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Negative	2,035
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Positive	41
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Negative	26,338
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Positive	2,130
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Negative	17,593
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Positive	1,434
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Negative	1,700
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Positive	193
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Negative	683
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Positive	13
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative	144,933
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive	13,413
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative	85,410
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Positive	7,032
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	18,947
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	400
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Female, Negative	680
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Female, Positive	10



HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Male,  Negative	679
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Male, Positive	19
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Negative	16,841
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Positive	1,432
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Negative	12,424
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Positive	959
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Female, Negative	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Female, Positive	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Male, Negative	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Male, Positive	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative	3,728
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive	309
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative	2,493
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive	194
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	13,214
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	13,416
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with	802



	1	
	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4,476
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,191
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6,745
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	815
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	4,553
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,207
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	6,760
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	4,592
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	4,628
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	417
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	275
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,354



TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,551
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	272
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,543
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	416
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,353
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	7,261
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	8,069
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	434
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2,452
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	659
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with	3,716



	\	
	documented HIV-positive status who are on ART during	
	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	483
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	2,723
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	832
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	4,120
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	3,247
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	3,605
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	185
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,090
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	291



	1	
	TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,671
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	205
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1,226
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	322
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1,852
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	16,102
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	200
PMTCT_EID_DSD	Unknown, 2 - 12 months	86
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	0
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	15,778
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 4,933	
PMTCT_EID_TA	Number of infants with a positive virological test result	43



	within 2 months of birth	
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	0
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	5
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	4,885
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	528,557
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	11,714
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	152,440
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	11,611
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	352,791
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	23,325
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	505,231
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	528,556
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	94,058
TX_CURR_TA	Aggregated Age/Sex: <15 Male 2	
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	27,018
TX_CURR_TA	Aggregated Age/Sex: <15 Female	1,977
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	63,019
TX_CURR_TA	Sum of Aggregated Age/Sex <15	4,021
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	90,037
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	94,058
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	2,607
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	44,570
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2,522
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	103,933
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	153,632
TX_NEW_DSD	Pregnancy status	34,688



TX_NEW_DSD	Breastfeeding status	21
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	39,502
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	599
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	11,527
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	533
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	26,843
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	39,502
TX_NEW_TA	Pregnancy status	9,538
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	409,420
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	454,921
TX_PVLS_DSD	Numerator: Indication: Routine	409,420
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	1,187
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	8,759
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	117,114
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	8,687
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	273,287
TX_PVLS_DSD	Denominator: Indication: Routine	262,959
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	1,065
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15  Male Routine	9,755
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+  Male Routine	130,636
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	9,665



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	304,562
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	86,599
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	96,213
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	1,823
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	1,883
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	58,001
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	24,892
TX_PVLS_TA	Numerator: Indication: Routine	86,599
TX_PVLS_TA	Denominator: Indication: Routine	58,975
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,007
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15  Male Routine	2,076
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	64,484
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+  Male Routine	27,646
TX_PVLS_TA	Denominator: Preg/BF by Indication: Pregnant Routine	1,489
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	256,113
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting	



TX_RET_DSD	Numerator by Status: Pregnant 30,637	
TX_RET_DSD	Denominator by Status: Pregnant	54,634
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,674
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,619
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	170,705
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,835
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	307,698
TX_RET_TA	Number of adults and children who are still alive and on	46,887



	treatment at 12 months after initiating ART	
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	118,104
TX_RET_TA	Numerator by Status: Pregnant	5,620
TX_RET_TA	Denominator by Status: Pregnant	14,166
TX_RET_TA	Denominator by Status: Breastfeeding	0
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,012
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13,442
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	978
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	31,355
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,923
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	34,335
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,722



TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	80,124
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	11,471
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	21,509
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,945
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,290
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female 10,9	
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	21,509
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	1,029
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	689
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	5,827
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	3,895
TB_PREV_DSD	TB_PREV_DSD By Therapy type (Numerator): 6-12 Month IPT	
TB_PREV_TA	PREV_TA  The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	
TB_PREV_TA	The number of ART patients who were newly started on	



	but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	673
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	450
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	3,803
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	2,506
TB_PREV_TA	By Therapy type (Denominator): 6-12 Month IPT	7,418
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	360
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	238
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	1,958
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	1,278
TB_PREV_TA	By Therapy type (Numerator): 6-12 Month IPT	3,838

**Implementing Mechanism Details** 

Mechanism ID: 17037	Mechanism Name: Systems Strengthening for Better HIV/TB Patient Outcomes	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Wits Reproductive Health& HI	V Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 7,401,625	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pip	eline Amount: 7,401,625
Funding Source	Funding Amount
GHP-State	7,401,625

**Cross-Cutting Budget Attribution(s)** 

Gender: Gender Equality	124,731



Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Condom programming	81,709
Human Resources for Health	1,355,826
Food and Nutrition: Policy, Tools, and Service Delivery	55,014

**Budget Code Information** 

Mechanism ID: Mechanism Name: Prime Partner Name:	Systems Strengthening for Better HIV/TB Patient Outcomes		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	1,225,379	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,006,555	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	268,027	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	MTCT	536,055	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,097,582	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	268,027	0

## **Implementing Mechanism Indicator Information**

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	7,482
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	26,863
PMTCT_ART_DSD	New on ART	4,405
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,077
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	829
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,986
PMTCT_ART_TA	New on ART	492
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	337
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	26,863
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	0



PMTCT_STAT_DSD	By Age (Denominator): <15-19	332
PMTCT_STAT_DSD	By Age (Denominator): 20-24	674
PMTCT_STAT_DSD	By Age (Denominator): 25-49	27,611
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	38
PMTCT_STAT_DSD	By Number of known positives: 20-24	73
PMTCT_STAT_DSD	By Number of known positives: 25-49	3,547
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	38
PMTCT_STAT_DSD	By Number of new positives: 20-24	73
PMTCT_STAT_DSD	By Number of new positives: 25-49	3,764
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	0
PMTCT_STAT_DSD	By Number of new negative: 15-19	242
PMTCT_STAT_DSD	By Number of new negative: 20-24	483
PMTCT_STAT_DSD	By Number of new negative: 25-49	18,605
PMTCT_STAT_DSD	By Number of new negative: 50+	0
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	0
PMTCT_STAT_DSD	By Age (Numerator): 15-19	316
PMTCT_STAT_DSD	By Age (Numerator): 20-24	628
PMTCT_STAT_DSD	By Age (Numerator): 25-49	25,919
PMTCT_STAT_DSD	By Age (Numerator): 50+	0



	Number of pregnant women with known HIV status	
PMTCT_STAT_TA	(includes women who were tested for HIV and received	2,986
	their results)	_,
PMTCT_STAT_TA	By Age (Denominator): 15-19	35
PMTCT_STAT_TA	By Age (Denominator): 20-24	71
PMTCT_STAT_TA	By Age (Denominator): 25-49	2,939
PMTCT_STAT_TA	By Age (Denominator): 50+	0
PMTCT_STAT_TA	By known positives: <unknown age<="" td=""><td>0</td></unknown>	0
PMTCT_STAT_TA	By known positives: <10	0
PMTCT_STAT_TA	By known positives: 10-14	0
PMTCT_STAT_TA	By known positives: 15-19	4
PMTCT_STAT_TA	By known positives: 20-24	9
PMTCT_STAT_TA	By known positives: 25-49	394
PMTCT_STAT_TA	By known positives: 50+	0
PMTCT_STAT_TA	By new positives: Unknown Age	0
PMTCT_STAT_TA	By new positives: <10	0
PMTCT_STAT_TA	By new positives: 10-14	0
PMTCT_STAT_TA	By new positives: 15-19	5
PMTCT_STAT_TA	By new positives: 20-24	11
PMTCT_STAT_TA	By new positives: 25-49	415
PMTCT_STAT_TA	By new positives: 50+	0
PMTCT_STAT_TA	By new negatives: Unknown Age	0
PMTCT_STAT_TA	By new negatives: <10	0
PMTCT_STAT_TA	By new negatives: 10-14	0
PMTCT_STAT_TA	By new negatives: 15-19	26
PMTCT_STAT_TA	By new negatives: 20-24	51
PMTCT_STAT_TA	By new negatives: 25-49	2,071
PMTCT_STAT_TA	By new negatives: 50+	0
PMTCT_STAT_TA	By Age (Numerator): Unknown Age	0
PMTCT_STAT_TA	By Age (Numerator): <10	0
PMTCT_STAT_TA	By Age (Numerator): 10-14	0
PMTCT_STAT_TA	By Age (Numerator): : 15-19	35



PMTCT_STAT_TA	By Age (Numerator): 20-24	71
PMTCT_STAT_TA	By Age (Numerator): 25-49	2,880
PMTCT_STAT_TA	By Age (Numerator): 50+	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	211,912
HTC_TST_DSD	By Test Result: Positive	21,007
HTC_TST_DSD	Sum of Test Result disaggregates	21,007
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	107
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	107
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	949
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	105
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	486
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	54
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	976
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	109
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	976
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	109
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	204
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	204



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	192
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	129
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,595
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	177
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,064
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	117
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	11,473
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	1,275
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	7,649
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	852
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	964
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	111
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	642
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	70



HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1,  Negative	1,697
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	188
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	958
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	111
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	1,828
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	200
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	1,728
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	200
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	88,521
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	9,832
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	59,016
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	6,556
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	2,949
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	327
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female,  Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0



HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female,  Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female,  Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	171
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	112
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	0



HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	679
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	77
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	455
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	55
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female,  Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female,	213



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	141
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT:	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	2,510
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	279
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	1,673
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	184



HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	23,544
HTC_TST_TA	By Test Result: Positive	2,348
HTC_TST_TA	Sum of Test Result disaggregates	2,348
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	13
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	12
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	100
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	58
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Positive	6
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: <15, Female, Negative	110
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: <15, Female, Positive	12
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Negative	110
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	22
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	22
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19,	15



	Female, Negative	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	10
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	122
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	83
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	9
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	916
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	98
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	614
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	66
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	74
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	8
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	50
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1,  Negative	188
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1,	21



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9,  Negative	109
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	12
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Negative	200
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Positive	22
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Negative	200
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Positive	22
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative	9,834
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive	1,094
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative	6,560
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Positive	728
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	331
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	38
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female,  Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female,  Negative	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female,	1



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female,  Negative	20
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Negative	13
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Negative	76
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Positive	7
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Negative	55
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	7
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	4



HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	57
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	38
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	406
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	45
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	271
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	30
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Negative	34
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	22
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Positive	2
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative	279
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive	31
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative	186
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive	21



TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	15,042
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	15,200
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	740
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	5,543
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	738
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8,021
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	761
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	5,598
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	763
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	8,078
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,558
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	2,789
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	157



	<u> </u>	
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	147
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,486
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	999
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	136
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	913
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	146
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,362
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	16,868
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	18,690
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	860
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6,133



TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	862
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9,013
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	942
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	7,088
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	943
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	9,717
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,103
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,281
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	135
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The	674



	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	
	TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	135
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,160
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	150
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	738
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	150
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1,244
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	6,986
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	270
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	4,983
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	11



PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	1,722
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	954
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	13
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	148
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	31
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	762
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	149,938
TX_CURR_DSD	Age/Sex: 15-19 Male	337
TX_CURR_DSD	Age/Sex: 15-19 Female	494
TX_CURR_DSD	Sum of age/sex disaggregates	831
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	994
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	19,785
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,098
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	44,706
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,092
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	64,491
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	66,583
TX_CURR_DSD	Age/Sex: <1	89
TX_CURR_DSD	Age/Sex: <1-9	795
TX_CURR_DSD	Age/Sex: 10-14 Male	330
TX_CURR_DSD	Age/Sex: 10-14 Female	354
TX_CURR_DSD	Age/Sex: 20-24 Male	651
TX_CURR_DSD	Age/Sex: 25-49 Male	24,412
TX_CURR_DSD	Age/Sex: 50+ Male	3,346
TX_CURR_DSD	Age/Sex: 20-24 Female	2,579
TX_CURR_DSD	Age/Sex: 25-49 Female	45,460



TX_CURR_DSD	Age/Sex: 50+ Female	4,508
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	16,660
TX_CURR_TA	Age/Sex: 15-19 Male	13
TX_CURR_TA	Age/Sex: 15-19 Female	40
TX_CURR_TA	Sum of Age/Sex disaggregations	53
TX_CURR_TA	Aggregated Age/Sex: <15 Male	129
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	2,104
TX_CURR_TA	Aggregated Age/Sex: <15 Female	140
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	5,025
TX_CURR_TA	Sum of Aggregated Age/Sex <15	269
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	7,129
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	7,398
TX_CURR_TA	Age/Sex: <1	6
TX_CURR_TA	Age/Sex: 1-9	17
TX_CURR_TA	Age/Sex: 10-14 Male	13
TX_CURR_TA	Age/Sex: 10-14 Female	18
TX_CURR_TA	Age/Sex: 20-24 Male	34
TX_CURR_TA	Age/Sex: 25-49 Male	2,247
TX_CURR_TA	Age/Sex: 50+ Male	321
TX_CURR_TA	Age/Sex: 20-24 Female	193
TX_CURR_TA	Age/Sex: 25-49 Female	5,489
TX_CURR_TA	Age/Sex: 50+ Female	871
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	21,137
TX_NEW_DSD	By Age/Sex: <1	103
TX_NEW_DSD	By Age/Sex: 1-9	91
TX_NEW_DSD	By Age/Sex: 10-14 Male	47
TX_NEW_DSD	By Age/Sex: 15-19 Male	35
TX_NEW_DSD	By Age/Sex: 20-24 Male	190
TX_NEW_DSD	By Age/Sex: 25-49 Male	2,252
TX_NEW_DSD	By Age/Sex: 50+ Male	233



<u></u>		
TX_NEW_DSD	By Age/Sex: 10-14 Female	59
TX_NEW_DSD	By Age/Sex: 15-19 Female	158
TX_NEW_DSD	By Age/Sex: 20-24 Female	941
TX_NEW_DSD	By Age/Sex: 25-49 Female	4,537
TX_NEW_DSD	By Age/Sex: 50+ Female	308
TX_NEW_DSD	Sum of Age/Sex disaggregates	8,760
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	143
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,889
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	176
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	7,975
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	12,183
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,350
TX_NEW_TA	By Age/Sex: <1	6
TX_NEW_TA	By Age/Sex: 1-9	5
TX_NEW_TA	By Age/Sex: 10-14 Male	5
TX_NEW_TA	By Age/Sex: 15-19 Male	4
TX_NEW_TA	By Age/Sex: 20-24 Male	11
TX_NEW_TA	By Age/Sex: 25-49 Male	235
TX_NEW_TA	By Age/Sex: 50+ Male	43
TX_NEW_TA	By Age/Sex: 10-14 Female	6
TX_NEW_TA	By Age/Sex: 15-19 Female	13
TX_NEW_TA	By Age/Sex: 20-24 Female	73
TX_NEW_TA	By Age/Sex: 25-49 Female	538
TX_NEW_TA	By Age/Sex: 50+ Female	56
TX_NEW_TA	Sum of Age/Sex disaggregates	984
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	21
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	402
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	23
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	909
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	1,355
TX_PVLS_DSD	Number of adults and pediatric patients on ART with	125,434
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	1,355



	suppressed viral load results (<1,000 copies/ml)	
	documented in the medical records and /or supporting	
	laboratory results within the past 12 months.	
	Number of adult and pediatric ART patients with a viral	
TX_PVLS_DSD	load result documented in the patient medical record	139,372
	and /or laboratory records in the past 12 months.	
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	2,261
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	2,159
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	90,860
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	44,092
TX_PVLS_DSD	Undocumented Test Indication	139,372
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	1,843
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	1,745
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	82,771
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	39,075
TX_PVLS_DSD	Undocumented Test Indication	125,434
	Number of adults and pediatric patients on ART with	
TV DV/LC TA	suppressed viral load results (<1,000 copies/ml)	12.027
TX_PVLS_TA	documented in the medical records and /or supporting	13,937
	laboratory results within the past 12 months.	
	Number of adult and pediatric ART patients with a viral	
TX_PVLS_TA	load result documented in the patient medical record	15,486
	and /or laboratory records in the past 12 months.	
TX_PVLS_TA	<15, Undocumented Test Indication, Female	162
TX_PVLS_TA	<15, Undocumented Test Indication, Male	158
TX_PVLS_TA	15+, Undocumented Test Indication, Female	11,060
TX_PVLS_TA	15+, Undocumented Test Indication, Male	4,106
TX_PVLS_TA	Undocumented Test Indication	15,486
TX_PVLS_TA	<15, Undocumented Test Indication, Female	130
TX_PVLS_TA	<15, Undocumented Test Indication, Male	106
TX_PVLS_TA	15+, Undocumented Test Indication, Female	10,092
TX_PVLS_TA	15+, Undocumented Test Indication, Male	3,609
TX_PVLS_TA	Undocumented Test Indication	13,937



TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	27,571
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	30,652
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	304
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,070
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	305
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17,892
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	342
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,898
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	350
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the	20,062



	1	
	12 months prior to the beginning of the reporting period, including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,062
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,405
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	767
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	12
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,276
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	857
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	12



_		
	stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,528
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	4,505
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	8,879
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	162
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	78
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	5,170
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	3,469
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	8,879
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	88
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	52
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	2,687
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,678
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	4,505
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	522
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period	1,008



	and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting	
	period).	
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	11
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	4
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	594
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	399
TB_PREV_TA	By Therapy type (Denominator): 6-12 Month IPT	1,008
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	6
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	4
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	314
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	198
TB_PREV_TA	By Therapy type (Numerator): 6-12 Month IPT	522

**Implementing Mechanism Details** 

implementing incondition betains				
Mechanism ID: 17038	Mechanism Name: Strengthening District Responses for Better HIV/TB Patient Outcomes in eThekwini & Umkhanyakude Districts in KwaZulu-Natal, South Africa			
Funding Agency: USAID	Procurement Type: Cooperative Agreement			
Prime Partner Name: Maternal, Adolscent and Child	Health (MatCH)			
Agreement Start Date: Redacted	Agreement End Date: Redacted			
TBD: No	New Mechanism: No			
Global Fund / Multilateral Engagement: N/A				
G2G: No	Managing Agency:			

Total All Funding Sources: 13,469,013	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 13,469,013			
Funding Source	Funding Amount		
GHP-State	13,469,013		



**Cross-Cutting Budget Attribution(s)** 

Key Populations: FSW	7,380
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	5,864
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	30,960
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Food and Nutrition: Policy, Tools, and Service	40,448
Delivery	
Condom programming	38,938
Human Resources for Health	49,392

**Budget Code Information** 

Mechanism ID:  Mechanism Name:  Prime Partner Name:  Maternal, Adolscent and Child Health (MatCH)			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	2,194,021	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,578,217	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	326,255	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	341,297	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	371,696	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	652,510	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	7,678,762	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment		326,255	

## Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	13,974
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	67,900
PMTCT_ART_DSD	New on ART	7,687
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	6,287
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	67,900
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	692
PMTCT_STAT_DSD	By Age (Denominator): <15-19	6,229
PMTCT_STAT_DSD	By Age (Denominator): 20-24	27,717
PMTCT_STAT_DSD	By Age (Denominator): 25-49	34,648
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	81
PMTCT_STAT_DSD	By Number of known positives: 15-19	735
PMTCT_STAT_DSD	By Number of known positives: 20-24	3,255
PMTCT_STAT_DSD	By Number of known positives: 25-49	4,072
PMTCT_STAT_DSD	By Number of known positives: 50+	0



PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	59
PMTCT_STAT_DSD	By Number of new positives: 15-19	556
PMTCT_STAT_DSD	By Number of new positives: 20-24	2,445
PMTCT_STAT_DSD	By Number of new positives: 25-49	3,056
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	535
PMTCT_STAT_DSD	By Number of new negative: 15-19	4,823
PMTCT_STAT_DSD	By Number of new negative: 20-24	21,459
PMTCT_STAT_DSD	By Number of new negative: 25-49	26,824
PMTCT_STAT_DSD	By Number of new negative: 50+	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	683
PMTCT_STAT_DSD	By Age (Numerator): 15-19	6,112
PMTCT_STAT_DSD	By Age (Numerator): 20-24	27,159
PMTCT_STAT_DSD	By Age (Numerator): 25-49	33,946
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,667
PrEP_NEW_DSD	Female 20-24	1,667
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	586,243
HTC_TST_DSD	By Test Result: Positive	69,853
HTC_TST_DSD	Sum of Test Result disaggregates	69,853
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	126
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	628



HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	50
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	717
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	43
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	215
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	323
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	378
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	52
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	255
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	2,262
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	308
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	1,509
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	207
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,716
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	370



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,809
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	246
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	3,896
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	529
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	2,594
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	355
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	177
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	120
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	953
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	130
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	488
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	52
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	2,446
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	264
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	1,957
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	212



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	838
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	91
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	1,258
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	137
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	711
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	96
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	481
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	70,406
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	9,613
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	46,983
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	6,484
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	84,468
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	11,537
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	56,381
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	7,779
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	121,085



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	16,531
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	80,816
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	11,156
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	5,636
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	769
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	3,757
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	523
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,781
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	251
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	1,504
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	1,312
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	183
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	872
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	118
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	1,578
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	217
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	1,047



HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	145
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	2,255
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	303
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	1,499
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	206
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	65
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	557
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	49
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	2,787
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	244
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	2,261
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	195
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	956
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	84
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49,	1,433



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	125
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	22,607
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	22,835
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	790
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8,415
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	791
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	12,611
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	797
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	8,499
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	798
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	12,741
GEND_GBV_DSD	Number of people receiving post-GBV care	808
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0



CEND CDV DCD	Dutimo of comings Coverd Vislance (Doct Der Cover)	000		
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	808		
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	808		
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	196		
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	234		
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	378		
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	14,109		
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	470		
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)			
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	519		
Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)		7,868		
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	13,546		
PMTCT_EID_DSD	PMTCT_EID_DSD Number of infants with a positive virological test result within 2 months of birth			
PMTCT_EID_DSD	PMTCT_EID_DSD Number of infants with a negative virological test result within 2 months of birth			
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	50		
PMTCT_EID_DSD	PMTCT_EID_DSD Number of infants with a negative virological test result			



	between 2 and 12 months of birth	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	502,803
TX_CURR_DSD	Age/Sex: 15-19 Male	18,702
TX_CURR_DSD	Age/Sex: 15-19 Female	28,053
TX_CURR_DSD	Sum of age/sex disaggregates	46,755
TX_CURR_DSD	Age/Sex: <1	352
TX_CURR_DSD	Age/Sex: <1-9	20,764
TX_CURR_DSD	Age/Sex: 10-14 Male	7,038
TX_CURR_DSD	Age/Sex: 10-14 Female	7,038
TX_CURR_DSD	Age/Sex: 20-24 Male	56,116
TX_CURR_DSD	Age/Sex: 25-49 Male	93,523
TX_CURR_DSD	Age/Sex: 50+ Male	18,708
TX_CURR_DSD	Age/Sex: 20-24 Female	84,165
TX_CURR_DSD	Age/Sex: 25-49 Female	140,290
TX_CURR_DSD	Age/Sex: 50+ Female	28,054
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	89,006
TX_NEW_DSD	By Age/Sex: <1	70
TX_NEW_DSD	By Age/Sex: 1-9	3,675
TX_NEW_DSD	By Age/Sex: 10-14 Male	1,242
TX_NEW_DSD	By Age/Sex: 15-19 Male	3,311
TX_NEW_DSD	By Age/Sex: 20-24 Male	9,934
TX_NEW_DSD	By Age/Sex: 25-49 Male	16,555
TX_NEW_DSD	By Age/Sex: 50+ Male	3,302
TX_NEW_DSD	By Age/Sex: 10-14 Female	1,242
TX_NEW_DSD	By Age/Sex: 15-19 Female	4,968
TX_NEW_DSD	By Age/Sex: 20-24 Female	14,903
TX_NEW_DSD	By Age/Sex: 25-49 Female	24,835
TX_NEW_DSD	By Age/Sex: 50+ Female	4,969
TX_NEW_DSD	Sum of Age/Sex disaggregates	85,261
TX_PVLS_DSD	Number of adults and pediatric patients on ART with	412,471



	suppressed viral load results (<1,000 copies/ml)		
	documented in the medical records and /or supporting		
	laboratory results within the past 12 months.		
TV DV 0 DOD	Number of adult and pediatric ART patients with a viral	450.004	
TX_PVLS_DSD	load result documented in the patient medical record	458,301	
TV DV/ 0 DOD	and /or laboratory records in the past 12 months.	440 474	
TX_PVLS_DSD	Numerator: Indication: Routine	412,471	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	15,109	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	152,698	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	15,473	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	229,052	
TX_PVLS_DSD	Denominator: Indication: Routine	458,301	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15  Male Routine	16,040	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+  Male Routine	170,489	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	16,030	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	255,742	
TX_PVLS_DSD	Unknown Age, Routine, Female	69	
TX_PVLS_DSD	Unknown Age, Routine, Male	70	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	144,311	
	Total number of adults and children who initiated ART		
TX_RET_DSD	in the 12 months prior to the beginning of the reporting	160,346	
	period, including those who have died, those who have stopped ART, and those lost to follow-up		
	Aggregated Age/Sex: <15 Male (Numerator: Number of		
TX_RET_DSD	adults and children who are still alive and on treatment	5,044	
	and on a daman on the daman of a		



	at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	53,679
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,044
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	80,544
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,608
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	59,655
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,608
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	89,475
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	14,382
TB_PREV_DSD	The number of ART patients who were newly started on	28,765



started on TB preventive therapy in this reporting period		
	and those who started in the previous reporting period	
	but had not been reported as they did not fulfill the	
	minimum requirements for the previous reporting	
	period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,009
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,009
TB_PREV_DSD	TB_PREV_DSD By Age/Sex (Denominator): 15+, Female 16,04	
TB_PREV_DSD	DSD By Age/Sex (Denominator): 15+, Male 10	
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	504
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	504
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	8,028
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	5,346

**Implementing Mechanism Details** 

Mechanism ID: 17039	Mechanism Name: Comprehensive Clinic-Based District Services (Hybrid)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Broadreach		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

otal All Funding Sources: 0 Total Mechanism Pipeline: N/A			
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 0			
Funding Source Funding Amount			
GHP-State	o		

### **Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information** 

Budget Code Information			
Mechanism ID: 17039			
Mechanism Name:	Mechanism Name: Comprehensive Clinic-Based District Services (Hybrid)		
Prime Partner Name:	, , ,		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

# **Implementing Mechanism Indicator Information**

(No data provided.)



**Implementing Mechanism Details** 

implementing meenanism betans			
Mechanism ID: 17043	Mechanism Name: Ikhwezi MAMA - Monitoring & Evaluation & Vodacom Ikhwezi mHealth		
	Program		
Funding Agency: USAID	Procurement Type: Cooperative Agreement		
Prime Partner Name: Wits Reproductive Health& HIV Institute			
Agreement Start Date: Redacted	Agreement End Date: Redacted		
TBD: No	New Mechanism: No		
Global Fund / Multilateral Engagement: N/A			
G2G: No	Managing Agency:		

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 0			
Funding Source Funding Amount			
GHP-State	0		

# **Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information** 

Buaget Gode Illionia	I		
Mechanism ID: Mechanism Name:	Ikhwezi MAMA - Monitoring & Evaluation & Vodacom Ikhwezi mHealth Program		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC 0 0		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



### **Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 17046	Mechanism Name: Systems Strengthening for Better HIV/TB Patient Outcomes	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Kheth'Impilo		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 9,449,379	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 333,333		
Total All Funding Sources and Applied Pip	eline Amount: 9,782,712	
Funding Source	Funding Amount	
GHP-State	9,449,379	

**Cross-Cutting Budget Attribution(s)** 

Gender: GBV	222,507
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	343,176



Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Human Resources for Health	1,804,443

**Budget Code Information** 

Budget Code Information			
Mechanism ID:	17046		
Mechanism Name:	Systems Strengthening for Better HIV/TB Patient Outcomes		
Prime Partner Name:	Kheth'Impilo		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	1,511,544	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,178,317	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	287,147	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	521,329	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	574,292	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	5,089,603	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	287,147	0

# **Implementing Mechanism Indicator Information**

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	9,729
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	34,093
PMTCT_ART_DSD	New on ART	4,467
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	5,262
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4,855
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	29,555
PMTCT_ART_TA	New on ART	1,888
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	2,967
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	34,093
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0



		1
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	0
PMTCT_STAT_DSD	By Age (Denominator): <15-19	4,288
PMTCT_STAT_DSD	By Age (Denominator): 20-24	6,350
PMTCT_STAT_DSD	By Age (Denominator): 25-49	23,961
PMTCT_STAT_DSD	By Age (Denominator): 50+	192
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	659
PMTCT_STAT_DSD	By Number of known positives: 20-24	973
PMTCT_STAT_DSD	By Number of known positives: 25-49	3,671
PMTCT_STAT_DSD	By Number of known positives: 50+	28
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	440
PMTCT_STAT_DSD	By Number of new positives: 20-24	649
PMTCT_STAT_DSD	By Number of new positives: 25-49	2,449
PMTCT_STAT_DSD	By Number of new positives: 50+	14
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	0
PMTCT_STAT_DSD	By Number of new negative: 15-19	3,109
PMTCT_STAT_DSD	By Number of new negative: 20-24	4,599
PMTCT_STAT_DSD	By Number of new negative: 25-49	17,366
PMTCT_STAT_DSD	By Number of new negative: 50+	136
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	0
PMTCT_STAT_DSD	By Age (Numerator): 15-19	4,210
PMTCT_STAT_DSD	By Age (Numerator): 20-24	6,219



PMTCT_STAT_DSD	By Age (Numerator): 25-49	23,487
PMTCT_STAT_DSD	By Age (Numerator): 50+	177
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	29,555
PMTCT_STAT_TA	By Age (Denominator): Unknown Age	0
PMTCT_STAT_TA	By Age (Denominator): <10	0
PMTCT_STAT_TA	By Age (Denominator): 10-14	0
PMTCT_STAT_TA	By Age (Denominator): 15-19	3,710
PMTCT_STAT_TA	By Age (Denominator): 20-24	5,493
PMTCT_STAT_TA	By Age (Denominator): 25-49	20,746
PMTCT_STAT_TA	By Age (Denominator): 50+	163
PMTCT_STAT_TA	By known positives: <unknown age<="" td=""><td>0</td></unknown>	0
PMTCT_STAT_TA	By known positives: <10	0
PMTCT_STAT_TA	By known positives: 10-14	0
PMTCT_STAT_TA	By known positives: 15-19	478
PMTCT_STAT_TA	By known positives: 20-24	692
PMTCT_STAT_TA	By known positives: 25-49	2,536
PMTCT_STAT_TA	By known positives: 50+	14
PMTCT_STAT_TA	By new positives: Unknown Age	0
PMTCT_STAT_TA	By new positives: <10	0
PMTCT_STAT_TA	By new positives: 10-14	0
PMTCT_STAT_TA	By new positives: 15-19	276
PMTCT_STAT_TA	By new positives: 20-24	409
PMTCT_STAT_TA	By new positives: 25-49	1,591
PMTCT_STAT_TA	By new positives: 50+	8
PMTCT_STAT_TA	By new negatives: Unknown Age	0
PMTCT_STAT_TA	By new negatives: <10	0
PMTCT_STAT_TA	By new negatives: 10-14	0
PMTCT_STAT_TA	By new negatives: 15-19	2,893
PMTCT_STAT_TA	By new negatives: 20-24	4,282
PMTCT_STAT_TA	By new negatives: 25-49	16,250



PMTCT_STAT_TA	By new negatives: 50+	126
PMTCT_STAT_TA	By Age (Numerator): Unknown Age	0
PMTCT_STAT_TA	By Age (Numerator): <10	0
PMTCT_STAT_TA	By Age (Numerator): 10-14	0
PMTCT_STAT_TA	By Age (Numerator): : 15-19	3,647
PMTCT_STAT_TA	By Age (Numerator): 20-24	5,383
PMTCT_STAT_TA	By Age (Numerator): 25-49	20,377
PMTCT_STAT_TA	By Age (Numerator): 50+	148
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	11,927
PP_PREV_DSD	Age/sex: 10-14 Female	5,730
PP_PREV_DSD	Age/sex: 15-19 Female	6,197
PP_PREV_DSD	Sum of Age/Sex disaggregates	11,927
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	476,348
HTC_TST_DSD	By Test Result: Positive	38,441
HTC_TST_DSD	Sum of Test Result disaggregates	38,441
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	4,411
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	723
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	4,716
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	772
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	5,269
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	864
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	5,143



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	842
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	6,037
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	989
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	5,992
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	983
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	19,664
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	3,219
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	18,076
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	2,968
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	9,732
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1,595
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	6,267
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	1,028
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0



HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1,  Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	8,569
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	1,403
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	24,013
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	431
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	75,045
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	3,375
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	90,394
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	5,541
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	130,503
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	9,600
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	10,668
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	95
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	60
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	27
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	62



HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female,  Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	73
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	70
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female,  Negative	38
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	84
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	83
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female,  Negative	115
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	266
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	106
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	244
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female,  Negative	58
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	135
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	86
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age,	0



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	52
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	120
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	127
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	126
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	407
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	405
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	494
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	494
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	726
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	718
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	144
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	152
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female,	172



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	168
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	200
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	195
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	647
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	107
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	588
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	99
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	322
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	206
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age,	0



	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VCT:	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	281
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	48
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	600
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	10
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	1,882
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	85
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	2,265
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	138
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	3,274
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	240
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	676,898
HTC_TST_TA	By Test Result: Positive	40,387
HTC_TST_TA	Sum of Test Result disaggregates	40,387
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	69
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	11
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14,	71



	Male, Negative	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	83
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	14
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	81
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	95
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	16
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	94
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	15
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	309
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	51
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	283
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	47
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	154
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	25
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	98
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male,	16



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1,  Negative	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9,  Negative	137
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	22
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <a href="https://www.enables.com/enables.com/">&lt;15, Female, Negative</a>	45,417
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Positive	828
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Negative	136,011
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Positive	5,553
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative	176,925
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive	11,319
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative	246,862
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Positive	18,151
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	11,254



HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	99
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female,  Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female,	1



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	2
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Female, Negative	236
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Female, Positive	236
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Male, Negative	734
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Male, Positive	730
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Negative	972
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Positive	975
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Negative	1,381
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Positive	1,349



HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	10
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female,  Negative	5



HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Female, Negative	1,138
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Female, Positive	5
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Male, Negative	3,418
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Male, Positive	133
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative	4,434
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive	284
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative	6,198
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive	456



TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	11,921
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	12,035
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	130
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,544
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	176
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8,071
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	130
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,573
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	180
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	8,152
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	10,964
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	11,781
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	137



TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	116
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	7,620
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,208
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	112
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,176
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	134
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7,742
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	5,991
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	6,447
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	70
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1,813



TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	94
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4,014
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	72
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1,960
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	100
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	4,315
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	5,225
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	5,480
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	56
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The	1,528



	1	
	number of registered new and relapse TB cases with	
	documented HIV-positive status who are on ART during	
	TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	67
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,574
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	56
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1,602
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	67
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	3,755
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	7,155
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	10
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	2,880
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	30



PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	4,235
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	6,987
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	42
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	2,662
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	27
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	4,256
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	234,262
TX_CURR_DSD	Age/Sex: 15-19 Male	426
TX_CURR_DSD	Age/Sex: 15-19 Female	2,271
TX_CURR_DSD	Sum of age/sex disaggregates	2,697
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,573
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	43,785
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,859
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	102,737
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,432
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	146,522
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	149,954
TX_CURR_DSD	Age/Sex: <1	704
TX_CURR_DSD	Age/Sex: <1-9	1,233
TX_CURR_DSD	Age/Sex: 10-14 Male	224
TX_CURR_DSD	Age/Sex: 10-14 Female	417
TX_CURR_DSD	Age/Sex: 20-24 Male	1,633
TX_CURR_DSD	Age/Sex: 25-49 Male	22,687
TX_CURR_DSD	Age/Sex: 50+ Male	2,301
TX_CURR_DSD	Age/Sex: 20-24 Female	9,217
TX_CURR_DSD	Age/Sex: 25-49 Female	39,379



TX_CURR_DSD	Age/Sex: 50+ Female	3,816
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	102,804
TX_CURR_TA	Age/Sex: 15-19 Male	15
TX_CURR_TA	Age/Sex: 15-19 Female	79
TX_CURR_TA	Sum of Age/Sex disaggregations	94
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,048
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	29,169
TX_CURR_TA	Aggregated Age/Sex: <15 Female	1,234
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	68,404
TX_CURR_TA	Sum of Aggregated Age/Sex <15	2,282
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	97,573
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	99,855
TX_CURR_TA	Age/Sex: <1	25
TX_CURR_TA	Age/Sex: 1-9	43
TX_CURR_TA	Age/Sex: 10-14 Male	8
TX_CURR_TA	Age/Sex: 10-14 Female	15
TX_CURR_TA	Age/Sex: 20-24 Male	57
TX_CURR_TA	Age/Sex: 25-49 Male	793
TX_CURR_TA	Age/Sex: 50+ Male	80
TX_CURR_TA	Age/Sex: 20-24 Female	322
TX_CURR_TA	Age/Sex: 25-49 Female	1,377
TX_CURR_TA	Age/Sex: 50+ Female	134
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	69,736
TX_NEW_DSD	By Age/Sex: <1	152
TX_NEW_DSD	By Age/Sex: 1-9	266
TX_NEW_DSD	By Age/Sex: 10-14 Male	47
TX_NEW_DSD	By Age/Sex: 15-19 Male	93
TX_NEW_DSD	By Age/Sex: 20-24 Male	353
TX_NEW_DSD	By Age/Sex: 25-49 Male	4,886
TX_NEW_DSD	By Age/Sex: 50+ Male	495



TX_NEW_DSD	By Age/Sex: 10-14 Female	91
TX_NEW_DSD	By Age/Sex: 15-19 Female	486
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,985
TX_NEW_DSD	By Age/Sex: 25-49 Female	8,479
TX_NEW_DSD	By Age/Sex: 50+ Female	826
TX_NEW_DSD	Sum of Age/Sex disaggregates	17,741
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	545
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	15,065
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	644
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	35,323
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	51,577
TX_NEW_DSD	Pregnancy status	2,608
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	38,735
TX_NEW_TA	By Age/Sex: <1	5
TX_NEW_TA	By Age/Sex: 1-9	8
TX_NEW_TA	By Age/Sex: 10-14 Male	1
TX_NEW_TA	By Age/Sex: 15-19 Male	3
TX_NEW_TA	By Age/Sex: 20-24 Male	11
TX_NEW_TA	By Age/Sex: 25-49 Male	151
TX_NEW_TA	By Age/Sex: 50+ Male	15
TX_NEW_TA	By Age/Sex: 10-14 Female	3
TX_NEW_TA	By Age/Sex: 15-19 Female	15
TX_NEW_TA	By Age/Sex: 20-24 Female	62
TX_NEW_TA	By Age/Sex: 25-49 Female	263
TX_NEW_TA	By Age/Sex: 50+ Female	26
TX_NEW_TA	Sum of Age/Sex disaggregates	550
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	400
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	11,148
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	473
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	26,150
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	38,171



TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	177,748
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	197,500
TX_PVLS_DSD	Numerator: Indication: Routine	177,748
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	2,390
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	53,423
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	3,739
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	118,163
TX_PVLS_DSD	Denominator: Indication: Routine	197,500
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15  Male Routine	2,218
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+  Male Routine	59,822
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	3,103
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	132,357
TX_PVLS_DSD	Unknown Age, Routine, Female	18
TX_PVLS_DSD	Unknown Age, Routine, Male	15
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	76,800
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	85,330



TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	971
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	815
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	52,531
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	22,483
TX_PVLS_TA	Numerator: Indication: Routine	76,800
TX_PVLS_TA	Denominator: Indication: Routine	85,330
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,084
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15  Male Routine	904
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	58,365
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	24,977
TX_PVLS_TA	Unknown Age, Routine, Male	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	29,412
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	32,679
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	325
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,849
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	447



TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19,791
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	361
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,833
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	494
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	21,991
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	15,040
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	16,709
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	283
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,403



	<u> </u>	
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on	190
TX_RET_TA	treatment at 12 months after initiating ART)  Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,164
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	176
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,888
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	213
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11,432
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	4,876
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting	9,744



	period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	156
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	114
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	6,490
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	2,984
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	78
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	52
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	3,249
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,497
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	2,155
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	4,317
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	48
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	41
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	2,969
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	1,259
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	22
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	18
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	1,483
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	632

Mechanism ID: 17452	Mechanism Name: AIHA Twinning Capacity Building (HRSA)	
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement	
Prime Partner Name: American International Health Alliance		



Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 204,685	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 204,685			
Funding Source Funding Amount			
GHP-State	204,685		

Human Resources for Health	204.685	
i lullian Nesoulces for Fleatin	204,003	

**Budget Code Information** 

Daagot Godo IIII oi III			
Mechanism ID:	17452		
Mechanism Name:	AIHA Twinning Capacity Building (HRSA)		
Prime Partner Name:	American International Health Alliance		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	204,685	0

#### **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 17459	Mechanism Name: HSRC (CDC GH001629)



Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Human Sciences Research Council		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 410,000	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 410,000			
Funding Source Funding Amount			
GHP-State	410,000		

Motor Vehicles: Leased	85,776

	17459 HSRC (CDC GH001629) Human Sciences Research Council			
Strategic Area	Budget Code Planned Amount On Hold Amount			
Governance and Systems	HLAB	100,000	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Governance and Systems	HVSI	310,000	0	



(No data provided.)

**Implementing Mechanism Details** 

promoningoonamoni = otamo		
Mechanism ID: 17493	Mechanism Name: NHLS (CDC GH001631)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: National Health Laboratory Services		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 4,930,269	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 4,930,269		
Funding Source Funding Amount		
GHP-State	4,930,269	

**Cross-Cutting Budget Attribution(s)** 

Motor Vehicles: Purchased	37,289

Mechanism ID:	17493		
Mechanism Name:	NHLS (CDC GH001631)		
Prime Partner Name:	National Health Laboratory Services		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	4,120,269	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	810,000	0

(No data provided.)

**Implementing Mechanism Details** 

implementing meentament betane		
Mechanism ID: 17505	Mechanism Name: UNICEF (CDC PS002027)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: United Nations Children's Fund		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 500,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pip	eline Amount: 500,000
Funding Source	Funding Amount
GHP-State	500,000

**Cross-Cutting Budget Attribution(s)** 

Human Resources for Health	150,000
i idiliali Nesodices idi Healti	130,000

	G. U. G. I.
Mechanism ID:	17505



	UNICEF (CDC PS002027) United Nations Children's Fund		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 17506	Mechanism Name: Beyond Zero Advanced Clinical Care Centres (CDC GH001143)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Beyond Zero		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 1,800,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 1,800,000		
Funding Source Funding Amount		
GHP-State	1,800,000	

#### **Cross-Cutting Budget Attribution(s)**



Human Resources for Health	150,000

**Budget Code Information** 

udget Code Information			
Mechanism ID:	Mechanism ID: 17506		
Mechanism Name: Beyond Zero Advanced Clinical Care Centres (CDC GH001143)			
Prime Partner Name:	Beyond Zero		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	315,594	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	253,951	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	67,628	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	90,507	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	970,108	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	102,212	0

### **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 17507	Mechanism Name: Kheth"Impilo Advanced



	Clinical Care Centres (CDC GH001145)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Kheth'Impilo	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,325,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 2,325,000		
Funding Source Funding Amount		
GHP-State	2,325,000	

Human Resources for Health	900,000
	,

Mechanism ID: Mechanism Name: Prime Partner Name:	Kheth"Impilo Advanced Clinical Care Centres (CDC GH001145)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	407,641	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	328,020	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	PDCS	87,353	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	116,905	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,253,057	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	132,024	0

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 17510	Mechanism Name: Technical Assistance (TA) Indicators	
Funding Agency: HHS/CDC	Procurement Type: Contract	
Prime Partner Name: Macro Atlanta		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source Funding Amount	
GHP-State	0

### **Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information** 

Baagot Godo Illiotillation			
Mechanism ID:	17510		
Mechanism Name:	Technical Assistance (TA) Indicators		
Prime Partner Name:	Macro Atlanta		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0

## **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 17512	Mechanism Name: WHO HIV Prevention (CDC GH001180)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: World Health Organization		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 256,177	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 256,177		
Funding Source Funding Amount		
GHP-State	256,177	



Water	25,000
Water	25,000

Budget Code Information			
Mechanism ID: 17512  Mechanism Name: WHO HIV Prevention (CDC GH001180)  Prime Partner Name: World Health Organization			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	75,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	106,177	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	25,000	0

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 17533	Mechanism Name: SA Partners Care and Support (CDC GH001554)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: South Africa Partners	s
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	A
G2G: No	Managing Agency:

Total All Funding Sources: 4,258,017	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 4,258,017		
Funding Source	Funding Amount	
GHP-State	4,258,017	

**Cross-Cutting Budget Attribution(s)** 

Human Resources for Health	900.000



**Budget Code Information** 

Budget Code Information				
Mechanism ID:	17533			
Mechanism Name:	Mechanism Name: SA Partners Care and Support (CDC GH001554)			
Prime Partner Name:				
Strategic Area	Budget Code Planned Amount On Hold Amount			
Care	НВНС	613,653	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HVTB	493,793	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	PDCS	131,499	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVCT	212,444	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	HVOP	545,574	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Prevention	МТСТ	175,986	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	HTXS	1,886,322	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Treatment	PDTX	198,746	0	

# Implementing Mechanism Indicator Information

Indicator Number	Label	2018



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	11,571
HTC_TST_DSD	By Test Result: Positive	687
HTC_TST_DSD	Sum of Test Result disaggregates	687
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	51
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	253
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	202
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	87
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	130
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 1-9, Negative	414
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	367
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	1,835



	15-19, Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	117
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	1,468
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	94
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	629
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	944
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	60
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	312
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	1,558
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	99
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	1,247
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	80
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	534
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	801
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49,	51



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9,  Negative	51
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	1

**Implementing Mechanism Details** 

Mechanism ID: 17536	Mechanism Name: Accelerating Strategies for Practical Innovation & Research in Economic Strengthening (ASPIRES)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: FHI 360		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/	4	
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 0
Funding Source	Funding Amount
GHP-State	0

# **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Saaget Sode information		
Mechanism ID:	17536	
Mechanism Name:	Accelerating Strategies for Practical Innovation & Research in	
Prime Partner Name:	Economic Strengthening (ASPIRES)	



	FHI 360		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

(No data provided.)

Implementing Mechanism Details

implementing wechanism Details		
Mechanism ID: 17537	Mechanism Name: Strategic, Evidence-Based Communication Interventions Systematically Applied at Multiple Levels for Greater Effectiveness of HIV Prevention Programs	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Johns Hopkins Health and Education in South Africa		
reement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 4,966,195	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pip	eline Amount: 4,966,195	
Funding Source	Funding Amount	
GHP-State	4,966,195	

**Cross-Cutting Budget Attribution(s)** 

Motor Vehicles: Purchased	21,838
---------------------------	--------



**Budget Code Information** 

Budget Code Information			
	17537		
Mechanism ID:	ID: Strategic, Evidence-Based Communication Interventions Systematically		
Mechanism Name:	Applied at Multiple Level	s for Greater Effectivene	ss of HIV Prevention
Prime Partner Name:	Programs		
	Johns Hopkins Health a	nd Education in South A	frica
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	3,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	966,195	0
O	Budget Code	Planned Amount	On Hold Amount
Strategic Area	Duaget Code	Tiamica Amount	

## **Implementing Mechanism Indicator Information**

(No data provided.)

implementing meenamem betane		
Mechanism ID: 17538	Mechanism Name: Community-Based Comprehensive HIV Prevention, Counseling and testing Program to Reduce HIV Incidence	
Funding Agency: USAID Procurement Type: Cooperative Agreement		
Prime Partner Name: Johns Hopkins Health and Education in South Africa		
Agreement Start Date: Redacted	Agreement End Date: Redacted	



TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 6,342,102	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 386,224	
Total All Funding Sources and Applied Pipe	line Amount: 6,728,326
Funding Source	Funding Amount
GHP-State	6,342,102

groce catting badget / ttiribat	
Gender: GBV	59,883
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	59,883
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: GBV	59,883
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information

adget bode information	
Mechanism ID:	17538



	Mechanism Name: Community-Based Comprehensive HIV Prevention, Counseling and Prime Partner Name: testing Program to Reduce HIV Incidence  Johns Hopkins Health and Education in South Africa		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	655,925	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	737,764	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	4,948,413	0

Indicator Number	Label	2018
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	139,207
PP_PREV_DSD	Age/sex: 10-14 Male	0
PP_PREV_DSD	Age/sex: 15-19 Male	25,957
PP_PREV_DSD	Age/sex: 20-24 Male	19,824
PP_PREV_DSD	Age/sex: 25-49 Male	25,957
PP_PREV_DSD	Age/sex: 50+ Male	0
PP_PREV_DSD	Age/sex: 10-14 Female	2,687
PP_PREV_DSD	Age/sex: 15-19 Female	31,329
PP_PREV_DSD	Age/sex: 20-24 Female	25,957



PP_PREV_DSD	Age/sex: 25-49 Female	7,485
PP_PREV_DSD	Age/sex: 50+ Female	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	139,196
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	40,183
HTC_TST_DSD	By Test Result: Positive	2,412
HTC_TST_DSD	Sum of Test Result disaggregates	2,412
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	1,812
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	116
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	9,056
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	580
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	7,248
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	464
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	3,104
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	200
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	0



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	4,660
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	296
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Positive	0



	•	
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	6,002
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	384
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	4,001
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	255
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	96
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	476
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	0



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	380
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	164
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	244
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Positive	0



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1,  Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative	315
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive	21
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	210
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	13
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Positive	0



Mechanism ID: 17767	Mechanism Name: Broadreach (CDC GH001202)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Broadreach	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 300,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 300,000		
Funding Source	Funding Amount	
GHP-State	300,000	

Human Resources for Health	300.000
· · · · · · · · · · · · · · · · · · ·	000,000

**Budget Code Information** 

Mechanism ID:	17767		
Mechanism Name:	Broadreach (CDC GH001202)		
Prime Partner Name:	Broadreach		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	OHSS	300,000	0

#### **Implementing Mechanism Indicator Information**

(No data provided.)



**Implementing Mechanism Details** 

mprementally meeticalled betains		
Mechanism ID: 17768	Mechanism Name: Columbia University Nimart Evaluation (CDC GH001194)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Columbia University Mailman School of Public Health		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 450,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 450,000	
Funding Source Funding Amount	
GHP-State	450,000

**Cross-Cutting Budget Attribution(s)** 

Huma	ın Resources for Health	-	50,000	

Mechanism ID:	17768		
Mechanism Name:	Columbia University Nii	mart Evaluation (CDC GH	001194)
Prime Partner Name:	Columbia University Ma	ailman School of Public H	lealth
Strategic Area	Budget Code Planned Amount On Hold Amount		On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	450,000	0



(No data provided.)

Implementing Mechanism Details

inplementing Mechanism Details		
	Mechanism Name: University of Washington	
Mechanism ID: 17769	Capacity Building for Systems Strengthening	
	CDC GH001197)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of Washington		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 4,175,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 4,175,000		
Funding Source Funding Amount		
GHP-State	4,175,000	

**Cross-Cutting Budget Attribution(s)** 

Human Resources for Health	11,674,564	

Mechanism ID:	17769 University of Washington Capacity Building for Systems Strengthening
Mechanism Name:	University of Washington Capacity Building for Systems Strengthening
Mechanism Name:	CDC GH001197)
Prime Partner Name:	CDC GH001197) University of Washington



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	644,336	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	518,483	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	138,074	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	184,786	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,980,638	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	208,683	0



(No data provided.)

Implementing Mechanism Details

implementing mechanism betalls		
	Mechanism Name: Comprehensive VMMC	
Mechanism ID: 17790	Training Programs/Ongoing Mentoring and	
	Private Sector VMMC Training and Mentoring	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: The Centre for HIV and AIDS Prevention Studies		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

### **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Mechanism ID:	17790
Mechanism Name:	Comprehensive VMMC Training Programs/Ongoing Mentoring and
Prime Partner Name:	Private Sector VMMC Training and Mentoring
i illie i aitilei Naille.	The Centre for HIV and AIDS Prevention Studies



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 17791	Mechanism Name: Catalyzing an Adolescent Combination Prevention Program in South Africa (Activity 1), & Community SKILLZ for Health: Scaling-up Soccer-Based HIV and SGBV Prevention Programmes for Adolescents through Partnerships in South Africa (Activity 2)	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Grassroots Soccer		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source Funding Amount		
GHP-State	0	

### **Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information** 

Baaget oode inform	u		
Mechanism ID:  Mechanism Name:  Prime Partner Name:	Africa (Activity 1), & Community SKILLZ for Health: Scaling-up Soccer-Based HIV and SGBV Prevention Programmes for Adolescents		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Prevention	HVOP	0	0

## **Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 17792	Mechanism Name: Integrated HIV Wellness and Combating Stigma	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Program for Appropriate Technology in Health		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

### **Cross-Cutting Budget Attribution(s)**



(No data provided.)

**Budget Code Information** 

Daaget Code Inform	ation		
Mechanism ID:	17792		
Mechanism Name:	Integrated HIV Wellness	and Combating Stigma	
Prime Partner Name:	Program for Appropriat	e Technology in Health	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

## **Implementing Mechanism Indicator Information**

(No data provided.)

more management and a second m		
Mechanism ID: 17801	Mechanism Name: MEASURE Evaluation Phase IV	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 600,000	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 600,000		
Funding Source Funding Amount		
GHP-State	600,000	



Education	50.000
_aaaa	00,000

**Budget Code Information** 

Baaget Goac Illionii			
Mechanism ID:	17801		
Mechanism Name:	MEASURE Evaluation Phase IV		
Prime Partner Name:	University of North Carolina at Chapel Hill, Carolina Population Center		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Prevention	HVAB	600,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

### **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 17968	Mechanism Name: Wits Health Consortium Capacity Building (CDC GH001538)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Wits Health Consortium, Reproductive Health Research Unit		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 818,550	Total Mechanism Pipeline: N/A			
Applied Pipeline Amount: 0				
Total All Funding Sources and Applied Pipeline Amount: 818,550				



Funding Source	Funding Amount
GHP-State	818,550

Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	50,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Human Resources for Health	300,000

Mechanism ID:	17968		
Mechanism Name:	Wits Health Consortium Capacity Building (CDC GH001538)		
Prime Partner Name:	Wits Health Consortium, Reproductive Health Research Unit		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	218,550	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	200,000	0

Indicator Number	Label	2018
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	5,002
PP_PREV_DSD	Age/sex: 10-14 Male	123
PP_PREV_DSD	Age/sex: 15-19 Male	503
PP_PREV_DSD	Age/sex: 20-24 Male	754
PP_PREV_DSD	Age/sex: 25-49 Male	742
PP_PREV_DSD	Age/sex: 50+ Male	0
PP_PREV_DSD	Age/sex: 10-14 Female	251
PP_PREV_DSD	Age/sex: 15-19 Female	877
PP_PREV_DSD	Age/sex: 20-24 Female	1,004



	<u>,                                      </u>	
PP_PREV_DSD	Age/sex: 25-49 Female	748
PP_PREV_DSD	Age/sex: 50+ Female	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	5,002
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	786
PP_PREV_TA	Age/sex: 10-14 Male	19
PP_PREV_TA	Age/sex: 15-19 Male	79
PP_PREV_TA	Age/sex: 20-24 Male	119
PP_PREV_TA	Age/sex: 25-49 Male	119
PP_PREV_TA	Age/sex: 50+ Male	0
PP_PREV_TA	Age/sex: 10-14 Female	40
PP_PREV_TA	Age/sex: 15-19 Female	138
PP_PREV_TA	Age/sex: 20-24 Female	157
PP_PREV_TA	Age/sex: 25-49 Female	119
PP_PREV_TA	Age/sex: 50+ Female	0
PP_PREV_TA	Sum of Age/Sex disaggregates	790

Mechanism ID: 17969	Mechanism Name: SURMEPI: Stellenbosch University Rural Medical Education Partenreship Initiative HQ T84HA21652
Funding Agency: HHS/HRSA Procurement Type: Cooperative Agreem	
Prime Partner Name: University of Stellenbos	ch, South Africa
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No New Mechanism: No	
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount



|--|

(No data provided.)

**Budget Code Information** 

Budget Code inform	alion		
Mechanism ID: Mechanism Name:	SURMEPI: Stellenbosch		ıl Education
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

## **Implementing Mechanism Indicator Information**

(No data provided.)

inplementing Mechanism Details		
Mechanism ID: 17980	Mechanism Name: Masibambisane1	
Funding Agency: DOD	Procurement Type: Cooperative Agreement	
Prime Partner Name: South African Military Health Service		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	



Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

(No data provided.)

**Budget Code Information** 

Budget Code Illionia			
Mechanism ID:	17980		
Mechanism Name:	Masibambisane1		
Prime Partner Name:	South African Military H	lealth Service	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

## Implementing Mechanism Indicator Information

(No data provided.)

Mechanism ID: 17981	Mechanism Name: Society For Family



	Health/Population Services International
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Society for Family Health - Sou	uth Africa
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline A	Amount: 0
Funding Source	Funding Amount
GHP-State	0

(No data provided.)

	17981 Society For Family Heal	•	nternational
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0



(No data provided.)

Implementing Mechanism Details

implementing meenament betans	
Mechanism ID: 18021	Mechanism Name: Health Information Systems Programs (CDC GH001922)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Information Systems Pr	rogram
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 4,350,000	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pip	eline Amount: 4,350,000
Funding Source	Funding Amount
GHP-State	4,350,000

**Cross-Cutting Budget Attribution(s)** 

Human Resources for Health	1,500,	0,000

Mechanism ID:	18021		
Mechanism Name:	Health Information Syst	ems Programs (CDC GH	001922)
Prime Partner Name:	Health Information Syst	ems Program	
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	2,350,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,500,000	0

(No data provided.)

#### **Implementing Mechanism Details**

Mechanism ID: 18022	TBD: Yes
REDA	CTED

#### **Implementing Mechanism Details**

Mechanism ID: 18023	TBD: Yes
REDA	CTED

Mechanism ID: 18083	Mechanism Name: Council for Scientific and Industrial Research (CDC GH001937)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: COUNCIL OF SCIENTIFIC AN	ID INDUSTRIAL RESEARCH
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No Managing Agency:
--------------------------

Total All Funding Sources: 650,000	Total Mechanism Pipeline: N/A			
Applied Pipeline Amount: 0	•			
Total All Funding Sources and Applied Pip	peline Amount: 650,000			
Funding Source Funding Amount				
GHP-State	650,000			

Human Resources for Health	200.000
i idiliali Nesodices foi i leatti	200,000

**Budget Code Information** 

Baagot Godo information			
Mechanism ID:	18083		
Mechanism Name:	Council for Scientific and Industrial Research (CDC GH001937)		
Prime Partner Name:	COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH		
Strategic Area	Budget Code Planned Amount On Hold Amount		On Hold Amount
Care	HVTB	650,000	0

## **Implementing Mechanism Indicator Information**

(No data provided.)

<u> </u>	
Mechanism ID: 18231	Mechanism Name: Society for Family Health
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: Population Services Internation	nal/Society for Family Health
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 187,723		
Total All Funding Sources and Applied Pipeline Amount: 187,723		
Funding Source	Funding Amount	
GHP-State	0	

(No data provided.)

**Budget Code Information** 

Budget Code Inform	ation		
Mechanism ID:	8231		
Mechanism Name:	Society for Family Health		
Prime Partner Name:	Population Services International/Society for Family Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

#### **Implementing Mechanism Indicator Information**

(No data provided.)



Mechanism ID: 18254	TBD: Yes
REDA	CTED

**Implementing Mechanism Details** 

militarianing moontainem betains		
Mechanism ID: 18298	Mechanism Name: Health Finance and Governance	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Abt Associates		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 1,000,000	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 1,000,000			
Funding Source Funding Amount			
GHP-State	1,000,000		

## **Cross-Cutting Budget Attribution(s)**

(No data provided.)

Mechanism ID:	18298		
Mechanism Name:	Health Finance and Governance		
Prime Partner Name:	Abt Associates		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	OHSS	1,000,000	0



(No data provided.)

#### **Implementing Mechanism Details**

Mechanism ID: 18299	TBD: Yes	
	REDACTED	

**Implementing Mechanism Details** 

Mechanism ID: 18300 Mechanism Name: HRH2030		
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Chemonics International		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipeline Amount: 0		
Funding Source Funding Amount		
GHP-State	0	

#### **Cross-Cutting Budget Attribution(s)**

(No data provided.)



Mechanism ID: Mechanism Name: Prime Partner Name:		al	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 18307	Mechanism Name: UCFS (GH000977 - Central Mech)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: UCSF CDC HQ		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
BD: No New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

otal All Funding Sources: 200,000 Total Mechanism Pipeline: N/A			
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 200,000			
Funding Source Funding Amount			
GHP-State	200,000		

## **Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information** 

Baagot Coao IIIIOIIII				
Mechanism ID:	18307			
Mechanism Name:	: UCFS (GH000977 - Central Mech)			
Prime Partner Name: UCSF CDC HQ				
Strategic Area	Budget Code Planned Amount On Hold Amount			
Governance and Systems	HVSI	200,000	0	

## **Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 18313 Mechanism Name: UNAIDS (CDC GH0		
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 350,000	Total Mechanism Pipeline: N/A			
Applied Pipeline Amount: 0				
Total All Funding Sources and Applied Pipeline Amount: 350,000				
Funding Source Funding Amount				
GHP-State	350,000			

## **Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information** 

Mechanism ID:	18313			
Mechanism Name:	UNAIDS (CDC GH001971)			
Prime Partner Name:	UNAIDS - Joint United Nations Programme on HIV/AIDS			
Strategic Area	Budget Code Planned Amount On Hold Amount			
Governance and Systems	HVSI	350,000	0	

## **Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 18314	Mechanism Name: NASTAD (GH001508 - Central Mech)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: National Alliance of State and	Territorial AIDS Directors	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 0	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 0			
Funding Source Funding Amount			
GHP-State	o		

### **Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information** 

Mechanism ID:	18314			
Mechanism Name:	NASTAD (GH001508 - Central Mech)			
Prime Partner Name:	National Alliance of State and Territorial AIDS Directors			
Strategic Area	Budget Code Planned Amount On Hold Amount			
Governance and Systems	HVSI	0	0	

## **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 18321	Mechanism Name: Global Health Supply Chain Program	
Funding Agency: USAID	Procurement Type: Inter-Agency Agreement	
Prime Partner Name: Global Health Supply Chain Program		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 8,076,885	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 1,400,000			
Total All Funding Sources and Applied Pipeline Amount: 9,476,885			
Funding Source Funding Amount			
GHP-State	8,076,885		



807,689

**Budget Code Information** 

Budget Code information			
Mechanism ID: 18321			
Mechanism Name:	Mechanism Name: Global Health Supply Chain Program		
Prime Partner Name:	Global Health Supply C	hain Program	
Strategic Area	Budget Code Planned Amount On Hold Amount		
Governance and Systems	HVSI	1,000,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	2,176,885	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,900,000	0

## **Implementing Mechanism Indicator Information**

(No data provided.)

Mechanism ID: 18480	Mechanism Name: Foundation for Professional Development Comprehensive (CDC GH001932)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Foundation for Professional Development		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		



G2G: No	Managing Agency:
---------	------------------

Total All Funding Sources: 4,943,068	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 338,975			
Total All Funding Sources and Applied Pipe	eline Amount: 5,282,043		
Funding Source Funding Amount			
GHP-State	4,943,068		

Gender: GBV	97,275
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Sub Area:	Implementation
Human Resources for Health	283,019
Motor Vehicles: Purchased	18,778

Mechanism ID: Mechanism Name:	Foundation for Professional Development Comprehensive (CDC : GH001932)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	350,659	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	282,167	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	75,142	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	317,414	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	1,370,507	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	1,005,146	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	100,565	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,077,899	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	113,569	0

Indicator Number	Label	2018
	Number of HIV-positive pregnant women who received	
PMTCT_ART_TA	ART to reduce risk of mother-to-child-transmission	638
	(MTCT) during pregnancy	
	Number of pregnant women with known HIV status	
PMTCT_ART_TA	(includes women who were tested for HIV and received	192
	their results)	
PMTCT_ART_TA	New on ART	444



PMTCT_ART_TA	Already on ART at beginning of current pregnancy	194
	Number of pregnant women with known HIV status	
PMTCT_STAT_TA	(includes women who were tested for HIV and received	192
	their results)	
PMTCT_STAT_TA	By Age (Denominator): <10	0
PMTCT_STAT_TA	By Age (Denominator): 10-14	16
PMTCT_STAT_TA	By Age (Denominator): 15-19	31
PMTCT_STAT_TA	By Age (Denominator): 20-24	58
PMTCT_STAT_TA	By Age (Denominator): 25-49	91
PMTCT_STAT_TA	By Age (Denominator): 50+	0
PMTCT_STAT_TA	By known positives: <10	0
PMTCT_STAT_TA	By known positives: 10-14	3
PMTCT_STAT_TA	By known positives: 15-19	5
PMTCT_STAT_TA	By known positives: 20-24	10
PMTCT_STAT_TA	By known positives: 25-49	16
PMTCT_STAT_TA	By known positives: 50+	0
PMTCT_STAT_TA	By new positives: <10	0
PMTCT_STAT_TA	By new positives: 10-14	2
PMTCT_STAT_TA	By new positives: 15-19	4
PMTCT_STAT_TA	By new positives: 20-24	8
PMTCT_STAT_TA	By new positives: 25-49	12
PMTCT_STAT_TA	By new positives: 50+	0
PMTCT_STAT_TA	By new negatives: <10	0
PMTCT_STAT_TA	By new negatives: 10-14	11
PMTCT_STAT_TA	By new negatives: 15-19	21
PMTCT_STAT_TA	By new negatives: 20-24	39
PMTCT_STAT_TA	By new negatives: 25-49	61
PMTCT_STAT_TA	By new negatives: 50+	0
PMTCT_STAT_TA	By Age (Numerator): <10	0
PMTCT_STAT_TA	By Age (Numerator): 10-14	15
PMTCT_STAT_TA	By Age (Numerator): : 15-19	31
PMTCT_STAT_TA	By Age (Numerator): 20-24	57



PMTCT_STAT_TA	By Age (Numerator): 25-49	89
PMTCT_STAT_TA	By Age (Numerator): 50+	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	32,000
PP_PREV_DSD	Age/sex: 15-19 Male	1,600
PP_PREV_DSD	Age/sex: 20-24 Male	8,000
PP_PREV_DSD	Age/sex: 25-49 Male	8,960
PP_PREV_DSD	Age/sex: 50+ Male	960
PP_PREV_DSD	Age/sex: 15-19 Female	640
PP_PREV_DSD	Age/sex: 20-24 Female	3,840
PP_PREV_DSD	Age/sex: 25-49 Female	6,400
PP_PREV_DSD	Age/sex: 50+ Female	1,600
PP_PREV_DSD	Sum of Age/Sex disaggregates	32,000
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	93,109
HTC_TST_DSD	By Test Result: Positive	8,742
HTC_TST_DSD	Sum of Test Result disaggregates	8,742
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	15,579
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	1,926
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile  Testing: 15+, Male, Negative	23,369
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	2,888
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	13,021
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	1,132
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	19,530



HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	1,699
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Negative	123
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Positive	2
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Negative	186
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Positive	4
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative	5,024
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive	436
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	7,535
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	655
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	49
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	1
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	0
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	0
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	48

Mechanism ID: 18481	Mechanism Name: Health Systems Trust Comprehensive (CDC GH001980)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Systems Trust	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 46,958,429	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 0		
Total All Funding Sources and Applied Pipe	line Amount: 46,958,429	
Funding Source	Funding Amount	
GHP-State	46,958,429	

Gender: GBV	182,375
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	1,960,000
Economic Strengthening	91,187
Food and Nutrition: Commodities	182,375
Motor Vehicles: Purchased	1,068,944
Education	91,187

Mechanism ID:	18481		
Mechanism Name:	Health Systems Trust Comprehensive (CDC GH001980)		
Prime Partner Name:	Health Systems Trust		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	6,569,725	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	2,930,755	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	5,525,960	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	1,499,940	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	28,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	1,960,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	966,379	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	917,977	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	2,925,299	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	22,076,313	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,557,581	0



Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	25,260
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	87,427
PMTCT_ART_DSD	New on ART	15,028
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	10,232
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,311
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	11,158
PMTCT_ART_TA	New on ART	1,964
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,347
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	87,427
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	1,780
PMTCT_STAT_DSD	By Age (Denominator): <15-19	7,978
PMTCT_STAT_DSD	By Age (Denominator): 20-24	23,190
PMTCT_STAT_DSD	By Age (Denominator): 25-49	55,269
PMTCT_STAT_DSD	By Age (Denominator): 50+	939
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	235
PMTCT_STAT_DSD	By Number of known positives: 15-19	1,155



PMTCT_STAT_DSD	By Number of known positives: 20-24	3,380
PMTCT_STAT_DSD	By Number of known positives: 25-49	8,016
PMTCT_STAT_DSD	By Number of known positives: 50+	109
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	222
PMTCT_STAT_DSD	By Number of new positives: 15-19	1,142
PMTCT_STAT_DSD	By Number of new positives: 20-24	3,359
PMTCT_STAT_DSD	By Number of new positives: 25-49	7,935
PMTCT_STAT_DSD	By Number of new positives: 50+	107
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	1,237
PMTCT_STAT_DSD	By Number of new negative: 15-19	5,571
PMTCT_STAT_DSD	By Number of new negative: 20-24	16,039
PMTCT_STAT_DSD	By Number of new negative: 25-49	38,285
PMTCT_STAT_DSD	By Number of new negative: 50+	620
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	1,746
PMTCT_STAT_DSD	By Age (Numerator): 15-19	7,891
PMTCT_STAT_DSD	By Age (Numerator): 20-24	22,741
PMTCT_STAT_DSD	By Age (Numerator): 25-49	54,189
PMTCT_STAT_DSD	By Age (Numerator): 50+	854
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	11,158
PMTCT_STAT_TA	By Age (Denominator): <10	1
PMTCT_STAT_TA	By Age (Denominator): 10-14	225
PMTCT_STAT_TA	By Age (Denominator): 15-19	1,046
PMTCT_STAT_TA	By Age (Denominator): 20-24	3,010
PMTCT_STAT_TA	By Age (Denominator): 25-49	7,242
PMTCT_STAT_TA	By Age (Denominator): 50+	105
PMTCT_STAT_TA	By known positives: <10	0
PMTCT_STAT_TA	By known positives: 10-14	15



T-		
PMTCT_STAT_TA	By known positives: 15-19	148
PMTCT_STAT_TA	By known positives: 20-24	421
PMTCT_STAT_TA	By known positives: 25-49	1,031
PMTCT_STAT_TA	By known positives: 50+	3
PMTCT_STAT_TA	By new positives: <10	0
PMTCT_STAT_TA	By new positives: 10-14	12
PMTCT_STAT_TA	By new positives: 15-19	140
PMTCT_STAT_TA	By new positives: 20-24	435
PMTCT_STAT_TA	By new positives: 25-49	1,025
PMTCT_STAT_TA	By new positives: 50+	2
PMTCT_STAT_TA	By new negatives: <10	0
PMTCT_STAT_TA	By new negatives: 10-14	151
PMTCT_STAT_TA	By new negatives: 15-19	725
PMTCT_STAT_TA	By new negatives: 20-24	2,058
PMTCT_STAT_TA	By new negatives: 25-49	4,933
PMTCT_STAT_TA	By new negatives: 50+	89
PMTCT_STAT_TA	By Age (Numerator): Unknown Age	0
PMTCT_STAT_TA	By Age (Numerator): <10	1
PMTCT_STAT_TA	By Age (Numerator): 10-14	218
PMTCT_STAT_TA	By Age (Numerator): : 15-19	1,016
PMTCT_STAT_TA	By Age (Numerator): 20-24	2,916
PMTCT_STAT_TA	By Age (Numerator): 25-49	6,898
PMTCT_STAT_TA	By Age (Numerator): 50+	108
	Number of the target population who completed a	
PP_PREV_DSD	standardized HIV prevention intervention including the	15,925
	minimum components during the reporting period.	
PP_PREV_DSD	Age/sex: 10-14 Male	399
PP_PREV_DSD	Age/sex: 15-19 Male	1,591
PP_PREV_DSD	Age/sex: 20-24 Male	2,388
PP_PREV_DSD	Age/sex: 25-49 Male	2,388
PP_PREV_DSD	Age/sex: 50+ Male	1
PP_PREV_DSD	Age/sex: 10-14 Female	795



PP_PREV_DSD	Age/sex: 15-19 Female	2,786
PP_PREV_DSD	Age/sex: 20-24 Female	3,188
PP_PREV_DSD	Age/sex: 25-49 Female	2,390
PP_PREV_DSD	Age/sex: 50+ Female	2
PP_PREV_DSD	Sum of Age/Sex disaggregates	15,928
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,042,278
HTC_TST_DSD	By Test Result: Positive	119,363
HTC_TST_DSD	Sum of Test Result disaggregates	119,363
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	623
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	52
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	3,106
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	272
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	2,483
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	214
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	1,066
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	94
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	1,596
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	131
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 1-9, Negative	4,003
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 1-9, Positive	37



HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	1,339
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	146
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	6,697
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	746
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	5,357
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	593
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	2,295
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	258
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	3,439
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	384
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	2,703
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	304
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	602
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	66
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	3,061
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	343
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	2,266



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	242
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	34,558
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	4,128
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	11,056
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	1,134
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	51,749
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	6,696
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	20,111
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	2,481
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	12,283
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1,370
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	4,958
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	555
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	1,929
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	217
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9,  Negative	5,645
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	628



HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	28,381
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	3,169
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	11,307
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	1,620
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	445,041
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	49,478
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	211,644
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	28,695
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	1,496
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	264
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	5,370
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	3,082
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female,  Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	1



HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female,  Negative	27
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	55
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	43
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	73
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female,  Negative	165
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	258
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	75
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	124
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female,  Negative	292
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	500
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	215
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	383
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female,  Negative	73
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	133
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	53
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	18



HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	41
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	146
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	224
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	101
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15,  Male, Positive	141
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	2,819
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	3,713
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	1,914
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	2,557
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Negative	29
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Negative	450
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	1,102
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	105
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	5,512
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	510
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	4,410
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	405
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24,	1,889



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	172
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	2,837
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	258
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	493
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female,  Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male,  Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	0



Service Delivery Point (Facility) VCT: 15-19, Female, Negative	37
Service Delivery Point (Facility) VCT: 15-19, Female, Positive	11
Service Delivery Point (Facility) VCT: 15-19, Male, Negative	40
Service Delivery Point (Facility) VCT: 15-19, Male, Positive	2
Service Delivery Point (Facility) VCT: 20-24, Female, Negative	468
Service Delivery Point (Facility) VCT: 20-24, Female, Positive	56
Service Delivery Point (Facility) VCT: 20-24, Male, Negative	223
Service Delivery Point (Facility) VCT: 20-24, Male, Positive	11
Service Delivery Point (Facility) VCT: 25-49, Female, Negative	835
Service Delivery Point (Facility) VCT: 25-49, Female, Positive	103
Service Delivery Point (Facility) VCT: 25-49, Male, Negative	641
Service Delivery Point (Facility) VCT: 25-49, Male, Positive	69
Service Delivery Point (Facility) VCT: 50+, Female, Negative	164
Service Delivery Point (Facility) VCT: 50+, Female, Positive	5
Service Delivery Point (Facility) VCT: 50+, Male, Negative	93
Service Delivery Point (Facility) VCT: 50+, Male, Positive	2
Service Delivery Point (Facility) VCT: <1, Negative	14
Service Delivery Point (Facility) VCT: <1, Positive	0
	Negative  Service Delivery Point (Facility) VCT: 15-19, Female, Positive  Service Delivery Point (Facility) VCT: 15-19, Male, Negative  Service Delivery Point (Facility) VCT: 15-19, Male, Positive  Service Delivery Point (Facility) VCT: 20-24, Female, Negative  Service Delivery Point (Facility) VCT: 20-24, Female, Positive  Service Delivery Point (Facility) VCT: 20-24, Male, Negative  Service Delivery Point (Facility) VCT: 20-24, Male, Positive  Service Delivery Point (Facility) VCT: 25-49, Female, Negative  Service Delivery Point (Facility) VCT: 25-49, Female, Positive  Service Delivery Point (Facility) VCT: 25-49, Male, Negative  Service Delivery Point (Facility) VCT: 25-49, Male, Positive  Service Delivery Point (Facility) VCT: 50+, Female, Negative  Service Delivery Point (Facility) VCT: 50+, Female, Positive  Service Delivery Point (Facility) VCT: 50+, Female, Positive  Service Delivery Point (Facility) VCT: 50+, Male, Negative  Service Delivery Point (Facility) VCT: 50+, Male, Negative  Service Delivery Point (Facility) VCT: 50+, Male, Negative  Service Delivery Point (Facility) VCT: 50+, Male, Negative



HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	80
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	401
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	9
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	214
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	10
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	6,131
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	676
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	4,114
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	470
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male, Negative	1,122
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male, Positive	198
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	266,756
HTC_TST_TA	By Test Result: Positive	29,114
HTC_TST_TA	Sum of Test Result disaggregates	29,114
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	641
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14,	76



	Female, Positive	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	131
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	12
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	642
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	76
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	443
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	44
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	8,480
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	955
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,417
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	269
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	14,665
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	1,663
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	5,289
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	574
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	2,834
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	322
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male,	1,136



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	128
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1,  Negative	448
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Positive	51
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9,  Negative	1,344
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	151
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Negative	7,808
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Positive	878
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Negative	3,114
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Positive	432
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative	118,075
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive	12,955
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative	60,390
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Positive	6,594
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	1,421
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	866
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female,  Negative	1
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male,	0



	Negative	
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Negative	13
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	20
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	13
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	19
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female,  Negative	44
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female, Positive	60
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	12
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	26
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female,  Negative	67
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Positive	110
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Negative	45
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Positive	83
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Negative	11
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	33
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	3



HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	1
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Female, Negative	13
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Female, Positive	52
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Male,  Negative	2
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Male, Positive	16
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Negative	535
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Positive	941
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Negative	356
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Positive	634
HTC_TST_TA	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 10-14, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 10-14, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 15-19, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 1-9, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 20-24, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 25-49, Positive	0



		1
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) ANC: 50+, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female,  Negative	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female,  Negative	10
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	127
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	19
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	70
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	221
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	30
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	166
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	13



HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female,  Negative	41
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	29
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	14
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Female, Negative	93
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Female, Positive	1
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Male, Negative	36
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Male, Positive	2
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative	1,457
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive	169
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative	986
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive	109
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	26,300
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	26,583
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with	749



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	9,765
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,101
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	14,681
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	748
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	9,886
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,113
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	14,817
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	4,110
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	4,146
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	175
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	106
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,311



TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,552
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	105
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,544
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	172
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,287
GEND_GBV_DSD	Number of people receiving post-GBV care	615
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	206
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	409
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	615
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	8
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	1



GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	41
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	86
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	19
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	36
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	87
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	136
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	52
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	102
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	7
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	24
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	4
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	14
GEND_GBV_TA	Number of people receiving post-GBV care	51
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	17
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	34
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	51
GEND_GBV_TA	<10, Female, Physical and/or Emotional Violence	0
GEND_GBV_TA	<10, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	<10, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	<10, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	10-14, Female, Physical and/or Emotional Violence	0
GEND_GBV_TA	10-14, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	10-14, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	10-14, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	15-19, Female, Physical and/or Emotional Violence	0
GEND_GBV_TA	15-19, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	15-19, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	15-19, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	20-24, Female, Physical and/or Emotional Violence	3
GEND_GBV_TA	20-24, Female, Sexual Violence (Post-Rape Care)	11



GEND_GBV_TA	20-24, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	20-24, Male, Sexual Violence (Post-Rape Care)	4
GEND_GBV_TA	25-49, Female, Physical and/or Emotional Violence	9
GEND_GBV_TA	25-49, Female, Sexual Violence (Post-Rape Care)	11
GEND_GBV_TA	25-49, Male, Physical and/or Emotional Violence	5
GEND_GBV_TA	25-49, Male, Sexual Violence (Post-Rape Care)	8
GEND_GBV_TA	50+, Female, Physical and/or Emotional Violence	0
GEND_GBV_TA	50+, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_TA	50+, Male, Physical and/or Emotional Violence	0
GEND_GBV_TA	50+, Male, Sexual Violence (Post-Rape Care)	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	28,216
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,877
OVC_SERV_DSD	Age/Sex: 15-17 Male	2,336
OVC_SERV_DSD	By: Age/sex: Male 18-24	513
OVC_SERV_DSD	By: Age/sex: Male 25+	227
OVC_SERV_DSD	Age/Sex: 10-14 Female	4,767
OVC_SERV_DSD	Age/Sex: 15-17 Female	8,781
OVC_SERV_DSD	By: Age/sex: 18-24 Female	3,997
OVC_SERV_DSD	By: Age/sex: 25+ Female	1,929
OVC_SERV_DSD	Sum of Age/Sex disaggregates	17,761
OVC_SERV_DSD	Age/Sex: <1	0
OVC_SERV_DSD	Age/Sex: 1-9	3,789
OVC_SERV_DSD	Program Completion: Active	25,372
OVC_SERV_DSD	Program Completion: Graduation	2,844
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	19,960
OVC_SERV_TA	Age/Sex: 10-14 Male	1,997
OVC_SERV_TA	Age/Sex: 15-17 Male	1,995
OVC_SERV_TA	By age/sex: 18-24 Male	396



OVC_SERV_TA	By age/sex: 25+ Male	198
OVC_SERV_TA	Age/Sex: 10-14 Female	2,396
OVC_SERV_TA	Age/Sex: 15-17 Female	5,988
OVC_SERV_TA	By age/sex: 18-24 Female	1,994
OVC_SERV_TA	By age/sex: 25+ Female	1,002
OVC_SERV_TA	Sum of Age/Sex disaggregates	12,376
OVC_SERV_TA	Age/Sex: <1	0
OVC_SERV_TA	Age/Sex: 1-9	3,994
OVC_SERV_TA	Program Completion: Active	17,966
OVC_SERV_TA	Program Completion: Graduated	1,994
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	14,808
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	16,641
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	446
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5,455
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	619
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8,279
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with	796



	,	
	documented HIV-positive status during TB treatment	
	during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	6,155
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	686
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	8,892
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,022
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	2,586
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	42
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	775
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	68
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	1,136



	1	
	TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	67
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	970
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	92
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1,451
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	24,270
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	238
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	23,921
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	0
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	111
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,028
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	11
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	3,017



PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	0
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	570,001
TX_CURR_DSD	Age/Sex: 15-19 Male	1,716
TX_CURR_DSD	Age/Sex: 15-19 Female	1,291
TX_CURR_DSD	Sum of age/sex disaggregates	3,007
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	9,881
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	131,615
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	14,834
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	197,238
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	24,715
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	328,853
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	353,568
TX_CURR_DSD	Age/Sex: <1	2,146
TX_CURR_DSD	Age/Sex: <1-9	10,732
TX_CURR_DSD	Age/Sex: 10-14 Male	861
TX_CURR_DSD	Age/Sex: 10-14 Female	1,290
TX_CURR_DSD	Age/Sex: 20-24 Male	21,513
TX_CURR_DSD	Age/Sex: 25-49 Male	50,045
TX_CURR_DSD	Age/Sex: 50+ Male	7,812
TX_CURR_DSD	Age/Sex: 20-24 Female	25,776
TX_CURR_DSD	Age/Sex: 25-49 Female	82,162
TX_CURR_DSD	Age/Sex: 50+ Female	11,097
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	55,601
TX_CURR_TA	Age/Sex: 15-19 Male	141
TX_CURR_TA	Age/Sex: 15-19 Female	112
TX_CURR_TA	Sum of Age/Sex disaggregations	253
TX_CURR_TA	Aggregated Age/Sex: <15 Male	1,032



TX_CURR_TA	Aggregated Age/Sex: 15+ Male	13,826
TX_CURR_TA	Aggregated Age/Sex: <15 Female	1,546
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	20,765
TX_CURR_TA	Sum of Aggregated Age/Sex <15	2,578
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	34,591
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	37,169
TX_CURR_TA	Age/Sex: <1	176
TX_CURR_TA	Age/Sex: 1-9	913
TX_CURR_TA	Age/Sex: 10-14 Male	73
TX_CURR_TA	Age/Sex: 10-14 Female	109
TX_CURR_TA	Age/Sex: 20-24 Male	1,843
TX_CURR_TA	Age/Sex: 25-49 Male	4,263
TX_CURR_TA	Age/Sex: 50+ Male	586
TX_CURR_TA	Age/Sex: 20-24 Female	2,201
TX_CURR_TA	Age/Sex: 25-49 Female	6,931
TX_CURR_TA	Age/Sex: 50+ Female	1,002
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	140,988
TX_NEW_DSD	By Age/Sex: <1	363
TX_NEW_DSD	By Age/Sex: 1-9	1,810
TX_NEW_DSD	By Age/Sex: 10-14 Male	149
TX_NEW_DSD	By Age/Sex: 15-19 Male	300
TX_NEW_DSD	By Age/Sex: 20-24 Male	3,626
TX_NEW_DSD	By Age/Sex: 25-49 Male	8,403
TX_NEW_DSD	By Age/Sex: 50+ Male	1,153
TX_NEW_DSD	By Age/Sex: 10-14 Female	218
TX_NEW_DSD	By Age/Sex: 15-19 Female	218
TX_NEW_DSD	By Age/Sex: 20-24 Female	4,330
TX_NEW_DSD	By Age/Sex: 25-49 Female	13,607
TX_NEW_DSD	By Age/Sex: 50+ Female	1,980
TX_NEW_DSD	Sum of Age/Sex disaggregates	33,984
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	2,916



TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	38,656
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	4,392
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	58,785
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	104,749
TX_NEW_DSD	Pregnancy status	25,318
TX_NEW_DSD	Breastfeeding status	0
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	14,644
TX_NEW_TA	By Age/Sex: <1	32
TX_NEW_TA	By Age/Sex: 1-9	160
TX_NEW_TA	By Age/Sex: 10-14 Male	4
TX_NEW_TA	By Age/Sex: 15-19 Male	26
TX_NEW_TA	By Age/Sex: 20-24 Male	323
TX_NEW_TA	By Age/Sex: 25-49 Male	742
TX_NEW_TA	By Age/Sex: 50+ Male	102
TX_NEW_TA	By Age/Sex: 10-14 Female	15
TX_NEW_TA	By Age/Sex: 15-19 Female	15
TX_NEW_TA	By Age/Sex: 20-24 Female	385
TX_NEW_TA	By Age/Sex: 25-49 Female	1,213
TX_NEW_TA	By Age/Sex: 50+ Female	182
TX_NEW_TA	Sum of Age/Sex disaggregates	3,007
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	318
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	4,257
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	481
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	6,321
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	11,377
TX_NEW_TA	Pregnancy status	2,642
TX_NEW_TA	Breastfeeding status	0
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	433,481



TV DVI 0 D0D	Number of adult and pediatric ART patients with a viral	400.050
TX_PVLS_DSD	load result documented in the patient medical record and /or laboratory records in the past 12 months.	498,352
TX_PVLS_DSD	Numerator: Indication: Routine	433,481
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	79,197
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	12,141
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	160,127
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	18,189
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	243,013
TX_PVLS_DSD	Denominator: Indication: Routine	482,593
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	89,851
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15  Male Routine	13,788
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+  Male Routine	182,833
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	20,846
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	276,839
TX_PVLS_DSD	<15, Routine, Unknown Sex	283
TX_PVLS_DSD	15+, Routine, Unknown Sex	3,761
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	44,174
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	49,917
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	1,898



TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	1,264
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	25,069
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	16,694
TX_PVLS_TA	Numerator: Indication: Routine	44,174
TX_PVLS_TA	Numerator: Preg/BF by Indication: Pregnant Routine	8,102
TX_PVLS_TA	Denominator: Indication: Routine	47,623
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,099
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15  Male Routine	1,396
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	27,900
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+  Male Routine	18,521
TX_PVLS_TA	Denominator: Preg/BF by Indication: Pregnant Routine	8,882
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	104,406
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting	
TX_RET_DSD	Numerator by Status: Pregnant	18,813
TX_RET_DSD	Numerator by Status: Breastfeeding	0
TX_RET_DSD	Denominator by Status: Pregnant	21,159
TX_RET_DSD	Denominator by Status: Breastfeeding	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,927
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	38,859



TX_RET_TA	TX_RET_TA Denominator by Status: Pregnant	
TX_RET_TA	Numerator by Status: Breastfeeding	0
TX_RET_TA	Numerator by Status: Pregnant 1,882	
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	11,640
TX_RET_TA	A Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	64,325
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,863
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	43,105
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,228
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	58,232
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,381



TX_RET_TA	Denominator by Status: Breastfeeding	0
IA_NET_TA		U
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment	296
172.1212171	at 12 months after initiating ART)	200
	Aggregated Age/Sex: 15+ Male (Numerator: Number of	
TX_RET_TA	adults and children who are still alive and on treatment	3,880
	at 12 months after initiating ART)	
TV DET TA	Aggregated Age/Sex: <15 Female (Numerator: Number	440
TX_RET_TA	of adults and children who are still alive and on treatment at 12 months after initiating ART)	440
	Aggregated Age/Sex: 15+ Female (Numerator: Number	
TX_RET_TA	of adults and children who are still alive and on	5,834
	treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Male (Denominator: Total	
TV DET TA	number of adults and children who initiated ART in the	000
TX_RET_TA	12 months prior to the beginning of the reporting period, including those who have died, those who have	326
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_TA	12 months prior to the beginning of the reporting period,	4,328
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)  Aggregated Age/Sex: <15 Female (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_TA	12 months prior to the beginning of the reporting period,	490
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total	
TX_RET_TA	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	6,494
	including those who have died, those who have	5, .5 1
	stopped ART, and those lost to follow-up)	
TB_PREV_DSD	The number of ART patients who completed a course	19,203
10_11(2 v_000	of TB preventive therapy or at least 6 months of	10,200



Isoniazid Preventive Therapy (IPT) during the reporting		
	period	
	The number of ART patients who were newly started on	
	TB preventive therapy (including those who newly	
TB_PREV_DSD	started on TB preventive therapy in this reporting period and those who started in the previous reporting period	38,326
ID_FREV_D3D	but had not been reported as they did not fulfill the	30,320
	minimum requirements for the previous reporting	
	period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,610
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,077
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	21,401
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	14,215
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	37,871
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	809
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	529
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	10,733
TB_PREV_DSD	EV_DSD By Age/Sex (Numerator): 15+, Male	
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	18,998
	The number of ART patients who completed a course	
TB_PREV_TA	of TB preventive therapy or at least 6 months of	2,826
ID_I NEV_IA	Isoniazid Preventive Therapy (IPT) during the reporting	2,020
	period	
	The number of ART patients who were newly started on	
	TB preventive therapy (including those who newly	
	started on TB preventive therapy in this reporting period	
TB_PREV_TA	and those who started in the previous reporting period	5,782
	but had not been reported as they did not fulfill the	
	minimum requirements for the previous reporting	
TB_PREV_TA	period).  By Age/Sex (Denominator): <15, Female	254
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	161
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	3,202
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	2,121
ID_I I\LV_IA	by Agoroux (Denominator). 10+, Maie	۷,۱۷۱



TB_PREV_TA	By Therapy type (Denominator): 6-12 Month IPT	5,692
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	108
TB_PREV_TA	By Age/Sex (Numerator): <15, Male 63	
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female 1,61	
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male 1,6	
TB_PREV_TA	By Therapy type (Numerator): 6-12 Month IPT 2,823	

**Implementing Mechanism Details** 

Mechanism ID: 18482	Mechanism Name: TB/HIV Care Comprehensive (CDC GH001933)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: TB/HIV Care		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 35,640,460	Total Mechanism Pipeline: N/A
Applied Pipeline Amount: 3,142,710	
Total All Funding Sources and Applied Pipelin	ne Amount: 38,783,170
Funding Source	Funding Amount
GHP-State	35,640,460

**Cross-Cutting Budget Attribution(s)** 

Key Populations: FSW	1,548,785
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Key Populations: MSM and TG	370,983



Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Gender: GBV	250,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Condom programming	1,000,000
Food and Nutrition: Commodities	37,274
Economic Strengthening	18,637
Education	18,637
Motor Vehicles: Purchased	945,259
Human Resources for Health	2,237,401

**Budget Code Information** 

Budget Code Inform	ation			
Mechanism ID:	18482	18482		
Mechanism Name:	TB/HIV Care Comprehe	nsive (CDC GH001933)		
Prime Partner Name:	TB/HIV Care			
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	НВНС	1,439,457	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HKID	372,371	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	HVTB	1,296,154	0	
Strategic Area	Budget Code	Planned Amount	On Hold Amount	
Care	PDCS	384,284	0	



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	12,117,205	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	468,312	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	9,422,060	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	4,071,809	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	70,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	768,567	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	4,845,957	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	384,284	0

## Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,748
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received	15,542



	their results)	
PMTCT_ART_DSD	New on ART	1,769
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,979
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	417
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,727
PMTCT_ART_TA	New on ART	188
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	229
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	15,542
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	0
PMTCT_STAT_DSD	By Age (Denominator): <15-19	473
PMTCT_STAT_DSD	By Age (Denominator): 20-24	2,438
PMTCT_STAT_DSD	By Age (Denominator): 25-49	11,564
PMTCT_STAT_DSD	By Age (Denominator): 50+	1,385
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	61
PMTCT_STAT_DSD	By Number of known positives: 20-24	370
PMTCT_STAT_DSD	By Number of known positives: 25-49	1,849
PMTCT_STAT_DSD	By Number of known positives: 50+	220
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	26
PMTCT_STAT_DSD	By Number of new positives: 20-24	213
PMTCT_STAT_DSD	By Number of new positives: 25-49	976
PMTCT_STAT_DSD	By Number of new positives: 50+	110
PMTCT_STAT_DSD	By Number of new negative: <10	0



	•	
PMTCT_STAT_DSD	By Number of new negative: 10-14	0
PMTCT_STAT_DSD	By Number of new negative: 15-19	371
PMTCT_STAT_DSD	By Number of new negative: 20-24	1,838
PMTCT_STAT_DSD	By Number of new negative: 25-49	8,606
PMTCT_STAT_DSD	By Number of new negative: 50+	902
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	0
PMTCT_STAT_DSD	By Age (Numerator): 15-19	468
PMTCT_STAT_DSD	By Age (Numerator): 20-24	2,333
PMTCT_STAT_DSD	By Age (Numerator): 25-49	11,379
PMTCT_STAT_DSD	By Age (Numerator): 50+	1,363
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,727
PMTCT_STAT_TA	By Age (Denominator): <10	0
PMTCT_STAT_TA	By Age (Denominator): 10-14	0
PMTCT_STAT_TA	By Age (Denominator): 15-19	53
PMTCT_STAT_TA	By Age (Denominator): 20-24	266
PMTCT_STAT_TA	By Age (Denominator): 25-49	1,285
PMTCT_STAT_TA	By Age (Denominator): 50+	158
PMTCT_STAT_TA	By known positives: <10	0
PMTCT_STAT_TA	By known positives: 10-14	0
PMTCT_STAT_TA	By known positives: 15-19	7
PMTCT_STAT_TA	By known positives: 20-24	44
PMTCT_STAT_TA	By known positives: 25-49	202
PMTCT_STAT_TA	By known positives: 50+	25
PMTCT_STAT_TA	By new positives: <10	0
PMTCT_STAT_TA	By new positives: 10-14	0
PMTCT_STAT_TA	By new positives: 15-19	2
PMTCT_STAT_TA	By new positives: 20-24	22
PMTCT_STAT_TA	By new positives: 25-49	109
PMTCT_STAT_TA	By new positives: 50+	14



PMTCT_STAT_TA	By new negatives: <10	0
PMTCT_STAT_TA	By new negatives: 10-14	0
PMTCT_STAT_TA	By new negatives: 15-19	38
PMTCT_STAT_TA	By new negatives: 20-24	197
PMTCT_STAT_TA	By new negatives: 25-49	952
PMTCT_STAT_TA	By new negatives: 50+	115
PMTCT_STAT_TA	By Age (Numerator): <10	0
PMTCT_STAT_TA	By Age (Numerator): 10-14	0
PMTCT_STAT_TA	By Age (Numerator): : 15-19	53
PMTCT_STAT_TA	By Age (Numerator): 20-24	258
PMTCT_STAT_TA	By Age (Numerator): 25-49	1,258
PMTCT_STAT_TA	By Age (Numerator): 50+	158
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	309,305
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	15,463
VMMC_CIRC_DSD	By Age: 15-19	83,512
VMMC_CIRC_DSD	By Age: 20-24	83,512
VMMC_CIRC_DSD	By Age: 25-29	83,512
VMMC_CIRC_DSD	By Age: 30-49	40,209
VMMC_CIRC_DSD	By Age: 50+	3,097
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	185,584
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	309,305
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	309,305
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0
VMMC_CIRC_TA	By Age: 10-14	0
VMMC_CIRC_TA	By Age: 15-19	0
I .	By Age: 20-24	0



	<u> </u>	
VMMC_CIRC_TA	By Age: 25-49	0
VMMC_CIRC_TA	By Age: 30-49	0
VMMC_CIRC_TA	By Age: 50+	0
VMMC_CIRC_TA	Sum of Age disaggregations (Prior to FY15)	0
VMMC_CIRC_TA	Sum of age disaggregates (FY15-Current)	0
VMMC_CIRC_TA	By circumcision technique: Surgical VMMC	0
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	6,570
PrEP_NEW_DSD	Male 20-24	250
PrEP_NEW_DSD	Male 25-49	250
PrEP_NEW_DSD	Female 15-19	1,098
PrEP_NEW_DSD	Female 20-24	2,697
PrEP_NEW_DSD	Female 25-49	2,275
PrEP_NEW_DSD	FSW	2,479
PrEP_NEW_DSD	MSM	500
PrEP_NEW_TA	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	3,062
PrEP_NEW_TA	Male 15-19	282
PrEP_NEW_TA	Male 20-24	422
PrEP_NEW_TA	Male 25-49	424
PrEP_NEW_TA	Male 50+	0
PrEP_NEW_TA	Female 15-19	563
PrEP_NEW_TA	Female 20-24	725
PrEP_NEW_TA	Female 25-49	506
PrEP_NEW_TA	Female 50+	140
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	48,261
PP_PREV_DSD	Age/sex: 10-14 Male	482
PP_PREV_DSD	Age/sex: 15-19 Male	4,829
PP_PREV_DSD	Age/sex: 20-24 Male	7,236



PP_PREV_DSD	Age/sex: 25-49 Male	7,236
PP_PREV_DSD	Age/sex: 50+ Male	0
PP_PREV_DSD	Age/sex: 10-14 Female	1,448
PP_PREV_DSD	Age/sex: 15-19 Female	8,210
PP_PREV_DSD	Age/sex: 20-24 Female	8,203
PP_PREV_DSD	Age/sex: 25-49 Female	8,685
PP_PREV_DSD	Age/sex: 50+ Female	1,932
PP_PREV_DSD	Sum of Age/Sex disaggregates	48,261
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	29,826
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	6,228
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive	23,598



	_ <del>_</del>	
	interventions that are based on evidence and/or meet	
	the minimum standards required)	
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	808,137
HTC_TST_DSD	By Test Result: Positive	73,751
HTC_TST_DSD	Sum of Test Result disaggregates	73,751
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	343
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	1,281
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	95
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	948
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	76
HTC_TST_DSD	Service Delivery Point (Community) Homebased	408



	tenting 20 24 Male Negative	
HTC_TST_DSD	testing: 20-24, Male, Negative  Service Delivery Point (Community) Homebased	33
	testing: 20-24, Male, Positive  Service Delivery Point (Community) Homebased	
HTC_TST_DSD	testing: 25-49, Male, Negative	611
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	51
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: <1, Negative	1,573
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: <1, Positive	21
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative	15,575
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: <15, Female, Positive	160
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: <15, Male, Negative	9,856
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: <15, Male, Positive	106
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative	63,414
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: 15+, Female, Positive	5,578
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: 15+, Male, Negative	41,299
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: 15+, Male, Positive	3,696
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	1,299
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	54
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	1,284
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient:	47



	<15, Male, Positive	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	664
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	87
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	949
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	106
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	311
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	32
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	1,394
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	155
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	1,179
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	125
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	541
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	59
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	50
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	805
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	84
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile	92,378



	Testing: 15+, Female, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	10,185
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	62,233
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	6,916
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	2,473
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	103
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	2,475
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	169
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	88,340
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	8,608
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	132,503
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	12,899
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	3,885
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	678
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	2,787
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	487
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	2,231
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	59
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15,	0



	Female, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	522
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	697
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	832
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	1,333
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <15, Negative	62
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: <15, Positive	1
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative	1,172
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive	24
HTC_TST_DSD	By Key Population: FSW, Negative	17,887
HTC_TST_DSD	By Key Population: FSW, Positive	2,979
HTC_TST_DSD	By Key Population: MSM, Negative	11,225
HTC_TST_DSD	By Key Population: MSM, Positive	1,275
HTC_TST_DSD	By Key Population: PWID, Negative	8,138
HTC_TST_DSD	By Key Population: PWID, Positive	1,112
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	240
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	1,206



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	102
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	966
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	84
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	414
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	36
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	618
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	54
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1,  Negative	186
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	6
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Negative	1,931
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Positive	38
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Negative	1,290
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Positive	23
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative	78,288
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive	6,769
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	53,151
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	4,676



	•	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	1,274
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	512
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	1,281
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	513
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	8,653
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	1,024
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	16,486
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	1,736
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	31,468
HTC_TST_TA	By Test Result: Positive	3,128
HTC_TST_TA	Sum of Test Result disaggregates	3,128
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: <15, Female, Negative	135
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: <15, Female, Positive	8
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Negative	136
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Positive	8
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Negative	82
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Positive	6
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+,	112



	Male, Negative	
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Positive	12
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Negative	273
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Positive	13
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Negative	273
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Positive	13
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative	9,816
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive	958
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative	14,715
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Positive	1,447
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	247
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	7
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Female, Negative	2
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Female, Positive	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Male, Negative	3
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Male, Positive	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Negative	45
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Positive	89
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male,	72



	Negative	
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Positive	165
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Female, Negative	141
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Female, Positive	58
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Male, Negative	141
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15,  Male, Positive	58
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative	961
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive	114
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative	1,186
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive	172
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	3,504
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	3,539
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	155
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,594
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	155
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with	1,600



	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	170
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,594
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	170
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,602
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	389
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	393
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	20
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	20
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	177
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	176
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	20
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	174



	Aggregated Age/Sex: Female <15 (Numerator: Number	
TB_STAT_TA	of registered new and relapsed TB cases with	20
	documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: Number	
TB_STAT_TA	of registered new and relapsed TB cases with	175
	documented HIV status, during the reporting period)	
	Number of active beneficiaries served by PEPFAR	
OVC_SERV_DSD	OVC programs for children and families affected by	6,136
	HIV/AIDS	
OVC_SERV_DSD	Age/Sex: 10-14 Male	920
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,527
OVC_SERV_DSD	By: Age/sex: Male 18-24	402
OVC_SERV_DSD	By: Age/sex: Male 25+	215
OVC_SERV_DSD	Age/Sex: 10-14 Female	614
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,228
OVC_SERV_DSD	By: Age/sex: 18-24 Female	402
OVC_SERV_DSD	By: Age/sex: 25+ Female	215
OVC_SERV_DSD	Sum of Age/Sex disaggregates	4,289
OVC_SERV_DSD	Age/Sex: <1	0
OVC_SERV_DSD	Age/Sex: 1-9	613
OVC_SERV_DSD	Program Completion: Active	4,731
OVC_SERV_DSD	Program Completion: Graduation	1,102
OVC_SERV_DSD	Program Completion: Transferred	58
OVC_SERV_DSD	Program Completion: Exited without graduation	245
	Number of active beneficiaries served by PEPFAR	
OVC_SERV_TA	OVC programs for children and families affected by	1,064
	HIV/AIDS	
OVC_SERV_TA	Age/Sex: 10-14 Male	160
OVC_SERV_TA	Age/Sex: 15-17 Male	265
OVC_SERV_TA	By age/sex: 18-24 Male	70
OVC_SERV_TA	By age/sex: 25+ Male	37
OVC_SERV_TA	Age/Sex: 10-14 Female	105
OVC_SERV_TA	Age/Sex: 15-17 Female	215



	,	
OVC_SERV_TA	By age/sex: 18-24 Female	70
OVC_SERV_TA	By age/sex: 25+ Female	35
OVC_SERV_TA	Sum of Age/Sex disaggregates	745
OVC_SERV_TA	Age/Sex: <1	0
OVC_SERV_TA	Age/Sex: 1-9	107
OVC_SERV_TA	Program Completion: Active	819
OVC_SERV_TA	Program Completion: Graduated	191
OVC_SERV_TA	Program Completion: Transferred	10
OVC_SERV_TA	Program Completion: Exited without graduation	44
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,425
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,423
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	61
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	654
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	61
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	649
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment	61



	<u> </u>	
	during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	655
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	61
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	646
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	157
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	159
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	75
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	74



TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	4
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	76
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	4
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	75
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,634
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	8
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	1,765
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	8
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	1,853
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	404
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	196
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	1
PMTCT_EID_TA	Number of infants with a negative virological test result	207



	between 2 and 12 months of birth	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	82,730
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	3,993
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	37,398
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	3,991
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	37,348
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	7,984
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	74,746
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	82,730
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	9,192
TX_CURR_TA	Aggregated Age/Sex: <15 Male	460
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	4,142
TX_CURR_TA	Aggregated Age/Sex: <15 Female	460
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	4,130
TX_CURR_TA	Sum of Aggregated Age/Sex <15	920
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	8,272
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	9,192
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	29,737
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,446
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	14,659
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,453
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	12,179
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	29,737
TX_NEW_DSD	Pregnancy status	5,943
TX_NEW_DSD	Breastfeeding status	0
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,304
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	166
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	1,644



T)/ NIE)A/ TA		400
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	166
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	1,328
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	3,304
TX_NEW_TA	Pregnancy status	661
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	61,083
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	67,864
TX_PVLS_DSD	Numerator: Indication: Routine	61,083
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	3,016
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	27,461
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	3,016
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	27,591
TX_PVLS_DSD	Denominator: Indication: Routine	67,864
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15  Male Routine	3,346
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+  Male Routine	30,571
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	3,346
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	30,596
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	6,788
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral	7,540



	Land and the day was asked in the conflict of the Park	
	load result documented in the patient medical record and /or laboratory records in the past 12 months.	
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	339
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	339
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	3,055
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,055
TX_PVLS_TA	Numerator: Indication: Routine	6,788
TX_PVLS_TA	Denominator: Indication: Routine	7,540
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	376
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15  Male Routine	376
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	3,394
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+  Male Routine	3,394
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	14,963
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	16,633
TX_RET_DSD	Numerator by Status: Pregnant	3,000
TX_RET_DSD	Denominator by Status: Pregnant	3,341
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	727
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,723



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	727
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,786
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	828
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,507
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	827
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,471
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,669
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,848
TX_RET_TA	Numerator by Status: Pregnant	332
TX_RET_TA	Denominator by Status: Pregnant	349
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of	85



	adults and children who are still alive and on treatment	
	at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of	
TX_RET_TA	adults and children who are still alive and on treatment	750
	at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Female (Numerator: Number	
TX_RET_TA	of adults and children who are still alive and on	85
	treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Female (Numerator: Number	
TX_RET_TA	of adults and children who are still alive and on	749
	treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Male (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_TA	12 months prior to the beginning of the reporting period,	86
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_TA	12 months prior to the beginning of the reporting period,	836
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: <15 Female (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_TA	12 months prior to the beginning of the reporting period,	85
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_TA	12 months prior to the beginning of the reporting period,	841
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	The number of ART patients who completed a course	
TR DREV DOD	of TB preventive therapy or at least 6 months of	3,442
TB_PREV_DSD	Isoniazid Preventive Therapy (IPT) during the reporting	J, <del>44</del> Z
	period	_



TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	6,883
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	349
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	349
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	3,082
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	3,107
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	160
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	160
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,538
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,584
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	0
TB_PREV_DSD	By Therapy type (Numerator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Numerator): Continuous IPT	0
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	382
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	765
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	39
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	39
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	355
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	332
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	18



TB_PREV_TA	By Age/Sex (Numerator): <15, Male	18
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	175
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	171

**Implementing Mechanism Details** 

implementing incontainem Betane		
Mechanism ID: 18483	Mechanism Name: MATCH (Wits Health Consortium) (CDC GH001934)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Wits Health Consortium (Pty) Limited		
Agreement Start Date: Redacted Agreement End Date: Redacted		
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 2,157,296	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 919,379		
Total All Funding Sources and Applied Pipeline Amount: 3,076,675		
Funding Source Funding Amount		
GHP-State	2,157,296	

**Cross-Cutting Budget Attribution(s)** 

Motor Vehicles: Leased	208,126
Motor Vehicles: Purchased	331,279

**Budget Code Information** 

Mechanism ID:	18483		
Mechanism Name:	MATCH (Wits Health Co	nsortium) (CDC GH0019	34)
Prime Partner Name:	Wits Health Consortium (Pty) Limited		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Coro	ПВПС	262.004	0
Care	HBHC	262,994	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	211,626	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	56,357	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	317,504	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	253,743	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	86,049	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	75,423	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	808,424	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	85,176	0

## **Implementing Mechanism Indicator Information**

Indicator Number	Label	2018
	Number of the target population who completed a	
PP_PREV_DSD	standardized HIV prevention intervention including the	32,009
	minimum components during the reporting period.	
PP_PREV_DSD	Age/sex: 10-14 Male	800



	<del>_</del>	
PP_PREV_DSD	Age/sex: 15-19 Male	3,201
PP_PREV_DSD	Age/sex: 20-24 Male	4,801
PP_PREV_DSD	Age/sex: 25-49 Male	4,801
PP_PREV_DSD	Age/sex: 10-14 Female	1,600
PP_PREV_DSD	Age/sex: 15-19 Female	5,602
PP_PREV_DSD	Age/sex: 20-24 Female	6,403
PP_PREV_DSD	Age/sex: 25-49 Female	4,801
PP_PREV_DSD	Sum of Age/Sex disaggregates	32,009
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	13,820
HTC_TST_DSD	By Test Result: Positive	1,048
HTC_TST_DSD	Sum of Test Result disaggregates	1,048
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative	1,110
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: <15, Female, Positive	11
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: <15, Male, Negative	740
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: <15, Male, Positive	7
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: 15+, Female, Negative	1,720
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: 15+, Female, Positive	150
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: 15+, Male, Negative	1,147
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: 15+, Male, Positive	100
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	2,356
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	262



HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	1,570
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	174
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Negative	137
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Positive	3
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Negative	92
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Positive	2
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative	2,340
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive	203
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	1,560
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	136

**Implementing Mechanism Details** 

Mechanism ID: 18484	Mechanism Name: Aurum Comprehensive (CDC GH001981)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Aurum Health Research		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 36,024,762	Total Mechanism Pipeline: N/A	
Applied Pipeline Amount: 1,427,563		
Total All Funding Sources and Applied Pipeline Amount: 37,452,325		



Funding Source	Funding Amount
GHP-State	36,024,762

**Cross-Cutting Budget Attribution(s)** 

Key Populations: MSM and TG	1,326,728
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Gender: GBV	200,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Human Resources for Health	2,200,000
Education	48,637
Condom procurement	152,780
Economic Strengthening	48,637
Condom programming	829,927
Motor Vehicles: Purchased	637,294
Food and Nutrition: Commodities	97,275
Water	75,000
Motor Vehicles: Leased	216,808

**Budget Code Information** 

Mechanism ID:	18484		
Mechanism Name:	Aurum Comprehensive	(CDC GH001981)	
Prime Partner Name:	Aurum Health Research		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	НВНС	3,810,968	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,785,870	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	2,951,332	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	697,232	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	2,280,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	241,541	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	468,105	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	5,006,636	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	3,201,608	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	1,394,465	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	12,989,773	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

## **Implementing Mechanism Indicator Information**

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	26,570
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	83,469
PMTCT_ART_DSD	New on ART	13,576
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	12,994
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,412
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,956
PMTCT_ART_TA	New on ART	1,796
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	1,616
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	83,469
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	860
PMTCT_STAT_DSD	By Age (Denominator): 10-14	900
PMTCT_STAT_DSD	By Age (Denominator): <15-19	2,667
PMTCT_STAT_DSD	By Age (Denominator): 20-24	10,401



PMTCT_STAT_DSD	By Age (Denominator): 25-49	66,023
PMTCT_STAT_DSD	By Age (Denominator): 50+	9,334
PMTCT_STAT_DSD	By Number of known positives: <10	2
PMTCT_STAT_DSD	By Number of known positives: 10-14	73
PMTCT_STAT_DSD	By Number of known positives: 15-19	2,023
PMTCT_STAT_DSD	By Number of known positives: 20-24	3,978
PMTCT_STAT_DSD	By Number of known positives: 25-49	5,677
PMTCT_STAT_DSD	By Number of known positives: 50+	821
PMTCT_STAT_DSD	By Number of new positives: <10	3
PMTCT_STAT_DSD	By Number of new positives: 10-14	95
PMTCT_STAT_DSD	By Number of new positives: 15-19	2,699
PMTCT_STAT_DSD	By Number of new positives: 20-24	4,781
PMTCT_STAT_DSD	By Number of new positives: 25-49	7,172
PMTCT_STAT_DSD	By Number of new positives: 50+	1,189
PMTCT_STAT_DSD	By Number of new negative: <10	105
PMTCT_STAT_DSD	By Number of new negative: 10-14	1,072
PMTCT_STAT_DSD	By Number of new negative: 15-19	9,935
PMTCT_STAT_DSD	By Number of new negative: 20-24	16,985
PMTCT_STAT_DSD	By Number of new negative: 25-49	24,040
PMTCT_STAT_DSD	By Number of new negative: 50+	2,735
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	239
PMTCT_STAT_DSD	By Age (Numerator): <10	885
PMTCT_STAT_DSD	By Age (Numerator): 10-14	915
PMTCT_STAT_DSD	By Age (Numerator): 15-19	3,415
PMTCT_STAT_DSD	By Age (Numerator): 20-24	10,273
PMTCT_STAT_DSD	By Age (Numerator): 25-49	58,181
PMTCT_STAT_DSD	By Age (Numerator): 50+	9,312
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,956
PMTCT_STAT_TA	By Age (Denominator): <10	59
PMTCT_STAT_TA	By Age (Denominator): 10-14	48



PMTCT_STAT_TA	By Age (Denominator): 15-19	786
PMTCT_STAT_TA	By Age (Denominator): 20-24	1,100
PMTCT_STAT_TA	By Age (Denominator): 25-49	6,319
PMTCT_STAT_TA	By Age (Denominator): 50+	941
PMTCT_STAT_TA	By known positives: 15-19	223
PMTCT_STAT_TA	By known positives: 20-24	345
PMTCT_STAT_TA	By known positives: 25-49	559
PMTCT_STAT_TA	By known positives: 50+	80
PMTCT_STAT_TA	By new positives: 15-19	185
PMTCT_STAT_TA	By new positives: 20-24	338
PMTCT_STAT_TA	By new positives: 25-49	402
PMTCT_STAT_TA	By new positives: 50+	91
PMTCT_STAT_TA	By new negatives: 15-19	721
PMTCT_STAT_TA	By new negatives: 20-24	1,023
PMTCT_STAT_TA	By new negatives: 25-49	1,640
PMTCT_STAT_TA	By new negatives: 50+	243
PMTCT_STAT_TA	By Age (Numerator): <10	44
PMTCT_STAT_TA	By Age (Numerator): 10-14	35
PMTCT_STAT_TA	By Age (Numerator): : 15-19	223
PMTCT_STAT_TA	By Age (Numerator): 20-24	538
PMTCT_STAT_TA	By Age (Numerator): 25-49	6,290
PMTCT_STAT_TA	By Age (Numerator): 50+	826
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	37,836
VMMC_CIRC_DSD	By Age: 10-14	3,778
VMMC_CIRC_DSD	By Age: 15-19	8,119
VMMC_CIRC_DSD	By Age: 20-24	8,096
VMMC_CIRC_DSD	By Age: 25-29	8,097
VMMC_CIRC_DSD	By Age: 30-49	7,905
VMMC_CIRC_DSD	By Age: 50+	1,841
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	21,834



VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	37,836
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	34,058
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	3,778
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	49,320
PP_PREV_DSD	Age/sex: 10-14 Male	1,233
PP_PREV_DSD	Age/sex: 15-19 Male	4,932
PP_PREV_DSD	Age/sex: 20-24 Male	7,398
PP_PREV_DSD	Age/sex: 25-49 Male	7,398
PP_PREV_DSD	Age/sex: 10-14 Female	2,466
PP_PREV_DSD	Age/sex: 15-19 Female	8,631
PP_PREV_DSD	Age/sex: 20-24 Female	9,864
PP_PREV_DSD	Age/sex: 25-49 Female	7,398
PP_PREV_DSD	Sum of Age/Sex disaggregates	49,320
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	11,847
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	11,847
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,229,263
HTC_TST_DSD	By Test Result: Positive	141,911
HTC_TST_DSD	Sum of Test Result disaggregates	141,911
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	1,590
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	138
HTC_TST_DSD	Service Delivery Point (Community) Homebased	7,753



	testing: 15-19, Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	693
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	6,363
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	552
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	2,727
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	237
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	4,089
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	357
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 1-9, Negative	4,509
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 1-9, Positive	45
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative	2,428
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive	24
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: <15, Male, Negative	1,619
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: <15, Male, Positive	16
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative	11,272
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: 15+, Female, Positive	980
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)  Homebased testing: 15+, Male, Negative	7,512
HTC_TST_DSD	Service Delivery Point by Agg Age (Community)	652



	Homebased testing: 15+, Male, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	4,440
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	492
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	21,796
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	2,466
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	17,754
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	1,974
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	7,608
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	846
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	11,412
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	1,269
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	15,436
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	1,716
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	10,292
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	1,144
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,664
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	166
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14,	1,309



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	104
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	2,019
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	418
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	3,767
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	5,001
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1,137
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	3,419
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	705
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	44,958
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	8,885
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	45,622
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	8,336
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	6,595
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	829
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	5,149
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male,	672



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1,  Negative	2,812
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	384
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9,  Negative	3,946
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	524
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	26,227
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	2,719
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	25,994
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	2,847
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	360,663
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	46,349
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	216,205
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	32,582
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	3,096
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	546
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	20,199



HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	854
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female,  Negative	40
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female,  Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female,  Negative	96
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	85
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	1,375
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	266
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	1,359
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	278
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female,	134



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	126
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	177
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	177
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	5,516
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	194
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	2,753
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	100
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	45
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24,	107



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49,  Negative	1,255
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	245
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	111
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	0
HTC_TST_DSD	By Key Population: MSM, Negative	11,096
HTC_TST_DSD	By Key Population: MSM, Positive	1,513
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	3,081
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	267
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	14,675
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	1,241
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	12,327
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	1,071
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	5,283
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	459
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	6,926
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	690
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9,	561



	Negative	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	12
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Negative	300
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Positive	8
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Negative	200
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Positive	4
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative	28,772
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive	2,504
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	19,184
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	1,668
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male,	0



	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	89
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	67
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female,  Negative	2,079
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	163
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	2,184
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	246
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female,  Negative	141
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	99
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	41
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT:	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	5
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	152



HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	152
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	4,953
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	72
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	2,483
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	33
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	144,063
HTC_TST_TA	By Test Result: Positive	13,070
HTC_TST_TA	Sum of Test Result disaggregates	13,070
HTC_TST_TA	Service Delivery Point (Facility) Malnutrition: Negative	3,650
HTC_TST_TA	Service Delivery Point (Facility) Malnutrition: Positive	490
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	299
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	35
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	246
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	19
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	207
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	73
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	2,030
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	405
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24,	2,349



	Female, Negative	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	497
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	448
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	73
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	20,060
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	4,012
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	7,423
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	1,535
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	788
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	268
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	726
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	127
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Negative	574
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Positive	75
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	625
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	82
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Negative	2,514
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC:	273



	415 Famala Pagitiya	
	<15, Female, Positive	
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Negative	2,514
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Positive	273
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative	62,155
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive	8,912
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative	17,661
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Positive	4,037
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Negative	1,872
HTC_TST_TA	Service Delivery Point (Facility) Pediatric : <5 Positive	150
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female,  Negative	15
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Negative	12
HTC_TST_TA	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female,  Negative	64
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Female, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Negative	22
HTC_TST_TA	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female,  Negative	166
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Female,	27



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Negative	71
HTC_TST_TA	Service Delivery Point (Facility) TB: 20-24, Male, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female,  Negative	642
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Female, Positive	106
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male,  Negative	358
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Positive	60
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female,  Negative	51
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Female, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Negative	44
HTC_TST_TA	Service Delivery Point (Facility) TB: 50+, Male, Positive	2
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Female, Negative	17
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: <15, Male, Negative	15
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Negative	545
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Positive	32
HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Negative	272



HTC_TST_TA	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Positive	29
HTC_TST_TA	Service Delivery Point (Facility) VMMC: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VMMC: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14,  Negative	135
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19,  Negative	219
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 1-9, Negative	153
HTC_TST_TA	Service Delivery Point (Facility) VMMC:	3
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24,  Negative	534
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Positive	1,000
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49,  Negative	1,944
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49, Positive	551
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Negative	1,270
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 50+, Positive	2
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VMMC: 15+, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female,  Negative	6
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female,	0



	Positive	
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	127
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	27
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	93
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	20
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	413
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	50
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	245
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	31
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female,  Negative	38
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	20
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Negative	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	4



HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Female, Negative	18
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Male, Negative	18
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative	598
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative	299
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	16,413
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	16,965
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	580
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	6,209
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	675
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8,929
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	607
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	6,435
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	732



TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	9,075
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,780
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	1,743
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	103
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	74
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	902
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	654
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	80
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	702
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	88
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	910
GEND_GBV_DSD	Number of people receiving post-GBV care	978
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	391
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	587



GEND_GBV_DSD	By PEP service provision (related to sexual violence	
	services provided)	815
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	13
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	136
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	216
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	6
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	6
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	211
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	325
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	7
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	21
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	10
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	4
GEND_GBV_TA	15-19, Female, Physical and/or Emotional Violence	26
GEND_GBV_TA	20-24, Female, Physical and/or Emotional Violence	39
	Number of active beneficiaries served by PEPFAR	
OVC_SERV_DSD	OVC programs for children and families affected by	28,405
	HIV/AIDS	
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,865
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,865
OVC_SERV_DSD	By: Age/sex: Male 18-24	372
OVC_SERV_DSD	By: Age/sex: Male 25+	186
OVC_SERV_DSD	Age/Sex: 10-14 Female	4,623
OVC_SERV_DSD	Age/Sex: 15-17 Female	9,491
OVC_SERV_DSD	By: Age/sex: 18-24 Female	4,308
OVC_SERV_DSD	By: Age/sex: 25+ Female	1,911
OVC_SERV_DSD	Sum of Age/Sex disaggregates	17,844
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	0



	and sex: Education Support Male 15-17	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	2,593
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	150
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	2,593
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	4,169
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	2,743
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	150
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	40
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	50
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	2,683
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	1,176
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	50
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	60
OVC_SERV_DSD	Age/Sex: <1	600
OVC_SERV_DSD	Age/Sex: 1-9	3,184
OVC_SERV_DSD	Program Completion: Active	28,405
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	10,707
TB_ART_DSD	The number of registered new and relapse TB cases	11,477



	with documented HIV-positive status during TB	
	treatment during the reporting period	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	404
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,977
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	469
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5,625
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	423
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	4,434
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	580
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	6,212
TB_ART_TA	The number of registered new and relapse TB cases	1,217



	with documented HIV-positive status who are on ART	
	during TB treatment during the reporting period	
	The number of registered new and relapse TB cases	
TB_ART_TA	with documented HIV-positive status during TB	620
	treatment during the reporting period	
	Aggregated Age/Sex: Male <15 (Numerator: The	
TD ADT TA	number of registered new and relapse TB cases with	-4
TB_ART_TA	documented HIV-positive status who are on ART during	54
	TB treatment during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Numerator: The	
	number of registered new and relapse TB cases with	
TB_ART_TA	documented HIV-positive status who are on ART during	472
	TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: The	
	number of registered new and relapse TB cases with	
TB_ART_TA	documented HIV-positive status who are on ART during	62
	TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The	
	number of registered new and relapse TB cases with	
TB_ART_TA	documented HIV-positive status who are on ART during	628
	TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The	
	number of registered new and relapse TB cases with	
TB_ART_TA	documented HIV-positive status during TB treatment	17
	during the reporting period)	
	Aggregated Age/Sex: Male 15+ (Denominator: The	
	number of registered new and relapse TB cases with	
TB_ART_TA	documented HIV-positive status during TB treatment	223
	during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The	
	number of registered new and relapse TB cases with	
TB_ART_TA	documented HIV-positive status during TB treatment	27
	during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The	352
	number of registered new and relapse TB cases with	



	documented HIV-positive status during TB treatment during the reporting period)	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	21,084
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	126
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	19,010
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	97
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	1,851
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	8,056
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	11
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	5,186
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	0
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	2,859
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	520,781
TX_CURR_DSD	Age/Sex: 15-19 Male	1,576
TX_CURR_DSD	Age/Sex: 15-19 Female	3,249
TX_CURR_DSD	Sum of age/sex disaggregates	4,825
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	4,561
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	73,224
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	4,603
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	145,585
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	9,164
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	218,809



TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	227,973
TX_CURR_DSD	Age/Sex: <1	0
TX_CURR_DSD	Age/Sex: <1-9	5,001
TX_CURR_DSD	Age/Sex: 10-14 Male	2,073
TX_CURR_DSD	Age/Sex: 10-14 Female	2,217
TX_CURR_DSD	Age/Sex: 20-24 Male	2,170
TX_CURR_DSD	Age/Sex: 25-49 Male	70,833
TX_CURR_DSD	Age/Sex: 50+ Male	18,713
TX_CURR_DSD	Age/Sex: 20-24 Female	11,926
TX_CURR_DSD	Age/Sex: 25-49 Female	143,767
TX_CURR_DSD	Age/Sex: 50+ Female	24,339
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	57,672
TX_CURR_TA	Age/Sex: 15-19 Male	147
TX_CURR_TA	Age/Sex: 15-19 Female	303
TX_CURR_TA	Sum of Age/Sex disaggregations	450
TX_CURR_TA	Aggregated Age/Sex: <15 Male	590
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	10,643
TX_CURR_TA	Aggregated Age/Sex: <15 Female	590
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	18,875
TX_CURR_TA	Sum of Aggregated Age/Sex <15	1,180
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	29,518
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	30,698
TX_CURR_TA	Age/Sex: 1-9	486
TX_CURR_TA	Age/Sex: 10-14 Male	193
TX_CURR_TA	Age/Sex: 10-14 Female	206
TX_CURR_TA	Age/Sex: 20-24 Male	147
TX_CURR_TA	Age/Sex: 25-49 Male	6,640
TX_CURR_TA	Age/Sex: 50+ Male	1,726
TX_CURR_TA	Age/Sex: 20-24 Female	1,110
TX_CURR_TA	Age/Sex: 25-49 Female	13,757
TX_CURR_TA	Age/Sex: 50+ Female	2,258



	Niverban of adults as Lat 9 to a 1919	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	138,348
TX_NEW_DSD	By Age/Sex: <1	34
TX_NEW_DSD	By Age/Sex: 1-9	1,145
TX_NEW_DSD	By Age/Sex: 10-14 Male	631
TX_NEW_DSD	By Age/Sex: 15-19 Male	510
TX_NEW_DSD	By Age/Sex: 20-24 Male	652
TX_NEW_DSD		14,171
	By Age/Sex: 25-49 Male	
TX_NEW_DSD	By Age/Sex: 50+ Male	3,846
TX_NEW_DSD	By Age/Sex: 10-14 Female	673
TX_NEW_DSD	By Age/Sex: 15-19 Female	837
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,486
TX_NEW_DSD	By Age/Sex: 25-49 Female	27,248
TX_NEW_DSD	By Age/Sex: 50+ Female	5,052
TX_NEW_DSD	Sum of Age/Sex disaggregates	56,106
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	2,650
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	27,805
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2,972
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	47,704
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	81,131
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	10,151
TX_NEW_TA	By Age/Sex: <1	14
TX_NEW_TA	By Age/Sex: 1-9	173
TX_NEW_TA	By Age/Sex: 10-14 Male	105
TX_NEW_TA	By Age/Sex: 15-19 Male	85
TX_NEW_TA	By Age/Sex: 20-24 Male	123
TX_NEW_TA	By Age/Sex: 25-49 Male	847
TX_NEW_TA	By Age/Sex: 50+ Male	482
TX_NEW_TA	By Age/Sex: 10-14 Female	100
TX_NEW_TA	By Age/Sex: 15-19 Female	139
TX_NEW_TA	By Age/Sex: 20-24 Female	255



T)/ NIE\A/ TA	D A /0 05 t0 5	4.700
TX_NEW_TA	By Age/Sex: 25-49 Female	1,730
TX_NEW_TA	By Age/Sex: 50+ Female	555
TX_NEW_TA	Sum of Age/Sex disaggregates	4,421
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	205
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	2,168
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	195
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	2,975
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	5,543
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	411,917
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	457,286
TX_PVLS_DSD	Numerator: Indication: Routine	411,917
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	16,637
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	44,147
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	140,696
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	35,613
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	191,953
TX_PVLS_DSD	Denominator: Indication: Routine	414,226
TX_PVLS_DSD	Denominator: Indication: Targeted	2,088
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15  Male Routine	15,233
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+  Male Routine	152,385
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	20,632



Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	273,332
Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	40,682
Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	49,251
Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	3,436
Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	3,258
Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	20,218
Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	13,772
Numerator: Indication: Routine	40,682
Denominator: Indication: Routine	41,267
Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,527
Denominator: Aggregate Age/Sex by Indication: <15  Male Routine	1,795
Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	28,653
Denominator: Aggregate Age/Sex by Indication: 15+  Male Routine	16,276
Number of adults and children who are still alive and on treatment at 12 months after initiating ART	121,540
Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	135,460
Aggregated Age/Sex: <15 Male (Numerator: Number of	1,726
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.  Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.  Numerator: Aggregate Age/Sex by Indication: <15 Female Routine  Numerator: Aggregate Age/Sex by Indication: <15 Male Routine  Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine  Numerator: Indication: Routine  Numerator: Indication: Routine  Denominator: Aggregate Age/Sex by Indication: <15 Female Routine  Denominator: Aggregate Age/Sex by Indication: <15 Female Routine  Denominator: Aggregate Age/Sex by Indication: <15 Female Routine  Denominator: Aggregate Age/Sex by Indication: <15 Male Routine  Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine  Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine  Denominator: Aggregate Age/Sex by Indication: 15+ Temale Routine  Number of adults and children who are still alive and on treatment at 12 months after initiating ART  Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up



	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	41,678
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,772
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	76,363
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,777
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	44,498
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,817
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	86,518
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6,903
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting	7,198



	<u> </u>	
	period, including those who have died, those who have	
	stopped ART, and those lost to follow-up	
	Aggregated Age/Sex: <15 Male (Numerator: Number of	
TX_RET_TA	adults and children who are still alive and on treatment	121
	at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Male (Numerator: Number of	
TX_RET_TA	adults and children who are still alive and on treatment	2,210
	at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Female (Numerator: Number	
TX_RET_TA	of adults and children who are still alive and on	123
	treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: 15+ Female (Numerator: Number	
TX_RET_TA	of adults and children who are still alive and on	4,449
	treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Male (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_TA	12 months prior to the beginning of the reporting period,	134
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_TA	12 months prior to the beginning of the reporting period,	2,732
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: <15 Female (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_TA	12 months prior to the beginning of the reporting period,	135
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Female (Denominator: Total	
	number of adults and children who initiated ART in the	
TX_RET_TA	12 months prior to the beginning of the reporting period,	4,197
	including those who have died, those who have	
	stopped ART, and those lost to follow-up)	
TB_PREV_DSD	The number of ART patients who completed a course	2,123



	of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	4,245
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	56
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	47
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	2,169
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,299
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	36
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	26
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,148
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	747
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	3
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	7
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	0
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	0
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	4
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	3
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	0



TB_PREV_TA	By Age/Sex (Numerator): <15, Male	0
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	2
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	1

### **Implementing Mechanism Details**

Mechanism ID: 18547	TBD: Yes	
REDACTED		

**Implementing Mechanism Details** 

Mechanism ID: 18576	Mechanism Name: Cardno Emerging Markets (CDC-HQ GH001531)	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Cardno Emerging Markets		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
BD: No New Mechanism: Yes		
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 300,000	Total Mechanism Pipeline: N/A		
Applied Pipeline Amount: 0			
Total All Funding Sources and Applied Pipeline Amount: 300,000			
Funding Source Funding Amount			
GHP-State	300,000		

## **Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information** 

Mechanism ID: 18576	Mechanism ID:	: 18576

Custom



	Cardno Emerging Markets (CDC-HQ GH001531) Cardno Emerging Markets		
Strategic Area	Budget Code Planned Amount On Hold Amount		
Prevention	CIRC	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	100,000	0

#### **Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details** 

Mechanism ID: 18594 Mechanism Name: Project SOAR		
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: Population Council		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: Yes	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

Total All Funding Sources: 400,000	Total Mechanism Pipeline: N/A			
Applied Pipeline Amount: 0				
Total All Funding Sources and Applied Pipeline Amount: 400,000				
Funding Source Funding Amount				
GHP-State	400,000			

#### **Cross-Cutting Budget Attribution(s)**

(No data provided.)



**Budget Code Information** 

Budget Code Illionia	411011		
Mechanism ID:	18594		
Mechanism Name:	Project SOAR		
Prime Partner Name:	Population Council		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	300,000	0

#### **Implementing Mechanism Indicator Information**

(No data provided.)

## **Implementing Mechanism Details**

Mechanism ID: 18650	TBD: Yes
REDA	CTED



## **Agency Information - Costs of Doing Business**

**U.S.** Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		350,244		350,244	0	350,244
ICASS		776,656		776,656	0	776,656
Institutional Contractors		1,313,072		1,313,072	0	1,313,072
Management Meetings/Profes sional Development		530,861		530,861	0	530,861
Non-ICASS Administrative Costs		1,591,570		1,591,570	0	1,591,570
Peace Corps Volunteer Costs		60,459		60,459	0	60,459
Staff Program Travel		251,932		251,932	0	251,932
USG Staff Salaries and Benefits - Internationally Recruited		3,459,244		3,459,244	0	3,459,244
USG Staff Salaries and Benefits -		3,097,645		3,097,645	0	3,097,645



Locally						
Recruited						
Total	0	11,431,683	0	11,431,683	0	11,431,683

**U.S.** Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
ICASS		0		0	60,000	60,000
Management Meetings/Profes sional Development		0		0	2,334	2,334
Staff Program Travel				0	13,877	13,877
USG Staff Salaries and Benefits - Locally Recruited				0	135,803	135,803
Total	0	0	0	0	212,014	212,014

# U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost						Total All
of Doing	GAP	GHP-State	GHP-USAID	Funding	Applied	Funding
•	GAP	GHF-State	GHP-03AID	Source Total	Pipeline	Sources and
Business						Applied



						Pipeline Amount
Capital Security Cost Sharing	2,126,586	186,653		2,313,239	0	2,313,239
Computers/IT Services	765,571			765,571	0	765,571
ICASS	557,843	1,055,786		1,613,629	0	1,613,629
Indirect Costs		1,147,213		1,147,213	0	1,147,213
Institutional Contractors		594,312		594,312	0	594,312
Management Meetings/Profes sional Development		236,516		236,516	0	236,516
Non-ICASS Administrative Costs		1,157,912		1,157,912	0	1,157,912
Non-ICASS Motor Vehicles		189,160		189,160	0	189,160
Staff Program Travel		1,129,066		1,129,066	0	1,129,066
USG Staff Salaries and Benefits - Internationally Recruited		2,936,957		2,936,957	0	2,936,957
USG Staff Salaries and Benefits - Locally Recruited		3,712,115		3,712,115	0	3,712,115
Total	3,450,000	12,345,690	0	15,795,690	0	15,795,690



**U.S. Department of State** 

Agency Cost of Doing Business	ent of State	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
ICASS		575,697		575,697	0	575,697
Institutional Contractors		0		0	0	0
Management Meetings/Profes sional Development		331,350		331,350	0	331,350
Non-ICASS Administrative Costs		323,876		323,876	0	323,876
Peace Corps Volunteer Costs		0		0	0	0
Staff Program Travel		134,889		134,889	306,352	441,241
USG Staff Salaries and Benefits - Internationally Recruited		321,351		321,351	0	321,351
USG Staff Salaries and Benefits - Locally Recruited		0		0	1,211,295	1,211,295
Total	0	1,687,163	0	1,687,163	1,517,647	3,204,810



**U.S. Peace Corps** 

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		0		0	3,000	3,000
Institutional Contractors		0		0	30,000	30,000
Management Meetings/Profes sional Development		0		0	287,500	287,500
Non-ICASS Administrative Costs		0		0	22,000	22,000
Peace Corps Volunteer Costs		0		0	1,073,500	1,073,500
Staff Program Travel		0		0	55,894	55,894
USG Staff Salaries and Benefits - Internationally Recruited		0		0	0	0
USG Staff Salaries and Benefits - Locally Recruited		0		0	478,106	478,106
Total	0	0	0	0	1,950,000	1,950,000

